INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'1'', 'b'Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Gu\xc3\xa9rin? Predictors and Nomograms.'', 'b'The best predictors of response to intravesical immunotherapy are tumor grade and stage, tumor recurrence pattern, nomograms, panels of urinary cytokines, and fluorescent in situ hybridization patterns of urine cytology examinations. Future investigations on predictors of Bacillus Calmette-Gu\xc3\xa9rin efficacy are needed to better select those patients who will really benefit from a conservative treatment. Hardly any of the proposed nomograms were designed to precisely predict the outcome of Bacillus Calmette-Gu\xc3\xa9rin immunotherapy. A new nomogram for NMIBC recurrence and progression based on all non-muscle-invasive bladder cancer subgroups would include factors already proven in cancer prognosis and prediction.'', 'b'619'', 'b'96'', 'b"[('predictors', 4), ('immunotherapy', 4), ('tumor', 4), ('recurrence', 4), ('nomograms', 4), ('bacillus', 4), ('cancer', 4), ('best', 2), ('response', 2), ('intravesical', 2), ('grade', 2), ('stage', 2), ('pattern', 2), ('panels', 2), ('urinary', 2), ('cytokines', 2), ('fluorescent', 2), ('situ', 2), ('hybridization', 2), ('patterns', 2), ('urine', 2), ('cytology', 2), ('examinations', 2), ('future', 2), ('investigations', 2), ('efficacy', 2), ('needed', 2), ('better', 2), ('select', 2), ('patients', 2), ('really', 2), ('benefit', 2), ('conservative', 2), ('treatment', 2), ('hardly', 2), ('proposed', 2), ('designed', 2), ('precisely', 2), ('predict', 2), ('outcome', 2), ('new', 2), ('nomogram', 2), ('nmibc', 2), ('progression', 2), ('based', 2), ('bladder', 2), ('subgroups', 2), ('would', 2), ('include', 2), ('factors', 2), ('already', 2), ('proven', 2), ('prognosis', 2), ('prediction', 2)]"', 'b"[('of', 6), ('and', 4), (',', 4), ('.', 4), ('the', 3), ('to', 3), ('nomogram', 3), ('predictor', 2), ('immunotherapi', 2), ('are', 2), ('tumor', 2), ('recurr', 2), ('pattern', 2), ('in', 2), ('on', 2), ('bacillu', 2), ('calmette-gu\xc3\xa9rin', 2), ('predict', 2), ('cancer', 2), ('best', 1), ('respons', 1), ('intraves', 1), ('grade', 1), ('stage', 1), ('panel', 1), ('urinari', 1), ('cytokin', 1), ('fluoresc', 1), ('situ', 1), ('hybrid', 1), ('urin', 1), ('cytolog', 1), ('examin', 1), ('futur', 1), ('investig', 1), ('efficaci', 1), ('need', 1), ('better', 1), ('select', 1), ('those', 1), ('patient', 1), ('who', 1), ('will', 1), ('realli', 1), ('benefit', 1), ('from', 1), ('a', 1), ('conserv', 1), ('treatment', 1), ('hardli', 1), ('ani', 1), ('propos', 1), ('were', 1), ('design', 1), ('precis', 1), ('outcom', 1), ('A', 1), ('new', 1), ('for', 1), ('nmibc', 1), ('progress', 1), ('base', 1), ('all', 1), ('non-muscle-invas', 1), ('bladder', 1), ('subgroup', 1), ('would', 1), ('includ', 1), ('factor', 1), ('alreadi', 1), ('proven', 1), ('prognosi', 1)]"', 'b'4'', 'b"('predictors', 'immunotherapy', 'tumor', 'recurrence', 'nomograms', 'bacillus', 'cancer', 'best', 'response', 'intravesical', 'grade', 'stage', 'pattern', 'panels', 'urinary', 'cytokines', 'fluorescent', 'situ', 'hybridization', 'patterns', 'urine', 'cytology', 'examinations', 'future', 'investigations', 'efficacy', 'needed', 'better', 'select', 'patients', 'really', 'benefit', 'conservative', 'treatment', 'hardly', 'proposed', 'designed', 'precisely', 'predict', 'outcome', 'new', 'nomogram', 'nmibc', 'progression', 'based', 'bladder', 'subgroups', 'would', 'include', 'factors', 'already', 'proven', 'prognosis', 'prediction')"', 'b'(4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.1493074390688702'', 'b'[0, 0, 0, 0.2846173057250338]'', 'b'-2.417726683613366'', 'b'[1, 1, 1, -1.7725887222397811]'', 'b'-11.01002967471292'', 'b'[0, 0, 0, -8.072150820519468]'', 'b'3'', 'b'0.24252557035977668'', 'b"['Adjuvants, Immunologic', 'Administration, Intravesical', 'BCG Vaccine', 'Disease Progression', 'Humans', 'Immunotherapy', 'Neoplasm Invasiveness', 'Nomograms', 'Salvage Therapy', 'Treatment Outcome', 'Urinary Bladder Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'2'', 'b'Effect of annual influenza vaccination on reducing lung cancer in patients with chronic obstructive pulmonary disease from a population-based cohort study.'', 'b'Chronic obstructive pulmonary disease (COPD) patients are at a higher risk of development of lung cancer. Frequent exacerbations of COPD trigger the disease course to chronic inflammation which likely plays a role in the pathogenesis of lung cancer. Previous studies showed influenza virus infection is one of important causes for exacerbations of COPD. Therefore, the aim of this study was to know whether influenza vaccination could reduce the incidence of lung cancer in patients with COPD.This cohort study enrolled patients (\xe2\x89\xa555 years old) with a recorded diagnosis of COPD between January 1, 2000 and December 31, 2012 by using the Taiwan Health Insurance Database. A propensity score was calculated to reduce vaccine therapy selection bias. Cox proportional hazard regressions were used to investigate the association between the influenza vaccination and lung cancer incidence after adjusting for known confounding factors. Besides, we categorized the patients into 4 groups according to vaccination status (unvaccinated, total number of vaccinations: 1, 2-3, \xe2\x89\xa54) to evaluate the dose-dependent effect on reducing lung cancer occurrence of lung cancer in COPD patients.Our study comprised of 28,752 eligible individuals from the COPD cohort database. Among them, 51% (14,630) received influenza vaccination; the rest (49%) of the COPD patients did not receive influenza vaccination. We observed that COPD patients receiving influenza vaccination had a lower risk of lung cancer (adjusted HR\xe2\x80\x8a=\xe2\x80\x8a0.40, 95% CI (0.35-0.45), P\xe2\x80\x8a<\xe2\x80\x8a.001). We also founded comparable protective effect in both sexes and all age groups (55-64, 65-74, \xe2\x89\xa575) regardless of influenza seasonality. Furthermore, dose-dependent protective effect could be seen after stratifying patients according to the total number vaccinations, the adjusted HRs for lung cancer risk were 0.48 (0.40-0.54) and 0.24 (0.20-0.29) for patients who received 2 to 3 and \xe2\x89\xa54 vaccinations during the follow-up period.This population-based cohort study demonstrated that annual influenza vaccination administration could reduce incidence of lung cancer in COPD patients.'', 'b'1808'', 'b'311'', 'b"[('copd', 18), ('patients', 18), ('lung', 18), ('cancer', 18), ('influenza', 16), ('vaccination', 14), ('study', 8), ('risk', 6), ('could', 6), ('reduce', 6), ('incidence', 6), ('cohort', 6), ('vaccinations', 6), ('effect', 6), ('chronic', 4), ('disease', 4), ('exacerbations', 4), ('database', 4), ('groups', 4), ('according', 4), ('total', 4), ('number', 4), ('received', 4), ('adjusted', 4), ('protective', 4), ('obstructive', 2), ('pulmonary', 2), ('higher', 2), ('development', 2), ('frequent', 2), ('trigger', 2), ('course', 2), ('inflammation', 2), ('likely', 2), ('plays', 2), ('role', 2), ('pathogenesis', 2), ('previous', 2), ('studies', 2), ('showed', 2), ('virus', 2), ('infection', 2), ('one', 2), ('important', 2), ('causes', 2), ('therefore', 2), ('aim', 2), ('know', 2), ('whether', 2), ('enrolled', 2), ('years', 2), ('old', 2), ('recorded', 2), ('diagnosis', 2), ('january', 2), ('december', 2), ('using', 2), ('taiwan', 2), ('health', 2), ('insurance', 2), ('propensity', 2), ('score', 2), ('calculated', 2), ('vaccine', 2), ('therapy', 2), ('selection', 2), ('bias', 2), ('cox', 2), ('proportional', 2), ('hazard', 2), ('regressions', 2), ('used', 2), ('investigate', 2), ('association', 2), ('adjusting', 2), ('known', 2), ('confounding', 2), ('factors', 2), ('besides', 2), ('categorized', 2), ('status', 2), ('unvaccinated', 2), ('evaluate', 2), ('reducing', 2), ('occurrence', 2), ('comprised', 2), ('eligible', 2), ('individuals', 2), ('among', 2), ('rest', 2), ('receive', 2), ('observed', 2), ('receiving', 2), ('lower', 2), ('hr', 2), ('ci', 2), ('p', 2), ('also', 2), ('founded', 2), ('comparable', 2), ('sexes', 2), ('age', 2), ('regardless', 2), ('seasonality', 2), ('furthermore', 2), ('seen', 2), ('stratifying', 2), ('hrs', 2), ('demonstrated', 2), ('annual', 2), ('administration', 2)]"', 'b"[('of', 16), ('the', 15), (',', 14), ('.', 11), ('vaccin', 11), ('(', 10), (')', 10), ('copd', 9), ('patient', 9), ('lung', 9), ('cancer', 9), ('to', 8), ('influenza', 8), ('in', 5), ('studi', 5), ('and', 5), ('a', 4), ('for', 4), ('reduc', 4), ('receiv', 4), ('risk', 3), ('could', 3), ('incid', 3), ('cohort', 3), ('adjust', 3), ('effect', 3), ('%', 3), ('chronic', 2), ('diseas', 2), ('exacerb', 2), ('wa', 2), ('with', 2), ('between', 2), ('1', 2), ('use', 2), ('databas', 2), ('were', 2), ('after', 2), ('group', 2), ('accord', 2), ('total', 2), ('number', 2), ('\xe2\x89\xa54', 2), ('dose-depend', 2), ('We', 2), ('that', 2), ('protect', 2), ('obstruct', 1), ('pulmonari', 1), ('are', 1), ('at', 1), ('higher', 1), ('develop', 1), ('frequent', 1), ('trigger', 1), ('cours', 1), ('inflamm', 1), ('which', 1), ('like', 1), ('play', 1), ('role', 1), ('pathogenesi', 1), ('previou', 1), ('show', 1), ('viru', 1), ('infect', 1), ('is', 1), ('one', 1), ('import', 1), ('caus', 1), ('therefor', 1), ('aim', 1), ('thi', 1), ('know', 1), ('whether', 1), ('copd.thi', 1), ('enrol', 1), ('\xe2\x89\xa555', 1), ('year', 1), ('old', 1), ('record', 1), ('diagnosi', 1), ('januari', 1), ('2000', 1), ('decemb', 1), ('31', 1), ('2012', 1), ('by', 1), ('taiwan', 1), ('health', 1), ('insur', 1), ('A', 1), ('propens', 1), ('score', 1), ('calcul', 1), ('therapi', 1), ('select', 1), ('bia', 1), ('cox', 1), ('proport', 1), ('hazard', 1), ('regress', 1), ('investig', 1), ('associ', 1), ('known', 1), ('confound', 1), ('factor', 1), ('besid', 1), ('we', 1), ('categor', 1), ('into', 1), ('4', 1), ('statu', 1), ('unvaccin', 1), (':', 1), ('2-3', 1), ('evalu', 1), ('on', 1), ('occurr', 1), ('patients.our', 1), ('compris', 1), ('28,752', 1), ('elig', 1), ('individu', 1), ('from', 1), ('among', 1), ('them', 1), ('51', 1), ('14,630', 1), (';', 1), ('rest', 1), ('49', 1), ('did', 1), ('not', 1), ('observ', 1), ('had', 1), ('lower', 1), ('HR', 1), ('=', 1), ('0.40', 1), ('95', 1), ('CI', 1), ('0.35-0.45', 1), ('P', 1), ('<', 1), ('.001', 1), ('also', 1), ('found', 1), ('compar', 1), ('both', 1), ('sex', 1), ('all', 1), ('age', 1), ('55-64', 1), ('65-74', 1), ('\xe2\x89\xa575', 1), ('regardless', 1), ('season', 1), ('furthermor', 1), ('be', 1), ('seen', 1), ('stratifi', 1), ('hr', 1), ('0.48', 1), ('0.40-0.54', 1), ('0.24', 1), ('0.20-0.29', 1), ('who', 1), ('2', 1), ('3', 1), ('dure', 1), ('follow-up', 1), ('period.thi', 1), ('population-bas', 1), ('demonstr', 1), ('annual', 1), ('administr', 1)]"', 'b'11'', 'b"('copd', 'patients', 'lung', 'cancer', 'influenza', 'vaccination', 'study', 'risk', 'could', 'reduce', 'incidence', 'cohort', 'vaccinations', 'effect', 'chronic', 'disease', 'exacerbations', 'database', 'groups', 'according', 'total', 'number', 'received', 'adjusted', 'protective', 'obstructive', 'pulmonary', 'higher', 'development', 'frequent', 'trigger', 'course', 'inflammation', 'likely', 'plays', 'role', 'pathogenesis', 'previous', 'studies', 'showed', 'virus', 'infection', 'one', 'important', 'causes', 'therefore', 'aim', 'know', 'whether', 'enrolled', 'years', 'old', 'recorded', 'diagnosis', 'january', 'december', 'using', 'taiwan', 'health', 'insurance', 'propensity', 'score', 'calculated', 'vaccine', 'therapy', 'selection', 'bias', 'cox', 'proportional', 'hazard', 'regressions', 'used', 'investigate', 'association', 'adjusting', 'known', 'confounding', 'factors', 'besides', 'categorized', 'status', 'unvaccinated', 'evaluate', 'reducing', 'occurrence', 'comprised', 'eligible', 'individuals', 'among', 'rest', 'receive', 'observed', 'receiving', 'lower', 'hr', 'ci', 'p', 'also', 'founded', 'comparable', 'sexes', 'age', 'regardless', 'seasonality', 'furthermore', 'seen', 'stratifying', 'hrs', 'demonstrated', 'annual', 'administration')"', 'b'(18, 18, 18, 18, 16, 14, 8, 6, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.18884004021394218'', 'b'[3.8607297110405954, 0.23035097352882875, 0.13289479242047814, 0.05976570812227642, 0.05192758246689591, 0.038239467261901826, 0.04455028100600784, 0.03945882031960694, 0.015999795966535137, 0.014988314612328892, 0.02209317276714915]'', 'b'-2.0177111802727663'', 'b'[1.0, -1.70805020110221, -2.258096538021482, -2.970291913552122, -3.1108738641733114, -3.343805421853684, -3.1271343850450917, -3.2484952420493594, -4.093750200806762, -4.159055299214529, -3.718498871295094]'', 'b'-7.789837501977856'', 'b'[3.8607297110405954, -5.901765399900087, -7.802321037829894, -9.408644775795644, -9.853949706684217, -9.84563102285407, -8.637512367033118, -8.972725304558661, -10.676364375991882, -10.846677900757982, -9.201185055772823]'', 'b'74'', 'b'0.1562605837399405'', 'b"['Aged', 'Cohort Studies', 'Disease Progression', 'Female', 'Humans', 'Immunization Schedule', 'Incidence', 'Influenza Vaccines', 'Influenza, Human', 'Lung Neoplasms', 'Male', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'3'', 'b'Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.'', 'b'Non-muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Gu\xc3\xa9rin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.'', 'b'689'', 'b'96'', 'b"[('treatment', 6), ('bladder', 4), ('cancer', 4), ('tumor', 4), ('new', 4), ('nmibc', 2), ('heterogeneous', 2), ('current', 2), ('diagnostic', 2), ('strategies', 2), ('rely', 2), ('primarily', 2), ('clinical', 2), ('parameters', 2), ('lacking', 2), ('individualization', 2), ('host', 2), ('genetics', 2), ('biology', 2), ('heterogeneity', 2), ('nmibcs', 2), ('derived', 2), ('mutations', 2), ('mutation', 2), ('signatures', 2), ('chromosomal', 2), ('loss', 2), ('disruption', 2), ('molecular', 2), ('pathways', 2), ('ultimately', 2), ('affects', 2), ('progression', 2), ('recurrence', 2), ('responsiveness', 2), ('intravesical', 2), ('systemic', 2), ('chemotherapy', 2), ('although', 2), ('research', 2), ('still', 2), ('underway', 2), ('advances', 2), ('sequencing', 2), ('technology', 2), ('insight', 2), ('differential', 2), ('bacillus', 2), ('responses', 2), ('investigational', 2), ('targets', 2), ('soon', 2), ('offer', 2), ('clinicians', 2), ('tools', 2), ('risk', 2), ('stratify', 2), ('determine', 2), ('regimens', 2), ('future', 2), ('patients', 2)]"', 'b"[(',', 12), ('and', 8), ('is', 3), ('treatment', 3), ('to', 3), ('.', 3), ('bladder', 2), ('cancer', 2), ('nmibc', 2), ('heterogen', 2), ('tumor', 2), ('of', 2), ('mutat', 2), ('respons', 2), ('new', 2), ('non-muscle-invas', 1), ('(', 1), (')', 1), ('but', 1), ('current', 1), ('diagnost', 1), ('strategi', 1), ('reli', 1), ('primarili', 1), ('on', 1), ('clinic', 1), ('paramet', 1), ('lack', 1), ('individu', 1), ('host', 1), ('genet', 1), ('biolog', 1), ('the', 1), ('deriv', 1), ('from', 1), ('signatur', 1), ('chromosom', 1), ('loss', 1), ('disrupt', 1), ('molecular', 1), ('pathway', 1), ('which', 1), ('ultim', 1), ('affect', 1), ('progress', 1), ('recurr', 1), ('intraves', 1), ('system', 1), ('chemotherapi', 1), ('although', 1), ('research', 1), ('still', 1), ('underway', 1), ('advanc', 1), ('in', 1), ('sequenc', 1), ('technolog', 1), ('insight', 1), ('into', 1), ('differenti', 1), ('bacillu', 1), ('calmette-gu\xc3\xa9rin', 1), ('investig', 1), ('target', 1), ('will', 1), ('soon', 1), ('offer', 1), ('clinician', 1), ('precision-bas', 1), ('tool', 1), ('risk', 1), ('stratifi', 1), ('determin', 1), ('regimen', 1), ('for', 1), ('futur', 1), ('patient', 1), ('with', 1)]"', 'b'3'', 'b"('treatment', 'bladder', 'cancer', 'tumor', 'new', 'nmibc', 'heterogeneous', 'current', 'diagnostic', 'strategies', 'rely', 'primarily', 'clinical', 'parameters', 'lacking', 'individualization', 'host', 'genetics', 'biology', 'heterogeneity', 'nmibcs', 'derived', 'mutations', 'mutation', 'signatures', 'chromosomal', 'loss', 'disruption', 'molecular', 'pathways', 'ultimately', 'affects', 'progression', 'recurrence', 'responsiveness', 'intravesical', 'systemic', 'chemotherapy', 'although', 'research', 'still', 'underway', 'advances', 'sequencing', 'technology', 'insight', 'differential', 'bacillus', 'responses', 'investigational', 'targets', 'soon', 'offer', 'clinicians', 'tools', 'risk', 'stratify', 'determine', 'regimens', 'future', 'patients')"', 'b'(6, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.1031422269532069'', 'b'[0.13862660672143068, 0.06369330579092762, 0.03517643435322649]'', 'b'-2.5115454388310208'', 'b'[-1.8332133440562162, -2.6109179126442243, -3.1588830833596715]'', 'b'-8.678054053449225'', 'b'[-4.320246469810318, -6.153025741187183, -7.1115675783244265]'', 'b'1'', 'b'0.24252557035977668'', 'b"['Adjuvants, Immunologic', 'Administration, Intravesical', 'BCG Vaccine', 'Biomarkers, Tumor', 'DNA Mutational Analysis', 'DNA, Neoplasm', 'Disease Progression', 'Genomics', 'Humans', 'Immunotherapy', 'Mutation', 'Neoplasm Invasiveness', 'Urinary Bladder Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'4'', 'b'Association between TGF-\xce\xb21 rs1982073_rs1800469 polymorphism and lung cancer susceptibility: An updated meta-analysis involving 7698 cases and controls.'', 'b'There have been several case-control studies to assess the relationship between the transforming growth factor-\xce\xb21 (TGF-\xce\xb21) T\xe2\x80\x8a+\xe2\x80\x8a869C (rs1982073)_C-509T (rs1800469) gene polymorphism and lung cancer in recent years; however, the results remain controversial. In this study, we investigated the potential correlation between the TGF-\xce\xb21 T\xe2\x80\x8a+\xe2\x80\x8a869C_C-509T polymorphism and increased risk of lung cancer through meta-analysis.We searched the Cochrane Library database, Embase, PubMed, Web of Science, China National Knowledge Infrastructure, and the Wanfang Data Information Service platform to identify relevant case-control studies in strict accordance with the inclusion and exclusion criteria. The odds ratio (OR) and its 95% confidence interval (95% CI) were used to evaluate the correlation between TGF-\xce\xb21 gene polymorphism and lung tumor risk. Sensitivity analysis and Egger test were used to evaluate the stability of the results and possible publication bias.A total of 8 studies, with 3680 patients and 4018 controls, were included. The meta-analysis revealed that there was no conspicuous correlation between the TGF-\xce\xb21 T\xe2\x80\x8a+\xe2\x80\x8a869C (rs1982073)_C-509T (rs1800469) variant and lung cancer in the overall population. For TGF-\xce\xb21 C-509T, a significant decreased risk was identified in patients with nonsmall-cell lung cancer (NSCLC) in the analysis stratified by disease (TT vs CT\xe2\x80\x8a+\xe2\x80\x8aCC: P\xe2\x80\x8a=\xe2\x80\x8a.02, OR\xe2\x80\x8a=\xe2\x80\x8a0.49, 95% CI 0.27-0.90). However, for TGF-\xce\xb21 T\xe2\x80\x8a+\xe2\x80\x8a869C, subgroup analysis showed no correlation between the T\xe2\x80\x8a+\xe2\x80\x8a869C polymorphism and lung cancer susceptibility in patients with NSCLC. In the subgroup analysis by ethnicity, no distinct association was observed between T\xe2\x80\x8a+\xe2\x80\x8a869C (rs1982073)_C-509T (rs1800469) polymorphism and lung cancer susceptibility in the Asian and Caucasian groups. Moreover, no significant association was found in the analysis of groups stratified by age, sex, and smoking history.The TGF-\xce\xb21 T\xe2\x80\x8a+\xe2\x80\x8a869C (rs1982073) and C-509T (rs1800469) polymorphisms are not implicated in lung cancer susceptibility in the overall population. However, our analysis indicated that the C-509T (rs1800469) polymorphism decreases the risk of lung cancer in patients with NSCLC.'', 'b'1858'', 'b'318'', 'b"[('lung', 18), ('cancer', 16), ('polymorphism', 12), ('analysis', 12), ('correlation', 8), ('risk', 8), ('patients', 8), ('studies', 6), ('however', 6), ('nsclc', 6), ('susceptibility', 6), ('gene', 4), ('results', 4), ('ci', 4), ('used', 4), ('evaluate', 4), ('overall', 4), ('population', 4), ('significant', 4), ('stratified', 4), ('subgroup', 4), ('association', 4), ('groups', 4), ('several', 2), ('assess', 2), ('relationship', 2), ('transforming', 2), ('growth', 2), ('recent', 2), ('years', 2), ('remain', 2), ('controversial', 2), ('study', 2), ('investigated', 2), ('potential', 2), ('increased', 2), ('searched', 2), ('cochrane', 2), ('library', 2), ('database', 2), ('embase', 2), ('pubmed', 2), ('web', 2), ('science', 2), ('china', 2), ('national', 2), ('knowledge', 2), ('infrastructure', 2), ('wanfang', 2), ('data', 2), ('information', 2), ('service', 2), ('platform', 2), ('identify', 2), ('relevant', 2), ('strict', 2), ('accordance', 2), ('inclusion', 2), ('exclusion', 2), ('criteria', 2), ('odds', 2), ('ratio', 2), ('confidence', 2), ('interval', 2), ('tumor', 2), ('sensitivity', 2), ('egger', 2), ('test', 2), ('stability', 2), ('possible', 2), ('publication', 2), ('total', 2), ('controls', 2), ('included', 2), ('revealed', 2), ('conspicuous', 2), ('variant', 2), ('decreased', 2), ('identified', 2), ('disease', 2), ('tt', 2), ('vs', 2), ('ct', 2), ('cc', 2), ('p', 2), ('showed', 2), ('ethnicity', 2), ('distinct', 2), ('observed', 2), ('asian', 2), ('caucasian', 2), ('moreover', 2), ('found', 2), ('age', 2), ('sex', 2), ('smoking', 2), ('polymorphisms', 2), ('implicated', 2), ('indicated', 2), ('decreases', 2)]"', 'b"[('the', 23), (',', 19), ('and', 15), ('(', 14), (')', 14), ('in', 11), ('.', 10), ('lung', 9), ('+', 8), ('cancer', 8), ('tgf-\xce\xb21', 7), ('T', 7), ('polymorph', 7), ('between', 6), ('869c', 6), ('of', 6), ('analysi', 6), ('rs1800469', 5), ('with', 5), ('studi', 4), ('to', 4), ('rs1982073', 4), ('correl', 4), ('risk', 4), ('patient', 4), ('wa', 4), ('no', 4), ('_c-509t', 3), ('howev', 3), ('95', 3), ('%', 3), ('were', 3), ('c-509t', 3), ('nsclc', 3), ('by', 3), ('suscept', 3), ('there', 2), ('case-control', 2), ('gene', 2), ('result', 2), ('In', 2), ('identifi', 2), ('OR', 2), ('CI', 2), ('use', 2), ('evalu', 2), ('that', 2), ('overal', 2), ('popul', 2), ('for', 2), ('signific', 2), ('decreas', 2), ('stratifi', 2), ('=', 2), ('subgroup', 2), ('associ', 2), ('group', 2), ('have', 1), ('been', 1), ('sever', 1), ('assess', 1), ('relationship', 1), ('transform', 1), ('growth', 1), ('factor-\xce\xb21', 1), ('recent', 1), ('year', 1), (';', 1), ('remain', 1), ('controversi', 1), ('thi', 1), ('we', 1), ('investig', 1), ('potenti', 1), ('869c_c-509t', 1), ('increas', 1), ('through', 1), ('meta-analysis.w', 1), ('search', 1), ('cochran', 1), ('librari', 1), ('databas', 1), ('embas', 1), ('pubm', 1), ('web', 1), ('scienc', 1), ('china', 1), ('nation', 1), ('knowledg', 1), ('infrastructur', 1), ('wanfang', 1), ('data', 1), ('inform', 1), ('servic', 1), ('platform', 1), ('relev', 1), ('strict', 1), ('accord', 1), ('inclus', 1), ('exclus', 1), ('criteria', 1), ('odd', 1), ('ratio', 1), ('it', 1), ('confid', 1), ('interv', 1), ('tumor', 1), ('sensit', 1), ('egger', 1), ('test', 1), ('stabil', 1), ('possibl', 1), ('public', 1), ('bias.a', 1), ('total', 1), ('8', 1), ('3680', 1), ('4018', 1), ('control', 1), ('includ', 1), ('meta-analysi', 1), ('reveal', 1), ('conspicu', 1), ('variant', 1), ('a', 1), ('nonsmall-cel', 1), ('diseas', 1), ('TT', 1), ('vs', 1), ('CT', 1), ('CC', 1), (':', 1), ('P', 1), ('.02', 1), ('0.49', 1), ('0.27-0.90', 1), ('show', 1), ('ethnic', 1), ('distinct', 1), ('observ', 1), ('asian', 1), ('caucasian', 1), ('moreov', 1), ('found', 1), ('age', 1), ('sex', 1), ('smoke', 1), ('history.th', 1), ('are', 1), ('not', 1), ('implic', 1), ('our', 1), ('indic', 1)]"', 'b'10'', 'b"('lung', 'cancer', 'polymorphism', 'analysis', 'correlation', 'risk', 'patients', 'studies', 'however', 'nsclc', 'susceptibility', 'gene', 'results', 'ci', 'used', 'evaluate', 'overall', 'population', 'significant', 'stratified', 'subgroup', 'association', 'groups', 'several', 'assess', 'relationship', 'transforming', 'growth', 'recent', 'years', 'remain', 'controversial', 'study', 'investigated', 'potential', 'increased', 'searched', 'cochrane', 'library', 'database', 'embase', 'pubmed', 'web', 'science', 'china', 'national', 'knowledge', 'infrastructure', 'wanfang', 'data', 'information', 'service', 'platform', 'identify', 'relevant', 'strict', 'accordance', 'inclusion', 'exclusion', 'criteria', 'odds', 'ratio', 'confidence', 'interval', 'tumor', 'sensitivity', 'egger', 'test', 'stability', 'possible', 'publication', 'total', 'controls', 'included', 'revealed', 'conspicuous', 'variant', 'decreased', 'identified', 'disease', 'tt', 'vs', 'ct', 'cc', 'p', 'showed', 'ethnicity', 'distinct', 'observed', 'asian', 'caucasian', 'moreover', 'found', 'age', 'sex', 'smoking', 'polymorphisms', 'implicated', 'indicated', 'decreases')"', 'b'(18, 16, 12, 12, 8, 8, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.1645497418431507'', 'b'[0.30799737411459577, 0.05046268882469611, 0.03831426373726927, 0.02998507596829769, 0.02583022771609096, 0.020370420872183853, 0.017579301814269817, 0.015095662452209828, 0.012745655907735739, 0.011472449197961214]'', 'b'-1.9575110607337933'', 'b'[-0.9459101490553135, -2.713572066704308, -2.9889840465642745, -3.2341065045972597, -3.343805421853684, -3.543294782270004, -3.653960350157523, -3.770684624465665, -3.9052747784384296, -3.976733742420574]'', 'b'-6.200577839203011'', 'b'[-2.039364894401677, -5.614299855024967, -6.184119045593913, -6.691270116864102, -6.65058667232808, -6.784770162970984, -6.744577540343382, -6.716675911951208, -6.719663954403244, -6.615316995892041]'', 'b'74'', 'b'0.18418453037182622'', 'b"['Case-Control Studies', 'Genetic Predisposition to Disease', 'Humans', 'Lung Neoplasms', 'Polymorphism, Single Nucleotide', 'Transforming Growth Factor beta1']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'5'', 'b'Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.'', 'b'Bacillus Calmette-Guerin (BCG)-refractory high-grade non-muscle-invasive bladder cancer remains a challenging problem. Radical cystectomy is standard of care, but carries significant morbidity. Therefore, there is a need for effective treatments. Previous salvage intravesical therapies have had disappointing results with long-term follow-up; however, a wide array of novel agents is currently under investigation. These include novel combinations of existing intravesical agents, novel modes of delivery such as hyperthermia, viral mediated therapies, and immunotherapy. We review the need for novel treatment with existing agents and their long-term results, and discuss novel intravesical therapies and the data currently available on these therapies.'', 'b'658'', 'b'98'', 'b"[('novel', 10), ('therapies', 8), ('intravesical', 6), ('agents', 6), ('need', 4), ('results', 4), ('currently', 4), ('existing', 4), ('bacillus', 2), ('bcg', 2), ('bladder', 2), ('cancer', 2), ('remains', 2), ('challenging', 2), ('problem', 2), ('radical', 2), ('cystectomy', 2), ('standard', 2), ('care', 2), ('carries', 2), ('significant', 2), ('morbidity', 2), ('therefore', 2), ('effective', 2), ('treatments', 2), ('previous', 2), ('salvage', 2), ('disappointing', 2), ('however', 2), ('wide', 2), ('array', 2), ('investigation', 2), ('include', 2), ('combinations', 2), ('modes', 2), ('delivery', 2), ('hyperthermia', 2), ('viral', 2), ('mediated', 2), ('immunotherapy', 2), ('review', 2), ('treatment', 2), ('discuss', 2), ('data', 2), ('available', 2)]"', 'b"[(',', 7), ('.', 6), ('novel', 5), ('of', 4), ('therapi', 4), ('and', 4), ('a', 3), ('is', 3), ('intraves', 3), ('agent', 3), ('need', 2), ('for', 2), ('treatment', 2), ('result', 2), ('with', 2), ('long-term', 2), ('current', 2), ('these', 2), ('exist', 2), ('the', 2), ('bacillu', 1), ('calmette-guerin', 1), ('(', 1), ('bcg', 1), (')', 1), ('-refractori', 1), ('high-grad', 1), ('non-muscle-invas', 1), ('bladder', 1), ('cancer', 1), ('remain', 1), ('challeng', 1), ('problem', 1), ('radic', 1), ('cystectomi', 1), ('standard', 1), ('care', 1), ('but', 1), ('carri', 1), ('signific', 1), ('morbid', 1), ('therefor', 1), ('there', 1), ('effect', 1), ('previou', 1), ('salvag', 1), ('have', 1), ('had', 1), ('disappoint', 1), ('follow-up', 1), (';', 1), ('howev', 1), ('wide', 1), ('array', 1), ('under', 1), ('investig', 1), ('includ', 1), ('combin', 1), ('mode', 1), ('deliveri', 1), ('such', 1), ('as', 1), ('hyperthermia', 1), ('viral', 1), ('mediat', 1), ('immunotherapi', 1), ('We', 1), ('review', 1), ('their', 1), ('discuss', 1), ('data', 1), ('avail', 1), ('on', 1)]"', 'b'6'', 'b"('novel', 'therapies', 'intravesical', 'agents', 'need', 'results', 'currently', 'existing', 'bacillus', 'bcg', 'bladder', 'cancer', 'remains', 'challenging', 'problem', 'radical', 'cystectomy', 'standard', 'care', 'carries', 'significant', 'morbidity', 'therefore', 'effective', 'treatments', 'previous', 'salvage', 'disappointing', 'however', 'wide', 'array', 'investigation', 'include', 'combinations', 'modes', 'delivery', 'hyperthermia', 'viral', 'mediated', 'immunotherapy', 'review', 'treatment', 'discuss', 'data', 'available')"', 'b'(10, 8, 6, 6, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.04907398298610734'', 'b'[0.40235947810852507, 0.14631253749400913, 0.10729586082894002, 0.05747992544407501, 0.03925458323010001, 0.02980440578581667]'', 'b'-3.0943445622221004'', 'b'[-0.3862943611198906, -1.3978952727983707, -1.70805020110221, -2.332204510175204, -2.713572066704308, -2.9889840465642745]'', 'b'-9.111108743978466'', 'b'[-0.6217167901458611, -2.249825649654107, -2.749000749994586, -3.7535383582257733, -4.367325762276068, -4.810584244201236]'', 'b'7'', 'b'0.3035273388069595'', 'b"['Adjuvants, Immunologic', 'Administration, Intravesical', 'Antineoplastic Agents', 'BCG Vaccine', 'Drug Therapy, Combination', 'Humans', 'Neoplasm Invasiveness', 'Salvage Therapy', 'Treatment Outcome', 'Urinary Bladder Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'6'', 'b'Safety and efficacy of laparoscopic gastrectomy in obese patients with gastric cancer.'', 'b'The present study aimed to investigate the safety and short-term outcome of laparoscopy-assisted distal radical gastrectomy in treating gastric cancer among obese patients.Perioperative outcomes were compared between 67 gastric cancer patients with a body mass index (BMI) \xe2\x89\xa525\xe2\x80\x8akg_m (obese group) and 198 ones with BMI <25\xe2\x80\x8akg_m (non-obese group). All the cases underwent laparoscopic radical resection between April 2009 and October 2013.The value of BMI was 27.3\xe2\x80\x8a\xc2\xb1\xe2\x80\x8a2.67\xe2\x80\x8akg_m in the obese group and 21.3\xe2\x80\x8a\xc2\xb1\xe2\x80\x8a2.64\xe2\x80\x8akg_m in non-obese group. There were no significant differences between 2 groups in age, sex, presence of diabetes, tumor size, number of metastatic lymph nodes, or metastatic lymph node ratio. Postoperative complications did not differ between the 2 groups (P\xe2\x80\x8a>\xe2\x80\x8a.05). There were significant differences between the 2 groups in operation time (non-obese: [234.2\xe2\x80\x8a\xc2\xb1\xe2\x80\x8a67.1]\xe2\x80\x8aminutes vs obese group: [259.4\xe2\x80\x8a\xc2\xb1\xe2\x80\x8a78.5]; P\xe2\x80\x8a=\xe2\x80\x8a.017), postoperative hospital stay (obese group [19.7\xe2\x80\x8a\xc2\xb1\xe2\x80\x8a14.8] day vs non-obese [15.4\xe2\x80\x8a\xc2\xb1\xe2\x80\x8a7.1], P\xe2\x80\x8a=\xe2\x80\x8a.002), and retrieved lymph nodes ([27.6\xe2\x80\x8a\xc2\xb1\xe2\x80\x8a11.0] day vs non-obese [31.9\xe2\x80\x8a\xc2\xb1\xe2\x80\x8a12.5] day, P\xe2\x80\x8a=\xe2\x80\x8a.002).Obesity may prolong operation time and postoperative hospital stay, and cause less retrieved lymph nodes, but does not increase the incidence of postoperative complications. The experienced center can properly conduct laparoscopic assisted radical gastrectomy in obese patients.'', 'b'1177'', 'b'216'', 'b"[('obese', 12), ('group', 12), ('lymph', 8), ('postoperative', 8), ('p', 8), ('radical', 6), ('bmi', 6), ('groups', 6), ('nodes', 6), ('vs', 6), ('day', 6), ('gastrectomy', 4), ('gastric', 4), ('cancer', 4), ('patients', 4), ('laparoscopic', 4), ('significant', 4), ('differences', 4), ('metastatic', 4), ('complications', 4), ('operation', 4), ('time', 4), ('hospital', 4), ('stay', 4), ('retrieved', 4), ('present', 2), ('study', 2), ('aimed', 2), ('investigate', 2), ('safety', 2), ('outcome', 2), ('distal', 2), ('treating', 2), ('among', 2), ('outcomes', 2), ('compared', 2), ('body', 2), ('mass', 2), ('index', 2), ('ones', 2), ('cases', 2), ('underwent', 2), ('resection', 2), ('april', 2), ('october', 2), ('value', 2), ('age', 2), ('sex', 2), ('presence', 2), ('diabetes', 2), ('tumor', 2), ('size', 2), ('number', 2), ('node', 2), ('ratio', 2), ('differ', 2), ('minutes', 2), ('may', 2), ('prolong', 2), ('cause', 2), ('less', 2), ('increase', 2), ('incidence', 2), ('experienced', 2), ('center', 2), ('properly', 2), ('conduct', 2), ('assisted', 2)]"', 'b"[(',', 11), ('group', 9), ('the', 8), ('\xc2\xb1', 8), ('and', 7), ('(', 7), (')', 7), ('in', 6), ('obes', 6), ('.', 6), ('[', 6), (']', 6), ('of', 5), ('between', 5), ('non-obes', 5), ('kg_m', 4), ('lymph', 4), ('node', 4), ('postop', 4), ('P', 4), ('radic', 3), ('were', 3), ('bmi', 3), ('differ', 3), ('2', 3), ('vs', 3), ('=', 3), ('day', 3), ('outcom', 2), ('gastrectomi', 2), ('gastric', 2), ('cancer', 2), ('patient', 2), ('with', 2), ('laparoscop', 2), ('there', 2), ('signific', 2), ('metastat', 2), ('complic', 2), ('not', 2), ('oper', 2), ('time', 2), (':', 2), ('hospit', 2), ('stay', 2), ('.002', 2), ('retriev', 2), ('present', 1), ('studi', 1), ('aim', 1), ('to', 1), ('investig', 1), ('safeti', 1), ('short-term', 1), ('laparoscopy-assist', 1), ('distal', 1), ('treat', 1), ('among', 1), ('patients.periop', 1), ('compar', 1), ('67', 1), ('a', 1), ('bodi', 1), ('mass', 1), ('index', 1), ('\xe2\x89\xa525', 1), ('198', 1), ('one', 1), ('<', 1), ('25', 1), ('all', 1), ('case', 1), ('underw', 1), ('resect', 1), ('april', 1), ('2009', 1), ('octob', 1), ('2013.the', 1), ('valu', 1), ('wa', 1), ('27.3', 1), ('2.67', 1), ('21.3', 1), ('2.64', 1), ('no', 1), ('age', 1), ('sex', 1), ('presenc', 1), ('diabet', 1), ('tumor', 1), ('size', 1), ('number', 1), ('or', 1), ('ratio', 1), ('did', 1), ('>', 1), ('.05', 1), ('234.2', 1), ('67.1', 1), ('minut', 1), ('259.4', 1), ('78.5', 1), (';', 1), ('.017', 1), ('19.7', 1), ('14.8', 1), ('15.4', 1), ('7.1', 1), ('27.6', 1), ('11.0', 1), ('31.9', 1), ('12.5', 1), ('.obes', 1), ('may', 1), ('prolong', 1), ('caus', 1), ('less', 1), ('but', 1), ('doe', 1), ('increas', 1), ('incid', 1), ('experienc', 1), ('center', 1), ('can', 1), ('properli', 1), ('conduct', 1), ('assist', 1)]"', 'b'6'', 'b"('obese', 'group', 'lymph', 'postoperative', 'p', 'radical', 'bmi', 'groups', 'nodes', 'vs', 'day', 'gastrectomy', 'gastric', 'cancer', 'patients', 'laparoscopic', 'significant', 'differences', 'metastatic', 'complications', 'operation', 'time', 'hospital', 'stay', 'retrieved', 'present', 'study', 'aimed', 'investigate', 'safety', 'outcome', 'distal', 'treating', 'among', 'outcomes', 'compared', 'body', 'mass', 'index', 'ones', 'cases', 'underwent', 'resection', 'april', 'october', 'value', 'age', 'sex', 'presence', 'diabetes', 'tumor', 'size', 'number', 'node', 'ratio', 'differ', 'minutes', 'may', 'prolong', 'cause', 'less', 'increase', 'incidence', 'experienced', 'center', 'properly', 'conduct', 'assisted')"', 'b'(12, 12, 8, 8, 8, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.04888703402429179'', 'b'[0.07082475536575226, 0.04721650357716818, 0.03246134620930312, 0.029398955057482072, 0.020235644390214934, 0.01790970825340862]'', 'b'-3.0342406381523954'', 'b'[-2.0910424533583156, -2.4965075614664802, -2.871201010907891, -2.970291913552122, -3.343805421853684, -3.4659081186545837]'', 'b'-8.380928930311342'', 'b'[-3.258146544807113, -3.8899198208115124, -4.473746402475944, -4.628144359128427, -5.2101324218561915, -5.4003860817254825]'', 'b'44'', 'b'0.10283514706953431'', 'b"['Female', 'Gastrectomy', 'Humans', 'Laparoscopy', 'Male', 'Middle Aged', 'Obesity', 'Retrospective Studies', 'Stomach Neoplasms', 'Time Factors', 'Treatment Outcome']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'7'', 'b'Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer.'', 'b'Due to significant risks of cancer recurrence and progression, and limited options after intravesical Bacillus Calmette Guerin (BCG) therapy, there is a critical unmet need to identify novel treatments for those patients with BCG-unresponsive bladder cancer. There is active investigation of immunotherapies which provide both biologic and clinical rationales for indoleamine-2,3- dioxygenase inhibitors in salvage therapy for non-muscle invasive bladder cancer.'', 'b'402'', 'b'61'', 'b"[('cancer', 6), ('therapy', 4), ('bladder', 4), ('due', 2), ('significant', 2), ('risks', 2), ('recurrence', 2), ('progression', 2), ('limited', 2), ('options', 2), ('intravesical', 2), ('bacillus', 2), ('calmette', 2), ('guerin', 2), ('bcg', 2), ('critical', 2), ('unmet', 2), ('need', 2), ('identify', 2), ('novel', 2), ('treatments', 2), ('patients', 2), ('active', 2), ('investigation', 2), ('immunotherapies', 2), ('provide', 2), ('biologic', 2), ('clinical', 2), ('rationales', 2), ('dioxygenase', 2), ('inhibitors', 2), ('salvage', 2), ('invasive', 2)]"', 'b"[('cancer', 3), ('and', 3), ('for', 3), ('to', 2), ('of', 2), (',', 2), ('therapi', 2), ('there', 2), ('is', 2), ('bladder', 2), ('.', 2), ('due', 1), ('signific', 1), ('risk', 1), ('recurr', 1), ('progress', 1), ('limit', 1), ('option', 1), ('after', 1), ('intraves', 1), ('bacillu', 1), ('calmett', 1), ('guerin', 1), ('(', 1), ('bcg', 1), (')', 1), ('a', 1), ('critic', 1), ('unmet', 1), ('need', 1), ('identifi', 1), ('novel', 1), ('treatment', 1), ('those', 1), ('patient', 1), ('with', 1), ('bcg-unrespons', 1), ('activ', 1), ('investig', 1), ('immunotherapi', 1), ('which', 1), ('provid', 1), ('both', 1), ('biolog', 1), ('clinic', 1), ('rational', 1), ('indoleamine-2,3-', 1), ('dioxygenas', 1), ('inhibitor', 1), ('in', 1), ('salvag', 1), ('non-muscl', 1), ('invas', 1)]"', 'b'2'', 'b"('cancer', 'therapy', 'bladder', 'due', 'significant', 'risks', 'recurrence', 'progression', 'limited', 'options', 'intravesical', 'bacillus', 'calmette', 'guerin', 'bcg', 'critical', 'unmet', 'need', 'identify', 'novel', 'treatments', 'patients', 'active', 'investigation', 'immunotherapies', 'provide', 'biologic', 'clinical', 'rationales', 'dioxygenase', 'inhibitors', 'salvage', 'invasive')"', 'b'(6, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.2114567629090725'', 'b'[0.06860702063077809, 0.02060330194707359]'', 'b'-1.5123056239761148'', 'b'[-2.0910424533583156, -3.2626798770413155]'', 'b'-3.9440427718938156'', 'b'[-3.156124240222509, -4.772760485095944]'', 'b'5'', 'b'0.3035273388069595'', 'b"['Acetamides', 'Administration, Intravesical', 'Enzyme Inhibitors', 'Humans', 'Indoleamine-Pyrrole 2,3,-Dioxygenase', 'Neoplasm Invasiveness', 'Oximes', 'Quinolines', 'Salvage Therapy', 'Sulfonamides', 'Treatment Outcome', 'Tryptophan', 'Tryptophan Oxygenase', 'Urinary Bladder Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'8'', 'b'Cancer Immunotherapy Targeting Co-signal Molecules.'', 'b'Great success of immune checkpoint blockade represented by anti-PD-1 monoclonal antibodies (mAbs) has changed a landscape of cancer immunotherapy. There is no doubt about an importance of co-signal molecules as one of the most promising targets in anti-cancer drugs. However, it should be noted that the proportion of patients who have objective and durable responses to immune checkpoint blockade remains less than 30% in majority of cancers. Thus, in addition to refine the usage of existing drugs for checkpoint blockade, identification and characterization of novel checkpoint molecules other than CTLA-4 and PD-1 is a highly anticipated research subject. In addition, agonists of stimulatory co-signal molecules have a potential to further improve anti-tumor effects, rendering them attractive in research and drug development. In this chapter, functions of co-signal molecules in anti-tumor immunity in terms of pre-clinical animal models as well as clinical trials are described.'', 'b'843'', 'b'144'', 'b"[('checkpoint', 8), ('molecules', 8), ('blockade', 6), ('immune', 4), ('drugs', 4), ('addition', 4), ('research', 4), ('great', 2), ('success', 2), ('represented', 2), ('monoclonal', 2), ('antibodies', 2), ('mabs', 2), ('changed', 2), ('landscape', 2), ('cancer', 2), ('immunotherapy', 2), ('doubt', 2), ('importance', 2), ('one', 2), ('promising', 2), ('targets', 2), ('however', 2), ('noted', 2), ('proportion', 2), ('patients', 2), ('objective', 2), ('durable', 2), ('responses', 2), ('remains', 2), ('less', 2), ('majority', 2), ('cancers', 2), ('thus', 2), ('refine', 2), ('usage', 2), ('existing', 2), ('identification', 2), ('characterization', 2), ('novel', 2), ('highly', 2), ('anticipated', 2), ('subject', 2), ('agonists', 2), ('stimulatory', 2), ('potential', 2), ('improve', 2), ('effects', 2), ('rendering', 2), ('attractive', 2), ('drug', 2), ('development', 2), ('chapter', 2), ('functions', 2), ('immunity', 2), ('terms', 2), ('animal', 2), ('models', 2), ('well', 2), ('clinical', 2), ('trials', 2), ('described', 2)]"', 'b"[('of', 11), ('.', 6), ('in', 6), (',', 6), ('checkpoint', 4), ('molecul', 4), ('and', 4), ('immun', 3), ('blockad', 3), ('a', 3), ('co-sign', 3), ('as', 3), ('the', 3), ('drug', 3), ('to', 3), ('cancer', 2), ('is', 2), ('have', 2), ('than', 2), ('addit', 2), ('research', 2), ('In', 2), ('anti-tumor', 2), ('great', 1), ('success', 1), ('repres', 1), ('by', 1), ('anti-pd-1', 1), ('monoclon', 1), ('antibodi', 1), ('(', 1), ('mab', 1), (')', 1), ('ha', 1), ('chang', 1), ('landscap', 1), ('immunotherapi', 1), ('there', 1), ('no', 1), ('doubt', 1), ('about', 1), ('an', 1), ('import', 1), ('one', 1), ('most', 1), ('promis', 1), ('target', 1), ('anti-canc', 1), ('howev', 1), ('it', 1), ('should', 1), ('be', 1), ('note', 1), ('that', 1), ('proport', 1), ('patient', 1), ('who', 1), ('object', 1), ('durabl', 1), ('respons', 1), ('remain', 1), ('less', 1), ('30', 1), ('%', 1), ('major', 1), ('thu', 1), ('refin', 1), ('usag', 1), ('exist', 1), ('for', 1), ('identif', 1), ('character', 1), ('novel', 1), ('other', 1), ('ctla-4', 1), ('pd-1', 1), ('highli', 1), ('anticip', 1), ('subject', 1), ('agonist', 1), ('stimulatori', 1), ('potenti', 1), ('further', 1), ('improv', 1), ('effect', 1), ('render', 1), ('them', 1), ('attract', 1), ('develop', 1), ('thi', 1), ('chapter', 1), ('function', 1), ('term', 1), ('pre-clin', 1), ('anim', 1), ('model', 1), ('well', 1), ('clinic', 1), ('trial', 1), ('are', 1), ('describ', 1)]"', 'b'6'', 'b"('checkpoint', 'molecules', 'blockade', 'immune', 'drugs', 'addition', 'research', 'great', 'success', 'represented', 'monoclonal', 'antibodies', 'mabs', 'changed', 'landscape', 'cancer', 'immunotherapy', 'doubt', 'importance', 'one', 'promising', 'targets', 'however', 'noted', 'proportion', 'patients', 'objective', 'durable', 'responses', 'remains', 'less', 'majority', 'cancers', 'thus', 'refine', 'usage', 'existing', 'identification', 'characterization', 'novel', 'highly', 'anticipated', 'subject', 'agonists', 'stimulatory', 'potential', 'improve', 'effects', 'rendering', 'attractive', 'drug', 'development', 'chapter', 'functions', 'immunity', 'terms', 'animal', 'models', 'well', 'clinical', 'trials', 'described')"', 'b'(8, 8, 6, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.03343831553946899'', 'b'[0.7091913378356955, 0.157598075074599, 0.061668811985712654, 0.03636878655567669, 0.02781142501316453, 0.022877139930183726]'', 'b'-3.3040650932041693'', 'b'[0.3068528194400547, -1.1972245773362196, -2.1354942159291497, -2.6635616461296463, -2.9318256327243257, -3.1271343850450917]'', 'b'-8.175695465063445'', 'b'[0.4352347230746951, -1.6981225993816973, -3.0289479998703666, -3.7779496944530626, -4.158450685545498, -4.435473236244268]'', 'b'89'', 'b'0.11772480826409867'', 'b"['Animals', 'Antibodies, Monoclonal', 'CTLA-4 Antigen', 'Humans', 'Immunotherapy', 'Neoplasms', 'Programmed Cell Death 1 Receptor']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'9'', 'b'Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer.'', 'b'This article provides a comprehensive review of the available data for immunotherapy being used as a salvage treatment in non-muscle-invasive bladder cancer. The literature demonstrates that the immune system has an important role in bladder cancer progression. Initial results from studies using checkpoint inhibitors, recombinant interferon-\xce\xb12b protein, and oncolytic adenoviruses have shown promising responses with acceptable toxicities. However, the majority of the current data arises from small trials with limited follow-up. There are currently several ongoing studies in this setting, which we await completion, to increase our understanding of immunotherapy as a salvage treatment in non-muscle-invasive bladder cancer.'', 'b'632'', 'b'98'', 'b"[('bladder', 6), ('cancer', 6), ('data', 4), ('immunotherapy', 4), ('salvage', 4), ('treatment', 4), ('studies', 4), ('article', 2), ('provides', 2), ('comprehensive', 2), ('review', 2), ('available', 2), ('used', 2), ('literature', 2), ('demonstrates', 2), ('immune', 2), ('system', 2), ('important', 2), ('role', 2), ('progression', 2), ('initial', 2), ('results', 2), ('using', 2), ('checkpoint', 2), ('inhibitors', 2), ('recombinant', 2), ('protein', 2), ('oncolytic', 2), ('adenoviruses', 2), ('shown', 2), ('promising', 2), ('responses', 2), ('acceptable', 2), ('toxicities', 2), ('however', 2), ('majority', 2), ('current', 2), ('arises', 2), ('small', 2), ('trials', 2), ('limited', 2), ('currently', 2), ('several', 2), ('ongoing', 2), ('setting', 2), ('await', 2), ('completion', 2), ('increase', 2), ('understanding', 2)]"', 'b"[('the', 5), ('.', 5), (',', 5), ('in', 4), ('a', 3), ('of', 3), ('bladder', 3), ('cancer', 3), ('thi', 2), ('data', 2), ('immunotherapi', 2), ('use', 2), ('as', 2), ('salvag', 2), ('treatment', 2), ('non-muscle-invas', 2), ('from', 2), ('studi', 2), ('with', 2), ('current', 2), ('articl', 1), ('provid', 1), ('comprehens', 1), ('review', 1), ('avail', 1), ('for', 1), ('be', 1), ('literatur', 1), ('demonstr', 1), ('that', 1), ('immun', 1), ('system', 1), ('ha', 1), ('an', 1), ('import', 1), ('role', 1), ('progress', 1), ('initi', 1), ('result', 1), ('checkpoint', 1), ('inhibitor', 1), ('recombin', 1), ('interferon-\xce\xb12b', 1), ('protein', 1), ('and', 1), ('oncolyt', 1), ('adenovirus', 1), ('have', 1), ('shown', 1), ('promis', 1), ('respons', 1), ('accept', 1), ('toxic', 1), ('howev', 1), ('major', 1), ('aris', 1), ('small', 1), ('trial', 1), ('limit', 1), ('follow-up', 1), ('there', 1), ('are', 1), ('sever', 1), ('ongo', 1), ('set', 1), ('which', 1), ('we', 1), ('await', 1), ('complet', 1), ('to', 1), ('increas', 1), ('our', 1), ('understand', 1)]"', 'b'5'', 'b"('bladder', 'cancer', 'data', 'immunotherapy', 'salvage', 'treatment', 'studies', 'article', 'provides', 'comprehensive', 'review', 'available', 'used', 'literature', 'demonstrates', 'immune', 'system', 'important', 'role', 'progression', 'initial', 'results', 'using', 'checkpoint', 'inhibitors', 'recombinant', 'protein', 'oncolytic', 'adenoviruses', 'shown', 'promising', 'responses', 'acceptable', 'toxicities', 'however', 'majority', 'current', 'arises', 'small', 'trials', 'limited', 'currently', 'several', 'ongoing', 'setting', 'await', 'completion', 'increase', 'understanding')"', 'b'(6, 6, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.12189580935849939'', 'b'[1.3758230612525952, 0.133500106673234, 0.0534000426692936, 0.04045457777976788, 0.02756979475700125]'', 'b'-1.9618307218783095'', 'b'[1.0, -1.3025850929940455, -2.2188758248682006, -2.4965075614664802, -2.8501476017100584]'', 'b'-4.623352910909363'', 'b'[1.3758230612525952, -1.738952488656695, -2.9622015931456485, -3.3328402576631038, -3.693165267096366]'', 'b'7'', 'b'0.2572785106405883'', 'b"['Administration, Intravesical', 'Disease Progression', 'Humans', 'Immunity, Innate', 'Immunologic Factors', 'Immunotherapy', 'Neoplasm Invasiveness', 'Salvage Therapy', 'Urinary Bladder Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'10'', 'b'Commentary: the chronic inhalation study in rats for assessing lung cancer risk may be better than its reputation.'', 'b'Recently, Borm and Driscoll published a commentary discussing grouping of Poorly Soluble particles of Low Toxicity (PSLTs) and the use of rats as an animal model for human hazard assessment of PSLTs (Particle and Fibre Toxicology (2019) 16(1):11). The commentary was based on the scientific opinion of several international experts on these topics. The general conclusion from the authors was a cautious approach towards using chronic inhalation studies in rats for human hazard assessment of PSLTs. This was based on evidence of inhibition of particle clearance leading to overload in the rats after high dose exposure, and a suggested over reactivity of rat lung cancer responses compared to human risk.As a response to the commentary, we here discuss evidence from the scientific literature showing that a) diesel exhaust particles, carbon black nanoparticles and TiO'', 'b'737'', 'b'134'', 'b"[('commentary', 6), ('pslts', 6), ('rats', 6), ('human', 6), ('particles', 4), ('hazard', 4), ('assessment', 4), ('particle', 4), ('based', 4), ('scientific', 4), ('evidence', 4), ('recently', 2), ('borm', 2), ('driscoll', 2), ('published', 2), ('discussing', 2), ('grouping', 2), ('poorly', 2), ('soluble', 2), ('low', 2), ('toxicity', 2), ('use', 2), ('animal', 2), ('model', 2), ('fibre', 2), ('toxicology', 2), ('opinion', 2), ('several', 2), ('international', 2), ('experts', 2), ('topics', 2), ('general', 2), ('conclusion', 2), ('authors', 2), ('cautious', 2), ('approach', 2), ('towards', 2), ('using', 2), ('chronic', 2), ('inhalation', 2), ('studies', 2), ('inhibition', 2), ('clearance', 2), ('leading', 2), ('overload', 2), ('high', 2), ('dose', 2), ('exposure', 2), ('suggested', 2), ('reactivity', 2), ('rat', 2), ('lung', 2), ('cancer', 2), ('responses', 2), ('compared', 2), ('response', 2), ('discuss', 2), ('literature', 2), ('showing', 2), ('diesel', 2), ('exhaust', 2), ('carbon', 2), ('black', 2), ('nanoparticles', 2), ('tio', 2)]"', 'b"[('of', 9), ('the', 8), ('and', 5), ('a', 5), (')', 5), (',', 4), ('particl', 4), ('(', 4), ('rat', 4), ('commentari', 3), ('pslt', 3), ('human', 3), ('.', 3), ('wa', 3), ('on', 3), ('to', 3), ('discuss', 2), ('use', 2), ('for', 2), ('hazard', 2), ('assess', 2), ('base', 2), ('scientif', 2), ('from', 2), ('in', 2), ('evid', 2), ('respons', 2), ('recent', 1), ('borm', 1), ('driscol', 1), ('publish', 1), ('group', 1), ('poorli', 1), ('solubl', 1), ('low', 1), ('toxic', 1), ('as', 1), ('an', 1), ('anim', 1), ('model', 1), ('fibr', 1), ('toxicolog', 1), ('2019', 1), ('16', 1), ('1', 1), (':11', 1), ('opinion', 1), ('sever', 1), ('intern', 1), ('expert', 1), ('these', 1), ('topic', 1), ('gener', 1), ('conclus', 1), ('author', 1), ('cautiou', 1), ('approach', 1), ('toward', 1), ('chronic', 1), ('inhal', 1), ('studi', 1), ('thi', 1), ('inhibit', 1), ('clearanc', 1), ('lead', 1), ('overload', 1), ('after', 1), ('high', 1), ('dose', 1), ('exposur', 1), ('suggest', 1), ('over', 1), ('reactiv', 1), ('lung', 1), ('cancer', 1), ('compar', 1), ('risk.a', 1), ('we', 1), ('here', 1), ('literatur', 1), ('show', 1), ('that', 1), ('diesel', 1), ('exhaust', 1), ('carbon', 1), ('black', 1), ('nanoparticl', 1), ('tio', 1)]"', 'b'4'', 'b"('commentary', 'pslts', 'rats', 'human', 'particles', 'hazard', 'assessment', 'particle', 'based', 'scientific', 'evidence', 'recently', 'borm', 'driscoll', 'published', 'discussing', 'grouping', 'poorly', 'soluble', 'low', 'toxicity', 'use', 'animal', 'model', 'fibre', 'toxicology', 'opinion', 'several', 'international', 'experts', 'topics', 'general', 'conclusion', 'authors', 'cautious', 'approach', 'towards', 'using', 'chronic', 'inhalation', 'studies', 'inhibition', 'clearance', 'leading', 'overload', 'high', 'dose', 'exposure', 'suggested', 'reactivity', 'rat', 'lung', 'cancer', 'responses', 'compared', 'response', 'discuss', 'literature', 'showing', 'diesel', 'exhaust', 'carbon', 'black', 'nanoparticles', 'tio')"', 'b'(6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.028141147482581192'', 'b'[0.0, 0.0, 0.0, 0.07400235444683599]'', 'b'-3.382026634673881'', 'b'[1, 1, 1, -1.8332133440562162]'', 'b'-7.613928825310034'', 'b'[1.2957803535790589, 1.2957803535790589, 1.2957803535790589, -2.3062557622797994]'', 'b'86'', 'b'0.07671527225847066'', 'b"['Administration, Inhalation', 'Animals', 'Humans', 'Lung', 'Lung Neoplasms', 'Rats', 'Soot', 'Vehicle Emissions']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'11'', 'b'A Humanized Cancer-Bone Metastasis Mouse Model Based on Silica Nanoparticles-Incorporated Human Demineralized Bone Matrix.'', 'b'Breast cancer tends to spread to other organs and bone metastasis has the highest frequency in breast cancer metastasis, while its mechanisms are not clear and the current treatments are not very effective. To better study the mechanisms and facilitate drug screening for breast cancer bone metastasis, an '', 'b'258'', 'b'48'', 'b"[('breast', 6), ('cancer', 6), ('metastasis', 6), ('bone', 4), ('mechanisms', 4), ('tends', 2), ('spread', 2), ('organs', 2), ('highest', 2), ('frequency', 2), ('clear', 2), ('current', 2), ('treatments', 2), ('effective', 2), ('better', 2), ('study', 2), ('facilitate', 2), ('drug', 2), ('screening', 2)]"', 'b"[('breast', 3), ('cancer', 3), ('and', 3), ('metastasi', 3), ('the', 3), ('to', 2), ('bone', 2), (',', 2), ('mechan', 2), ('are', 2), ('not', 2), ('tend', 1), ('spread', 1), ('other', 1), ('organ', 1), ('ha', 1), ('highest', 1), ('frequenc', 1), ('in', 1), ('while', 1), ('it', 1), ('clear', 1), ('current', 1), ('treatment', 1), ('veri', 1), ('effect', 1), ('.', 1), ('To', 1), ('better', 1), ('studi', 1), ('facilit', 1), ('drug', 1), ('screen', 1), ('for', 1), ('an', 1)]"', 'b'2'', 'b"('breast', 'cancer', 'metastasis', 'bone', 'mechanisms', 'tends', 'spread', 'organs', 'highest', 'frequency', 'clear', 'current', 'treatments', 'effective', 'better', 'study', 'facilitate', 'drug', 'screening')"', 'b'(6, 6, 6, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.23955351320024115'', 'b'[0.09397479857117977, 0.02759490840962946]'', 'b'-1.1972245773362196'', 'b'[-1.5649493574615367, -2.7612001156935624]'', 'b'-2.581194182315087'', 'b'[-1.9118554083400865, -3.2763877646085513]'', 'b'85'', 'b'0.18811124466597165'', 'b"['Animals', 'Bone Matrix', 'Bone Neoplasms', 'Humans', 'Mice', 'Nanoparticles', 'Silicon Dioxide', 'Tissue Engineering', 'Tumor Microenvironment']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'12'', 'b'Intercellular Crosstalk of Mesenchymal Stem Cells with Prostate Cancer Cells via Microvesicles Loaded with Magnetic Nanocubes for Targeted Magnetic Hyperthermia.'', 'b'The targeted delivery of nanomedicines into solid tumors remains challenging in cancer treatment. Stem cells with tumortropic migration ability are promising as biocarriers to transport nanomedicines. The transportation of nanomedicines into cancer cells is the key step for tumor targeted delivery via stem cells. In this study, we designed a magnetic nanocube (scMNP) loaded in mesenchymal stem cells for magnetic hyperthermia of prostate cancer, and the delivery and transportation pathways into the cancer cells were fully investigated. The MSCs acted as the carrier of the loaded scMNPs along with the upregulation of CXCR4 for the migration to cancer cells. The therapeutic effect was mainly due to scMNPs via magnetic hyperthermia. Stem cell-derived microvesicles containing scMNPs played an essential role in the crosstalk between stem cells and cancer cells for targeted delivery. Both '', 'b'763'', 'b'132'', 'b"[('cells', 16), ('cancer', 12), ('stem', 10), ('delivery', 8), ('targeted', 6), ('nanomedicines', 6), ('magnetic', 6), ('scmnps', 6), ('migration', 4), ('transportation', 4), ('via', 4), ('loaded', 4), ('hyperthermia', 4), ('solid', 2), ('tumors', 2), ('remains', 2), ('challenging', 2), ('treatment', 2), ('tumortropic', 2), ('ability', 2), ('promising', 2), ('biocarriers', 2), ('transport', 2), ('key', 2), ('step', 2), ('tumor', 2), ('study', 2), ('designed', 2), ('nanocube', 2), ('scmnp', 2), ('mesenchymal', 2), ('prostate', 2), ('pathways', 2), ('fully', 2), ('investigated', 2), ('mscs', 2), ('acted', 2), ('carrier', 2), ('along', 2), ('upregulation', 2), ('therapeutic', 2), ('effect', 2), ('mainly', 2), ('due', 2), ('microvesicles', 2), ('containing', 2), ('played', 2), ('essential', 2), ('role', 2), ('crosstalk', 2)]"', 'b"[('the', 12), ('cell', 8), ('.', 7), ('cancer', 6), ('of', 5), ('stem', 5), ('deliveri', 4), ('for', 4), ('scmnp', 4), ('target', 3), ('nanomedicin', 3), ('into', 3), ('in', 3), ('to', 3), ('transport', 3), ('magnet', 3), ('and', 3), ('tumor', 2), ('with', 2), ('migrat', 2), ('as', 2), ('via', 2), (',', 2), ('load', 2), ('hyperthermia', 2), ('solid', 1), ('remain', 1), ('challeng', 1), ('treatment', 1), ('tumortrop', 1), ('abil', 1), ('are', 1), ('promis', 1), ('biocarri', 1), ('is', 1), ('key', 1), ('step', 1), ('In', 1), ('thi', 1), ('studi', 1), ('we', 1), ('design', 1), ('a', 1), ('nanocub', 1), ('(', 1), (')', 1), ('mesenchym', 1), ('prostat', 1), ('pathway', 1), ('were', 1), ('fulli', 1), ('investig', 1), ('msc', 1), ('act', 1), ('carrier', 1), ('along', 1), ('upregul', 1), ('cxcr4', 1), ('therapeut', 1), ('effect', 1), ('wa', 1), ('mainli', 1), ('due', 1), ('cell-deriv', 1), ('microvesicl', 1), ('contain', 1), ('play', 1), ('an', 1), ('essenti', 1), ('role', 1), ('crosstalk', 1), ('between', 1), ('both', 1)]"', 'b'8'', 'b"('cells', 'cancer', 'stem', 'delivery', 'targeted', 'nanomedicines', 'magnetic', 'scmnps', 'migration', 'transportation', 'via', 'loaded', 'hyperthermia', 'solid', 'tumors', 'remains', 'challenging', 'treatment', 'tumortropic', 'ability', 'promising', 'biocarriers', 'transport', 'key', 'step', 'tumor', 'study', 'designed', 'nanocube', 'scmnp', 'mesenchymal', 'prostate', 'pathways', 'fully', 'investigated', 'mscs', 'acted', 'carrier', 'along', 'upregulation', 'therapeutic', 'effect', 'mainly', 'due', 'microvesicles', 'containing', 'played', 'essential', 'role', 'crosstalk')"', 'b'(16, 12, 10, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.1513880664740883'', 'b'[0.5763397549691927, 0.10478904635803503, 0.050904076687063385, 0.040301518103733856, 0.01468568514075084, 0.013217116626675757, 0.01116865616287369, 0.01116865616287369]'', 'b'-1.6149597780361984'', 'b'[0.3068528194400547, -1.3978952727983707, -2.0910424533583156, -2.295836866004329, -3.2766661190160553, -3.382026634673881, -3.5217885770490405, -3.5217885770490405]'', 'b'-3.3413037224810798'', 'b'[0.3537029575353741, -1.6113252379944114, -2.3417368788364508, -2.498194197499313, -3.4646462593369782, -3.576051237200673, -3.6186954039765173, -3.6186954039765173]'', 'b'53'', 'b'0.24897369413886306'', 'b"['Cell Line, Tumor', 'Humans', 'Hyperthermia, Induced', 'Magnetics', 'Male', 'Mesenchymal Stem Cells', 'Prostatic Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'13'', 'b'Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now?'', 'b'Apaziquone is an interesting drug for intravesical use in patients with nonmuscle invasive bladder cancer; however, more research is needed to prove its actual benefit. Although the apaziquone trials demonstrate the potential of this new drug, the singular phase 3 trials did not reach their primary endpoint. To date, no new trials are recruiting, so the development of apaziquone seems to have stopped.'', 'b'342'', 'b'63'', 'b"[('apaziquone', 6), ('trials', 6), ('drug', 4), ('new', 4), ('interesting', 2), ('intravesical', 2), ('use', 2), ('patients', 2), ('nonmuscle', 2), ('invasive', 2), ('bladder', 2), ('cancer', 2), ('however', 2), ('research', 2), ('needed', 2), ('prove', 2), ('actual', 2), ('benefit', 2), ('although', 2), ('demonstrate', 2), ('potential', 2), ('singular', 2), ('phase', 2), ('reach', 2), ('primary', 2), ('endpoint', 2), ('date', 2), ('recruiting', 2), ('development', 2), ('seems', 2), ('stopped', 2)]"', 'b"[(',', 4), ('the', 4), ('apaziquon', 3), ('.', 3), ('trial', 3), ('is', 2), ('drug', 2), ('to', 2), ('of', 2), ('new', 2), ('an', 1), ('interest', 1), ('for', 1), ('intraves', 1), ('use', 1), ('in', 1), ('patient', 1), ('with', 1), ('nonmuscl', 1), ('invas', 1), ('bladder', 1), ('cancer', 1), (';', 1), ('howev', 1), ('more', 1), ('research', 1), ('need', 1), ('prove', 1), ('it', 1), ('actual', 1), ('benefit', 1), ('although', 1), ('demonstr', 1), ('potenti', 1), ('thi', 1), ('singular', 1), ('phase', 1), ('3', 1), ('did', 1), ('not', 1), ('reach', 1), ('their', 1), ('primari', 1), ('endpoint', 1), ('To', 1), ('date', 1), ('no', 1), ('are', 1), ('recruit', 1), ('so', 1), ('develop', 1), ('seem', 1), ('have', 1), ('stop', 1)]"', 'b'3'', 'b"('apaziquone', 'trials', 'drug', 'new', 'interesting', 'intravesical', 'use', 'patients', 'nonmuscle', 'invasive', 'bladder', 'cancer', 'however', 'research', 'needed', 'prove', 'actual', 'benefit', 'although', 'demonstrate', 'potential', 'singular', 'phase', 'reach', 'primary', 'endpoint', 'date', 'recruiting', 'development', 'seems', 'stopped')"', 'b'(6, 6, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.05375479821997309'', 'b'[0.14264697573016102, 0.05255414895321722, 0.03698254926337508]'', 'b'-2.6109179126442243'', 'b'[-0.9459101490553135, -1.9444389791664407, -2.295836866004329]'', 'b'-5.1929265258348325'', 'b'[-0.9445185545264442, -1.9415783790895407, -2.2924592999372995]'', 'b'9'', 'b'0.11582588307607383'', 'b"['Administration, Intravesical', 'Antineoplastic Agents', 'Aziridines', 'Carcinoma, Transitional Cell', 'Humans', 'Indolequinones', 'Neoplasm Invasiveness', 'Treatment Outcome', 'Urinary Bladder Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'14'', 'b'Gramicidin inhibits human gastric cancer cell proliferation, cell cycle and induced apoptosis.'', 'b'Gastric cancer is a common malignant tumor with high morbidity and mortality worldwide, which seriously affects human health. Gramicidin is a short peptide antibiotic which could be used for treating infection induced by bacteria or fungi. However, the anti-cancer effect of gramicidin on gastric cancer cells and its underlying mechanism remains largely unknown.Gastric cancer cells SGC-7901, BGC-823 and normal gastric mucosal cells GES-1 were treated with different concentrations of gramicidin respectively. The results of CCK-8 experiment revealed cellular toxicity of gramicidin to cancer cells while cell colony formation assay showed that gramicidin significantly inhibited the proliferation of gastric cancer cells, but had little effect on normal gastric mucosal cells. In addition, the wound healing assay showed that gramicidin inhibited the migration of SGC-7901 cell. Meanwhile, apoptosis and cell cycle analysis revealed that gramicidin induced cell apoptosis with G2_M cell cycle inhibition. Furthermore, western blot analysis demonstrated that gramicidin down-regulated the expression of cyclinD1 and Bcl-2 as well as the FoxO1 phosphorylation.The current study illustrated the anti-tumor activity of gramicidin on gastric cancer cells, providing a possibility for gramicidin to be applied in clinical practice for the treatment of gastric cancer.'', 'b'1175'', 'b'190'', 'b"[('gramicidin', 20), ('gastric', 14), ('cancer', 14), ('cells', 14), ('cell', 10), ('induced', 4), ('effect', 4), ('normal', 4), ('mucosal', 4), ('revealed', 4), ('assay', 4), ('showed', 4), ('inhibited', 4), ('apoptosis', 4), ('cycle', 4), ('analysis', 4), ('common', 2), ('malignant', 2), ('tumor', 2), ('high', 2), ('morbidity', 2), ('mortality', 2), ('worldwide', 2), ('seriously', 2), ('affects', 2), ('human', 2), ('health', 2), ('short', 2), ('peptide', 2), ('antibiotic', 2), ('could', 2), ('used', 2), ('treating', 2), ('infection', 2), ('bacteria', 2), ('fungi', 2), ('however', 2), ('underlying', 2), ('mechanism', 2), ('remains', 2), ('largely', 2), ('treated', 2), ('different', 2), ('concentrations', 2), ('respectively', 2), ('results', 2), ('experiment', 2), ('cellular', 2), ('toxicity', 2), ('colony', 2), ('formation', 2), ('significantly', 2), ('proliferation', 2), ('little', 2), ('addition', 2), ('wound', 2), ('healing', 2), ('migration', 2), ('meanwhile', 2), ('inhibition', 2), ('furthermore', 2), ('western', 2), ('blot', 2), ('demonstrated', 2), ('expression', 2), ('well', 2), ('current', 2), ('study', 2), ('illustrated', 2), ('activity', 2), ('providing', 2), ('possibility', 2), ('applied', 2), ('clinical', 2), ('practice', 2), ('treatment', 2)]"', 'b"[('cell', 12), ('gramicidin', 10), ('the', 9), ('of', 9), (',', 8), ('gastric', 7), ('cancer', 7), ('.', 7), ('and', 5), ('that', 4), ('a', 3), ('with', 3), ('for', 3), ('on', 3), ('inhibit', 3), ('is', 2), ('which', 2), ('be', 2), ('treat', 2), ('induc', 2), ('effect', 2), ('sgc-7901', 2), ('normal', 2), ('mucos', 2), ('reveal', 2), ('to', 2), ('assay', 2), ('show', 2), ('apoptosi', 2), ('cycl', 2), ('analysi', 2), ('as', 2), ('common', 1), ('malign', 1), ('tumor', 1), ('high', 1), ('morbid', 1), ('mortal', 1), ('worldwid', 1), ('serious', 1), ('affect', 1), ('human', 1), ('health', 1), ('short', 1), ('peptid', 1), ('antibiot', 1), ('could', 1), ('use', 1), ('infect', 1), ('by', 1), ('bacteria', 1), ('or', 1), ('fungi', 1), ('howev', 1), ('anti-canc', 1), ('it', 1), ('underli', 1), ('mechan', 1), ('remain', 1), ('larg', 1), ('unknown.gastr', 1), ('bgc-823', 1), ('ges-1', 1), ('were', 1), ('differ', 1), ('concentr', 1), ('respect', 1), ('result', 1), ('cck-8', 1), ('experi', 1), ('cellular', 1), ('toxic', 1), ('while', 1), ('coloni', 1), ('format', 1), ('significantli', 1), ('prolifer', 1), ('but', 1), ('had', 1), ('littl', 1), ('In', 1), ('addit', 1), ('wound', 1), ('heal', 1), ('migrat', 1), ('meanwhil', 1), ('g2_m', 1), ('furthermor', 1), ('western', 1), ('blot', 1), ('demonstr', 1), ('down-regul', 1), ('express', 1), ('cyclind1', 1), ('bcl-2', 1), ('well', 1), ('foxo1', 1), ('phosphorylation.th', 1), ('current', 1), ('studi', 1), ('illustr', 1), ('anti-tumor', 1), ('activ', 1), ('provid', 1), ('possibl', 1), ('appli', 1), ('in', 1), ('clinic', 1), ('practic', 1), ('treatment', 1)]"', 'b'7'', 'b"('gramicidin', 'gastric', 'cancer', 'cells', 'cell', 'induced', 'effect', 'normal', 'mucosal', 'revealed', 'assay', 'showed', 'inhibited', 'apoptosis', 'cycle', 'analysis', 'common', 'malignant', 'tumor', 'high', 'morbidity', 'mortality', 'worldwide', 'seriously', 'affects', 'human', 'health', 'short', 'peptide', 'antibiotic', 'could', 'used', 'treating', 'infection', 'bacteria', 'fungi', 'however', 'underlying', 'mechanism', 'remains', 'largely', 'treated', 'different', 'concentrations', 'respectively', 'results', 'experiment', 'cellular', 'toxicity', 'colony', 'formation', 'significantly', 'proliferation', 'little', 'addition', 'wound', 'healing', 'migration', 'meanwhile', 'inhibition', 'furthermore', 'western', 'blot', 'demonstrated', 'expression', 'well', 'current', 'study', 'illustrated', 'activity', 'providing', 'possibility', 'applied', 'clinical', 'practice', 'treatment')"', 'b'(20, 14, 14, 14, 10, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.11359099096522861'', 'b'[0.0808631627620359, 0.042189476223670905, 0.0362676530367814, 0.01949554748668415, 0.01636233449775277, 0.014096780490371618, 0.010352502854312724]'', 'b'-1.8247744754103516'', 'b'[-1.4849066497880004, -2.1354942159291497, -2.258096538021482, -2.8501476017100584, -3.0253516907351496, -3.174387269895637, -3.4543472962535073]'', 'b'-3.4941138617271728'', 'b'[-1.4408909772988383, -2.072193796320781, -2.1292924058775298, -2.6115638319202774, -2.772101714880423, -2.908661634784674, -3.0754580610056617]'', 'b'33'', 'b'0.15963655070037594'', 'b"['Apoptosis', 'Cell Cycle', 'Cell Line, Tumor', 'Cell Movement', 'Cell Proliferation', 'Cyclin D1', 'Down-Regulation', 'Forkhead Box Protein O1', 'Gramicidin', 'Humans', 'Phosphorylation', 'Proto-Oncogene Proteins c-bcl-2', 'Stomach Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'15'', 'b'Immunoglobulin G4 (IgG4)-related disease of the stomach - a challenging differential diagnosis in suspected gastric cancer.'', 'b'\xe2\x80\x82Immunoglobulin G4-related disease (IgG4-RD) can involve different organs and is diagnosed by a combination of clinicopathological features, including storiform fibrosclerosis infiltrated by numerous IgG4-positive plasma cells that frequently forms tumor-like lesions with or without associated obliterative phlebitis. Involvement of the stomach is rare and can occur as part of a multiorgan involvement of IgG4-RD or as isolated gastric involvement.\xe2\x80\x82We report 2 female patients with therapy-refractory gastric ulcers associated with gastric wall thickening and lymphadenopathy that were highly suggestive of gastric cancer or lymphoma. Biopsies failed to confirm a diagnosis, and IgG4-RD was diagnosed only after surgical resection in both patients. The previous literature on gastric IgG4-RD is summarized and shows different characteristics in patients with multiorgan IgG4-RD and isolated gastric IgG4-RD. As reported for autoimmune pancreatitis type 1, patients with multiorgan IgG4-RD are mainly elderly men with frequently elevated serum IgG4 concentrations. In contrast, isolated gastric IgG4-RD predominantly affects female patients with normal serum IgG4 levels. Surgical resection is commonly performed due to the clinical suspicion of malignancy and the absence of findings indicative of IgG4-RD on biopsy. Today, diagnosis is confirmed histopathologically only after resection.\xe2\x80\x82IgG4-RD should be taken into account when gastric malignancy is suspected endoscopically or radiologically and biopsies fail to confirm the presence of a malignancy (especially subepithelial tumors or refractory gastric ulcers). Serum IgG4 concentrations are insufficient to confirm localized gastric IgG4-RD. Diagnostic workups need to be improved to avoid unnecessary surgical resections with the attendant potential morbidity and mortality.'', 'b'1588'', 'b'246'', 'b"[('gastric', 20), ('patients', 10), ('involvement', 6), ('multiorgan', 6), ('isolated', 6), ('confirm', 6), ('surgical', 6), ('resection', 6), ('serum', 6), ('malignancy', 6), ('different', 4), ('diagnosed', 4), ('frequently', 4), ('associated', 4), ('female', 4), ('ulcers', 4), ('biopsies', 4), ('diagnosis', 4), ('concentrations', 4), ('immunoglobulin', 2), ('disease', 2), ('involve', 2), ('organs', 2), ('combination', 2), ('clinicopathological', 2), ('features', 2), ('including', 2), ('storiform', 2), ('fibrosclerosis', 2), ('infiltrated', 2), ('numerous', 2), ('plasma', 2), ('cells', 2), ('forms', 2), ('lesions', 2), ('without', 2), ('obliterative', 2), ('phlebitis', 2), ('stomach', 2), ('rare', 2), ('occur', 2), ('part', 2), ('report', 2), ('wall', 2), ('thickening', 2), ('lymphadenopathy', 2), ('highly', 2), ('suggestive', 2), ('cancer', 2), ('lymphoma', 2), ('failed', 2), ('previous', 2), ('literature', 2), ('summarized', 2), ('shows', 2), ('characteristics', 2), ('reported', 2), ('autoimmune', 2), ('pancreatitis', 2), ('type', 2), ('mainly', 2), ('elderly', 2), ('men', 2), ('elevated', 2), ('contrast', 2), ('predominantly', 2), ('affects', 2), ('normal', 2), ('levels', 2), ('commonly', 2), ('performed', 2), ('due', 2), ('clinical', 2), ('suspicion', 2), ('absence', 2), ('findings', 2), ('indicative', 2), ('biopsy', 2), ('today', 2), ('confirmed', 2), ('histopathologically', 2), ('taken', 2), ('account', 2), ('suspected', 2), ('endoscopically', 2), ('radiologically', 2), ('fail', 2), ('presence', 2), ('especially', 2), ('subepithelial', 2), ('tumors', 2), ('refractory', 2), ('insufficient', 2), ('localized', 2), ('diagnostic', 2), ('workups', 2), ('need', 2), ('improved', 2), ('avoid', 2), ('unnecessary', 2), ('resections', 2), ('attendant', 2), ('potential', 2), ('morbidity', 2), ('mortality', 2)]"', 'b"[('.', 12), ('igg4-rd', 11), ('gastric', 10), ('and', 9), ('of', 9), ('with', 8), ('is', 6), ('the', 6), ('to', 6), (',', 5), ('or', 5), ('patient', 5), ('involv', 4), ('a', 4), ('confirm', 4), ('resect', 4), ('multiorgan', 3), ('isol', 3), ('biopsi', 3), ('surgic', 3), ('serum', 3), ('igg4', 3), ('malign', 3), ('(', 2), (')', 2), ('can', 2), ('differ', 2), ('diagnos', 2), ('by', 2), ('that', 2), ('frequent', 2), ('associ', 2), ('as', 2), ('report', 2), ('femal', 2), ('ulcer', 2), ('fail', 2), ('diagnosi', 2), ('onli', 2), ('after', 2), ('in', 2), ('on', 2), ('are', 2), ('concentr', 2), ('be', 2), ('immunoglobulin', 1), ('g4-relat', 1), ('diseas', 1), ('organ', 1), ('combin', 1), ('clinicopatholog', 1), ('featur', 1), ('includ', 1), ('storiform', 1), ('fibrosclerosi', 1), ('infiltr', 1), ('numer', 1), ('igg4-posit', 1), ('plasma', 1), ('cell', 1), ('form', 1), ('tumor-lik', 1), ('lesion', 1), ('without', 1), ('oblit', 1), ('phlebiti', 1), ('stomach', 1), ('rare', 1), ('occur', 1), ('part', 1), ('We', 1), ('2', 1), ('therapy-refractori', 1), ('wall', 1), ('thicken', 1), ('lymphadenopathi', 1), ('were', 1), ('highli', 1), ('suggest', 1), ('cancer', 1), ('lymphoma', 1), ('wa', 1), ('both', 1), ('previou', 1), ('literatur', 1), ('summar', 1), ('show', 1), ('characterist', 1), ('As', 1), ('for', 1), ('autoimmun', 1), ('pancreat', 1), ('type', 1), ('1', 1), ('mainli', 1), ('elderli', 1), ('men', 1), ('elev', 1), ('In', 1), ('contrast', 1), ('predominantli', 1), ('affect', 1), ('normal', 1), ('level', 1), ('commonli', 1), ('perform', 1), ('due', 1), ('clinic', 1), ('suspicion', 1), ('absenc', 1), ('find', 1), ('indic', 1), ('today', 1), ('histopatholog', 1), ('should', 1), ('taken', 1), ('into', 1), ('account', 1), ('when', 1), ('suspect', 1), ('endoscop', 1), ('radiolog', 1), ('presenc', 1), ('especi', 1), ('subepitheli', 1), ('tumor', 1), ('refractori', 1), ('insuffici', 1), ('local', 1), ('diagnost', 1), ('workup', 1), ('need', 1), ('improv', 1), ('avoid', 1), ('unnecessari', 1), ('attend', 1), ('potenti', 1), ('morbid', 1), ('mortal', 1)]"', 'b'12'', 'b"('gastric', 'patients', 'involvement', 'multiorgan', 'isolated', 'confirm', 'surgical', 'resection', 'serum', 'malignancy', 'different', 'diagnosed', 'frequently', 'associated', 'female', 'ulcers', 'biopsies', 'diagnosis', 'concentrations', 'immunoglobulin', 'disease', 'involve', 'organs', 'combination', 'clinicopathological', 'features', 'including', 'storiform', 'fibrosclerosis', 'infiltrated', 'numerous', 'plasma', 'cells', 'forms', 'lesions', 'without', 'obliterative', 'phlebitis', 'stomach', 'rare', 'occur', 'part', 'report', 'wall', 'thickening', 'lymphadenopathy', 'highly', 'suggestive', 'cancer', 'lymphoma', 'failed', 'previous', 'literature', 'summarized', 'shows', 'characteristics', 'reported', 'autoimmune', 'pancreatitis', 'type', 'mainly', 'elderly', 'men', 'elevated', 'contrast', 'predominantly', 'affects', 'normal', 'levels', 'commonly', 'performed', 'due', 'clinical', 'suspicion', 'absence', 'findings', 'indicative', 'biopsy', 'today', 'confirmed', 'histopathologically', 'taken', 'account', 'suspected', 'endoscopically', 'radiologically', 'fail', 'presence', 'especially', 'subepithelial', 'tumors', 'refractory', 'insufficient', 'localized', 'diagnostic', 'workups', 'need', 'improved', 'avoid', 'unnecessary', 'resections', 'attendant', 'potential', 'morbidity', 'mortality')"', 'b'(20, 10, 6, 6, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.012907878954533781'', 'b'[0.0, 0.0, 0.43249871874330226, 0.08649974374866046, 0.04324987187433023, 0.026212043560200137, 0.020116219476432662, 0.01572722613612008, 0.014416623958110076, 0.0113815452300869, 0.010548749237641519, 0.009202100398793664]'', 'b'-3.962844630259907'', 'b'[1, 1, 0.3068528194400547, -1.3025850929940455, -1.9957322735539909, -2.4965075614664802, -2.7612001156935624, -3.007333185232471, -3.0943445622221004, -3.330733340286331, -3.4067192472642533, -3.543294782270004]'', 'b'-7.314724388831725'', 'b'[0.8903152454708944, 0.8903152454708944, 0.26542690250118706, -1.1267327675480998, -1.7263033025335173, -2.1594726433344373, -2.388431024462647, -2.6013354988945157, -2.676600117022726, -2.881075804298875, -2.9468034191198735, -3.0649409069232094]'', 'b'14'', 'b'0.11999225325955569'', 'b"['Aged', 'Biomarkers', 'Diagnosis, Differential', 'Female', 'Humans', 'Immunoglobulin G', 'Immunoglobulin G4-Related Disease', 'Lymphadenopathy', 'Plasma Cells', 'Stomach Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'16'', 'b'Associations Between Apparent Diffusion Coefficient Values and the Prognostic Factors of Breast Cancer.'', 'b'Breast imaging can offer great information about breast cancer heterogeneity. The purpose of this study was to analyze the relationship between apparent diffusion coefficient (ADC) values and various prognostic factors and investigate whether ADC values are useful for breast cancer diagnosis, evaluation of treatment response, and determination of prognosis.A total of 111 cases of breast cancer were included in this study. Magnetic resonance findings were recorded according to the Breast Imaging Reporting and Data System magnetic resonance imaging lexicon. Diffusion-weighted imaging rim sign and minimum, maximum, and difference ADC values (ADCdiff) were also evaluated.ADCdiff was related to all prognostic factors such as histological grade, Ki-67, tumor size, molecular subtype, axillary node metastasis, lymphvascular invasion, internal enhancement pattern, intratumoral high T2 signal, peritumoral edema, and diffusion-weighted imaging rim sign, whereas minimum and maximum ADC values showed variable associations.Apparent diffusion coefficient values were shown to be correlated with many proven or possible prognostic factors of breast cancer. In particular, ADCdiff can reflect tumor heterogeneity and showed higher correlation.'', 'b'1077'', 'b'166'', 'b"[('breast', 12), ('imaging', 10), ('values', 10), ('cancer', 8), ('adc', 8), ('prognostic', 6), ('factors', 6), ('heterogeneity', 4), ('study', 4), ('diffusion', 4), ('coefficient', 4), ('magnetic', 4), ('resonance', 4), ('rim', 4), ('sign', 4), ('minimum', 4), ('maximum', 4), ('adcdiff', 4), ('tumor', 4), ('showed', 4), ('offer', 2), ('great', 2), ('information', 2), ('purpose', 2), ('analyze', 2), ('relationship', 2), ('apparent', 2), ('various', 2), ('investigate', 2), ('whether', 2), ('useful', 2), ('diagnosis', 2), ('evaluation', 2), ('treatment', 2), ('response', 2), ('determination', 2), ('total', 2), ('cases', 2), ('included', 2), ('findings', 2), ('recorded', 2), ('according', 2), ('reporting', 2), ('data', 2), ('system', 2), ('lexicon', 2), ('difference', 2), ('also', 2), ('related', 2), ('histological', 2), ('grade', 2), ('size', 2), ('molecular', 2), ('subtype', 2), ('axillary', 2), ('node', 2), ('metastasis', 2), ('lymphvascular', 2), ('invasion', 2), ('internal', 2), ('enhancement', 2), ('pattern', 2), ('intratumoral', 2), ('high', 2), ('signal', 2), ('peritumoral', 2), ('edema', 2), ('whereas', 2), ('variable', 2), ('shown', 2), ('correlated', 2), ('many', 2), ('proven', 2), ('possible', 2), ('particular', 2), ('reflect', 2), ('higher', 2), ('correlation', 2)]"', 'b"[(',', 15), ('and', 9), ('breast', 6), ('of', 6), ('imag', 5), ('.', 5), ('valu', 5), ('cancer', 4), ('to', 4), ('adc', 4), ('were', 4), ('the', 3), ('prognost', 3), ('factor', 3), ('can', 2), ('heterogen', 2), ('thi', 2), ('studi', 2), ('wa', 2), ('diffus', 2), ('coeffici', 2), ('(', 2), (')', 2), ('magnet', 2), ('reson', 2), ('diffusion-weight', 2), ('rim', 2), ('sign', 2), ('minimum', 2), ('maximum', 2), ('adcdiff', 2), ('tumor', 2), ('show', 2), ('correl', 2), ('offer', 1), ('great', 1), ('inform', 1), ('about', 1), ('purpos', 1), ('analyz', 1), ('relationship', 1), ('between', 1), ('appar', 1), ('variou', 1), ('investig', 1), ('whether', 1), ('are', 1), ('use', 1), ('for', 1), ('diagnosi', 1), ('evalu', 1), ('treatment', 1), ('respons', 1), ('determin', 1), ('prognosis.a', 1), ('total', 1), ('111', 1), ('case', 1), ('includ', 1), ('in', 1), ('find', 1), ('record', 1), ('accord', 1), ('report', 1), ('data', 1), ('system', 1), ('lexicon', 1), ('differ', 1), ('also', 1), ('evaluated.adcdiff', 1), ('relat', 1), ('all', 1), ('such', 1), ('as', 1), ('histolog', 1), ('grade', 1), ('ki-67', 1), ('size', 1), ('molecular', 1), ('subtyp', 1), ('axillari', 1), ('node', 1), ('metastasi', 1), ('lymphvascular', 1), ('invas', 1), ('intern', 1), ('enhanc', 1), ('pattern', 1), ('intratumor', 1), ('high', 1), ('T2', 1), ('signal', 1), ('peritumor', 1), ('edema', 1), ('wherea', 1), ('variabl', 1), ('associations.appar', 1), ('shown', 1), ('be', 1), ('with', 1), ('mani', 1), ('proven', 1), ('or', 1), ('possibl', 1), ('In', 1), ('particular', 1), ('reflect', 1), ('higher', 1)]"', 'b'5'', 'b"('breast', 'imaging', 'values', 'cancer', 'adc', 'prognostic', 'factors', 'heterogeneity', 'study', 'diffusion', 'coefficient', 'magnetic', 'resonance', 'rim', 'sign', 'minimum', 'maximum', 'adcdiff', 'tumor', 'showed', 'offer', 'great', 'information', 'purpose', 'analyze', 'relationship', 'apparent', 'various', 'investigate', 'whether', 'useful', 'diagnosis', 'evaluation', 'treatment', 'response', 'determination', 'total', 'cases', 'included', 'findings', 'recorded', 'according', 'reporting', 'data', 'system', 'lexicon', 'difference', 'also', 'related', 'histological', 'grade', 'size', 'molecular', 'subtype', 'axillary', 'node', 'metastasis', 'lymphvascular', 'invasion', 'internal', 'enhancement', 'pattern', 'intratumoral', 'high', 'signal', 'peritumoral', 'edema', 'whereas', 'variable', 'shown', 'correlated', 'many', 'proven', 'possible', 'particular', 'reflect', 'higher', 'correlation')"', 'b'(12, 10, 10, 8, 8, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.06250133927581612'', 'b'[0.42015241244811646, 0.03400863638821552, 0.02332020780906207, 0.005048896661827888, 0.004804101672163505]'', 'b'-2.349904087274605'', 'b'[0.3068528194400547, -2.1780538303479458, -2.5553480614894135, -4.056245805348308, -4.10594547390058]'', 'b'-4.185856349794747'', 'b'[0.25784990470849056, -1.77774337800632, -2.0856936736445966, -3.2152918472697016, -3.2546876203013624]'', 'b'82'', 'b'0.15015427820826424'', 'b"['Adult', 'Aged', 'Aged, 80 and over', 'Breast Neoplasms', 'Diffusion Magnetic Resonance Imaging', 'Female', 'Humans', 'Middle Aged', 'Prognosis', 'Radiographic Image Interpretation, Computer-Assisted', 'Retrospective Studies']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'17'', 'b'Surveillance Magnetic Resonance Imaging in Detecting the Second Breast Cancer in Women With a Personal History of Breast Cancer.'', 'b'The objective of this study was to evaluate the diagnostic performance of magnetic resonance imaging (MRI) in detecting the secondary breast cancer among women with a personal history of the lesion.We retrospectively reviewed breast MRI examinations performed between 2007 and 2011. A total of 798 women with a history of breast cancer were included in the study. Cancer detection rate, positive predictive value (PPV), recall rate, sensitivity, and specificity were assed. Cancer detection rate was stratified by interval after surgery of the primary breast cancer. Also, we derived 1 comparison group from the women for comparing the performance of x-ray mammography, ultrasound, and MRI in detecting the second breast cancer.Of the 798 patients, 47 of the 49 secondary breast carcinomas were detected by MRI. The sensitivity and specificity of MRI in detecting the secondary lesions were 95.9% and 96.3%, respectively. The recall rate was 9.5%, and the PPV was 61.8%. Cancer detection rate of MRI examinations performed at more than 36 months after initial surgery was significantly higher than that at 36 months or less after initial surgery (13.7% vs 3.6, P < 0.001). In comparison group, the sensitivity and specificity of MRI, mammography, and ultrasound were 96.7% and 96.1%, 48.4% and 93.9%, and 77.4% and 96.1%, respectively.Surveillance MRI for women with a personal history of breast cancer has high sensitivity in finding the secondary malignancies with a reasonable recall rate and PPV.'', 'b'1268'', 'b'233'', 'b"[('mri', 16), ('breast', 14), ('cancer', 14), ('rate', 12), ('secondary', 8), ('women', 8), ('sensitivity', 8), ('detecting', 6), ('history', 6), ('detection', 6), ('ppv', 6), ('recall', 6), ('specificity', 6), ('surgery', 6), ('study', 4), ('performance', 4), ('personal', 4), ('examinations', 4), ('performed', 4), ('comparison', 4), ('group', 4), ('mammography', 4), ('ultrasound', 4), ('months', 4), ('initial', 4), ('objective', 2), ('evaluate', 2), ('diagnostic', 2), ('magnetic', 2), ('resonance', 2), ('imaging', 2), ('among', 2), ('retrospectively', 2), ('reviewed', 2), ('total', 2), ('included', 2), ('positive', 2), ('predictive', 2), ('value', 2), ('assed', 2), ('stratified', 2), ('interval', 2), ('primary', 2), ('also', 2), ('derived', 2), ('comparing', 2), ('second', 2), ('patients', 2), ('carcinomas', 2), ('detected', 2), ('lesions', 2), ('respectively', 2), ('significantly', 2), ('higher', 2), ('less', 2), ('vs', 2), ('p', 2), ('high', 2), ('finding', 2), ('malignancies', 2), ('reasonable', 2)]"', 'b"[('the', 17), (',', 17), ('and', 13), ('of', 12), ('%', 11), ('.', 9), ('mri', 8), ('detect', 7), ('breast', 7), ('cancer', 7), ('rate', 6), ('wa', 5), ('in', 5), ('were', 5), ('perform', 4), ('secondari', 4), ('women', 4), ('with', 4), ('a', 4), ('sensit', 4), ('(', 3), (')', 3), ('histori', 3), ('ppv', 3), ('recal', 3), ('specif', 3), ('after', 3), ('surgeri', 3), ('studi', 2), ('person', 2), ('examin', 2), ('798', 2), ('by', 2), ('comparison', 2), ('group', 2), ('for', 2), ('mammographi', 2), ('ultrasound', 2), ('at', 2), ('than', 2), ('36', 2), ('month', 2), ('initi', 2), ('96.1', 2), ('object', 1), ('thi', 1), ('to', 1), ('evalu', 1), ('diagnost', 1), ('magnet', 1), ('reson', 1), ('imag', 1), ('among', 1), ('lesion.w', 1), ('retrospect', 1), ('review', 1), ('between', 1), ('2007', 1), ('2011', 1), ('A', 1), ('total', 1), ('includ', 1), ('posit', 1), ('predict', 1), ('valu', 1), ('ass', 1), ('stratifi', 1), ('interv', 1), ('primari', 1), ('also', 1), ('we', 1), ('deriv', 1), ('1', 1), ('from', 1), ('compar', 1), ('x-ray', 1), ('second', 1), ('cancer.of', 1), ('patient', 1), ('47', 1), ('49', 1), ('carcinoma', 1), ('lesion', 1), ('95.9', 1), ('96.3', 1), ('respect', 1), ('9.5', 1), ('61.8', 1), ('more', 1), ('significantli', 1), ('higher', 1), ('that', 1), ('or', 1), ('less', 1), ('13.7', 1), ('vs', 1), ('3.6', 1), ('P', 1), ('<', 1), ('0.001', 1), ('In', 1), ('96.7', 1), ('48.4', 1), ('93.9', 1), ('77.4', 1), ('respectively.surveil', 1), ('ha', 1), ('high', 1), ('find', 1), ('malign', 1), ('reason', 1)]"', 'b'9'', 'b"('mri', 'breast', 'cancer', 'rate', 'secondary', 'women', 'sensitivity', 'detecting', 'history', 'detection', 'ppv', 'recall', 'specificity', 'surgery', 'study', 'performance', 'personal', 'examinations', 'performed', 'comparison', 'group', 'mammography', 'ultrasound', 'months', 'initial', 'objective', 'evaluate', 'diagnostic', 'magnetic', 'resonance', 'imaging', 'among', 'retrospectively', 'reviewed', 'total', 'included', 'positive', 'predictive', 'value', 'assed', 'stratified', 'interval', 'primary', 'also', 'derived', 'comparing', 'second', 'patients', 'carcinomas', 'detected', 'lesions', 'respectively', 'significantly', 'higher', 'less', 'vs', 'p', 'high', 'finding', 'malignancies', 'reasonable')"', 'b'(16, 14, 14, 12, 8, 8, 8, 6, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.10121550279672498'', 'b'[0.08552080640914218, 0.04670090011438882, 0.02686057389301651, 0.032731594878627084, 0.018278682854298244, 0.015466577799790823, 0.01450988226578314, 0.0059883849183565785, 0.004940720846939658]'', 'b'-1.8332133440562162'', 'b'[-1.1972245773362196, -1.7725887222397811, -2.295836866004329, -2.068052935133617, -2.6506582412937383, -2.817712325956905, -2.8815637979434374, -3.7361984483944957, -3.897839799950911]'', 'b'-3.1543433759893635'', 'b'[-0.9214885017597413, -1.324503821779394, -1.6650223862117597, -1.455349423497508, -1.8653458418879971, -1.9829066942613118, -2.0278408453008567, -2.5506125662002246, -2.5805905399249087]'', 'b'85'', 'b'0.16226986726239903'', 'b"['Adult', 'Aged', 'Aged, 80 and over', 'Breast Neoplasms', 'Female', 'Humans', 'Magnetic Resonance Imaging', 'Mammography', 'Middle Aged', 'Neoplasms, Second Primary', 'Population Surveillance', 'Predictive Value of Tests', 'Retrospective Studies', 'Sensitivity and Specificity', 'Ultrasonography, Mammary']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'17'', 'b'Surveillance Magnetic Resonance Imaging in Detecting the Second Breast Cancer in Women With a Personal History of Breast Cancer.'', 'b'The objective of this study was to evaluate the diagnostic performance of magnetic resonance imaging (MRI) in detecting the secondary breast cancer among women with a personal history of the lesion.We retrospectively reviewed breast MRI examinations performed between 2007 and 2011. A total of 798 women with a history of breast cancer were included in the study. Cancer detection rate, positive predictive value (PPV), recall rate, sensitivity, and specificity were assed. Cancer detection rate was stratified by interval after surgery of the primary breast cancer. Also, we derived 1 comparison group from the women for comparing the performance of x-ray mammography, ultrasound, and MRI in detecting the second breast cancer.Of the 798 patients, 47 of the 49 secondary breast carcinomas were detected by MRI. The sensitivity and specificity of MRI in detecting the secondary lesions were 95.9% and 96.3%, respectively. The recall rate was 9.5%, and the PPV was 61.8%. Cancer detection rate of MRI examinations performed at more than 36 months after initial surgery was significantly higher than that at 36 months or less after initial surgery (13.7% vs 3.6, P < 0.001). In comparison group, the sensitivity and specificity of MRI, mammography, and ultrasound were 96.7% and 96.1%, 48.4% and 93.9%, and 77.4% and 96.1%, respectively.Surveillance MRI for women with a personal history of breast cancer has high sensitivity in finding the secondary malignancies with a reasonable recall rate and PPV.'', 'b'1268'', 'b'233'', 'b"[('mri', 16), ('breast', 14), ('cancer', 14), ('rate', 12), ('secondary', 8), ('women', 8), ('sensitivity', 8), ('detecting', 6), ('history', 6), ('detection', 6), ('ppv', 6), ('recall', 6), ('specificity', 6), ('surgery', 6), ('study', 4), ('performance', 4), ('personal', 4), ('examinations', 4), ('performed', 4), ('comparison', 4), ('group', 4), ('mammography', 4), ('ultrasound', 4), ('months', 4), ('initial', 4), ('objective', 2), ('evaluate', 2), ('diagnostic', 2), ('magnetic', 2), ('resonance', 2), ('imaging', 2), ('among', 2), ('retrospectively', 2), ('reviewed', 2), ('total', 2), ('included', 2), ('positive', 2), ('predictive', 2), ('value', 2), ('assed', 2), ('stratified', 2), ('interval', 2), ('primary', 2), ('also', 2), ('derived', 2), ('comparing', 2), ('second', 2), ('patients', 2), ('carcinomas', 2), ('detected', 2), ('lesions', 2), ('respectively', 2), ('significantly', 2), ('higher', 2), ('less', 2), ('vs', 2), ('p', 2), ('high', 2), ('finding', 2), ('malignancies', 2), ('reasonable', 2)]"', 'b"[('the', 17), (',', 17), ('and', 13), ('of', 12), ('%', 11), ('.', 9), ('mri', 8), ('detect', 7), ('breast', 7), ('cancer', 7), ('rate', 6), ('wa', 5), ('in', 5), ('were', 5), ('perform', 4), ('secondari', 4), ('women', 4), ('with', 4), ('a', 4), ('sensit', 4), ('(', 3), (')', 3), ('histori', 3), ('ppv', 3), ('recal', 3), ('specif', 3), ('after', 3), ('surgeri', 3), ('studi', 2), ('person', 2), ('examin', 2), ('798', 2), ('by', 2), ('comparison', 2), ('group', 2), ('for', 2), ('mammographi', 2), ('ultrasound', 2), ('at', 2), ('than', 2), ('36', 2), ('month', 2), ('initi', 2), ('96.1', 2), ('object', 1), ('thi', 1), ('to', 1), ('evalu', 1), ('diagnost', 1), ('magnet', 1), ('reson', 1), ('imag', 1), ('among', 1), ('lesion.w', 1), ('retrospect', 1), ('review', 1), ('between', 1), ('2007', 1), ('2011', 1), ('A', 1), ('total', 1), ('includ', 1), ('posit', 1), ('predict', 1), ('valu', 1), ('ass', 1), ('stratifi', 1), ('interv', 1), ('primari', 1), ('also', 1), ('we', 1), ('deriv', 1), ('1', 1), ('from', 1), ('compar', 1), ('x-ray', 1), ('second', 1), ('cancer.of', 1), ('patient', 1), ('47', 1), ('49', 1), ('carcinoma', 1), ('lesion', 1), ('95.9', 1), ('96.3', 1), ('respect', 1), ('9.5', 1), ('61.8', 1), ('more', 1), ('significantli', 1), ('higher', 1), ('that', 1), ('or', 1), ('less', 1), ('13.7', 1), ('vs', 1), ('3.6', 1), ('P', 1), ('<', 1), ('0.001', 1), ('In', 1), ('96.7', 1), ('48.4', 1), ('93.9', 1), ('77.4', 1), ('respectively.surveil', 1), ('ha', 1), ('high', 1), ('find', 1), ('malign', 1), ('reason', 1)]"', 'b'9'', 'b"('mri', 'breast', 'cancer', 'rate', 'secondary', 'women', 'sensitivity', 'detecting', 'history', 'detection', 'ppv', 'recall', 'specificity', 'surgery', 'study', 'performance', 'personal', 'examinations', 'performed', 'comparison', 'group', 'mammography', 'ultrasound', 'months', 'initial', 'objective', 'evaluate', 'diagnostic', 'magnetic', 'resonance', 'imaging', 'among', 'retrospectively', 'reviewed', 'total', 'included', 'positive', 'predictive', 'value', 'assed', 'stratified', 'interval', 'primary', 'also', 'derived', 'comparing', 'second', 'patients', 'carcinomas', 'detected', 'lesions', 'respectively', 'significantly', 'higher', 'less', 'vs', 'p', 'high', 'finding', 'malignancies', 'reasonable')"', 'b'(16, 14, 14, 12, 8, 8, 8, 6, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.10121550279672498'', 'b'[0.08552080640914218, 0.04670090011438882, 0.02686057389301651, 0.032731594878627084, 0.018278682854298244, 0.015466577799790823, 0.01450988226578314, 0.0059883849183565785, 0.004940720846939658]'', 'b'-1.8332133440562162'', 'b'[-1.1972245773362196, -1.7725887222397811, -2.295836866004329, -2.068052935133617, -2.6506582412937383, -2.817712325956905, -2.8815637979434374, -3.7361984483944957, -3.897839799950911]'', 'b'-3.1543433759893635'', 'b'[-0.9214885017597413, -1.324503821779394, -1.6650223862117597, -1.455349423497508, -1.8653458418879971, -1.9829066942613118, -2.0278408453008567, -2.5506125662002246, -2.5805905399249087]'', 'b'85'', 'b'0.16226986726239903'', 'b"['Adult', 'Aged', 'Aged, 80 and over', 'Breast Neoplasms', 'Female', 'Humans', 'Magnetic Resonance Imaging', 'Mammography', 'Middle Aged', 'Neoplasms, Second Primary', 'Population Surveillance', 'Predictive Value of Tests', 'Retrospective Studies', 'Sensitivity and Specificity', 'Ultrasonography, Mammary']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'18'', 'b'Value of Dual-Energy Computed Tomography for Diagnosing Cervical Lymph Node Metastasis in Patients With Papillary Thyroid Cancer.'', 'b'The objective of this study was to determine the value of dual-energy computed tomography (DECT) for the diagnosis of cervical lymph node metastasis in papillary thyroid cancer.The normalized iodine concentration (NIC) and the slope of the spectral Hounsfield unit curve (\xce\xbbHU) in the arterial and venous phases were measured using iodine-overlay images and spectral curves. Quantitative DECT data and qualitative conventional CT data were analyzed by radiologists.The best qualitative parameter for lymph node metastasis detection was obvious node enhancement, and the best quantitative parameter for detection was arterial-phase NIC, which showed high sensitivity, specificity, and accuracy values at an optimal threshold of 25.8%. The best combination of qualitative and quantitative parameters consisted of obvious enhancement and arterial-phase NIC; this combination showed a sensitivity of 90.8% and a specificity of 80.5%.The DECT quantitative parameters NIC and \xce\xbbHU can be an additional tool to diagnose cervical lymph node metastasis.'', 'b'896'', 'b'147'', 'b"[('node', 8), ('nic', 8), ('quantitative', 8), ('dect', 6), ('lymph', 6), ('metastasis', 6), ('qualitative', 6), ('best', 6), ('cervical', 4), ('spectral', 4), ('\xce\xbbhu', 4), ('data', 4), ('parameter', 4), ('detection', 4), ('obvious', 4), ('enhancement', 4), ('showed', 4), ('sensitivity', 4), ('specificity', 4), ('combination', 4), ('parameters', 4), ('objective', 2), ('study', 2), ('determine', 2), ('value', 2), ('computed', 2), ('tomography', 2), ('diagnosis', 2), ('papillary', 2), ('thyroid', 2), ('normalized', 2), ('iodine', 2), ('concentration', 2), ('slope', 2), ('hounsfield', 2), ('unit', 2), ('curve', 2), ('arterial', 2), ('venous', 2), ('phases', 2), ('measured', 2), ('using', 2), ('images', 2), ('curves', 2), ('conventional', 2), ('ct', 2), ('analyzed', 2), ('high', 2), ('accuracy', 2), ('values', 2), ('optimal', 2), ('threshold', 2), ('consisted', 2), ('additional', 2), ('tool', 2), ('diagnose', 2)]"', 'b"[('and', 10), ('of', 9), ('the', 8), ('node', 4), ('nic', 4), ('quantit', 4), ('paramet', 4), (',', 4), ('wa', 3), ('(', 3), ('dect', 3), (')', 3), ('for', 3), ('lymph', 3), ('metastasi', 3), ('.', 3), ('qualit', 3), ('best', 3), ('%', 3), ('thi', 2), ('to', 2), ('valu', 2), ('cervic', 2), ('in', 2), ('spectral', 2), ('curv', 2), ('\xce\xbbhu', 2), ('were', 2), ('data', 2), ('detect', 2), ('obviou', 2), ('enhanc', 2), ('arterial-phas', 2), ('show', 2), ('sensit', 2), ('specif', 2), ('an', 2), ('combin', 2), ('a', 2), ('object', 1), ('studi', 1), ('determin', 1), ('dual-energi', 1), ('comput', 1), ('tomographi', 1), ('diagnosi', 1), ('papillari', 1), ('thyroid', 1), ('cancer.th', 1), ('normal', 1), ('iodin', 1), ('concentr', 1), ('slope', 1), ('hounsfield', 1), ('unit', 1), ('arteri', 1), ('venou', 1), ('phase', 1), ('measur', 1), ('use', 1), ('iodine-overlay', 1), ('imag', 1), ('convent', 1), ('CT', 1), ('analyz', 1), ('by', 1), ('radiologists.th', 1), ('which', 1), ('high', 1), ('accuraci', 1), ('at', 1), ('optim', 1), ('threshold', 1), ('25.8', 1), ('consist', 1), (';', 1), ('90.8', 1), ('80.5', 1), ('.the', 1), ('can', 1), ('be', 1), ('addit', 1), ('tool', 1), ('diagnos', 1)]"', 'b'3'', 'b"('node', 'nic', 'quantitative', 'dect', 'lymph', 'metastasis', 'qualitative', 'best', 'cervical', 'spectral', '\xce\xbbhu', 'data', 'parameter', 'detection', 'obvious', 'enhancement', 'showed', 'sensitivity', 'specificity', 'combination', 'parameters', 'objective', 'study', 'determine', 'value', 'computed', 'tomography', 'diagnosis', 'papillary', 'thyroid', 'normalized', 'iodine', 'concentration', 'slope', 'hounsfield', 'unit', 'curve', 'arterial', 'venous', 'phases', 'measured', 'using', 'images', 'curves', 'conventional', 'ct', 'analyzed', 'high', 'accuracy', 'values', 'optimal', 'threshold', 'consisted', 'additional', 'tool', 'diagnose')"', 'b'(8, 8, 8, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.09785324315908094'', 'b'[0.0713170984635994, 0.03887820367976344, 0.022319747148856053, 0.027143487351089256, 0.015158051377881015, 0.012826043473591628, 0.012032679959761216, 0.004955200395054969, 0.004078684375881119]'', 'b'-1.8332133440562162'', 'b'[-1.1972245773362196, -1.7725887222397811, -2.295836866004329, -2.068052935133617, -2.6506582412937383, -2.817712325956905, -2.8815637979434374, -3.7361984483944957, -3.897839799950911]'', 'b'-3.0495598090128824'', 'b'[-0.7684432475843552, -1.1026410461390372, -1.383547455294446, -1.2068846267529203, -1.5468843315592673, -1.64437458589032, -1.6816373457679399, -2.1105517711336512, -2.130339811094147]'', 'b'37'', 'b'0.08541643318595099'', 'b"['Adolescent', 'Adult', 'Aged', 'Child', 'Female', 'Humans', 'Lymph Nodes', 'Lymphatic Metastasis', 'Male', 'Middle Aged', 'Neck', 'Observer Variation', 'Radiographic Image Interpretation, Computer-Assisted', 'Sensitivity and Specificity', 'Thyroid Cancer, Papillary', 'Thyroid Neoplasms', 'Tomography, X-Ray Computed', 'Young Adult']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'19'', 'b'Patient-derived tumor models of esophageal cancer.'', 'b'Tumor models are powerful tools to plan preclinical therapeutic strategies that cannot be conducted on humans. Recently, patient-derived tumor models such as patient-derived xenograft (PDX) and_or patient-derived organoid (PDO), are widely used to investigate the antitumor effects of various drugs, because those tumors resemble original tumors at the physiological and molecular level. In this chapter, we describe patient-derived tumor models of esophageal cancers and outline the latest research as well as the molecular pathology of esophageal cancers.'', 'b'481'', 'b'77'', 'b"[('tumor', 6), ('models', 6), ('tumors', 4), ('molecular', 4), ('esophageal', 4), ('cancers', 4), ('powerful', 2), ('tools', 2), ('plan', 2), ('preclinical', 2), ('therapeutic', 2), ('strategies', 2), ('conducted', 2), ('humans', 2), ('recently', 2), ('xenograft', 2), ('pdx', 2), ('organoid', 2), ('pdo', 2), ('widely', 2), ('used', 2), ('investigate', 2), ('antitumor', 2), ('effects', 2), ('various', 2), ('drugs', 2), ('resemble', 2), ('original', 2), ('physiological', 2), ('level', 2), ('chapter', 2), ('describe', 2), ('outline', 2), ('latest', 2), ('research', 2), ('well', 2), ('pathology', 2)]"', 'b"[('tumor', 5), (',', 4), ('patient-deriv', 4), ('the', 4), ('model', 3), ('.', 3), ('as', 3), ('of', 3), ('are', 2), ('to', 2), ('(', 2), (')', 2), ('and', 2), ('molecular', 2), ('esophag', 2), ('cancer', 2), ('power', 1), ('tool', 1), ('plan', 1), ('preclin', 1), ('therapeut', 1), ('strategi', 1), ('that', 1), ('can', 1), ('not', 1), ('be', 1), ('conduct', 1), ('on', 1), ('human', 1), ('recent', 1), ('such', 1), ('xenograft', 1), ('pdx', 1), ('and_or', 1), ('organoid', 1), ('pdo', 1), ('wide', 1), ('use', 1), ('investig', 1), ('antitumor', 1), ('effect', 1), ('variou', 1), ('drug', 1), ('becaus', 1), ('those', 1), ('resembl', 1), ('origin', 1), ('at', 1), ('physiolog', 1), ('level', 1), ('In', 1), ('thi', 1), ('chapter', 1), ('we', 1), ('describ', 1), ('outlin', 1), ('latest', 1), ('research', 1), ('well', 1), ('patholog', 1)]"', 'b'3'', 'b"('tumor', 'models', 'tumors', 'molecular', 'esophageal', 'cancers', 'powerful', 'tools', 'plan', 'preclinical', 'therapeutic', 'strategies', 'conducted', 'humans', 'recently', 'xenograft', 'pdx', 'organoid', 'pdo', 'widely', 'used', 'investigate', 'antitumor', 'effects', 'various', 'drugs', 'resemble', 'original', 'physiological', 'level', 'chapter', 'describe', 'outline', 'latest', 'research', 'well', 'pathology')"', 'b'(6, 6, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0'', 'b'[0.0, 0.0, 0.0]'', 'b'1'', 'b'[1, 1, 1]'', 'b'1.663505133704376'', 'b'[0.5465437063680699, 0.5465437063680699, 0.5465437063680699]'', 'b'3'', 'b'0.11595458784670026'', 'b"['Animals', 'Disease Models, Animal', 'Esophageal Neoplasms', 'Humans', 'Xenograft Model Antitumor Assays']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'20'', 'b'Variation in post-colonoscopy colorectal cancer across colonoscopy providers in English National Health Service: population based cohort study.'', 'b'To quantify post-colonoscopy colorectal cancer (PCCRC) rates in England by using recent World Endoscopy Organisation guidelines, compare incidence among colonoscopy providers, and explore associated factors that could benefit from quality improvement initiatives.Population based cohort study.National Health Service in England between 2005 and 2013.All people undergoing colonoscopy and subsequently diagnosed as having colorectal cancer up to three years after their investigation (PCCRC-3yr).National trends in incidence of PCCRC (within 6-36 months of colonoscopy), univariable and multivariable analyses to explore factors associated with occurrence, and funnel plots to measure variation among providers.The overall unadjusted PCCRC-3yr rate was 7.4% (9317_126\xe2\x80\x89152), which decreased from 9.0% in 2005 to 6.5% in 2013 (P<0.01). Rates were lower for colonoscopies performed under the NHS bowel cancer screening programme (593_16\xe2\x80\x89640, 3.6%), while they were higher for those conducted by non-NHS providers (187_2009, 9.3%). Rates were higher in women, in older age groups, and in people with inflammatory bowel disease or diverticular disease, in those with higher comorbidity scores, and in people with previous cancers. Substantial variation in rates among colonoscopy providers remained after adjustment for case mix.Wide variation exists in PCCRC-3yr rates across NHS colonoscopy providers in England. The lowest incidence was seen in colonoscopies performed under the NHS bowel cancer screening programme. Quality improvement initiatives are needed to address this variation in rates and prevent colorectal cancer by enabling earlier diagnosis, removing premalignant polyps, and therefore improving outcomes.'', 'b'1485'', 'b'232'', 'b"[('rates', 12), ('cancer', 10), ('colonoscopy', 10), ('providers', 8), ('variation', 8), ('colorectal', 6), ('england', 6), ('incidence', 6), ('among', 6), ('people', 6), ('nhs', 6), ('bowel', 6), ('higher', 6), ('pccrc', 4), ('explore', 4), ('associated', 4), ('factors', 4), ('quality', 4), ('improvement', 4), ('colonoscopies', 4), ('performed', 4), ('screening', 4), ('programme', 4), ('disease', 4), ('quantify', 2), ('using', 2), ('recent', 2), ('world', 2), ('endoscopy', 2), ('organisation', 2), ('guidelines', 2), ('compare', 2), ('could', 2), ('benefit', 2), ('based', 2), ('cohort', 2), ('health', 2), ('service', 2), ('undergoing', 2), ('subsequently', 2), ('diagnosed', 2), ('three', 2), ('years', 2), ('investigation', 2), ('trends', 2), ('within', 2), ('months', 2), ('univariable', 2), ('multivariable', 2), ('analyses', 2), ('occurrence', 2), ('funnel', 2), ('plots', 2), ('measure', 2), ('overall', 2), ('unadjusted', 2), ('rate', 2), ('decreased', 2), ('p', 2), ('lower', 2), ('conducted', 2), ('women', 2), ('older', 2), ('age', 2), ('groups', 2), ('inflammatory', 2), ('diverticular', 2), ('comorbidity', 2), ('scores', 2), ('previous', 2), ('cancers', 2), ('substantial', 2), ('remained', 2), ('adjustment', 2), ('case', 2), ('exists', 2), ('across', 2), ('lowest', 2), ('seen', 2), ('initiatives', 2), ('needed', 2), ('address', 2), ('prevent', 2), ('enabling', 2), ('earlier', 2), ('diagnosis', 2), ('removing', 2), ('premalignant', 2), ('polyps', 2), ('therefore', 2), ('improving', 2), ('outcomes', 2)]"', 'b"[('in', 15), (',', 14), ('and', 9), ('(', 7), (')', 7), ('rate', 7), ('colonoscopi', 7), ('cancer', 6), ('.', 6), ('to', 5), ('%', 5), ('provid', 4), ('with', 4), ('variat', 4), ('colorect', 3), ('england', 3), ('by', 3), ('incid', 3), ('among', 3), ('improv', 3), ('peopl', 3), ('pccrc-3yr', 3), ('were', 3), ('for', 3), ('the', 3), ('nh', 3), ('bowel', 3), ('higher', 3), ('pccrc', 2), ('explor', 2), ('associ', 2), ('factor', 2), ('from', 2), ('qualiti', 2), ('2005', 2), ('after', 2), ('of', 2), ('wa', 2), ('perform', 2), ('under', 2), ('screen', 2), ('programm', 2), ('those', 2), ('diseas', 2), ('To', 1), ('quantifi', 1), ('post-colonoscopi', 1), ('use', 1), ('recent', 1), ('world', 1), ('endoscopi', 1), ('organis', 1), ('guidelin', 1), ('compar', 1), ('that', 1), ('could', 1), ('benefit', 1), ('initiatives.popul', 1), ('base', 1), ('cohort', 1), ('study.n', 1), ('health', 1), ('servic', 1), ('between', 1), ('2013.all', 1), ('undergo', 1), ('subsequ', 1), ('diagnos', 1), ('as', 1), ('have', 1), ('up', 1), ('three', 1), ('year', 1), ('their', 1), ('investig', 1), ('.nation', 1), ('trend', 1), ('within', 1), ('6-36', 1), ('month', 1), ('univari', 1), ('multivari', 1), ('analys', 1), ('occurr', 1), ('funnel', 1), ('plot', 1), ('measur', 1), ('providers.th', 1), ('overal', 1), ('unadjust', 1), ('7.4', 1), ('9317_126', 1), ('152', 1), ('which', 1), ('decreas', 1), ('9.0', 1), ('6.5', 1), ('2013', 1), ('P', 1), ('<', 1), ('0.01', 1), ('lower', 1), ('593_16', 1), ('640', 1), ('3.6', 1), ('while', 1), ('they', 1), ('conduct', 1), ('non-nh', 1), ('187_2009', 1), ('9.3', 1), ('women', 1), ('older', 1), ('age', 1), ('group', 1), ('inflammatori', 1), ('or', 1), ('diverticular', 1), ('comorbid', 1), ('score', 1), ('previou', 1), ('substanti', 1), ('remain', 1), ('adjust', 1), ('case', 1), ('mix.wid', 1), ('exist', 1), ('across', 1), ('lowest', 1), ('seen', 1), ('initi', 1), ('are', 1), ('need', 1), ('address', 1), ('thi', 1), ('prevent', 1), ('enabl', 1), ('earlier', 1), ('diagnosi', 1), ('remov', 1), ('premalign', 1), ('polyp', 1), ('therefor', 1), ('outcom', 1)]"', 'b'6'', 'b"('rates', 'cancer', 'colonoscopy', 'providers', 'variation', 'colorectal', 'england', 'incidence', 'among', 'people', 'nhs', 'bowel', 'higher', 'pccrc', 'explore', 'associated', 'factors', 'quality', 'improvement', 'colonoscopies', 'performed', 'screening', 'programme', 'disease', 'quantify', 'using', 'recent', 'world', 'endoscopy', 'organisation', 'guidelines', 'compare', 'could', 'benefit', 'based', 'cohort', 'health', 'service', 'undergoing', 'subsequently', 'diagnosed', 'three', 'years', 'investigation', 'trends', 'within', 'months', 'univariable', 'multivariable', 'analyses', 'occurrence', 'funnel', 'plots', 'measure', 'overall', 'unadjusted', 'rate', 'decreased', 'p', 'lower', 'conducted', 'women', 'older', 'age', 'groups', 'inflammatory', 'diverticular', 'comorbidity', 'scores', 'previous', 'cancers', 'substantial', 'remained', 'adjustment', 'case', 'exists', 'across', 'lowest', 'seen', 'initiatives', 'needed', 'address', 'prevent', 'enabling', 'earlier', 'diagnosis', 'removing', 'premalignant', 'polyps', 'therefore', 'improving', 'outcomes')"', 'b'(12, 10, 10, 8, 8, 6, 6, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0'', 'b'[0.0, 0.0, 0.0]'', 'b'1'', 'b'[1, 1, 1]'', 'b'1.663505133704376'', 'b'[0.5465437063680699, 0.5465437063680699, 0.5465437063680699]'', 'b'80'', 'b'0.06537140033139721'', 'b"['Aged', 'Colonoscopy', 'Colorectal Neoplasms', 'Early Detection of Cancer', 'England', 'Female', 'Humans', 'Incidence', 'Male', 'Middle Aged', 'Quality Improvement', 'Risk Factors', 'State Medicine']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'21'', 'b'Synthesis of Zinc oxide nanoparticles from Marsdenia tenacissima inhibits the cell proliferation and induces apoptosis in laryngeal cancer cells (Hep-2).'', 'b'Biosynthesis of Zinc oxide nanoparticles (ZnONPs) from natural plants stands as a promising nanodrug delivery system in cancer therapeutics. Marsdenia tenacissima (M.t), a Chinese medicinal plant has been extensively used as clinical remedy for treating several types of cancer. In this present study, ZnONPs were synthesized from Marsdenia tenacissima and its anti cancer potency was assessed against in vitro laryngeal cancer cell line Hep-2. The biosynthesized Marsdenia tenacissima Zinc Oxide Nanoparticles [M.t-ZnONPs] was characterized using UV-visible Spec, SEM, TEM and EDAX analysis. The cytotoxic and apoptotic inducing potential of M.t-ZnONPs was assessed by MTT assay and staining such as DCFH-DA, AO_EtBr, Rhodamine 123, DAPI and comet assay. The anticancer potential of M.t-ZnONPs was analysed by Real time PCR analysis of proapoptotic, antiapoptotic and caspases proteins. Our present findings showed characteristic and morphological representation of synthesized M.t-ZnONPs by UV-visible Spec, SEM, TEM and EDAX analysis. M.t-ZnONPs exhibits its cytotoxicity by inhibiting the viability of Hep-2 cells and IC'', 'b'968'', 'b'157'', 'b"[('cancer', 8), ('marsdenia', 6), ('tenacissima', 6), ('analysis', 6), ('zinc', 4), ('oxide', 4), ('nanoparticles', 4), ('znonps', 4), ('present', 4), ('synthesized', 4), ('assessed', 4), ('spec', 4), ('sem', 4), ('tem', 4), ('edax', 4), ('potential', 4), ('assay', 4), ('biosynthesis', 2), ('natural', 2), ('plants', 2), ('stands', 2), ('promising', 2), ('nanodrug', 2), ('delivery', 2), ('system', 2), ('therapeutics', 2), ('chinese', 2), ('medicinal', 2), ('plant', 2), ('extensively', 2), ('used', 2), ('clinical', 2), ('remedy', 2), ('treating', 2), ('several', 2), ('types', 2), ('study', 2), ('anti', 2), ('potency', 2), ('vitro', 2), ('laryngeal', 2), ('cell', 2), ('line', 2), ('biosynthesized', 2), ('characterized', 2), ('using', 2), ('cytotoxic', 2), ('apoptotic', 2), ('inducing', 2), ('mtt', 2), ('staining', 2), ('rhodamine', 2), ('dapi', 2), ('comet', 2), ('anticancer', 2), ('analysed', 2), ('real', 2), ('time', 2), ('pcr', 2), ('proapoptotic', 2), ('antiapoptotic', 2), ('caspases', 2), ('proteins', 2), ('findings', 2), ('showed', 2), ('characteristic', 2), ('morphological', 2), ('representation', 2), ('exhibits', 2), ('cytotoxicity', 2), ('inhibiting', 2), ('viability', 2), ('cells', 2), ('ic', 2)]"', 'b"[(',', 10), ('and', 9), ('of', 7), ('.', 7), ('m.t-znonp', 5), ('cancer', 4), ('wa', 4), ('the', 4), ('by', 4), ('as', 3), ('marsdenia', 3), ('tenacissima', 3), ('analysi', 3), ('zinc', 2), ('oxid', 2), ('nanoparticl', 2), ('(', 2), ('znonp', 2), (')', 2), ('from', 2), ('plant', 2), ('a', 2), ('in', 2), ('use', 2), ('present', 2), ('synthes', 2), ('it', 2), ('assess', 2), ('cell', 2), ('hep-2', 2), ('uv-vis', 2), ('spec', 2), ('sem', 2), ('tem', 2), ('edax', 2), ('cytotox', 2), ('potenti', 2), ('assay', 2), ('biosynthesi', 1), ('natur', 1), ('stand', 1), ('promis', 1), ('nanodrug', 1), ('deliveri', 1), ('system', 1), ('therapeut', 1), ('m.t', 1), ('chines', 1), ('medicin', 1), ('ha', 1), ('been', 1), ('extens', 1), ('clinic', 1), ('remedi', 1), ('for', 1), ('treat', 1), ('sever', 1), ('type', 1), ('In', 1), ('thi', 1), ('studi', 1), ('were', 1), ('anti', 1), ('potenc', 1), ('against', 1), ('vitro', 1), ('laryng', 1), ('line', 1), ('biosynthes', 1), ('[', 1), (']', 1), ('character', 1), ('apoptot', 1), ('induc', 1), ('mtt', 1), ('stain', 1), ('such', 1), ('dcfh-da', 1), ('ao_etbr', 1), ('rhodamin', 1), ('123', 1), ('dapi', 1), ('comet', 1), ('anticanc', 1), ('analys', 1), ('real', 1), ('time', 1), ('pcr', 1), ('proapoptot', 1), ('antiapoptot', 1), ('caspas', 1), ('protein', 1), ('our', 1), ('find', 1), ('show', 1), ('characterist', 1), ('morpholog', 1), ('represent', 1), ('exhibit', 1), ('inhibit', 1), ('viabil', 1), ('IC', 1)]"', 'b'8'', 'b"('cancer', 'marsdenia', 'tenacissima', 'analysis', 'zinc', 'oxide', 'nanoparticles', 'znonps', 'present', 'synthesized', 'assessed', 'spec', 'sem', 'tem', 'edax', 'potential', 'assay', 'biosynthesis', 'natural', 'plants', 'stands', 'promising', 'nanodrug', 'delivery', 'system', 'therapeutics', 'chinese', 'medicinal', 'plant', 'extensively', 'used', 'clinical', 'remedy', 'treating', 'several', 'types', 'study', 'anti', 'potency', 'vitro', 'laryngeal', 'cell', 'line', 'biosynthesized', 'characterized', 'using', 'cytotoxic', 'apoptotic', 'inducing', 'mtt', 'staining', 'rhodamine', 'dapi', 'comet', 'anticancer', 'analysed', 'real', 'time', 'pcr', 'proapoptotic', 'antiapoptotic', 'caspases', 'proteins', 'findings', 'showed', 'characteristic', 'morphological', 'representation', 'exhibits', 'cytotoxicity', 'inhibiting', 'viability', 'cells', 'ic')"', 'b'(8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.05831296784181523'', 'b'[0.010786228589089623, 0.004403669170396472, 0.0038994322424884785, 0.003547400165041602, 0.003204116110741049, 0.002753407212108794]'', 'b'-2.317815772723104'', 'b'[-2.891820298110627, -3.7535901911063645, -3.875197323201151, -3.9698132995760007, -4.0369526024136295, -4.153291594497779]'', 'b'-3.7303805786583037'', 'b'[-1.5283999039255356, -1.917430050733813, -1.9795500898405256, -2.0278823549904366, -1.9919691902404932, -1.978376624238616]'', 'b'34'', 'b'0.054936771783163585'', 'b"['Apoptosis', 'Cell Line, Tumor', 'Cell Proliferation', 'DNA Damage', 'Gene Expression Regulation, Neoplastic', 'Green Chemistry Technology', 'Humans', 'Laryngeal Neoplasms', 'Marsdenia', 'Membrane Potential, Mitochondrial', 'Metal Nanoparticles', 'Plant Extracts', 'Proto-Oncogene Proteins c-bcl-2', 'Reactive Oxygen Species', 'Zinc Oxide']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'22'', 'b'Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.'', 'b'Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated in phase 3 investigation.We randomly assigned patients with recurrent ovarian cancer who had received one previous therapy, had an interval during which no platinum-based chemotherapy was used (platinum-free interval) of 6 months or more, and had investigator-determined resectable disease (to no macroscopic residual disease) to undergo secondary surgical cytoreduction and then receive platinum-based chemotherapy or to receive platinum-based chemotherapy alone. Adjuvant chemotherapy (paclitaxel-carboplatin or gemcitabine-carboplatin) and use of bevacizumab were at the discretion of the investigator. The primary end point was overall survival.A total of 485 patients underwent randomization, 240 to secondary cytoreduction before chemotherapy and 245 to chemotherapy alone. The median follow-up was 48.1 months. Complete gross resection was achieved in 67% of the patients assigned to surgery who underwent the procedure. Platinum-based chemotherapy with bevacizumab followed by bevacizumab maintenance was administered to 84% of the patients overall and was equally distributed between the two groups. The hazard ratio for death (surgery vs. no surgery) was 1.29 (95% confidence interval [CI], 0.97 to 1.72; P\xe2\x80\x89=\xe2\x80\x890.08), which corresponded to a median overall survival of 50.6 months and 64.7 months, respectively. Adjustment for platinum-free interval and chemotherapy choice did not alter the effect. The hazard ratio for disease progression or death (surgery vs. no surgery) was 0.82 (95% CI, 0.66 to 1.01; median progression-free survival, 18.9 months and 16.2 months, respectively). Surgical morbidity at 30 days was 9%; 1 patient (0.4%) died from postoperative complications. Patient-reported quality of life decreased significantly after surgery but did not differ significantly between the two groups after recovery.In this trial involving patients with platinum-sensitive, recurrent ovarian cancer, secondary surgical cytoreduction followed by chemotherapy did not result in longer overall survival than chemotherapy alone. (Funded by the National Cancer Institute and others; GOG-0213 ClinicalTrials.gov number, NCT00565851.).'', 'b'2027'', 'b'316'', 'b"[('chemotherapy', 20), ('months', 12), ('surgery', 12), ('patients', 10), ('secondary', 8), ('surgical', 8), ('cytoreduction', 8), ('ovarian', 8), ('cancer', 8), ('interval', 8), ('overall', 8), ('recurrent', 6), ('disease', 6), ('alone', 6), ('bevacizumab', 6), ('median', 6), ('survival', 6), ('primary', 4), ('assigned', 4), ('receive', 4), ('underwent', 4), ('followed', 4), ('two', 4), ('groups', 4), ('hazard', 4), ('ratio', 4), ('death', 4), ('ci', 4), ('respectively', 4), ('significantly', 4), ('women', 2), ('epithelial', 2), ('peritoneal', 2), ('widely', 2), ('practiced', 2), ('evaluated', 2), ('phase', 2), ('randomly', 2), ('received', 2), ('one', 2), ('previous', 2), ('therapy', 2), ('used', 2), ('resectable', 2), ('macroscopic', 2), ('residual', 2), ('undergo', 2), ('adjuvant', 2), ('use', 2), ('discretion', 2), ('investigator', 2), ('end', 2), ('point', 2), ('total', 2), ('randomization', 2), ('complete', 2), ('gross', 2), ('resection', 2), ('achieved', 2), ('procedure', 2), ('maintenance', 2), ('administered', 2), ('equally', 2), ('distributed', 2), ('confidence', 2), ('p', 2), ('corresponded', 2), ('adjustment', 2), ('choice', 2), ('alter', 2), ('effect', 2), ('progression', 2), ('morbidity', 2), ('days', 2), ('patient', 2), ('died', 2), ('postoperative', 2), ('complications', 2), ('quality', 2), ('life', 2), ('decreased', 2), ('differ', 2), ('trial', 2), ('involving', 2), ('result', 2), ('longer', 2), ('funded', 2), ('national', 2), ('institute', 2), ('others', 2), ('number', 2)]"', 'b'[(\',\', 15), (\'.\', 13), (\'the\', 13), (\'(\', 10), (\')\', 10), (\'chemotherapi\', 10), (\'to\', 10), (\'wa\', 9), (\'and\', 9), (\'of\', 8), (\'patient\', 6), (\'month\', 6), (\'%\', 6), (\'surgeri\', 6), (\'or\', 5), (\'secondari\', 4), (\'surgic\', 4), (\'cytoreduct\', 4), (\'in\', 4), (\'with\', 4), (\'ovarian\', 4), (\'cancer\', 4), (\'not\', 4), (\'interv\', 4), (\'no\', 4), (\'platinum-bas\', 4), (\'overal\', 4), (\';\', 4), (\'recurr\', 3), (\'had\', 3), (\'receiv\', 3), (\'diseas\', 3), (\'alon\', 3), (\'bevacizumab\', 3), (\'median\', 3), (\'by\', 3), (\'for\', 3), (\'surviv\', 3), (\'did\', 3), (\'platinum-sensit\', 2), (\'primari\', 2), (\'but\', 2), (\'assign\', 2), (\'who\', 2), (\'which\', 2), (\'use\', 2), (\'platinum-fre\', 2), (\'resect\', 2), (\'at\', 2), (\'underw\', 2), (\'follow\', 2), (\'between\', 2), (\'two\', 2), (\'group\', 2), (\'hazard\', 2), (\'ratio\', 2), (\'death\', 2), (\'vs.\', 2), (\'95\', 2), (\'CI\', 2), (\'respect\', 2), (\'significantli\', 2), (\'after\', 2), (\'women\', 1), (\'epitheli\', 1), (\'periton\', 1), (\'fallopian-tub\', 1), (\'``\', 1), ("\'\'", 1), (\'is\', 1), (\'wide\', 1), (\'practic\', 1), (\'ha\', 1), (\'been\', 1), (\'evalu\', 1), (\'phase\', 1), (\'3\', 1), (\'investigation.w\', 1), (\'randomli\', 1), (\'one\', 1), (\'previou\', 1), (\'therapi\', 1), (\'an\', 1), (\'dure\', 1), (\'6\', 1), (\'more\', 1), (\'investigator-determin\', 1), (\'macroscop\', 1), (\'residu\', 1), (\'undergo\', 1), (\'then\', 1), (\'adjuv\', 1), (\'paclitaxel-carboplatin\', 1), (\'gemcitabine-carboplatin\', 1), (\'were\', 1), (\'discret\', 1), (\'investig\', 1), (\'end\', 1), (\'point\', 1), (\'survival.a\', 1), (\'total\', 1), (\'485\', 1), (\'random\', 1), (\'240\', 1), (\'befor\', 1), (\'245\', 1), (\'follow-up\', 1), (\'48.1\', 1), (\'complet\', 1), (\'gross\', 1), (\'achiev\', 1), (\'67\', 1), (\'procedur\', 1), (\'mainten\', 1), (\'administ\', 1), (\'84\', 1), (\'equal\', 1), (\'distribut\', 1), (\'1.29\', 1), (\'confid\', 1), (\'[\', 1), (\']\', 1), (\'0.97\', 1), (\'1.72\', 1), (\'P\', 1), (\'=\', 1), (\'0.08\', 1), (\'correspond\', 1), (\'a\', 1), (\'50.6\', 1), (\'64.7\', 1), (\'adjust\', 1), (\'choic\', 1), (\'alter\', 1), (\'effect\', 1), (\'progress\', 1), (\'0.82\', 1), (\'0.66\', 1), (\'1.01\', 1), (\'progression-fre\', 1), (\'18.9\', 1), (\'16.2\', 1), (\'morbid\', 1), (\'30\', 1), (\'day\', 1), (\'9\', 1), (\'1\', 1), (\'0.4\', 1), (\'die\', 1), (\'from\', 1), (\'postop\', 1), (\'complic\', 1), (\'patient-report\', 1), (\'qualiti\', 1), (\'life\', 1), (\'decreas\', 1), (\'differ\', 1), (\'recovery.in\', 1), (\'thi\', 1), (\'trial\', 1), (\'involv\', 1), (\'result\', 1), (\'longer\', 1), (\'than\', 1), (\'fund\', 1), (\'nation\', 1), (\'institut\', 1), (\'other\', 1), (\'gog-0213\', 1), (\'clinicaltrials.gov\', 1), (\'number\', 1), (\'nct00565851\', 1)]'', 'b'13'', 'b"('chemotherapy', 'months', 'surgery', 'patients', 'secondary', 'surgical', 'cytoreduction', 'ovarian', 'cancer', 'interval', 'overall', 'recurrent', 'disease', 'alone', 'bevacizumab', 'median', 'survival', 'primary', 'assigned', 'receive', 'underwent', 'followed', 'two', 'groups', 'hazard', 'ratio', 'death', 'ci', 'respectively', 'significantly', 'women', 'epithelial', 'peritoneal', 'widely', 'practiced', 'evaluated', 'phase', 'randomly', 'received', 'one', 'previous', 'therapy', 'used', 'resectable', 'macroscopic', 'residual', 'undergo', 'adjuvant', 'use', 'discretion', 'investigator', 'end', 'point', 'total', 'randomization', 'complete', 'gross', 'resection', 'achieved', 'procedure', 'maintenance', 'administered', 'equally', 'distributed', 'confidence', 'p', 'corresponded', 'adjustment', 'choice', 'alter', 'effect', 'progression', 'morbidity', 'days', 'patient', 'died', 'postoperative', 'complications', 'quality', 'life', 'decreased', 'differ', 'trial', 'involving', 'result', 'longer', 'funded', 'national', 'institute', 'others', 'number')"', 'b'(20, 12, 12, 10, 8, 8, 8, 8, 8, 8, 8, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.06492269241860624'', 'b'[0.22976616468922006, 0.029533535161815304, 0.01984848867699764, 0.01236934801609998, 0.009378956188031853, 0.007552964717795562, 0.006229817613948164, 0.005728087336314755]'', 'b'-2.1780538303479458'', 'b'[0.3068528194400547, -1.70805020110221, -2.068052935133617, -2.5409593240373143, -2.817712325956905, -3.0342406381523954, -3.2268337452681797, -3.310799125385514]'', 'b'-3.393722853572325'', 'b'[0.14100879089363025, -0.7566714100859674, -0.8825260932282737, -1.0843353509951235, -1.2024376207310346, -1.294839455417559, -1.377027120693451, -1.4128587174686034]'', 'b'84'', 'b'0.21624495693494633'', 'b"['Aged', 'Antineoplastic Combined Chemotherapy Protocols', 'Bevacizumab', 'Carboplatin', 'Combined Modality Therapy', 'Cytoreduction Surgical Procedures', 'Female', 'Humans', 'Middle Aged', 'Neoplasm Recurrence, Local', 'Neoplasms, Glandular and Epithelial', 'Ovarian Neoplasms', 'Paclitaxel', 'Quality of Life', 'Reoperation', 'Survival Analysis']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'22'', 'b'Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.'', 'b'Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated in phase 3 investigation.We randomly assigned patients with recurrent ovarian cancer who had received one previous therapy, had an interval during which no platinum-based chemotherapy was used (platinum-free interval) of 6 months or more, and had investigator-determined resectable disease (to no macroscopic residual disease) to undergo secondary surgical cytoreduction and then receive platinum-based chemotherapy or to receive platinum-based chemotherapy alone. Adjuvant chemotherapy (paclitaxel-carboplatin or gemcitabine-carboplatin) and use of bevacizumab were at the discretion of the investigator. The primary end point was overall survival.A total of 485 patients underwent randomization, 240 to secondary cytoreduction before chemotherapy and 245 to chemotherapy alone. The median follow-up was 48.1 months. Complete gross resection was achieved in 67% of the patients assigned to surgery who underwent the procedure. Platinum-based chemotherapy with bevacizumab followed by bevacizumab maintenance was administered to 84% of the patients overall and was equally distributed between the two groups. The hazard ratio for death (surgery vs. no surgery) was 1.29 (95% confidence interval [CI], 0.97 to 1.72; P\xe2\x80\x89=\xe2\x80\x890.08), which corresponded to a median overall survival of 50.6 months and 64.7 months, respectively. Adjustment for platinum-free interval and chemotherapy choice did not alter the effect. The hazard ratio for disease progression or death (surgery vs. no surgery) was 0.82 (95% CI, 0.66 to 1.01; median progression-free survival, 18.9 months and 16.2 months, respectively). Surgical morbidity at 30 days was 9%; 1 patient (0.4%) died from postoperative complications. Patient-reported quality of life decreased significantly after surgery but did not differ significantly between the two groups after recovery.In this trial involving patients with platinum-sensitive, recurrent ovarian cancer, secondary surgical cytoreduction followed by chemotherapy did not result in longer overall survival than chemotherapy alone. (Funded by the National Cancer Institute and others; GOG-0213 ClinicalTrials.gov number, NCT00565851.).'', 'b'2027'', 'b'316'', 'b"[('chemotherapy', 20), ('months', 12), ('surgery', 12), ('patients', 10), ('secondary', 8), ('surgical', 8), ('cytoreduction', 8), ('ovarian', 8), ('cancer', 8), ('interval', 8), ('overall', 8), ('recurrent', 6), ('disease', 6), ('alone', 6), ('bevacizumab', 6), ('median', 6), ('survival', 6), ('primary', 4), ('assigned', 4), ('receive', 4), ('underwent', 4), ('followed', 4), ('two', 4), ('groups', 4), ('hazard', 4), ('ratio', 4), ('death', 4), ('ci', 4), ('respectively', 4), ('significantly', 4), ('women', 2), ('epithelial', 2), ('peritoneal', 2), ('widely', 2), ('practiced', 2), ('evaluated', 2), ('phase', 2), ('randomly', 2), ('received', 2), ('one', 2), ('previous', 2), ('therapy', 2), ('used', 2), ('resectable', 2), ('macroscopic', 2), ('residual', 2), ('undergo', 2), ('adjuvant', 2), ('use', 2), ('discretion', 2), ('investigator', 2), ('end', 2), ('point', 2), ('total', 2), ('randomization', 2), ('complete', 2), ('gross', 2), ('resection', 2), ('achieved', 2), ('procedure', 2), ('maintenance', 2), ('administered', 2), ('equally', 2), ('distributed', 2), ('confidence', 2), ('p', 2), ('corresponded', 2), ('adjustment', 2), ('choice', 2), ('alter', 2), ('effect', 2), ('progression', 2), ('morbidity', 2), ('days', 2), ('patient', 2), ('died', 2), ('postoperative', 2), ('complications', 2), ('quality', 2), ('life', 2), ('decreased', 2), ('differ', 2), ('trial', 2), ('involving', 2), ('result', 2), ('longer', 2), ('funded', 2), ('national', 2), ('institute', 2), ('others', 2), ('number', 2)]"', 'b'[(\',\', 15), (\'.\', 13), (\'the\', 13), (\'(\', 10), (\')\', 10), (\'chemotherapi\', 10), (\'to\', 10), (\'wa\', 9), (\'and\', 9), (\'of\', 8), (\'patient\', 6), (\'month\', 6), (\'%\', 6), (\'surgeri\', 6), (\'or\', 5), (\'secondari\', 4), (\'surgic\', 4), (\'cytoreduct\', 4), (\'in\', 4), (\'with\', 4), (\'ovarian\', 4), (\'cancer\', 4), (\'not\', 4), (\'interv\', 4), (\'no\', 4), (\'platinum-bas\', 4), (\'overal\', 4), (\';\', 4), (\'recurr\', 3), (\'had\', 3), (\'receiv\', 3), (\'diseas\', 3), (\'alon\', 3), (\'bevacizumab\', 3), (\'median\', 3), (\'by\', 3), (\'for\', 3), (\'surviv\', 3), (\'did\', 3), (\'platinum-sensit\', 2), (\'primari\', 2), (\'but\', 2), (\'assign\', 2), (\'who\', 2), (\'which\', 2), (\'use\', 2), (\'platinum-fre\', 2), (\'resect\', 2), (\'at\', 2), (\'underw\', 2), (\'follow\', 2), (\'between\', 2), (\'two\', 2), (\'group\', 2), (\'hazard\', 2), (\'ratio\', 2), (\'death\', 2), (\'vs.\', 2), (\'95\', 2), (\'CI\', 2), (\'respect\', 2), (\'significantli\', 2), (\'after\', 2), (\'women\', 1), (\'epitheli\', 1), (\'periton\', 1), (\'fallopian-tub\', 1), (\'``\', 1), ("\'\'", 1), (\'is\', 1), (\'wide\', 1), (\'practic\', 1), (\'ha\', 1), (\'been\', 1), (\'evalu\', 1), (\'phase\', 1), (\'3\', 1), (\'investigation.w\', 1), (\'randomli\', 1), (\'one\', 1), (\'previou\', 1), (\'therapi\', 1), (\'an\', 1), (\'dure\', 1), (\'6\', 1), (\'more\', 1), (\'investigator-determin\', 1), (\'macroscop\', 1), (\'residu\', 1), (\'undergo\', 1), (\'then\', 1), (\'adjuv\', 1), (\'paclitaxel-carboplatin\', 1), (\'gemcitabine-carboplatin\', 1), (\'were\', 1), (\'discret\', 1), (\'investig\', 1), (\'end\', 1), (\'point\', 1), (\'survival.a\', 1), (\'total\', 1), (\'485\', 1), (\'random\', 1), (\'240\', 1), (\'befor\', 1), (\'245\', 1), (\'follow-up\', 1), (\'48.1\', 1), (\'complet\', 1), (\'gross\', 1), (\'achiev\', 1), (\'67\', 1), (\'procedur\', 1), (\'mainten\', 1), (\'administ\', 1), (\'84\', 1), (\'equal\', 1), (\'distribut\', 1), (\'1.29\', 1), (\'confid\', 1), (\'[\', 1), (\']\', 1), (\'0.97\', 1), (\'1.72\', 1), (\'P\', 1), (\'=\', 1), (\'0.08\', 1), (\'correspond\', 1), (\'a\', 1), (\'50.6\', 1), (\'64.7\', 1), (\'adjust\', 1), (\'choic\', 1), (\'alter\', 1), (\'effect\', 1), (\'progress\', 1), (\'0.82\', 1), (\'0.66\', 1), (\'1.01\', 1), (\'progression-fre\', 1), (\'18.9\', 1), (\'16.2\', 1), (\'morbid\', 1), (\'30\', 1), (\'day\', 1), (\'9\', 1), (\'1\', 1), (\'0.4\', 1), (\'die\', 1), (\'from\', 1), (\'postop\', 1), (\'complic\', 1), (\'patient-report\', 1), (\'qualiti\', 1), (\'life\', 1), (\'decreas\', 1), (\'differ\', 1), (\'recovery.in\', 1), (\'thi\', 1), (\'trial\', 1), (\'involv\', 1), (\'result\', 1), (\'longer\', 1), (\'than\', 1), (\'fund\', 1), (\'nation\', 1), (\'institut\', 1), (\'other\', 1), (\'gog-0213\', 1), (\'clinicaltrials.gov\', 1), (\'number\', 1), (\'nct00565851\', 1)]'', 'b'13'', 'b"('chemotherapy', 'months', 'surgery', 'patients', 'secondary', 'surgical', 'cytoreduction', 'ovarian', 'cancer', 'interval', 'overall', 'recurrent', 'disease', 'alone', 'bevacizumab', 'median', 'survival', 'primary', 'assigned', 'receive', 'underwent', 'followed', 'two', 'groups', 'hazard', 'ratio', 'death', 'ci', 'respectively', 'significantly', 'women', 'epithelial', 'peritoneal', 'widely', 'practiced', 'evaluated', 'phase', 'randomly', 'received', 'one', 'previous', 'therapy', 'used', 'resectable', 'macroscopic', 'residual', 'undergo', 'adjuvant', 'use', 'discretion', 'investigator', 'end', 'point', 'total', 'randomization', 'complete', 'gross', 'resection', 'achieved', 'procedure', 'maintenance', 'administered', 'equally', 'distributed', 'confidence', 'p', 'corresponded', 'adjustment', 'choice', 'alter', 'effect', 'progression', 'morbidity', 'days', 'patient', 'died', 'postoperative', 'complications', 'quality', 'life', 'decreased', 'differ', 'trial', 'involving', 'result', 'longer', 'funded', 'national', 'institute', 'others', 'number')"', 'b'(20, 12, 12, 10, 8, 8, 8, 8, 8, 8, 8, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.06492269241860624'', 'b'[0.22976616468922006, 0.029533535161815304, 0.01984848867699764, 0.01236934801609998, 0.009378956188031853, 0.007552964717795562, 0.006229817613948164, 0.005728087336314755]'', 'b'-2.1780538303479458'', 'b'[0.3068528194400547, -1.70805020110221, -2.068052935133617, -2.5409593240373143, -2.817712325956905, -3.0342406381523954, -3.2268337452681797, -3.310799125385514]'', 'b'-3.393722853572325'', 'b'[0.14100879089363025, -0.7566714100859674, -0.8825260932282737, -1.0843353509951235, -1.2024376207310346, -1.294839455417559, -1.377027120693451, -1.4128587174686034]'', 'b'84'', 'b'0.21624495693494633'', 'b"['Aged', 'Antineoplastic Combined Chemotherapy Protocols', 'Bevacizumab', 'Carboplatin', 'Combined Modality Therapy', 'Cytoreduction Surgical Procedures', 'Female', 'Humans', 'Middle Aged', 'Neoplasm Recurrence, Local', 'Neoplasms, Glandular and Epithelial', 'Ovarian Neoplasms', 'Paclitaxel', 'Quality of Life', 'Reoperation', 'Survival Analysis']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'23'', 'b'Mechanotechnical faults and particular issues of anastomotic complications following robot-assisted anterior resection in 968 rectal cancer patients.'', 'b'As most risk factors for anastomotic complications (AC) in rectal cancer patients appear to be noncorrectable, it is needed to find the correctable causes. Additionally, the outcomes of indocyanine-green fluorescence imaging (IFI) and robot-stapled anastomosis have yet been undetermined.This study retrospectively analyzed 968 consecutive patients with rectal cancer, who underwent curative robot-assisted anterior resections between 2010 and 2018. IFI parameters and stapling features in the surgical records were reviewed, and reconfirmed.AC occurred in 54 patients (5.6%), 34 (3.5%) with anastomotic leakage (AL) and 24 (2.5%) with anastomotic stenosis (AS). Mechanotechnical faults including defective stapling configurations, including angles lesser than or equal to 150\xc2\xb0 and outer deviation (more than half from the center of the circle) of linear staples, between the two linear staples were independently associated with AL (P\xe2\x80\x89<\xe2\x80\x89.001 each). IFI significantly reduced AL rate (2.5% vs 5.3%, P\xe2\x80\x89=\xe2\x80\x89.029) and AS rate (2% vs 18.8%, P\xe2\x80\x89=\xe2\x80\x89.006), respectively. Robot linear stapling enabled to maintain the obtuse angle during consecutive staplings and reduced console time. AL and AS were independent risk factors for disease-free survival (P\xe2\x80\x89=\xe2\x80\x89.02) and local recurrence (P\xe2\x80\x89=\xe2\x80\x89.03), respectively.AC were associated with some correctable causes, namely, mechanotechnical errors and lack of use of IFI.'', 'b'1196'', 'b'204'', 'b"[('p', 10), ('ifi', 8), ('al', 8), ('anastomotic', 6), ('patients', 6), ('stapling', 6), ('linear', 6), ('risk', 4), ('factors', 4), ('rectal', 4), ('cancer', 4), ('correctable', 4), ('causes', 4), ('consecutive', 4), ('mechanotechnical', 4), ('including', 4), ('staples', 4), ('associated', 4), ('reduced', 4), ('rate', 4), ('vs', 4), ('complications', 2), ('ac', 2), ('appear', 2), ('noncorrectable', 2), ('needed', 2), ('find', 2), ('additionally', 2), ('outcomes', 2), ('fluorescence', 2), ('imaging', 2), ('anastomosis', 2), ('yet', 2), ('study', 2), ('retrospectively', 2), ('analyzed', 2), ('underwent', 2), ('curative', 2), ('anterior', 2), ('resections', 2), ('parameters', 2), ('features', 2), ('surgical', 2), ('records', 2), ('reviewed', 2), ('occurred', 2), ('leakage', 2), ('stenosis', 2), ('faults', 2), ('defective', 2), ('configurations', 2), ('angles', 2), ('lesser', 2), ('equal', 2), ('outer', 2), ('deviation', 2), ('half', 2), ('center', 2), ('circle', 2), ('two', 2), ('independently', 2), ('significantly', 2), ('respectively', 2), ('robot', 2), ('enabled', 2), ('maintain', 2), ('obtuse', 2), ('angle', 2), ('staplings', 2), ('console', 2), ('time', 2), ('independent', 2), ('survival', 2), ('local', 2), ('recurrence', 2), ('namely', 2), ('errors', 2), ('lack', 2), ('use', 2)]"', 'b"[('(', 13), (')', 13), (',', 13), ('and', 11), ('the', 7), ('.', 7), ('%', 7), ('stapl', 6), ('of', 5), ('with', 5), ('P', 5), ('to', 4), ('ifi', 4), ('were', 4), ('AL', 4), ('=', 4), ('anastomot', 3), ('in', 3), ('patient', 3), ('AS', 3), ('linear', 3), ('risk', 2), ('factor', 2), ('for', 2), ('rectal', 2), ('cancer', 2), ('correct', 2), ('caus', 2), ('consecut', 2), ('between', 2), ('2.5', 2), ('mechanotechn', 2), ('includ', 2), ('angl', 2), ('than', 2), ('independ', 2), ('associ', 2), ('reduc', 2), ('rate', 2), ('vs', 2), ('As', 1), ('most', 1), ('complic', 1), ('AC', 1), ('appear', 1), ('be', 1), ('noncorrect', 1), ('it', 1), ('is', 1), ('need', 1), ('find', 1), ('addit', 1), ('outcom', 1), ('indocyanine-green', 1), ('fluoresc', 1), ('imag', 1), ('robot-stapl', 1), ('anastomosi', 1), ('have', 1), ('yet', 1), ('been', 1), ('undetermined.thi', 1), ('studi', 1), ('retrospect', 1), ('analyz', 1), ('968', 1), ('who', 1), ('underw', 1), ('cur', 1), ('robot-assist', 1), ('anterior', 1), ('resect', 1), ('2010', 1), ('2018', 1), ('paramet', 1), ('featur', 1), ('surgic', 1), ('record', 1), ('review', 1), ('reconfirmed.ac', 1), ('occur', 1), ('54', 1), ('5.6', 1), ('34', 1), ('3.5', 1), ('leakag', 1), ('24', 1), ('stenosi', 1), ('fault', 1), ('defect', 1), ('configur', 1), ('lesser', 1), ('or', 1), ('equal', 1), ('150\xc2\xb0', 1), ('outer', 1), ('deviat', 1), ('more', 1), ('half', 1), ('from', 1), ('center', 1), ('circl', 1), ('two', 1), ('<', 1), ('.001', 1), ('each', 1), ('significantli', 1), ('5.3', 1), ('.029', 1), ('2', 1), ('18.8', 1), ('.006', 1), ('respect', 1), ('robot', 1), ('enabl', 1), ('maintain', 1), ('obtus', 1), ('dure', 1), ('consol', 1), ('time', 1), ('disease-fre', 1), ('surviv', 1), ('.02', 1), ('local', 1), ('recurr', 1), ('.03', 1), ('respectively.ac', 1), ('some', 1), ('name', 1), ('error', 1), ('lack', 1), ('use', 1)]"', 'b'7'', 'b"('p', 'ifi', 'al', 'anastomotic', 'patients', 'stapling', 'linear', 'risk', 'factors', 'rectal', 'cancer', 'correctable', 'causes', 'consecutive', 'mechanotechnical', 'including', 'staples', 'associated', 'reduced', 'rate', 'vs', 'complications', 'ac', 'appear', 'noncorrectable', 'needed', 'find', 'additionally', 'outcomes', 'fluorescence', 'imaging', 'anastomosis', 'yet', 'study', 'retrospectively', 'analyzed', 'underwent', 'curative', 'anterior', 'resections', 'parameters', 'features', 'surgical', 'records', 'reviewed', 'occurred', 'leakage', 'stenosis', 'faults', 'defective', 'configurations', 'angles', 'lesser', 'equal', 'outer', 'deviation', 'half', 'center', 'circle', 'two', 'independently', 'significantly', 'respectively', 'robot', 'enabled', 'maintain', 'obtuse', 'angle', 'staplings', 'console', 'time', 'independent', 'survival', 'local', 'recurrence', 'namely', 'errors', 'lack', 'use')"', 'b'(10, 8, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.037733861346927945'', 'b'[0.015797775584961853, 0.012835692662781504, 0.00933504920929564, 0.008929177504543655, 0.007468039367436511, 0.006223366139530426, 0.005134277065112602, 0.004776071688476839, 0.004234455311433074, 0.003949443896240463, 0.0016056658871580042, 0.0015059111972416813, 0.0015059111972416813]'', 'b'-2.6888794541139363'', 'b'[-2.258096538021482, -2.4657359027997265, -2.784189633918261, -2.828641396489095, -3.007333185232471, -3.189654742026425, -3.382026634673881, -3.4543472962535073, -3.574710978503383, -3.6443908991413725, -4.5053315359323625, -4.529429087511423, -4.529429087511423]'', 'b'-4.058472180005543'', 'b'[-0.9274954612779089, -1.012781703549548, -1.1435840785880622, -1.1618422917937634, -1.2352385440072884, -1.3101256950091142, -1.389140942720485, -1.4188460878470486, -1.4682845273068916, -1.4969050087813314, -1.7795780607656073, -1.7188713309588972, -1.7188713309588972]'', 'b'45'', 'b'0.09045576379880489'', 'b"['Adenocarcinoma', 'Anastomosis, Surgical', 'Anastomotic Leak', 'Constriction, Pathologic', 'Contrast Media', 'Disease-Free Survival', 'Enema', 'Female', 'Humans', 'Indocyanine Green', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local', 'Rectal Neoplasms', 'Retrospective Studies', 'Risk Factors', 'Robotic Surgical Procedures', 'Sensitivity and Specificity', 'Sex Factors', 'Surgical Stapling', 'Tomography, X-Ray Computed']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'24'', 'b'Impact of metabolic syndrome on functional outcomes and complications of surgical treatment of prostate cancer.'', 'b'Metabolic syndrome (MetS) has a negative impact on functional recovery and complications after many surgical procedures.To assess the role of Mets on functional outcomes and complications after radical prostatectomy (RP) for prostate cancer.Complete data were collected from 5758 patients, undergoing RP at a single referral centers in a 10-year period and the presence of MetS before surgery was ascertained in 17.7% of them using a modified version of the IDF-AHA_NHLBI criteria. Outcomes included 1-year continence and potency rates, early (\xe2\x89\xa490 days) and late (>90 days) complications.Postoperative continence (no pads) was significantly less likely in MetS patients (75.4% vs 82.6%, P\xe2\x80\x89<\xe2\x80\x89.01), despite no difference in preoperative continence. Erections with or without therapy were reached in 55.8% of non-MetS and 41.8% of MetS patients (P\xe2\x80\x89<\xe2\x80\x89.01), in this case a significant difference in preoperative function was seen. No differences in early and late complications, except for wound infections (5.8% vs 3.9%, P\xe2\x80\x89<\xe2\x80\x89.01) were observed.In the present study RP was safe from the complications standpoint in MetS patients, but the presence of the syndrome was a significant risk factor for post-RP incontinence and impotence.'', 'b'1042'', 'b'186'', 'b"[('mets', 12), ('complications', 8), ('patients', 8), ('rp', 6), ('continence', 6), ('p', 6), ('syndrome', 4), ('functional', 4), ('outcomes', 4), ('presence', 4), ('early', 4), ('days', 4), ('late', 4), ('vs', 4), ('difference', 4), ('preoperative', 4), ('significant', 4), ('metabolic', 2), ('negative', 2), ('impact', 2), ('recovery', 2), ('many', 2), ('surgical', 2), ('assess', 2), ('role', 2), ('radical', 2), ('prostatectomy', 2), ('prostate', 2), ('data', 2), ('collected', 2), ('undergoing', 2), ('single', 2), ('referral', 2), ('centers', 2), ('period', 2), ('surgery', 2), ('ascertained', 2), ('using', 2), ('modified', 2), ('version', 2), ('criteria', 2), ('included', 2), ('potency', 2), ('rates', 2), ('pads', 2), ('significantly', 2), ('less', 2), ('likely', 2), ('despite', 2), ('erections', 2), ('without', 2), ('therapy', 2), ('reached', 2), ('case', 2), ('function', 2), ('seen', 2), ('differences', 2), ('except', 2), ('wound', 2), ('infections', 2), ('present', 2), ('study', 2), ('safe', 2), ('standpoint', 2), ('risk', 2), ('factor', 2), ('incontinence', 2), ('impotence', 2)]"', 'b"[('in', 9), ('(', 8), (')', 8), ('and', 8), (',', 8), ('the', 7), ('of', 7), ('%', 7), ('met', 6), ('a', 6), ('wa', 5), ('complic', 4), ('patient', 4), ('.', 4), ('function', 3), ('RP', 3), ('for', 3), ('were', 3), ('contin', 3), ('P', 3), ('<', 3), ('.01', 3), ('differ', 3), ('syndrom', 2), ('on', 2), ('after', 2), ('outcom', 2), ('from', 2), ('presenc', 2), ('earli', 2), ('day', 2), ('late', 2), ('no', 2), ('vs', 2), ('preoper', 2), ('signific', 2), ('metabol', 1), ('ha', 1), ('neg', 1), ('impact', 1), ('recoveri', 1), ('mani', 1), ('surgic', 1), ('procedures.to', 1), ('assess', 1), ('role', 1), ('radic', 1), ('prostatectomi', 1), ('prostat', 1), ('cancer.complet', 1), ('data', 1), ('collect', 1), ('5758', 1), ('undergo', 1), ('at', 1), ('singl', 1), ('referr', 1), ('center', 1), ('10-year', 1), ('period', 1), ('befor', 1), ('surgeri', 1), ('ascertain', 1), ('17.7', 1), ('them', 1), ('use', 1), ('modifi', 1), ('version', 1), ('idf-aha_nhlbi', 1), ('criteria', 1), ('includ', 1), ('1-year', 1), ('potenc', 1), ('rate', 1), ('\xe2\x89\xa490', 1), ('>', 1), ('90', 1), ('complications.postop', 1), ('pad', 1), ('significantli', 1), ('less', 1), ('like', 1), ('75.4', 1), ('82.6', 1), ('despit', 1), ('erect', 1), ('with', 1), ('or', 1), ('without', 1), ('therapi', 1), ('reach', 1), ('55.8', 1), ('non-met', 1), ('41.8', 1), ('thi', 1), ('case', 1), ('seen', 1), ('No', 1), ('except', 1), ('wound', 1), ('infect', 1), ('5.8', 1), ('3.9', 1), ('observed.in', 1), ('present', 1), ('studi', 1), ('safe', 1), ('standpoint', 1), ('but', 1), ('risk', 1), ('factor', 1), ('post-rp', 1), ('incontin', 1), ('impot', 1)]"', 'b'4'', 'b"('mets', 'complications', 'patients', 'rp', 'continence', 'p', 'syndrome', 'functional', 'outcomes', 'presence', 'early', 'days', 'late', 'vs', 'difference', 'preoperative', 'significant', 'metabolic', 'negative', 'impact', 'recovery', 'many', 'surgical', 'assess', 'role', 'radical', 'prostatectomy', 'prostate', 'data', 'collected', 'undergoing', 'single', 'referral', 'centers', 'period', 'surgery', 'ascertained', 'using', 'modified', 'version', 'criteria', 'included', 'potency', 'rates', 'pads', 'significantly', 'less', 'likely', 'despite', 'erections', 'without', 'therapy', 'reached', 'case', 'function', 'seen', 'differences', 'except', 'wound', 'infections', 'present', 'study', 'safe', 'standpoint', 'risk', 'factor', 'incontinence', 'impotence')"', 'b'(12, 8, 8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.03657086095605563'', 'b'[0.014008544214389051, 0.011381942174191103, 0.00827777612668444, 0.007917872816828594, 0.006622220901347551, 0.005518517417789626, 0.004552776869676442, 0.00423514127411762, 0.003754867521382632, 0.003502136053597263, 0.0014194482610145318, 0.0013268618508906114, 0.0013268618508906114]'', 'b'-2.6888794541139363'', 'b'[-2.258096538021482, -2.4657359027997265, -2.784189633918261, -2.828641396489095, -3.007333185232471, -3.189654742026425, -3.382026634673881, -3.4543472962535073, -3.574710978503383, -3.6443908991413725, -4.5053315359323625, -4.529429087511423, -4.529429087511423]'', 'b'-3.9333854657598204'', 'b'[-0.8224487750240522, -0.8980756307997882, -1.0140635332876782, -1.0302538498035856, -1.0953373572109417, -1.1617429065401348, -1.2318090107978321, -1.2581497976169858, -1.3019889166966911, -1.3273678871736136, -1.5731909134373878, -1.5145015189583615, -1.5145015189583615]'', 'b'6'', 'b'0.08866760672922054'', 'b"['Erectile Dysfunction', 'Humans', 'Male', 'Metabolic Syndrome', 'Middle Aged', 'Postoperative Complications', 'Prostatectomy', 'Prostatic Neoplasms', 'Retrospective Studies', 'Risk Factors', 'Surgical Wound Infection', 'Urinary Incontinence']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'25'', 'b'Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response.'', 'b'Tumor-associated macrophages (TAMs) exist as heterogeneous subsets and have dichotomous roles in cancer-immune evasion. This study aims to assess the clinical effects of Galectin-9We identified Gal-9The frequency of Gal-9Gal-9'', 'b'198'', 'b'29'', 'b"[('macrophages', 2), ('tams', 2), ('exist', 2), ('heterogeneous', 2), ('subsets', 2), ('dichotomous', 2), ('roles', 2), ('evasion', 2), ('study', 2), ('aims', 2), ('assess', 2), ('clinical', 2), ('effects', 2), ('identified', 2), ('frequency', 2)]"', 'b"[('of', 2), ('tumor-associ', 1), ('macrophag', 1), ('(', 1), ('tam', 1), (')', 1), ('exist', 1), ('as', 1), ('heterogen', 1), ('subset', 1), ('and', 1), ('have', 1), ('dichotom', 1), ('role', 1), ('in', 1), ('cancer-immun', 1), ('evas', 1), ('.', 1), ('thi', 1), ('studi', 1), ('aim', 1), ('to', 1), ('assess', 1), ('the', 1), ('clinic', 1), ('effect', 1), ('galectin-9w', 1), ('identifi', 1), ('gal-9th', 1), ('frequenc', 1), ('gal-9gal-9', 1)]"', 'b'2'', 'b"('macrophages', 'tams', 'exist', 'heterogeneous', 'subsets', 'dichotomous', 'roles', 'evasion', 'study', 'aims', 'assess', 'clinical', 'effects', 'identified', 'frequency')"', 'b'(2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.025556444606691733'', 'b'[0.03997129837541017, 0.011745448059660843, 0.007830298706440562, 0.005089694159186365, 0.004490906611046792, 0.003817270619389774, 0.0031482644283627]'', 'b'-3.0163830207523885'', 'b'[-1.0794415416798357, -2.258096538021482, -2.6635616461296463, -3.0943445622221004, -3.219507705176107, -3.382026634673881, -3.574710978503383]'', 'b'-4.278385419824526'', 'b'[-0.34517343953037977, -0.6895812456268133, -0.8134028491763329, -0.9449560466911149, -0.9831785737494197, -1.0328088725227422, -1.0916511352840825]'', 'b'87'', 'b'0.17114201376766508'', 'b"['Adult', 'Biomarkers, Pharmacological', 'Cell Movement', 'Chemotherapy, Adjuvant', 'Female', 'Galectins', 'Humans', 'Macrophages', 'Male', 'Microarray Analysis', 'Middle Aged', 'Muscles', 'Neoplasm Invasiveness', 'Neoplasm Staging', 'Prognosis', 'Survival Analysis', 'T-Lymphocytes, Regulatory', 'Tumor Escape', 'Tumor Microenvironment', 'Urinary Bladder Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'26'', 'b'Targeted therapies for ROS1-rearranged non-small cell lung cancer.'', 'b'ROS1 gene fusions account for approximately 1-2% of all cases of non-small cell lung cancer (NSCLC). Similarly to anaplastic lymphoma kinase (ALK)-positive NSCLC, patients with ROS1+ NSCLC tend to have minimal smoking and be of the female sex. In most cases, adenocarcinoma is the dominant histology. The ROS1 gene has homology to ALK and this structural similarity formed the basis for utilizing ALK inhibitors for ROS1+ NSCLC. On the basis of impressive progression-free survival of 19.2 months from the PROFILE 1001 trial, crizotinib obtained Food and Drug Administration (FDA) approval as first-line therapy for treatment of ROS1+ NSCLC. Since then, there has been a growing appreciation of the incidence of brain metastases in ROS1+ NSCLC and rates of central nervous system progression on crizotinib. Additionally, appreciation of novel resistance mechanisms to crizotinib has led to the development of newer tyrosine kinase inhibitors (TKIs). In this review, we highlight known and emerging TKIs for the management of ROS1+ NSCLC.'', 'b'880'', 'b'158'', 'b"[('nsclc', 14), ('alk', 6), ('crizotinib', 6), ('gene', 4), ('cases', 4), ('kinase', 4), ('basis', 4), ('inhibitors', 4), ('appreciation', 4), ('tkis', 4), ('fusions', 2), ('account', 2), ('approximately', 2), ('cell', 2), ('lung', 2), ('cancer', 2), ('similarly', 2), ('anaplastic', 2), ('lymphoma', 2), ('patients', 2), ('tend', 2), ('minimal', 2), ('smoking', 2), ('female', 2), ('sex', 2), ('adenocarcinoma', 2), ('dominant', 2), ('histology', 2), ('homology', 2), ('structural', 2), ('similarity', 2), ('formed', 2), ('utilizing', 2), ('impressive', 2), ('survival', 2), ('months', 2), ('profile', 2), ('trial', 2), ('obtained', 2), ('food', 2), ('drug', 2), ('administration', 2), ('fda', 2), ('approval', 2), ('therapy', 2), ('treatment', 2), ('since', 2), ('growing', 2), ('incidence', 2), ('brain', 2), ('metastases', 2), ('rates', 2), ('central', 2), ('nervous', 2), ('system', 2), ('progression', 2), ('additionally', 2), ('novel', 2), ('resistance', 2), ('mechanisms', 2), ('led', 2), ('development', 2), ('newer', 2), ('tyrosine', 2), ('review', 2), ('highlight', 2), ('known', 2), ('emerging', 2), ('management', 2)]"', 'b"[('of', 12), ('the', 9), ('.', 8), ('nsclc', 7), (',', 6), ('for', 5), ('to', 5), ('ros1+', 5), ('and', 5), ('(', 4), (')', 4), ('alk', 3), ('ha', 3), ('crizotinib', 3), ('ros1', 2), ('gene', 2), ('case', 2), ('kinas', 2), ('In', 2), ('thi', 2), ('basi', 2), ('inhibitor', 2), ('appreci', 2), ('tki', 2), ('fusion', 1), ('account', 1), ('approxim', 1), ('1-2', 1), ('%', 1), ('all', 1), ('non-smal', 1), ('cell', 1), ('lung', 1), ('cancer', 1), ('similarli', 1), ('anaplast', 1), ('lymphoma', 1), ('-posit', 1), ('patient', 1), ('with', 1), ('tend', 1), ('have', 1), ('minim', 1), ('smoke', 1), ('be', 1), ('femal', 1), ('sex', 1), ('most', 1), ('adenocarcinoma', 1), ('is', 1), ('domin', 1), ('histolog', 1), ('homolog', 1), ('structur', 1), ('similar', 1), ('form', 1), ('util', 1), ('On', 1), ('impress', 1), ('progression-fre', 1), ('surviv', 1), ('19.2', 1), ('month', 1), ('from', 1), ('profil', 1), ('1001', 1), ('trial', 1), ('obtain', 1), ('food', 1), ('drug', 1), ('administr', 1), ('fda', 1), ('approv', 1), ('as', 1), ('first-lin', 1), ('therapi', 1), ('treatment', 1), ('sinc', 1), ('then', 1), ('there', 1), ('been', 1), ('a', 1), ('grow', 1), ('incid', 1), ('brain', 1), ('metastas', 1), ('in', 1), ('rate', 1), ('central', 1), ('nervou', 1), ('system', 1), ('progress', 1), ('on', 1), ('addit', 1), ('novel', 1), ('resist', 1), ('mechan', 1), ('led', 1), ('develop', 1), ('newer', 1), ('tyrosin', 1), ('review', 1), ('we', 1), ('highlight', 1), ('known', 1), ('emerg', 1), ('manag', 1)]"', 'b'8'', 'b"('nsclc', 'alk', 'crizotinib', 'gene', 'cases', 'kinase', 'basis', 'inhibitors', 'appreciation', 'tkis', 'fusions', 'account', 'approximately', 'cell', 'lung', 'cancer', 'similarly', 'anaplastic', 'lymphoma', 'patients', 'tend', 'minimal', 'smoking', 'female', 'sex', 'adenocarcinoma', 'dominant', 'histology', 'homology', 'structural', 'similarity', 'formed', 'utilizing', 'impressive', 'survival', 'months', 'profile', 'trial', 'obtained', 'food', 'drug', 'administration', 'fda', 'approval', 'therapy', 'treatment', 'since', 'growing', 'incidence', 'brain', 'metastases', 'rates', 'central', 'nervous', 'system', 'progression', 'additionally', 'novel', 'resistance', 'mechanisms', 'led', 'development', 'newer', 'tyrosine', 'review', 'highlight', 'known', 'emerging', 'management')"', 'b'(14, 6, 6, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0'', 'b'[0.0, 0.0, 0.0, 0.0]'', 'b'1'', 'b'[1, 1, 1, 1]'', 'b'1.418382675671391'', 'b'[0.3053816495511819, 0.3053816495511819, 0.3053816495511819, 0.3053816495511819]'', 'b'81'', 'b'0.10695709966292073'', 'b"['Anaplastic Lymphoma Kinase', 'Carcinoma, Non-Small-Cell Lung', 'Humans', 'Lung Neoplasms', 'Molecular Targeted Therapy', 'Protein Kinase Inhibitors', 'Protein-Tyrosine Kinases', 'Proto-Oncogene Proteins']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'27'', 'b'In silico identification of microRNAs as candidate colorectal cancer biomarkers.'', 'b'The involvement of microRNA in cancers plays a significant role in their pathogenesis. Specific expressions of these non-coding RNAs also serve as biomarkers for early colorectal cancer diagnosis, but their laboratory_molecular identification is challenging and expensive. The aim of this study was to identify potential microRNAs for colorectal cancer diagnosis using in silico approach. Sequence similarity search was employed to obtain the candidate microRNA from the datasets, and three target prediction software were employed to determine their target genes. To determine the involvement of these microRNAs in colorectal cancer, the microRNA gene list obtained was used alongside with colorectal cancer expressed genes from gbCRC and CoReCG databases for gene intersection analysis. The involvement of these genes in the cancer subtype was further strengthened with the DAVID database. KEGG and Gene Ontology were used for the pathway and functional analysis, while STRING was employed for the interactions of protein network and further visualized by Cytoscape. The cBioPortal database was used to prioritize the target genes; prognostic and expression analysis were finally performed on the candidate microRNAs and the prioritized targets. This study, therefore, identified five candidate microRNAs, two hub genes (CTNNB1 and epidermal growth factor receptor), and seven significant target genes associated with colorectal cancer. The molecular validation studies are ongoing to ascertain the biological fitness of these findings.'', 'b'1321'', 'b'218'', 'b"[('cancer', 12), ('genes', 12), ('colorectal', 10), ('micrornas', 8), ('target', 8), ('involvement', 6), ('microrna', 6), ('employed', 6), ('candidate', 6), ('gene', 6), ('used', 6), ('analysis', 6), ('significant', 4), ('diagnosis', 4), ('study', 4), ('determine', 4), ('database', 4), ('cancers', 2), ('plays', 2), ('role', 2), ('pathogenesis', 2), ('specific', 2), ('expressions', 2), ('rnas', 2), ('also', 2), ('serve', 2), ('biomarkers', 2), ('early', 2), ('identification', 2), ('challenging', 2), ('expensive', 2), ('aim', 2), ('identify', 2), ('potential', 2), ('using', 2), ('silico', 2), ('approach', 2), ('sequence', 2), ('similarity', 2), ('search', 2), ('obtain', 2), ('datasets', 2), ('three', 2), ('prediction', 2), ('software', 2), ('list', 2), ('obtained', 2), ('alongside', 2), ('expressed', 2), ('gbcrc', 2), ('corecg', 2), ('databases', 2), ('intersection', 2), ('subtype', 2), ('strengthened', 2), ('david', 2), ('kegg', 2), ('ontology', 2), ('pathway', 2), ('functional', 2), ('string', 2), ('interactions', 2), ('protein', 2), ('network', 2), ('visualized', 2), ('cytoscape', 2), ('cbioportal', 2), ('prioritize', 2), ('prognostic', 2), ('expression', 2), ('finally', 2), ('performed', 2), ('prioritized', 2), ('targets', 2), ('therefore', 2), ('identified', 2), ('five', 2), ('two', 2), ('hub', 2), ('epidermal', 2), ('growth', 2), ('factor', 2), ('receptor', 2), ('seven', 2), ('associated', 2), ('molecular', 2), ('validation', 2), ('studies', 2), ('ongoing', 2), ('ascertain', 2), ('biological', 2), ('fitness', 2), ('findings', 2)]"', 'b"[('the', 17), ('.', 10), ('and', 10), ('gene', 9), (',', 8), ('of', 7), ('microrna', 7), ('cancer', 7), ('wa', 6), ('in', 5), ('for', 5), ('colorect', 5), ('to', 5), ('target', 5), ('these', 4), ('use', 4), ('involv', 3), ('their', 3), ('express', 3), ('studi', 3), ('employ', 3), ('candid', 3), ('were', 3), ('with', 3), ('databas', 3), ('analysi', 3), ('signific', 2), ('diagnosi', 2), ('thi', 2), ('identifi', 2), ('obtain', 2), ('from', 2), ('determin', 2), ('further', 2), ('priorit', 2), ('play', 1), ('a', 1), ('role', 1), ('pathogenesi', 1), ('specif', 1), ('non-cod', 1), ('rna', 1), ('also', 1), ('serv', 1), ('as', 1), ('biomark', 1), ('earli', 1), ('but', 1), ('laboratory_molecular', 1), ('identif', 1), ('is', 1), ('challeng', 1), ('expens', 1), ('aim', 1), ('potenti', 1), ('silico', 1), ('approach', 1), ('sequenc', 1), ('similar', 1), ('search', 1), ('dataset', 1), ('three', 1), ('predict', 1), ('softwar', 1), ('To', 1), ('list', 1), ('alongsid', 1), ('gbcrc', 1), ('corecg', 1), ('intersect', 1), ('subtyp', 1), ('strengthen', 1), ('david', 1), ('kegg', 1), ('ontolog', 1), ('pathway', 1), ('function', 1), ('while', 1), ('string', 1), ('interact', 1), ('protein', 1), ('network', 1), ('visual', 1), ('by', 1), ('cytoscap', 1), ('cbioport', 1), (';', 1), ('prognost', 1), ('final', 1), ('perform', 1), ('on', 1), ('therefor', 1), ('five', 1), ('two', 1), ('hub', 1), ('(', 1), ('ctnnb1', 1), ('epiderm', 1), ('growth', 1), ('factor', 1), ('receptor', 1), (')', 1), ('seven', 1), ('associ', 1), ('molecular', 1), ('valid', 1), ('are', 1), ('ongo', 1), ('ascertain', 1), ('biolog', 1), ('fit', 1), ('find', 1)]"', 'b'10'', 'b"('cancer', 'genes', 'colorectal', 'micrornas', 'target', 'involvement', 'microrna', 'employed', 'candidate', 'gene', 'used', 'analysis', 'significant', 'diagnosis', 'study', 'determine', 'database', 'cancers', 'plays', 'role', 'pathogenesis', 'specific', 'expressions', 'rnas', 'also', 'serve', 'biomarkers', 'early', 'identification', 'challenging', 'expensive', 'aim', 'identify', 'potential', 'using', 'silico', 'approach', 'sequence', 'similarity', 'search', 'obtain', 'datasets', 'three', 'prediction', 'software', 'list', 'obtained', 'alongside', 'expressed', 'gbcrc', 'corecg', 'databases', 'intersection', 'subtype', 'strengthened', 'david', 'kegg', 'ontology', 'pathway', 'functional', 'string', 'interactions', 'protein', 'network', 'visualized', 'cytoscape', 'cbioportal', 'prioritize', 'prognostic', 'expression', 'finally', 'performed', 'prioritized', 'targets', 'therefore', 'identified', 'five', 'two', 'hub', 'epidermal', 'growth', 'factor', 'receptor', 'seven', 'associated', 'molecular', 'validation', 'studies', 'ongoing', 'ascertain', 'biological', 'fitness', 'findings')"', 'b'(12, 12, 10, 8, 8, 6, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0'', 'b'[0.0, 0.0]'', 'b'1'', 'b'[1, 1]'', 'b'1.418382675671391'', 'b'[0.3053816495511819, 0.3053816495511819]'', 'b'54'', 'b'0.0976773489559653'', 'b"['Biomarkers, Tumor', 'Colorectal Neoplasms', 'Computational Biology', 'Computer Simulation', 'Databases, Genetic', 'Early Detection of Cancer', 'ErbB Receptors', 'Gene Expression Regulation, Neoplastic', 'Gene Ontology', 'Gene Regulatory Networks', 'Humans', 'MicroRNAs', 'Protein Interaction Mapping', 'Transcriptome', 'beta Catenin']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'28'', 'b'Oncobiome at the Forefront of a Novel Molecular Mechanism to Understand the Microbiome and Cancer.'', 'b"The microbiome comprises all the genetic material within a microbiota, that represents tenfold higher than that of our cells. The microbiota it includes a wide variety of microorganisms such as bacteria, viruses, protozoans, fungi, and archaea, and this ecosystem is personalized in any body space of every individual. Balanced microbial communities can positively contribute to training the immune system and maintaining immune homeostasis. Dysbiosis is a change in the normal microbiome composition that can initiate chronic inflammation, epithelial barrier breaches, and overgrowth of harmful bacteria. The next-generation sequencing methods have revolutionized the study of the microbiome. Bioinformatic tools to manage large volumes of new information, it became possible to assess species diversity and measure dynamic fluctuations in microbial communities. The burden of infections that are associated to human cancer is increasing but is underappreciated by the cancer research community. The rich content in microbes of normal and tumoral tissue reflect could be defining diverse physiological or pathological states. Genomic research has emerged a new focus on the interplay between the human microbiome and carcinogenesis and has been termed the 'oncobiome'. The interactions among the microbiota in all epithelium, induce changes in the host immune interactions and can be a cause of cancer. Microbes have been shown to have systemic effects on the host that influence the efficacy of anticancer drugs. Metagenomics allows to investigate the composition of microbial community. Metatranscriptome analysis applies RNA sequencing to microbial samples to determine which species are present. Cancer can be caused by changes in the microbiome. The roles of individual microbial species in cancer progression have been identified long ago for various tissue types. The identification of microbiomes of drug resistance in the treatment of cancer patients has been the subject of numerous microbiome studies. The complexity of cancer genetic alterations becomes irrelevant in certain cancers to explain the origin, the cause or the oncogenic maintenance by the oncogene addiction theory."', 'b'1876'', 'b'317'', 'b"[('cancer', 14), ('microbiome', 12), ('microbial', 10), ('microbiota', 6), ('immune', 6), ('species', 6), ('genetic', 4), ('bacteria', 4), ('individual', 4), ('communities', 4), ('normal', 4), ('composition', 4), ('sequencing', 4), ('new', 4), ('human', 4), ('research', 4), ('community', 4), ('microbes', 4), ('tissue', 4), ('interactions', 4), ('changes', 4), ('host', 4), ('cause', 4), ('comprises', 2), ('material', 2), ('within', 2), ('represents', 2), ('tenfold', 2), ('higher', 2), ('cells', 2), ('includes', 2), ('wide', 2), ('variety', 2), ('microorganisms', 2), ('viruses', 2), ('protozoans', 2), ('fungi', 2), ('archaea', 2), ('ecosystem', 2), ('personalized', 2), ('body', 2), ('space', 2), ('every', 2), ('balanced', 2), ('positively', 2), ('contribute', 2), ('training', 2), ('system', 2), ('maintaining', 2), ('homeostasis', 2), ('dysbiosis', 2), ('change', 2), ('initiate', 2), ('chronic', 2), ('inflammation', 2), ('epithelial', 2), ('barrier', 2), ('breaches', 2), ('overgrowth', 2), ('harmful', 2), ('methods', 2), ('revolutionized', 2), ('study', 2), ('bioinformatic', 2), ('tools', 2), ('manage', 2), ('large', 2), ('volumes', 2), ('information', 2), ('became', 2), ('possible', 2), ('assess', 2), ('diversity', 2), ('measure', 2), ('dynamic', 2), ('fluctuations', 2), ('burden', 2), ('infections', 2), ('associated', 2), ('increasing', 2), ('underappreciated', 2), ('rich', 2), ('content', 2), ('tumoral', 2), ('reflect', 2), ('could', 2), ('defining', 2), ('diverse', 2), ('physiological', 2), ('pathological', 2), ('states', 2), ('genomic', 2), ('emerged', 2), ('focus', 2), ('interplay', 2), ('carcinogenesis', 2), ('termed', 2), ('among', 2), ('epithelium', 2), ('induce', 2), ('shown', 2), ('systemic', 2), ('effects', 2), ('influence', 2), ('efficacy', 2), ('anticancer', 2), ('drugs', 2), ('metagenomics', 2), ('allows', 2), ('investigate', 2), ('metatranscriptome', 2), ('analysis', 2), ('applies', 2), ('rna', 2), ('samples', 2), ('determine', 2), ('present', 2), ('caused', 2), ('roles', 2), ('progression', 2), ('identified', 2), ('long', 2), ('ago', 2), ('various', 2), ('types', 2), ('identification', 2), ('microbiomes', 2), ('drug', 2), ('resistance', 2), ('treatment', 2), ('patients', 2), ('subject', 2), ('numerous', 2), ('studies', 2), ('complexity', 2), ('alterations', 2), ('becomes', 2), ('irrelevant', 2), ('certain', 2), ('cancers', 2), ('explain', 2), ('origin', 2), ('oncogenic', 2), ('maintenance', 2), ('oncogene', 2), ('addiction', 2), ('theory', 2)]"', 'b'[(\'the\', 30), (\'of\', 17), (\'.\', 17), (\',\', 11), (\'in\', 10), (\'and\', 9), (\'to\', 9), (\'cancer\', 8), (\'microbiom\', 7), (\'a\', 5), (\'that\', 5), (\'microbi\', 5), (\'is\', 4), (\'commun\', 4), (\'can\', 4), (\'have\', 4), (\'been\', 4), (\'microbiota\', 3), (\'immun\', 3), (\'chang\', 3), (\'speci\', 3), (\'by\', 3), (\'be\', 3), (\'ha\', 3), (\'caus\', 3), (\'all\', 2), (\'genet\', 2), (\'it\', 2), (\'bacteria\', 2), (\'individu\', 2), (\'system\', 2), (\'normal\', 2), (\'composit\', 2), (\'sequenc\', 2), (\'studi\', 2), (\'new\', 2), (\'divers\', 2), (\'are\', 2), (\'human\', 2), (\'research\', 2), (\'microb\', 2), (\'tissu\', 2), (\'or\', 2), (\'on\', 2), (\'interact\', 2), (\'host\', 2), (\'drug\', 2), (\'oncogen\', 2), (\'compris\', 1), (\'materi\', 1), (\'within\', 1), (\'repres\', 1), (\'tenfold\', 1), (\'higher\', 1), (\'than\', 1), (\'our\', 1), (\'cell\', 1), (\'includ\', 1), (\'wide\', 1), (\'varieti\', 1), (\'microorgan\', 1), (\'such\', 1), (\'as\', 1), (\'virus\', 1), (\'protozoan\', 1), (\'fungi\', 1), (\'archaea\', 1), (\'thi\', 1), (\'ecosystem\', 1), (\'person\', 1), (\'ani\', 1), (\'bodi\', 1), (\'space\', 1), (\'everi\', 1), (\'balanc\', 1), (\'posit\', 1), (\'contribut\', 1), (\'train\', 1), (\'maintain\', 1), (\'homeostasi\', 1), (\'dysbiosi\', 1), (\'initi\', 1), (\'chronic\', 1), (\'inflamm\', 1), (\'epitheli\', 1), (\'barrier\', 1), (\'breach\', 1), (\'overgrowth\', 1), (\'harm\', 1), (\'next-gener\', 1), (\'method\', 1), (\'revolution\', 1), (\'bioinformat\', 1), (\'tool\', 1), (\'manag\', 1), (\'larg\', 1), (\'volum\', 1), (\'inform\', 1), (\'becam\', 1), (\'possibl\', 1), (\'assess\', 1), (\'measur\', 1), (\'dynam\', 1), (\'fluctuat\', 1), (\'burden\', 1), (\'infect\', 1), (\'associ\', 1), (\'increas\', 1), (\'but\', 1), (\'underappreci\', 1), (\'rich\', 1), (\'content\', 1), (\'tumor\', 1), (\'reflect\', 1), (\'could\', 1), (\'defin\', 1), (\'physiolog\', 1), (\'patholog\', 1), (\'state\', 1), (\'genom\', 1), (\'emerg\', 1), (\'focu\', 1), (\'interplay\', 1), (\'between\', 1), (\'carcinogenesi\', 1), (\'term\', 1), ("\'oncobiom", 1), ("\'", 1), (\'among\', 1), (\'epithelium\', 1), (\'induc\', 1), (\'shown\', 1), (\'effect\', 1), (\'influenc\', 1), (\'efficaci\', 1), (\'anticanc\', 1), (\'metagenom\', 1), (\'allow\', 1), (\'investig\', 1), (\'metatranscriptom\', 1), (\'analysi\', 1), (\'appli\', 1), (\'rna\', 1), (\'sampl\', 1), (\'determin\', 1), (\'which\', 1), (\'present\', 1), (\'role\', 1), (\'progress\', 1), (\'identifi\', 1), (\'long\', 1), (\'ago\', 1), (\'for\', 1), (\'variou\', 1), (\'type\', 1), (\'identif\', 1), (\'resist\', 1), (\'treatment\', 1), (\'patient\', 1), (\'subject\', 1), (\'numer\', 1), (\'complex\', 1), (\'alter\', 1), (\'becom\', 1), (\'irrelev\', 1), (\'certain\', 1), (\'explain\', 1), (\'origin\', 1), (\'mainten\', 1), (\'addict\', 1), (\'theori\', 1)]'', 'b'17'', 'b"('cancer', 'microbiome', 'microbial', 'microbiota', 'immune', 'species', 'genetic', 'bacteria', 'individual', 'communities', 'normal', 'composition', 'sequencing', 'new', 'human', 'research', 'community', 'microbes', 'tissue', 'interactions', 'changes', 'host', 'cause', 'comprises', 'material', 'within', 'represents', 'tenfold', 'higher', 'cells', 'includes', 'wide', 'variety', 'microorganisms', 'viruses', 'protozoans', 'fungi', 'archaea', 'ecosystem', 'personalized', 'body', 'space', 'every', 'balanced', 'positively', 'contribute', 'training', 'system', 'maintaining', 'homeostasis', 'dysbiosis', 'change', 'initiate', 'chronic', 'inflammation', 'epithelial', 'barrier', 'breaches', 'overgrowth', 'harmful', 'methods', 'revolutionized', 'study', 'bioinformatic', 'tools', 'manage', 'large', 'volumes', 'information', 'became', 'possible', 'assess', 'diversity', 'measure', 'dynamic', 'fluctuations', 'burden', 'infections', 'associated', 'increasing', 'underappreciated', 'rich', 'content', 'tumoral', 'reflect', 'could', 'defining', 'diverse', 'physiological', 'pathological', 'states', 'genomic', 'emerged', 'focus', 'interplay', 'carcinogenesis', 'termed', 'among', 'epithelium', 'induce', 'shown', 'systemic', 'effects', 'influence', 'efficacy', 'anticancer', 'drugs', 'metagenomics', 'allows', 'investigate', 'metatranscriptome', 'analysis', 'applies', 'rna', 'samples', 'determine', 'present', 'caused', 'roles', 'progression', 'identified', 'long', 'ago', 'various', 'types', 'identification', 'microbiomes', 'drug', 'resistance', 'treatment', 'patients', 'subject', 'numerous', 'studies', 'complexity', 'alterations', 'becomes', 'irrelevant', 'certain', 'cancers', 'explain', 'origin', 'oncogenic', 'maintenance', 'oncogene', 'addiction', 'theory')"', 'b'(14, 12, 10, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.015997942572704597'', 'b'[0.1455985072796127, 0.020799786754230387, 0.016177611919956966, 0.010399893377115194, 0.006618113967255123, 0.005108719553670621, 0.004159957350846078, 0.0037817794098600707]'', 'b'-3.4543472962535073'', 'b'[0.3068528194400547, -1.6390573296152589, -1.890371757896165, -2.332204510175204, -2.784189633918261, -3.0430512678345503, -3.2484952420493594, -3.343805421853684]'', 'b'-4.752570671761126'', 'b'[0.08935462493002498, -0.4772886010753797, -0.5504706123064381, -0.67913099070458, -0.8107477093637403, -0.8861274443440869, -0.9459521162946218, -0.9737061561107442]'', 'b'31'', 'b'0.10617899614553113'', 'b"['Bacteria', 'Dysbiosis', 'High-Throughput Nucleotide Sequencing', 'Humans', 'Metagenomics', 'Microbiota', 'Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'29'', 'b'Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients.'', 'b'Omics technologies have revolutionised fundamental and medical research. Oncology is perhaps the field where these technologies have been most rapidly adopted and where they have had their biggest impact, dramatically transforming clinical practice guidelines over a very short period of time. Along with this transformation has come an even larger array of technologies, tools and jargon, that make following the most recent developments in the field a truly daunting task for those not involved in it. This chapter is intended to provide a general overview of evolving topics in oncology research in the era of big data analysis and precision medicine, with a specific focus on the use of tumour biomarkers, tumour biomarker tests, targeted drugs and the changing landscape of clinical trial designs.'', 'b'679'', 'b'124'', 'b"[('technologies', 6), ('research', 4), ('oncology', 4), ('field', 4), ('clinical', 4), ('tumour', 4), ('omics', 2), ('revolutionised', 2), ('fundamental', 2), ('medical', 2), ('perhaps', 2), ('rapidly', 2), ('adopted', 2), ('biggest', 2), ('impact', 2), ('dramatically', 2), ('transforming', 2), ('practice', 2), ('guidelines', 2), ('short', 2), ('period', 2), ('time', 2), ('along', 2), ('transformation', 2), ('come', 2), ('even', 2), ('larger', 2), ('array', 2), ('tools', 2), ('jargon', 2), ('make', 2), ('following', 2), ('recent', 2), ('developments', 2), ('truly', 2), ('daunting', 2), ('task', 2), ('involved', 2), ('chapter', 2), ('intended', 2), ('provide', 2), ('general', 2), ('overview', 2), ('evolving', 2), ('topics', 2), ('era', 2), ('big', 2), ('data', 2), ('analysis', 2), ('precision', 2), ('medicine', 2), ('specific', 2), ('focus', 2), ('use', 2), ('biomarkers', 2), ('biomarker', 2), ('tests', 2), ('targeted', 2), ('drugs', 2), ('changing', 2), ('landscape', 2), ('trial', 2), ('designs', 2)]"', 'b"[('the', 6), (',', 6), ('of', 6), ('and', 5), ('.', 4), ('a', 4), ('in', 4), ('technolog', 3), ('have', 3), ('research', 2), ('oncolog', 2), ('is', 2), ('field', 2), ('where', 2), ('most', 2), ('transform', 2), ('clinic', 2), ('with', 2), ('thi', 2), ('tumour', 2), ('biomark', 2), ('omic', 1), ('revolutionis', 1), ('fundament', 1), ('medic', 1), ('perhap', 1), ('these', 1), ('been', 1), ('rapidli', 1), ('adopt', 1), ('they', 1), ('had', 1), ('their', 1), ('biggest', 1), ('impact', 1), ('dramat', 1), ('practic', 1), ('guidelin', 1), ('over', 1), ('veri', 1), ('short', 1), ('period', 1), ('time', 1), ('along', 1), ('ha', 1), ('come', 1), ('an', 1), ('even', 1), ('larger', 1), ('array', 1), ('tool', 1), ('jargon', 1), ('that', 1), ('make', 1), ('follow', 1), ('recent', 1), ('develop', 1), ('truli', 1), ('daunt', 1), ('task', 1), ('for', 1), ('those', 1), ('not', 1), ('involv', 1), ('it', 1), ('chapter', 1), ('intend', 1), ('to', 1), ('provid', 1), ('gener', 1), ('overview', 1), ('evolv', 1), ('topic', 1), ('era', 1), ('big', 1), ('data', 1), ('analysi', 1), ('precis', 1), ('medicin', 1), ('specif', 1), ('focu', 1), ('on', 1), ('use', 1), ('test', 1), ('target', 1), ('drug', 1), ('chang', 1), ('landscap', 1), ('trial', 1), ('design', 1)]"', 'b'4'', 'b"('technologies', 'research', 'oncology', 'field', 'clinical', 'tumour', 'omics', 'revolutionised', 'fundamental', 'medical', 'perhaps', 'rapidly', 'adopted', 'biggest', 'impact', 'dramatically', 'transforming', 'practice', 'guidelines', 'short', 'period', 'time', 'along', 'transformation', 'come', 'even', 'larger', 'array', 'tools', 'jargon', 'make', 'following', 'recent', 'developments', 'truly', 'daunting', 'task', 'involved', 'chapter', 'intended', 'provide', 'general', 'overview', 'evolving', 'topics', 'era', 'big', 'data', 'analysis', 'precision', 'medicine', 'specific', 'focus', 'use', 'biomarkers', 'biomarker', 'tests', 'targeted', 'drugs', 'changing', 'landscape', 'trial', 'designs')"', 'b'(6, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.06068186666965182'', 'b'[0.0, 0.0554421545168971, 0.01646359065325936, 0.008780581681738325, 0.007686516873734495, 0.0031944429468139237, 0.0026862361143662537, 0.0022950366802352456, 0.00182904550257549, 0.0017164888562631521]'', 'b'-2.0910424533583156'', 'b'[1, -0.6094379124341003, -1.7725887222397811, -2.4011973816621555, -2.481240089335692, -3.3040650932041693, -3.477336814478207, -3.634728988229636, -3.8040210447332568, -3.867534450455582]'', 'b'-2.791543905815961'', 'b'[0.2911970145592254, -0.16894275454813296, -0.46693080191263703, -0.6325172923098226, -0.6198430489701217, -0.7810439100272109, -0.8220034004922665, -0.8592091441222399, -0.8488427651957693, -0.8630153721047092]'', 'b'32'', 'b'0.24197254638018334'', 'b"['Biomarkers, Tumor', 'Clinical Trials as Topic', 'Humans', 'Medical Oncology', 'Neoplasms', 'Precision Medicine']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'30'', 'b'Design and Implementing Pharmacogenomics Study in Cancer.'', 'b'The advances in technology has shifted healthcare from a "one size fits all" model to focus on personalized therapy. Understanding the relationship of genome variations and its effect on drug response has led to individualized drug selection, maximizing drug efficacy and improving toxicity profile. The developments in pharmacogenomics has led to the discovery of predictive and prognostic biomarkers, and has transformed cancer research leading to the creation of pharmacogenomics databases. While challenges associated with the implementation of pharmacogenomics based medicine exist, integrating data amongst collaborative networks will be crucial for researchers to identify all the functional elements of the human genome sequence. Future advances in the area of pharmacogenomics research will eventually lead to the identification of the right therapeutic drug for the right patient.'', 'b'766'', 'b'125'', 'b"[('drug', 8), ('pharmacogenomics', 8), ('advances', 4), ('genome', 4), ('led', 4), ('research', 4), ('right', 4), ('technology', 2), ('shifted', 2), ('healthcare', 2), ('one', 2), ('size', 2), ('fits', 2), ('model', 2), ('focus', 2), ('personalized', 2), ('therapy', 2), ('understanding', 2), ('relationship', 2), ('variations', 2), ('effect', 2), ('response', 2), ('individualized', 2), ('selection', 2), ('maximizing', 2), ('efficacy', 2), ('improving', 2), ('toxicity', 2), ('profile', 2), ('developments', 2), ('discovery', 2), ('predictive', 2), ('prognostic', 2), ('biomarkers', 2), ('transformed', 2), ('cancer', 2), ('leading', 2), ('creation', 2), ('databases', 2), ('challenges', 2), ('associated', 2), ('implementation', 2), ('based', 2), ('medicine', 2), ('exist', 2), ('integrating', 2), ('data', 2), ('amongst', 2), ('collaborative', 2), ('networks', 2), ('crucial', 2), ('researchers', 2), ('identify', 2), ('functional', 2), ('elements', 2), ('human', 2), ('sequence', 2), ('future', 2), ('area', 2), ('eventually', 2), ('lead', 2), ('identification', 2), ('therapeutic', 2), ('patient', 2)]"', 'b'[(\'the\', 12), (\'of\', 7), (\'to\', 6), (\'.\', 5), (\'ha\', 4), (\'and\', 4), (\'drug\', 4), (\'pharmacogenom\', 4), (\'in\', 3), (\',\', 3), (\'research\', 3), (\'advanc\', 2), (\'all\', 2), (\'on\', 2), (\'genom\', 2), (\'led\', 2), (\'lead\', 2), (\'will\', 2), (\'for\', 2), (\'right\', 2), (\'technolog\', 1), (\'shift\', 1), (\'healthcar\', 1), (\'from\', 1), (\'a\', 1), (\'``\', 1), (\'one\', 1), (\'size\', 1), (\'fit\', 1), ("\'\'", 1), (\'model\', 1), (\'focu\', 1), (\'person\', 1), (\'therapi\', 1), (\'understand\', 1), (\'relationship\', 1), (\'variat\', 1), (\'it\', 1), (\'effect\', 1), (\'respons\', 1), (\'individu\', 1), (\'select\', 1), (\'maxim\', 1), (\'efficaci\', 1), (\'improv\', 1), (\'toxic\', 1), (\'profil\', 1), (\'develop\', 1), (\'discoveri\', 1), (\'predict\', 1), (\'prognost\', 1), (\'biomark\', 1), (\'transform\', 1), (\'cancer\', 1), (\'creation\', 1), (\'databas\', 1), (\'while\', 1), (\'challeng\', 1), (\'associ\', 1), (\'with\', 1), (\'implement\', 1), (\'base\', 1), (\'medicin\', 1), (\'exist\', 1), (\'integr\', 1), (\'data\', 1), (\'amongst\', 1), (\'collabor\', 1), (\'network\', 1), (\'be\', 1), (\'crucial\', 1), (\'identifi\', 1), (\'function\', 1), (\'element\', 1), (\'human\', 1), (\'sequenc\', 1), (\'futur\', 1), (\'area\', 1), (\'eventu\', 1), (\'identif\', 1), (\'therapeut\', 1), (\'patient\', 1)]'', 'b'5'', 'b"('drug', 'pharmacogenomics', 'advances', 'genome', 'led', 'research', 'right', 'technology', 'shifted', 'healthcare', 'one', 'size', 'fits', 'model', 'focus', 'personalized', 'therapy', 'understanding', 'relationship', 'variations', 'effect', 'response', 'individualized', 'selection', 'maximizing', 'efficacy', 'improving', 'toxicity', 'profile', 'developments', 'discovery', 'predictive', 'prognostic', 'biomarkers', 'transformed', 'cancer', 'leading', 'creation', 'databases', 'challenges', 'associated', 'implementation', 'based', 'medicine', 'exist', 'integrating', 'data', 'amongst', 'collaborative', 'networks', 'crucial', 'researchers', 'identify', 'functional', 'elements', 'human', 'sequence', 'future', 'area', 'eventually', 'lead', 'identification', 'therapeutic', 'patient')"', 'b'(8, 8, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.04902952689218061'', 'b'[0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.02334127441631745, 0.009548703170311685, 0.006564733429589283, 0.0023755188543487836, 0.002143131140336402, 0.0020119190297035613, 0.0018256302306569351, 0.0016466878494064223, 0.0013858891687633808, 0.0011809461994674235, 0.0009745539360019049]'', 'b'-2.2744456760230114'', 'b'[1, 1, 1, 1, 1, 1, -1.1972245773362196, -2.0910424533583156, -2.4657359027997265, -3.4188406077965983, -3.5217885770490405, -3.5849674786705723, -3.68213122712422, -3.718498871295094, -3.820281565605037, -3.9052747784384296, -4.017279836814924]'', 'b'-2.9471820222734593'', 'b'[0.22314355131420976, 0.22314355131420976, 0.22314355131420976, 0.22314355131420976, 0.22314355131420976, 0.22314355131420976, -0.25150272657807937, -0.43926836148005516, -0.517980765108732, -0.6740861868782281, -0.694384238762244, -0.7068411005381606, -0.7259986888002605, -0.6857991738520304, -0.6565163685814056, -0.6226091200088344, -0.5911734374253503]'', 'b'31'', 'b'0.12878777280382234'', 'b"['Genome, Human', 'Humans', 'Neoplasms', 'Pharmacogenetics', 'Precision Medicine', 'Research Design']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'31'', 'b'Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.'', 'b'Following the completion of the Human Genome Project in 2003, research in oncology has progressively focused on the sequencing of cancer genomes, with the aim of better understanding the genetic basis of oncogenesis and identifying actionable alterations. The development of next-generation-sequencing (NGS) techniques, commercially available since 2006, allowed for a cost- and time-effective sequencing of tumor DNA, leading to a "genomic era" of cancer research and treatment. NGS provided a significant step forward in Personalized Medicine (PM) by enabling the detection of somatic driver mutations, resistance mechanisms, quantification of mutational burden, germline mutations which settled the foundation of a new approach in cancer care. In this chapter we discuss the history, available techniques and applications of NGS in oncology, with a particular referral to the PM approach and the emerging role of the research field of pharmacogenomics.'', 'b'819'', 'b'137'', 'b"[('research', 6), ('cancer', 6), ('ngs', 6), ('oncology', 4), ('sequencing', 4), ('techniques', 4), ('available', 4), ('pm', 4), ('mutations', 4), ('approach', 4), ('following', 2), ('completion', 2), ('human', 2), ('genome', 2), ('project', 2), ('progressively', 2), ('focused', 2), ('genomes', 2), ('aim', 2), ('better', 2), ('understanding', 2), ('genetic', 2), ('basis', 2), ('oncogenesis', 2), ('identifying', 2), ('actionable', 2), ('alterations', 2), ('development', 2), ('commercially', 2), ('since', 2), ('allowed', 2), ('tumor', 2), ('dna', 2), ('leading', 2), ('genomic', 2), ('era', 2), ('treatment', 2), ('provided', 2), ('significant', 2), ('step', 2), ('forward', 2), ('personalized', 2), ('medicine', 2), ('enabling', 2), ('detection', 2), ('somatic', 2), ('driver', 2), ('resistance', 2), ('mechanisms', 2), ('quantification', 2), ('mutational', 2), ('burden', 2), ('germline', 2), ('settled', 2), ('foundation', 2), ('new', 2), ('care', 2), ('chapter', 2), ('discuss', 2), ('history', 2), ('applications', 2), ('particular', 2), ('referral', 2), ('emerging', 2), ('role', 2), ('field', 2), ('pharmacogenomics', 2)]"', 'b'[(\'of\', 13), (\'the\', 12), (\',\', 10), (\'in\', 5), (\'and\', 5), (\'a\', 5), (\'.\', 4), (\'genom\', 3), (\'research\', 3), (\'cancer\', 3), (\'ng\', 3), (\'mutat\', 3), (\'oncolog\', 2), (\'sequenc\', 2), (\'with\', 2), (\'(\', 2), (\')\', 2), (\'techniqu\', 2), (\'avail\', 2), (\'to\', 2), (\'PM\', 2), (\'approach\', 2), (\'follow\', 1), (\'complet\', 1), (\'human\', 1), (\'project\', 1), (\'2003\', 1), (\'ha\', 1), (\'progress\', 1), (\'focus\', 1), (\'on\', 1), (\'aim\', 1), (\'better\', 1), (\'understand\', 1), (\'genet\', 1), (\'basi\', 1), (\'oncogenesi\', 1), (\'identifi\', 1), (\'action\', 1), (\'alter\', 1), (\'develop\', 1), (\'next-generation-sequenc\', 1), (\'commerci\', 1), (\'sinc\', 1), (\'2006\', 1), (\'allow\', 1), (\'for\', 1), (\'cost-\', 1), (\'time-effect\', 1), (\'tumor\', 1), (\'dna\', 1), (\'lead\', 1), (\'``\', 1), (\'era\', 1), ("\'\'", 1), (\'treatment\', 1), (\'provid\', 1), (\'signific\', 1), (\'step\', 1), (\'forward\', 1), (\'person\', 1), (\'medicin\', 1), (\'by\', 1), (\'enabl\', 1), (\'detect\', 1), (\'somat\', 1), (\'driver\', 1), (\'resist\', 1), (\'mechan\', 1), (\'quantif\', 1), (\'burden\', 1), (\'germlin\', 1), (\'which\', 1), (\'settl\', 1), (\'foundat\', 1), (\'new\', 1), (\'care\', 1), (\'In\', 1), (\'thi\', 1), (\'chapter\', 1), (\'we\', 1), (\'discuss\', 1), (\'histori\', 1), (\'applic\', 1), (\'particular\', 1), (\'referr\', 1), (\'emerg\', 1), (\'role\', 1), (\'field\', 1), (\'pharmacogenom\', 1)]'', 'b'4'', 'b"('research', 'cancer', 'ngs', 'oncology', 'sequencing', 'techniques', 'available', 'pm', 'mutations', 'approach', 'following', 'completion', 'human', 'genome', 'project', 'progressively', 'focused', 'genomes', 'aim', 'better', 'understanding', 'genetic', 'basis', 'oncogenesis', 'identifying', 'actionable', 'alterations', 'development', 'commercially', 'since', 'allowed', 'tumor', 'dna', 'leading', 'genomic', 'era', 'treatment', 'provided', 'significant', 'step', 'forward', 'personalized', 'medicine', 'enabling', 'detection', 'somatic', 'driver', 'resistance', 'mechanisms', 'quantification', 'mutational', 'burden', 'germline', 'settled', 'foundation', 'new', 'care', 'chapter', 'discuss', 'history', 'applications', 'particular', 'referral', 'emerging', 'role', 'field', 'pharmacogenomics')"', 'b'(6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0'', 'b'[0.0, 0.0, 0.0, 0.0]'', 'b'1'', 'b'[1, 1, 1, 1]'', 'b'1.2957803535790589'', 'b'[0.14715764433628764, 0.14715764433628764, 0.14715764433628764, 0.14715764433628764]'', 'b'29'', 'b'0.14754882223458393'', 'b"['High-Throughput Nucleotide Sequencing', 'Humans', 'Neoplasms', 'Pharmacogenetics', 'Precision Medicine']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'32'', 'b'Pharmaco-Geno-Proteo-Metabolomics and Translational Research in Cancer.'', 'b'The diagnosis, prognosis and treatment of cancer has had a great improvement due to the "omics" technologies such as genomics, proteomics, epigenomics, pharmacogenomics, and metabolomics. The technological progress of these technologies has allowed precision medicine to become a clinical reality. The study of different biomolecules such as DNA, RNA and proteins has helped to detect alterations in genes, changes in gene expression profiles and loss or gain of protein function, which allows us to make associations and better understand the cancer biology. Data obtained from different "omics" technologies gives a complementary spectrum of information that helps us to understand and unveil new information for a better diagnosis, prognosis, prediction of new molecular targets of anticancer therapies, etc. This chapter presents a general landscape of the interaction between the Pharmaco-Geno-Proteo-Metabolomic and translational medicine research in cancer.'', 'b'830'', 'b'135'', 'b"[('cancer', 6), ('technologies', 6), ('diagnosis', 4), ('prognosis', 4), ('omics', 4), ('medicine', 4), ('different', 4), ('us', 4), ('better', 4), ('understand', 4), ('information', 4), ('new', 4), ('treatment', 2), ('great', 2), ('improvement', 2), ('due', 2), ('genomics', 2), ('proteomics', 2), ('epigenomics', 2), ('pharmacogenomics', 2), ('metabolomics', 2), ('technological', 2), ('progress', 2), ('allowed', 2), ('precision', 2), ('become', 2), ('clinical', 2), ('reality', 2), ('study', 2), ('biomolecules', 2), ('dna', 2), ('rna', 2), ('proteins', 2), ('helped', 2), ('detect', 2), ('alterations', 2), ('genes', 2), ('changes', 2), ('gene', 2), ('expression', 2), ('profiles', 2), ('loss', 2), ('gain', 2), ('protein', 2), ('function', 2), ('allows', 2), ('make', 2), ('associations', 2), ('biology', 2), ('data', 2), ('obtained', 2), ('gives', 2), ('complementary', 2), ('spectrum', 2), ('helps', 2), ('unveil', 2), ('prediction', 2), ('molecular', 2), ('targets', 2), ('anticancer', 2), ('therapies', 2), ('etc', 2), ('chapter', 2), ('presents', 2), ('general', 2), ('landscape', 2), ('interaction', 2), ('translational', 2), ('research', 2)]"', 'b'[(\',\', 11), (\'of\', 8), (\'the\', 7), (\'and\', 7), (\'a\', 5), (\'to\', 5), (\'.\', 5), (\'technolog\', 4), (\'cancer\', 3), (\'ha\', 3), (\'in\', 3), (\'diagnosi\', 2), (\'prognosi\', 2), (\'``\', 2), (\'omic\', 2), ("\'\'", 2), (\'such\', 2), (\'as\', 2), (\'allow\', 2), (\'medicin\', 2), (\'differ\', 2), (\'protein\', 2), (\'help\', 2), (\'gene\', 2), (\'us\', 2), (\'better\', 2), (\'understand\', 2), (\'inform\', 2), (\'new\', 2), (\'treatment\', 1), (\'had\', 1), (\'great\', 1), (\'improv\', 1), (\'due\', 1), (\'genom\', 1), (\'proteom\', 1), (\'epigenom\', 1), (\'pharmacogenom\', 1), (\'metabolom\', 1), (\'progress\', 1), (\'these\', 1), (\'precis\', 1), (\'becom\', 1), (\'clinic\', 1), (\'realiti\', 1), (\'studi\', 1), (\'biomolecul\', 1), (\'dna\', 1), (\'rna\', 1), (\'detect\', 1), (\'alter\', 1), (\'chang\', 1), (\'express\', 1), (\'profil\', 1), (\'loss\', 1), (\'or\', 1), (\'gain\', 1), (\'function\', 1), (\'which\', 1), (\'make\', 1), (\'associ\', 1), (\'biolog\', 1), (\'data\', 1), (\'obtain\', 1), (\'from\', 1), (\'give\', 1), (\'complementari\', 1), (\'spectrum\', 1), (\'that\', 1), (\'unveil\', 1), (\'for\', 1), (\'predict\', 1), (\'molecular\', 1), (\'target\', 1), (\'anticanc\', 1), (\'therapi\', 1), (\'etc\', 1), (\'thi\', 1), (\'chapter\', 1), (\'present\', 1), (\'gener\', 1), (\'landscap\', 1), (\'interact\', 1), (\'between\', 1), (\'pharmaco-geno-proteo-metabolom\', 1), (\'translat\', 1), (\'research\', 1)]'', 'b'5'', 'b"('cancer', 'technologies', 'diagnosis', 'prognosis', 'omics', 'medicine', 'different', 'us', 'better', 'understand', 'information', 'new', 'treatment', 'great', 'improvement', 'due', 'genomics', 'proteomics', 'epigenomics', 'pharmacogenomics', 'metabolomics', 'technological', 'progress', 'allowed', 'precision', 'become', 'clinical', 'reality', 'study', 'biomolecules', 'dna', 'rna', 'proteins', 'helped', 'detect', 'alterations', 'genes', 'changes', 'gene', 'expression', 'profiles', 'loss', 'gain', 'protein', 'function', 'allows', 'make', 'associations', 'biology', 'data', 'obtained', 'gives', 'complementary', 'spectrum', 'helps', 'unveil', 'prediction', 'molecular', 'targets', 'anticancer', 'therapies', 'etc', 'chapter', 'presents', 'general', 'landscape', 'interaction', 'translational', 'research')"', 'b'(6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.016773867007949493'', 'b'[0.0, 0.0, 0.027007256760788585, 0.005401451352157717, 0.0036496292919984577]'', 'b'-3.31748811353631'', 'b'[1, 1, -0.6094379124341003, -2.2188758248682006, -2.6109179126442243]'', 'b'-4.173532831268348'', 'b'[0.14715764433628764, 0.14715764433628764, -0.08229623090433368, -0.29962874561261027, -0.3525686522406237]'', 'b'29'', 'b'0.24197254638018334'', 'b"['Humans', 'Metabolomics', 'Neoplasms', 'Pharmacogenetics', 'Proteomics', 'Translational Medical Research']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'33'', 'b'HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer.'', 'b'A HER2-specific second-generation chimeric antigen receptor (5.137.z) was introduced into NK-92 cells, designated as NK-92_5.137.z cells. To evaluate the function and effectiveness of NK-92_5.137.z cells against gastric cancer cells and further determined whether combination with apatinib can synergize with this NK cell-based practice to better suppress gastric cancer.The expression of HER2 was examined in gastric cancer. The in vitro and in vivo cytotoxic activities of NK-92_5.137.z cells with or without apatinib were evaluated against gastric cancer cell lines.HER2 proteins were over-expressed in a considerable proportion of gastric cancer cells. NK-92_5.137.z cells specifically lysed gastric cancer cells expressing HER2 and had higher levels of cytokine production. In vivo, NK-92_5.137.z cells were particularly efficient at eliminating small tumor xenografts, whereas larger solid tumors were not effectively controlled with NK-92_5.137.z cells. Treatment with apatinib increased NK cell infiltration into large tumor xenografts and improved the therapeutic efficacy of NK-92_5.137.z cells.NK-92_5.137.z cells could represent a novel treatment option for patients with gastric cancer, either used alone or combined with apatinib.'', 'b'1079'', 'b'166'', 'b"[('cells', 22), ('gastric', 14), ('cancer', 12), ('apatinib', 8), ('nk', 4), ('vivo', 4), ('cell', 4), ('tumor', 4), ('xenografts', 4), ('treatment', 4), ('chimeric', 2), ('antigen', 2), ('receptor', 2), ('introduced', 2), ('designated', 2), ('evaluate', 2), ('function', 2), ('effectiveness', 2), ('determined', 2), ('whether', 2), ('combination', 2), ('synergize', 2), ('practice', 2), ('better', 2), ('suppress', 2), ('expression', 2), ('examined', 2), ('vitro', 2), ('cytotoxic', 2), ('activities', 2), ('without', 2), ('evaluated', 2), ('proteins', 2), ('considerable', 2), ('proportion', 2), ('specifically', 2), ('lysed', 2), ('expressing', 2), ('higher', 2), ('levels', 2), ('cytokine', 2), ('production', 2), ('particularly', 2), ('efficient', 2), ('eliminating', 2), ('small', 2), ('whereas', 2), ('larger', 2), ('solid', 2), ('tumors', 2), ('effectively', 2), ('controlled', 2), ('increased', 2), ('infiltration', 2), ('large', 2), ('improved', 2), ('therapeutic', 2), ('efficacy', 2), ('could', 2), ('represent', 2), ('novel', 2), ('option', 2), ('patients', 2), ('either', 2), ('used', 2), ('alone', 2), ('combined', 2)]"', 'b"[('cell', 13), ('nk-92_5.137.z', 7), ('gastric', 7), ('with', 7), ('.', 6), ('of', 6), ('cancer', 6), ('and', 5), (',', 4), ('apatinib', 4), ('in', 4), ('were', 4), ('the', 3), ('tumor', 3), ('wa', 2), ('into', 2), ('evalu', 2), ('effect', 2), ('against', 2), ('combin', 2), ('NK', 2), ('express', 2), ('her2', 2), ('vivo', 2), ('or', 2), ('a', 2), ('xenograft', 2), ('treatment', 2), ('A', 1), ('her2-specif', 1), ('second-gener', 1), ('chimer', 1), ('antigen', 1), ('receptor', 1), ('(', 1), ('5.137.z', 1), (')', 1), ('introduc', 1), ('nk-92', 1), ('design', 1), ('as', 1), ('To', 1), ('function', 1), ('further', 1), ('determin', 1), ('whether', 1), ('can', 1), ('synerg', 1), ('thi', 1), ('cell-bas', 1), ('practic', 1), ('to', 1), ('better', 1), ('suppress', 1), ('cancer.th', 1), ('examin', 1), ('vitro', 1), ('cytotox', 1), ('activ', 1), ('without', 1), ('lines.her2', 1), ('protein', 1), ('over-express', 1), ('consider', 1), ('proport', 1), ('specif', 1), ('lyse', 1), ('had', 1), ('higher', 1), ('level', 1), ('cytokin', 1), ('product', 1), ('In', 1), ('particularli', 1), ('effici', 1), ('at', 1), ('elimin', 1), ('small', 1), ('wherea', 1), ('larger', 1), ('solid', 1), ('not', 1), ('control', 1), ('increas', 1), ('infiltr', 1), ('larg', 1), ('improv', 1), ('therapeut', 1), ('efficaci', 1), ('cells.nk-92_5.137.z', 1), ('could', 1), ('repres', 1), ('novel', 1), ('option', 1), ('for', 1), ('patient', 1), ('either', 1), ('use', 1), ('alon', 1)]"', 'b'6'', 'b"('cells', 'gastric', 'cancer', 'apatinib', 'nk', 'vivo', 'cell', 'tumor', 'xenografts', 'treatment', 'chimeric', 'antigen', 'receptor', 'introduced', 'designated', 'evaluate', 'function', 'effectiveness', 'determined', 'whether', 'combination', 'synergize', 'practice', 'better', 'suppress', 'expression', 'examined', 'vitro', 'cytotoxic', 'activities', 'without', 'evaluated', 'proteins', 'considerable', 'proportion', 'specifically', 'lysed', 'expressing', 'higher', 'levels', 'cytokine', 'production', 'particularly', 'efficient', 'eliminating', 'small', 'whereas', 'larger', 'solid', 'tumors', 'effectively', 'controlled', 'increased', 'infiltration', 'large', 'improved', 'therapeutic', 'efficacy', 'could', 'represent', 'novel', 'option', 'patients', 'either', 'used', 'alone', 'combined')"', 'b'(22, 14, 12, 8, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.04581271430345014'', 'b'[0.011187281159747929, 0.004119467967045348, 0.001914030679750636, 0.0014424579035801895]'', 'b'-2.283414346005772'', 'b'[-1.3978952727983707, -2.295836866004329, -2.951243718581427, -3.2341065045972597]'', 'b'-2.78958424186565'', 'b'[-0.17202512193545694, -0.2553559135307987, -0.29373609308088255, -0.3218893117117728]'', 'b'14'', 'b'0.15963655070037594'', 'b"['Animals', 'Antineoplastic Agents', 'CD56 Antigen', 'Cell Degranulation', 'Cell Line, Tumor', 'Combined Modality Therapy', 'Heterografts', 'Humans', 'Immunotherapy, Adoptive', 'Killer Cells, Natural', 'Lentivirus', 'Mice', 'Platelet Endothelial Cell Adhesion Molecule-1', 'Pyridines', 'Receptor, ErbB-2', 'Receptors, Chimeric Antigen', 'Stomach Neoplasms', 'Tumor Burden', 'Vascular Endothelial Growth Factor A']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'34'', 'b'Indocyanine green loaded APTMS coated SPIONs for dual phototherapy of cancer.'', 'b'Superparamagnetic iron oxide nanoparticles (SPIONs) have been recently recognized as highly efficient photothermal therapy (PTT) agents. Here, we demonstrate, for the first time to our knowledge, dose and laser intensity dependent PTT potential of small, spherical, 3-aminopropyltrimethoxysilane coated cationic superparamagnetic iron oxide nanoparticles (APTMS@SPIONs) in aqueous solutions upon irradiation at 795\xe2\x80\xafnm. Indocyanine green (ICG) which has been recently used for photodynamic therapy (PDT), was loaded to APTMS@SPIONs to improve the stability of ICG and to achieve an effective mild PTT and PDT (dual therapy) combination for synergistic therapeutic effect on cancer cells via a single laser treatment in the near infrared (NIR). Neither APTMS@SPIONs nor ICG-APTMS@SPIONs showed dark toxicity on MCF7 breast and HT29 colon cancer cell lines. A safe laser procedure was determined as 10\xe2\x80\xafmin irradiation at 795\xe2\x80\xafnm with 1.8\xe2\x80\xafW_cm'', 'b'804'', 'b'135'', 'b"[('spions', 10), ('therapy', 6), ('ptt', 6), ('laser', 6), ('aptms', 6), ('superparamagnetic', 4), ('iron', 4), ('oxide', 4), ('nanoparticles', 4), ('recently', 4), ('irradiation', 4), ('nm', 4), ('icg', 4), ('pdt', 4), ('cancer', 4), ('recognized', 2), ('highly', 2), ('efficient', 2), ('photothermal', 2), ('agents', 2), ('demonstrate', 2), ('first', 2), ('time', 2), ('knowledge', 2), ('dose', 2), ('intensity', 2), ('dependent', 2), ('potential', 2), ('small', 2), ('spherical', 2), ('coated', 2), ('cationic', 2), ('aqueous', 2), ('solutions', 2), ('upon', 2), ('indocyanine', 2), ('green', 2), ('used', 2), ('photodynamic', 2), ('loaded', 2), ('improve', 2), ('stability', 2), ('achieve', 2), ('effective', 2), ('mild', 2), ('dual', 2), ('combination', 2), ('synergistic', 2), ('therapeutic', 2), ('effect', 2), ('cells', 2), ('via', 2), ('single', 2), ('treatment', 2), ('near', 2), ('infrared', 2), ('nir', 2), ('neither', 2), ('showed', 2), ('dark', 2), ('toxicity', 2), ('breast', 2), ('colon', 2), ('cell', 2), ('lines', 2), ('safe', 2), ('procedure', 2), ('determined', 2), ('min', 2)]"', 'b"[('(', 7), (')', 7), (',', 6), ('spion', 5), ('.', 4), ('to', 4), ('and', 4), ('@', 4), ('therapi', 3), ('ptt', 3), ('for', 3), ('the', 3), ('laser', 3), ('aptm', 3), ('superparamagnet', 2), ('iron', 2), ('oxid', 2), ('nanoparticl', 2), ('been', 2), ('recent', 2), ('as', 2), ('of', 2), ('in', 2), ('irradi', 2), ('at', 2), ('795', 2), ('nm', 2), ('icg', 2), ('pdt', 2), ('wa', 2), ('effect', 2), ('on', 2), ('cancer', 2), ('cell', 2), ('have', 1), ('recogn', 1), ('highli', 1), ('effici', 1), ('phototherm', 1), ('agent', 1), ('here', 1), ('we', 1), ('demonstr', 1), ('first', 1), ('time', 1), ('our', 1), ('knowledg', 1), ('dose', 1), ('intens', 1), ('depend', 1), ('potenti', 1), ('small', 1), ('spheric', 1), ('3-aminopropyltrimethoxysilan', 1), ('coat', 1), ('cation', 1), ('aqueou', 1), ('solut', 1), ('upon', 1), ('indocyanin', 1), ('green', 1), ('which', 1), ('ha', 1), ('use', 1), ('photodynam', 1), ('load', 1), ('improv', 1), ('stabil', 1), ('achiev', 1), ('an', 1), ('mild', 1), ('dual', 1), ('combin', 1), ('synergist', 1), ('therapeut', 1), ('via', 1), ('a', 1), ('singl', 1), ('treatment', 1), ('near', 1), ('infrar', 1), ('nir', 1), ('neither', 1), ('nor', 1), ('icg-aptm', 1), ('show', 1), ('dark', 1), ('toxic', 1), ('mcf7', 1), ('breast', 1), ('ht29', 1), ('colon', 1), ('line', 1), ('A', 1), ('safe', 1), ('procedur', 1), ('determin', 1), ('10', 1), ('min', 1), ('with', 1), ('1.8', 1), ('w_cm', 1)]"', 'b'5'', 'b"('spions', 'therapy', 'ptt', 'laser', 'aptms', 'superparamagnetic', 'iron', 'oxide', 'nanoparticles', 'recently', 'irradiation', 'nm', 'icg', 'pdt', 'cancer', 'recognized', 'highly', 'efficient', 'photothermal', 'agents', 'demonstrate', 'first', 'time', 'knowledge', 'dose', 'intensity', 'dependent', 'potential', 'small', 'spherical', 'coated', 'cationic', 'aqueous', 'solutions', 'upon', 'indocyanine', 'green', 'used', 'photodynamic', 'loaded', 'improve', 'stability', 'achieve', 'effective', 'mild', 'dual', 'combination', 'synergistic', 'therapeutic', 'effect', 'cells', 'via', 'single', 'treatment', 'near', 'infrared', 'nir', 'neither', 'showed', 'dark', 'toxicity', 'breast', 'colon', 'cell', 'lines', 'safe', 'procedure', 'determined', 'min')"', 'b'(10, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.04288847210653254'', 'b'[0.007997161176905201, 0.004398438647297861, 0.0016639147200507478, 0.0011092764800338319, 0.0008364169470307814]'', 'b'-2.3202283191284883'', 'b'[-1.3978952727983707, -1.9957322735539909, -2.828641396489095, -3.2341065045972597, -3.3567088266895917]'', 'b'-2.7531389820985033'', 'b'[-0.1229711318550268, -0.17556211923318998, -0.21650443063870303, -0.2475387612837176, -0.2189934356134968]'', 'b'21'', 'b'0.054936771783163585'', 'b"['Apoptosis', 'Cell Line, Tumor', 'Cell Survival', 'Humans', 'Indocyanine Green', 'Infrared Rays', 'Magnetite Nanoparticles', 'Neoplasms', 'Photochemotherapy', 'Phototherapy', 'Propylamines', 'Reactive Oxygen Species', 'Silanes', 'Temperature']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'35'', 'b'ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression.'', 'b'Interferon-stimulated gene 15 (ISG15) is a 15 kDa protein induced by type I interferons (IFN-\xce\xb1 and IFN-\xce\xb2) and is a member of the ubiquitin-like superfamily of proteins. The ISG15 pathway is highly expressed in various malignancies, including pancreatic ductal adenocarcinoma (PDAC), suggesting a potential role of the ISG15 pathway (free ISG15 and ISG15 conjugates) in pancreatic carcinogenesis. However, very little is known about how the ISG15 pathway may contribute to pancreatic tumorigenesis. In the current study, we demonstrate that ISG15 pathway knockdown reverses the KRAS-associated phenotypes of PDAC cells such as increased proliferation and colony formation. Furthermore, clustered regularly interspaced short palindromic repeats (CRISPR)-mediated ISG15 knockdown decreased tumor programmed death ligand-1 (PDL-1) expression leading to increased number of CD8'', 'b'754'', 'b'119'', 'b"[('pathway', 8), ('pancreatic', 6), ('pdac', 4), ('knockdown', 4), ('increased', 4), ('gene', 2), ('kda', 2), ('protein', 2), ('induced', 2), ('type', 2), ('interferons', 2), ('member', 2), ('superfamily', 2), ('proteins', 2), ('highly', 2), ('expressed', 2), ('various', 2), ('malignancies', 2), ('including', 2), ('ductal', 2), ('adenocarcinoma', 2), ('suggesting', 2), ('potential', 2), ('role', 2), ('free', 2), ('conjugates', 2), ('carcinogenesis', 2), ('however', 2), ('little', 2), ('known', 2), ('may', 2), ('contribute', 2), ('tumorigenesis', 2), ('current', 2), ('study', 2), ('demonstrate', 2), ('reverses', 2), ('phenotypes', 2), ('cells', 2), ('proliferation', 2), ('colony', 2), ('formation', 2), ('furthermore', 2), ('clustered', 2), ('regularly', 2), ('interspaced', 2), ('short', 2), ('palindromic', 2), ('repeats', 2), ('crispr', 2), ('decreased', 2), ('tumor', 2), ('programmed', 2), ('death', 2), ('expression', 2), ('leading', 2), ('number', 2)]"', 'b"[('isg15', 8), ('(', 6), (')', 6), ('the', 6), ('of', 5), (',', 5), ('is', 4), ('and', 4), ('.', 4), ('pathway', 4), ('a', 3), ('pancreat', 3), ('15', 2), ('protein', 2), ('express', 2), ('in', 2), ('pdac', 2), ('to', 2), ('knockdown', 2), ('increas', 2), ('interferon-stimul', 1), ('gene', 1), ('kda', 1), ('induc', 1), ('by', 1), ('type', 1), ('I', 1), ('interferon', 1), ('ifn-\xce\xb1', 1), ('ifn-\xce\xb2', 1), ('member', 1), ('ubiquitin-lik', 1), ('superfamili', 1), ('highli', 1), ('variou', 1), ('malign', 1), ('includ', 1), ('ductal', 1), ('adenocarcinoma', 1), ('suggest', 1), ('potenti', 1), ('role', 1), ('free', 1), ('conjug', 1), ('carcinogenesi', 1), ('howev', 1), ('veri', 1), ('littl', 1), ('known', 1), ('about', 1), ('how', 1), ('may', 1), ('contribut', 1), ('tumorigenesi', 1), ('In', 1), ('current', 1), ('studi', 1), ('we', 1), ('demonstr', 1), ('that', 1), ('revers', 1), ('kras-associ', 1), ('phenotyp', 1), ('cell', 1), ('such', 1), ('as', 1), ('prolifer', 1), ('coloni', 1), ('format', 1), ('furthermor', 1), ('cluster', 1), ('regularli', 1), ('interspac', 1), ('short', 1), ('palindrom', 1), ('repeat', 1), ('crispr', 1), ('-mediat', 1), ('decreas', 1), ('tumor', 1), ('program', 1), ('death', 1), ('ligand-1', 1), ('pdl-1', 1), ('lead', 1), ('number', 1), ('cd8', 1)]"', 'b'5'', 'b"('pathway', 'pancreatic', 'pdac', 'knockdown', 'increased', 'gene', 'kda', 'protein', 'induced', 'type', 'interferons', 'member', 'superfamily', 'proteins', 'highly', 'expressed', 'various', 'malignancies', 'including', 'ductal', 'adenocarcinoma', 'suggesting', 'potential', 'role', 'free', 'conjugates', 'carcinogenesis', 'however', 'little', 'known', 'may', 'contribute', 'tumorigenesis', 'current', 'study', 'demonstrate', 'reverses', 'phenotypes', 'cells', 'proliferation', 'colony', 'formation', 'furthermore', 'clustered', 'regularly', 'interspaced', 'short', 'palindromic', 'repeats', 'crispr', 'decreased', 'tumor', 'programmed', 'death', 'expression', 'leading', 'number')"', 'b'(8, 6, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.07129976350134343'', 'b'[0.0, 0.003604481418018386, 0.0014833581063341675, 0.0004456710354375062, 0.00037311993664535404, 0.00019343089497531708]'', 'b'-1.7829515092753279'', 'b'[1, -1.70805020110221, -2.367295829986474, -3.2766661190160553, -3.4543472962535073, -3.7004803657924166]'', 'b'-2.055171671955389'', 'b'[0.06524052186840094, -0.09234952816373226, -0.10183487632554372, -0.10514269310723139, -0.11084418261230765, -0.07873659518931975]'', 'b'60'', 'b'0.12250430563016616'', 'b"['Animals', 'Antibodies, Monoclonal', 'B7-H1 Antigen', 'CD8-Positive T-Lymphocytes', 'Cell Line, Tumor', 'Cell Transformation, Neoplastic', 'Cytokines', 'Down-Regulation', 'Female', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Immunotherapy', 'Mice', 'Mice, Inbred C57BL', 'Neoplasms, Experimental', 'Pancreatic Neoplasms', 'Programmed Cell Death 1 Receptor', 'RNA, Small Interfering', 'Signal Transduction', 'T-Lymphocytes, Regulatory', 'Ubiquitins']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'35'', 'b'ISG15 pathway knockdown reverses pancreatic cancer cell transformation and decreases murine pancreatic tumor growth via downregulation of PDL-1 expression.'', 'b'Interferon-stimulated gene 15 (ISG15) is a 15 kDa protein induced by type I interferons (IFN-\xce\xb1 and IFN-\xce\xb2) and is a member of the ubiquitin-like superfamily of proteins. The ISG15 pathway is highly expressed in various malignancies, including pancreatic ductal adenocarcinoma (PDAC), suggesting a potential role of the ISG15 pathway (free ISG15 and ISG15 conjugates) in pancreatic carcinogenesis. However, very little is known about how the ISG15 pathway may contribute to pancreatic tumorigenesis. In the current study, we demonstrate that ISG15 pathway knockdown reverses the KRAS-associated phenotypes of PDAC cells such as increased proliferation and colony formation. Furthermore, clustered regularly interspaced short palindromic repeats (CRISPR)-mediated ISG15 knockdown decreased tumor programmed death ligand-1 (PDL-1) expression leading to increased number of CD8'', 'b'754'', 'b'119'', 'b"[('pathway', 8), ('pancreatic', 6), ('pdac', 4), ('knockdown', 4), ('increased', 4), ('gene', 2), ('kda', 2), ('protein', 2), ('induced', 2), ('type', 2), ('interferons', 2), ('member', 2), ('superfamily', 2), ('proteins', 2), ('highly', 2), ('expressed', 2), ('various', 2), ('malignancies', 2), ('including', 2), ('ductal', 2), ('adenocarcinoma', 2), ('suggesting', 2), ('potential', 2), ('role', 2), ('free', 2), ('conjugates', 2), ('carcinogenesis', 2), ('however', 2), ('little', 2), ('known', 2), ('may', 2), ('contribute', 2), ('tumorigenesis', 2), ('current', 2), ('study', 2), ('demonstrate', 2), ('reverses', 2), ('phenotypes', 2), ('cells', 2), ('proliferation', 2), ('colony', 2), ('formation', 2), ('furthermore', 2), ('clustered', 2), ('regularly', 2), ('interspaced', 2), ('short', 2), ('palindromic', 2), ('repeats', 2), ('crispr', 2), ('decreased', 2), ('tumor', 2), ('programmed', 2), ('death', 2), ('expression', 2), ('leading', 2), ('number', 2)]"', 'b"[('isg15', 8), ('(', 6), (')', 6), ('the', 6), ('of', 5), (',', 5), ('is', 4), ('and', 4), ('.', 4), ('pathway', 4), ('a', 3), ('pancreat', 3), ('15', 2), ('protein', 2), ('express', 2), ('in', 2), ('pdac', 2), ('to', 2), ('knockdown', 2), ('increas', 2), ('interferon-stimul', 1), ('gene', 1), ('kda', 1), ('induc', 1), ('by', 1), ('type', 1), ('I', 1), ('interferon', 1), ('ifn-\xce\xb1', 1), ('ifn-\xce\xb2', 1), ('member', 1), ('ubiquitin-lik', 1), ('superfamili', 1), ('highli', 1), ('variou', 1), ('malign', 1), ('includ', 1), ('ductal', 1), ('adenocarcinoma', 1), ('suggest', 1), ('potenti', 1), ('role', 1), ('free', 1), ('conjug', 1), ('carcinogenesi', 1), ('howev', 1), ('veri', 1), ('littl', 1), ('known', 1), ('about', 1), ('how', 1), ('may', 1), ('contribut', 1), ('tumorigenesi', 1), ('In', 1), ('current', 1), ('studi', 1), ('we', 1), ('demonstr', 1), ('that', 1), ('revers', 1), ('kras-associ', 1), ('phenotyp', 1), ('cell', 1), ('such', 1), ('as', 1), ('prolifer', 1), ('coloni', 1), ('format', 1), ('furthermor', 1), ('cluster', 1), ('regularli', 1), ('interspac', 1), ('short', 1), ('palindrom', 1), ('repeat', 1), ('crispr', 1), ('-mediat', 1), ('decreas', 1), ('tumor', 1), ('program', 1), ('death', 1), ('ligand-1', 1), ('pdl-1', 1), ('lead', 1), ('number', 1), ('cd8', 1)]"', 'b'5'', 'b"('pathway', 'pancreatic', 'pdac', 'knockdown', 'increased', 'gene', 'kda', 'protein', 'induced', 'type', 'interferons', 'member', 'superfamily', 'proteins', 'highly', 'expressed', 'various', 'malignancies', 'including', 'ductal', 'adenocarcinoma', 'suggesting', 'potential', 'role', 'free', 'conjugates', 'carcinogenesis', 'however', 'little', 'known', 'may', 'contribute', 'tumorigenesis', 'current', 'study', 'demonstrate', 'reverses', 'phenotypes', 'cells', 'proliferation', 'colony', 'formation', 'furthermore', 'clustered', 'regularly', 'interspaced', 'short', 'palindromic', 'repeats', 'crispr', 'decreased', 'tumor', 'programmed', 'death', 'expression', 'leading', 'number')"', 'b'(8, 6, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.07129976350134343'', 'b'[0.0, 0.003604481418018386, 0.0014833581063341675, 0.0004456710354375062, 0.00037311993664535404, 0.00019343089497531708]'', 'b'-1.7829515092753279'', 'b'[1, -1.70805020110221, -2.367295829986474, -3.2766661190160553, -3.4543472962535073, -3.7004803657924166]'', 'b'-2.055171671955389'', 'b'[0.06524052186840094, -0.09234952816373226, -0.10183487632554372, -0.10514269310723139, -0.11084418261230765, -0.07873659518931975]'', 'b'60'', 'b'0.12250430563016616'', 'b"['Animals', 'Antibodies, Monoclonal', 'B7-H1 Antigen', 'CD8-Positive T-Lymphocytes', 'Cell Line, Tumor', 'Cell Transformation, Neoplastic', 'Cytokines', 'Down-Regulation', 'Female', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Immunotherapy', 'Mice', 'Mice, Inbred C57BL', 'Neoplasms, Experimental', 'Pancreatic Neoplasms', 'Programmed Cell Death 1 Receptor', 'RNA, Small Interfering', 'Signal Transduction', 'T-Lymphocytes, Regulatory', 'Ubiquitins']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'36'', 'b'Full axillary lymph node dissection and increased breast epidermal thickness 1 year after radiation therapy for breast cancer.'', 'b"We previously reported a prospective study showing axillary lymph node dissection (ALND) is associated with increased breast skin thickening during and 6 weeks post-radiation therapy (RT), and now report ALND's long-term impact at 1 year.Among 66 women who received whole breast RT after lumpectomy, objective ultrasound measurements of epidermal thickness over four quadrants of the treated breast were measured at five time points: before RT, week 6 of RT, and 6 weeks, 6 months, and 1 year post-RT. Skin thickness ratio (STRA) was generated by normalizing for corresponding measurements of the contralateral breast.A total of 2,436 ultrasound images were obtained. Among 63 women with evaluable data at 1 year, mean STRA significantly increased at 6 months (absolute mean increase of 65%, SD 0.054), and remained elevated at 1 year post-RT (absolute mean increase of 44%, SD 0.048). In multivariable analysis, ALND compared to sentinel lymph node biopsy, longer interval between surgery and RT, increased baseline STRA, and Caucasian race predicted for more severe changes in STRA at 1 year compared to baseline (all P\xe2\x80\x89<\xe2\x80\x89.05).In the setting of whole breast RT, our findings suggest that ALND has long-term repercussions on breast skin thickening."', 'b'1056'', 'b'194'', 'b"[('rt', 12), ('breast', 10), ('alnd', 8), ('year', 8), ('stra', 8), ('increased', 6), ('skin', 6), ('mean', 6), ('lymph', 4), ('node', 4), ('thickening', 4), ('weeks', 4), ('women', 4), ('whole', 4), ('ultrasound', 4), ('measurements', 4), ('thickness', 4), ('months', 4), ('absolute', 4), ('increase', 4), ('sd', 4), ('compared', 4), ('baseline', 4), ('previously', 2), ('reported', 2), ('prospective', 2), ('study', 2), ('showing', 2), ('axillary', 2), ('dissection', 2), ('associated', 2), ('therapy', 2), ('report', 2), ('impact', 2), ('received', 2), ('lumpectomy', 2), ('objective', 2), ('epidermal', 2), ('four', 2), ('quadrants', 2), ('treated', 2), ('measured', 2), ('five', 2), ('time', 2), ('points', 2), ('week', 2), ('ratio', 2), ('generated', 2), ('normalizing', 2), ('corresponding', 2), ('contralateral', 2), ('total', 2), ('images', 2), ('obtained', 2), ('among', 2), ('evaluable', 2), ('data', 2), ('significantly', 2), ('remained', 2), ('elevated', 2), ('multivariable', 2), ('analysis', 2), ('sentinel', 2), ('biopsy', 2), ('longer', 2), ('interval', 2), ('surgery', 2), ('caucasian', 2), ('race', 2), ('predicted', 2), ('severe', 2), ('changes', 2), ('p', 2), ('setting', 2), ('findings', 2), ('suggest', 2), ('repercussions', 2)]"', 'b'[(\',\', 15), (\'of\', 8), (\'and\', 7), (\'(\', 6), (\')\', 6), (\'RT\', 6), (\'at\', 6), (\'increas\', 5), (\'breast\', 5), (\'6\', 5), (\'1\', 5), (\'alnd\', 4), (\'year\', 4), (\'.\', 4), (\'stra\', 4), (\'skin\', 3), (\'week\', 3), (\'measur\', 3), (\'the\', 3), (\'mean\', 3), (\'report\', 2), (\'lymph\', 2), (\'node\', 2), (\'with\', 2), (\'thicken\', 2), (\'long-term\', 2), (\'women\', 2), (\'whole\', 2), (\'ultrasound\', 2), (\'thick\', 2), (\'were\', 2), (\'month\', 2), (\'post-rt\', 2), (\'for\', 2), (\'absolut\', 2), (\'%\', 2), (\'SD\', 2), (\'compar\', 2), (\'to\', 2), (\'baselin\', 2), (\'We\', 1), (\'previous\', 1), (\'a\', 1), (\'prospect\', 1), (\'studi\', 1), (\'show\', 1), (\'axillari\', 1), (\'dissect\', 1), (\'is\', 1), (\'associ\', 1), (\'dure\', 1), (\'post-radi\', 1), (\'therapi\', 1), (\'now\', 1), ("\'s", 1), (\'impact\', 1), (\'year.among\', 1), (\'66\', 1), (\'who\', 1), (\'receiv\', 1), (\'after\', 1), (\'lumpectomi\', 1), (\'object\', 1), (\'epiderm\', 1), (\'over\', 1), (\'four\', 1), (\'quadrant\', 1), (\'treat\', 1), (\'five\', 1), (\'time\', 1), (\'point\', 1), (\':\', 1), (\'befor\', 1), (\'ratio\', 1), (\'wa\', 1), (\'gener\', 1), (\'by\', 1), (\'normal\', 1), (\'correspond\', 1), (\'contralater\', 1), (\'breast.a\', 1), (\'total\', 1), (\'2,436\', 1), (\'imag\', 1), (\'obtain\', 1), (\'among\', 1), (\'63\', 1), (\'evalu\', 1), (\'data\', 1), (\'significantli\', 1), (\'65\', 1), (\'0.054\', 1), (\'remain\', 1), (\'elev\', 1), (\'44\', 1), (\'0.048\', 1), (\'In\', 1), (\'multivari\', 1), (\'analysi\', 1), (\'sentinel\', 1), (\'biopsi\', 1), (\'longer\', 1), (\'interv\', 1), (\'between\', 1), (\'surgeri\', 1), (\'caucasian\', 1), (\'race\', 1), (\'predict\', 1), (\'more\', 1), (\'sever\', 1), (\'chang\', 1), (\'in\', 1), (\'all\', 1), (\'P\', 1), (\'<\', 1), (\'.05\', 1), (\'.in\', 1), (\'set\', 1), (\'our\', 1), (\'find\', 1), (\'suggest\', 1), (\'that\', 1), (\'ha\', 1), (\'repercuss\', 1), (\'on\', 1)]'', 'b'4'', 'b"('rt', 'breast', 'alnd', 'year', 'stra', 'increased', 'skin', 'mean', 'lymph', 'node', 'thickening', 'weeks', 'women', 'whole', 'ultrasound', 'measurements', 'thickness', 'months', 'absolute', 'increase', 'sd', 'compared', 'baseline', 'previously', 'reported', 'prospective', 'study', 'showing', 'axillary', 'dissection', 'associated', 'therapy', 'report', 'impact', 'received', 'lumpectomy', 'objective', 'epidermal', 'four', 'quadrants', 'treated', 'measured', 'five', 'time', 'points', 'week', 'ratio', 'generated', 'normalizing', 'corresponding', 'contralateral', 'total', 'images', 'obtained', 'among', 'evaluable', 'data', 'significantly', 'remained', 'elevated', 'multivariable', 'analysis', 'sentinel', 'biopsy', 'longer', 'interval', 'surgery', 'caucasian', 'race', 'predicted', 'severe', 'changes', 'p', 'setting', 'findings', 'suggest', 'repercussions')"', 'b'(12, 10, 8, 8, 8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0246129601563823'', 'b'[0.0, 0.0, 0.0011757899256152231, 0.0, 0.0]'', 'b'-2.817712325956905'', 'b'[1, 1, -1.1972245773362196, -1.9957322735539909, -2.295836866004329]'', 'b'-3.1555269750970685'', 'b'[0.02127739844728488, 0.02127739844728488, -0.012669161370577836, -0.0, -0.0]'', 'b'85'', 'b'0.15004200859959718'', 'b"['Adult', 'Aged', 'Axilla', 'Breast Neoplasms', 'Epidermis', 'European Continental Ancestry Group', 'Female', 'Follow-Up Studies', 'Humans', 'Lymph Node Excision', 'Mastectomy, Segmental', 'Middle Aged', 'Prospective Studies', 'Radiotherapy, Adjuvant', 'Time-to-Treatment', 'Ultrasonography']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'37'', 'b'Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.'', 'b'Cytokines, metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) take part in many processes involved in tumor progression and invasion such as degradation of the extracellular matrix, influence on immune cells associated with tumor tissue, and angiogenesis. Thus, the aim of this study was to compare the concentration of plasma levels and tissue expression of macrophage colony-stimulating factor (M-CSF), vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP)-2 and MMP9, and their tissue inhibitors TIMP1 and TIMP2 in patients with cervical cancer, patients with high-grade cervical intraepithelial dysplasia (CIN3) and patients with ectropion.Concentration and expression of all tested parameters was measured in serum with enzyme-linked immunosorbent assay (ELISA) and in tissue with immunohistochemistry method.The epithelial expression of M-CSF and TIMP1 in cancer tissue was much stronger as compared to that in ectropion and CIN3. In the case of MMP2, lack of or weak expression in epithelial cells was observed in all tested groups. Our studies showed statistical differences of tested parameters in tissue expression and in plasma concentrations in patients with cervical cancer, patients with CIN3 and patients with ectropion. Moreover, data revealed positive correlation between plasma level and cervical cancer cell expression of VEGF.Our findings indicate a potential role of all the proteins tested here in cervical cancer diagnosis, especially VEGF. However, further studies will show whether they play a role in the progression of cancerous changes in epithelial tissue of the cervix.'', 'b'1400'', 'b'232'', 'b"[('tissue', 16), ('expression', 12), ('patients', 12), ('cervical', 10), ('cancer', 10), ('tested', 8), ('plasma', 6), ('epithelial', 6), ('metalloproteinases', 4), ('inhibitors', 4), ('tumor', 4), ('progression', 4), ('matrix', 4), ('cells', 4), ('factor', 4), ('vegf', 4), ('parameters', 4), ('ectropion', 4), ('studies', 4), ('role', 4), ('cytokines', 2), ('mmps', 2), ('timps', 2), ('take', 2), ('part', 2), ('many', 2), ('processes', 2), ('involved', 2), ('invasion', 2), ('degradation', 2), ('extracellular', 2), ('influence', 2), ('immune', 2), ('associated', 2), ('angiogenesis', 2), ('thus', 2), ('aim', 2), ('study', 2), ('compare', 2), ('concentration', 2), ('levels', 2), ('macrophage', 2), ('vascular', 2), ('endothelial', 2), ('growth', 2), ('mmp', 2), ('intraepithelial', 2), ('dysplasia', 2), ('measured', 2), ('serum', 2), ('immunosorbent', 2), ('assay', 2), ('elisa', 2), ('immunohistochemistry', 2), ('much', 2), ('stronger', 2), ('compared', 2), ('case', 2), ('lack', 2), ('weak', 2), ('observed', 2), ('groups', 2), ('showed', 2), ('statistical', 2), ('differences', 2), ('concentrations', 2), ('moreover', 2), ('data', 2), ('revealed', 2), ('positive', 2), ('correlation', 2), ('level', 2), ('cell', 2), ('findings', 2), ('indicate', 2), ('potential', 2), ('proteins', 2), ('diagnosis', 2), ('especially', 2), ('however', 2), ('show', 2), ('whether', 2), ('play', 2), ('cancerous', 2), ('changes', 2), ('cervix', 2)]"', 'b"[('and', 15), ('in', 15), (',', 13), ('of', 13), ('with', 9), ('tissu', 8), ('(', 7), (')', 7), ('the', 7), ('.', 6), ('express', 6), ('patient', 6), ('cancer', 6), ('cervic', 5), ('wa', 4), ('test', 4), ('cell', 3), ('studi', 3), ('plasma', 3), ('cin3', 3), ('all', 3), ('epitheli', 3), ('metalloproteinas', 2), ('mmp', 2), ('their', 2), ('inhibitor', 2), ('tumor', 2), ('progress', 2), ('as', 2), ('matrix', 2), ('to', 2), ('compar', 2), ('concentr', 2), ('level', 2), ('factor', 2), ('m-csf', 2), ('vegf', 2), ('timp1', 2), ('paramet', 2), ('ectropion', 2), ('show', 2), ('a', 2), ('role', 2), ('cytokin', 1), ('timp', 1), ('take', 1), ('part', 1), ('mani', 1), ('process', 1), ('involv', 1), ('invas', 1), ('such', 1), ('degrad', 1), ('extracellular', 1), ('influenc', 1), ('on', 1), ('immun', 1), ('associ', 1), ('angiogenesi', 1), ('thu', 1), ('aim', 1), ('thi', 1), ('macrophag', 1), ('colony-stimul', 1), ('vascular', 1), ('endotheli', 1), ('growth', 1), ('-2', 1), ('mmp9', 1), ('timp2', 1), ('high-grad', 1), ('intraepitheli', 1), ('dysplasia', 1), ('ectropion.concentr', 1), ('measur', 1), ('serum', 1), ('enzyme-link', 1), ('immunosorb', 1), ('assay', 1), ('elisa', 1), ('immunohistochemistri', 1), ('method.th', 1), ('much', 1), ('stronger', 1), ('that', 1), ('In', 1), ('case', 1), ('mmp2', 1), ('lack', 1), ('or', 1), ('weak', 1), ('observ', 1), ('group', 1), ('our', 1), ('statist', 1), ('differ', 1), ('moreov', 1), ('data', 1), ('reveal', 1), ('posit', 1), ('correl', 1), ('between', 1), ('vegf.our', 1), ('find', 1), ('indic', 1), ('potenti', 1), ('protein', 1), ('here', 1), ('diagnosi', 1), ('especi', 1), ('howev', 1), ('further', 1), ('will', 1), ('whether', 1), ('they', 1), ('play', 1), ('chang', 1), ('cervix', 1)]"', 'b'6'', 'b"('tissue', 'expression', 'patients', 'cervical', 'cancer', 'tested', 'plasma', 'epithelial', 'metalloproteinases', 'inhibitors', 'tumor', 'progression', 'matrix', 'cells', 'factor', 'vegf', 'parameters', 'ectropion', 'studies', 'role', 'cytokines', 'mmps', 'timps', 'take', 'part', 'many', 'processes', 'involved', 'invasion', 'degradation', 'extracellular', 'influence', 'immune', 'associated', 'angiogenesis', 'thus', 'aim', 'study', 'compare', 'concentration', 'levels', 'macrophage', 'vascular', 'endothelial', 'growth', 'mmp', 'intraepithelial', 'dysplasia', 'measured', 'serum', 'immunosorbent', 'assay', 'elisa', 'immunohistochemistry', 'much', 'stronger', 'compared', 'case', 'lack', 'weak', 'observed', 'groups', 'showed', 'statistical', 'differences', 'concentrations', 'moreover', 'data', 'revealed', 'positive', 'correlation', 'level', 'cell', 'findings', 'indicate', 'potential', 'proteins', 'diagnosis', 'especially', 'however', 'show', 'whether', 'play', 'cancerous', 'changes', 'cervix')"', 'b'(16, 12, 12, 10, 10, 8, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0'', 'b'[0.0, 0.0, 0.0, 0.0, 0.0]'', 'b'1'', 'b'[1, 1, 1, 1, 1]'', 'b'1.1198896871153945'', 'b'[0.0, 0.0, 0.0, 0.0, 0.0]'', 'b'49'', 'b'0.20948608647883293'', 'b"['Adenocarcinoma', 'Adult', 'Carcinoma, Squamous Cell', 'Cytokines', 'Female', 'Humans', 'Macrophage Colony-Stimulating Factor', 'Matrix Metalloproteinase 2', 'Matrix Metalloproteinase 9', 'Metalloproteases', 'Middle Aged', 'Tissue Inhibitor of Metalloproteinase-1', 'Tissue Inhibitor of Metalloproteinase-2', 'Tissue Inhibitor of Metalloproteinases', 'Uterine Cervical Dysplasia', 'Uterine Cervical Neoplasms', 'Vascular Endothelial Growth Factor A', 'Young Adult']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'38'', 'b'Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.'', 'b'Cytokines, metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) take part in many processes involved in tumor progression and invasion such as degradation of the extracellular matrix, influence on immune cells associated with tumor tissue, and angiogenesis. Thus, the aim of this study was to compare the concentration of plasma levels and tissue expression of macrophage colony-stimulating factor (M-CSF), vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP)-2 and MMP9, and their tissue inhibitors TIMP1 and TIMP2 in patients with cervical cancer, patients with high-grade cervical intraepithelial dysplasia (CIN3) and patients with ectropion.Concentration and expression of all tested parameters was measured in serum with enzyme-linked immunosorbent assay (ELISA) and in tissue with immunohistochemistry method.The epithelial expression of M-CSF and TIMP1 in cancer tissue was much stronger as compared to that in ectropion and CIN3. In the case of MMP2, lack of or weak expression in epithelial cells was observed in all tested groups. Our studies showed statistical differences of tested parameters in tissue expression and in plasma concentrations in patients with cervical cancer, patients with CIN3 and patients with ectropion. Moreover, data revealed positive correlation between plasma level and cervical cancer cell expression of VEGF.Our findings indicate a potential role of all the proteins tested here in cervical cancer diagnosis, especially VEGF. However, further studies will show whether they play a role in the progression of cancerous changes in epithelial tissue of the cervix.'', 'b'1400'', 'b'232'', 'b"[('tissue', 16), ('expression', 12), ('patients', 12), ('cervical', 10), ('cancer', 10), ('tested', 8), ('plasma', 6), ('epithelial', 6), ('metalloproteinases', 4), ('inhibitors', 4), ('tumor', 4), ('progression', 4), ('matrix', 4), ('cells', 4), ('factor', 4), ('vegf', 4), ('parameters', 4), ('ectropion', 4), ('studies', 4), ('role', 4), ('cytokines', 2), ('mmps', 2), ('timps', 2), ('take', 2), ('part', 2), ('many', 2), ('processes', 2), ('involved', 2), ('invasion', 2), ('degradation', 2), ('extracellular', 2), ('influence', 2), ('immune', 2), ('associated', 2), ('angiogenesis', 2), ('thus', 2), ('aim', 2), ('study', 2), ('compare', 2), ('concentration', 2), ('levels', 2), ('macrophage', 2), ('vascular', 2), ('endothelial', 2), ('growth', 2), ('mmp', 2), ('intraepithelial', 2), ('dysplasia', 2), ('measured', 2), ('serum', 2), ('immunosorbent', 2), ('assay', 2), ('elisa', 2), ('immunohistochemistry', 2), ('much', 2), ('stronger', 2), ('compared', 2), ('case', 2), ('lack', 2), ('weak', 2), ('observed', 2), ('groups', 2), ('showed', 2), ('statistical', 2), ('differences', 2), ('concentrations', 2), ('moreover', 2), ('data', 2), ('revealed', 2), ('positive', 2), ('correlation', 2), ('level', 2), ('cell', 2), ('findings', 2), ('indicate', 2), ('potential', 2), ('proteins', 2), ('diagnosis', 2), ('especially', 2), ('however', 2), ('show', 2), ('whether', 2), ('play', 2), ('cancerous', 2), ('changes', 2), ('cervix', 2)]"', 'b"[('and', 15), ('in', 15), (',', 13), ('of', 13), ('with', 9), ('tissu', 8), ('(', 7), (')', 7), ('the', 7), ('.', 6), ('express', 6), ('patient', 6), ('cancer', 6), ('cervic', 5), ('wa', 4), ('test', 4), ('cell', 3), ('studi', 3), ('plasma', 3), ('cin3', 3), ('all', 3), ('epitheli', 3), ('metalloproteinas', 2), ('mmp', 2), ('their', 2), ('inhibitor', 2), ('tumor', 2), ('progress', 2), ('as', 2), ('matrix', 2), ('to', 2), ('compar', 2), ('concentr', 2), ('level', 2), ('factor', 2), ('m-csf', 2), ('vegf', 2), ('timp1', 2), ('paramet', 2), ('ectropion', 2), ('show', 2), ('a', 2), ('role', 2), ('cytokin', 1), ('timp', 1), ('take', 1), ('part', 1), ('mani', 1), ('process', 1), ('involv', 1), ('invas', 1), ('such', 1), ('degrad', 1), ('extracellular', 1), ('influenc', 1), ('on', 1), ('immun', 1), ('associ', 1), ('angiogenesi', 1), ('thu', 1), ('aim', 1), ('thi', 1), ('macrophag', 1), ('colony-stimul', 1), ('vascular', 1), ('endotheli', 1), ('growth', 1), ('-2', 1), ('mmp9', 1), ('timp2', 1), ('high-grad', 1), ('intraepitheli', 1), ('dysplasia', 1), ('ectropion.concentr', 1), ('measur', 1), ('serum', 1), ('enzyme-link', 1), ('immunosorb', 1), ('assay', 1), ('elisa', 1), ('immunohistochemistri', 1), ('method.th', 1), ('much', 1), ('stronger', 1), ('that', 1), ('In', 1), ('case', 1), ('mmp2', 1), ('lack', 1), ('or', 1), ('weak', 1), ('observ', 1), ('group', 1), ('our', 1), ('statist', 1), ('differ', 1), ('moreov', 1), ('data', 1), ('reveal', 1), ('posit', 1), ('correl', 1), ('between', 1), ('vegf.our', 1), ('find', 1), ('indic', 1), ('potenti', 1), ('protein', 1), ('here', 1), ('diagnosi', 1), ('especi', 1), ('howev', 1), ('further', 1), ('will', 1), ('whether', 1), ('they', 1), ('play', 1), ('chang', 1), ('cervix', 1)]"', 'b'6'', 'b"('tissue', 'expression', 'patients', 'cervical', 'cancer', 'tested', 'plasma', 'epithelial', 'metalloproteinases', 'inhibitors', 'tumor', 'progression', 'matrix', 'cells', 'factor', 'vegf', 'parameters', 'ectropion', 'studies', 'role', 'cytokines', 'mmps', 'timps', 'take', 'part', 'many', 'processes', 'involved', 'invasion', 'degradation', 'extracellular', 'influence', 'immune', 'associated', 'angiogenesis', 'thus', 'aim', 'study', 'compare', 'concentration', 'levels', 'macrophage', 'vascular', 'endothelial', 'growth', 'mmp', 'intraepithelial', 'dysplasia', 'measured', 'serum', 'immunosorbent', 'assay', 'elisa', 'immunohistochemistry', 'much', 'stronger', 'compared', 'case', 'lack', 'weak', 'observed', 'groups', 'showed', 'statistical', 'differences', 'concentrations', 'moreover', 'data', 'revealed', 'positive', 'correlation', 'level', 'cell', 'findings', 'indicate', 'potential', 'proteins', 'diagnosis', 'especially', 'however', 'show', 'whether', 'play', 'cancerous', 'changes', 'cervix')"', 'b'(16, 12, 12, 10, 10, 8, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0'', 'b'[0.0, 0.0, 0.0, 0.0, 0.0]'', 'b'1'', 'b'[1, 1, 1, 1, 1]'', 'b'1.1198896871153945'', 'b'[0.0, 0.0, 0.0, 0.0, 0.0]'', 'b'49'', 'b'0.20948608647883293'', 'b"['Adenocarcinoma', 'Adult', 'Carcinoma, Squamous Cell', 'Cytokines', 'Female', 'Humans', 'Macrophage Colony-Stimulating Factor', 'Matrix Metalloproteinase 2', 'Matrix Metalloproteinase 9', 'Metalloproteases', 'Middle Aged', 'Tissue Inhibitor of Metalloproteinase-1', 'Tissue Inhibitor of Metalloproteinase-2', 'Tissue Inhibitor of Metalloproteinases', 'Uterine Cervical Dysplasia', 'Uterine Cervical Neoplasms', 'Vascular Endothelial Growth Factor A', 'Young Adult']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'39'', 'b'Short- and Long-term Outcomes of 2-Step Stapled Intracorporeal '', 'b'Intracorporeal anastomosis (IA) in laparoscopic colectomy for colon cancer is technically difficult, and there is a lack of consensus on the risk of bacterial contamination and cancer cell dissemination. In this study, short- and long-term outcomes of IA were examined.Short and long-term outcomes of those who underwent IA (n=44) or extracorporeal anastomosis (EA) (n=61) were compared.IA was better than EA for blood loss, incision length, and first stool. Maximum temperature and C-reactive protein on postoperative day 1 were higher for the IA group. The rate of positive cultures from intraoperative lavage was higher for IA. The rate of positive cultures improved to an equivalent level by replacing mechanical pretreatment with chemical pretreatment. IA and EA were equivalent for the results of ascites cytology from lavage.With the use of appropriate preoperative treatment, IA takes advantage of the minimally invasive nature of laparoscopic surgery.'', 'b'819'', 'b'142'', 'b"[('ia', 14), ('ea', 6), ('anastomosis', 4), ('laparoscopic', 4), ('cancer', 4), ('outcomes', 4), ('higher', 4), ('rate', 4), ('positive', 4), ('cultures', 4), ('equivalent', 4), ('pretreatment', 4), ('intracorporeal', 2), ('colectomy', 2), ('colon', 2), ('technically', 2), ('difficult', 2), ('lack', 2), ('consensus', 2), ('risk', 2), ('bacterial', 2), ('contamination', 2), ('cell', 2), ('dissemination', 2), ('study', 2), ('underwent', 2), ('extracorporeal', 2), ('better', 2), ('blood', 2), ('loss', 2), ('incision', 2), ('length', 2), ('first', 2), ('stool', 2), ('maximum', 2), ('temperature', 2), ('protein', 2), ('postoperative', 2), ('day', 2), ('group', 2), ('intraoperative', 2), ('lavage', 2), ('improved', 2), ('level', 2), ('replacing', 2), ('mechanical', 2), ('chemical', 2), ('results', 2), ('ascites', 2), ('cytology', 2), ('use', 2), ('appropriate', 2), ('preoperative', 2), ('treatment', 2), ('takes', 2), ('advantage', 2), ('minimally', 2), ('invasive', 2), ('nature', 2), ('surgery', 2)]"', 'b"[('of', 10), ('IA', 7), ('and', 7), ('the', 7), ('.', 6), ('for', 5), (',', 5), ('(', 4), (')', 4), ('were', 4), ('EA', 3), ('anastomosi', 2), ('laparoscop', 2), ('cancer', 2), ('is', 2), ('on', 2), ('long-term', 2), ('outcom', 2), ('wa', 2), ('higher', 2), ('rate', 2), ('posit', 2), ('cultur', 2), ('from', 2), ('equival', 2), ('pretreat', 2), ('intracorpor', 1), ('in', 1), ('colectomi', 1), ('colon', 1), ('technic', 1), ('difficult', 1), ('there', 1), ('a', 1), ('lack', 1), ('consensu', 1), ('risk', 1), ('bacteri', 1), ('contamin', 1), ('cell', 1), ('dissemin', 1), ('In', 1), ('thi', 1), ('studi', 1), ('short-', 1), ('examined.short', 1), ('those', 1), ('who', 1), ('underw', 1), ('n=44', 1), ('or', 1), ('extracorpor', 1), ('n=61', 1), ('compared.ia', 1), ('better', 1), ('than', 1), ('blood', 1), ('loss', 1), ('incis', 1), ('length', 1), ('first', 1), ('stool', 1), ('maximum', 1), ('temperatur', 1), ('c-reactiv', 1), ('protein', 1), ('postop', 1), ('day', 1), ('1', 1), ('group', 1), ('intraop', 1), ('lavag', 1), ('improv', 1), ('to', 1), ('an', 1), ('level', 1), ('by', 1), ('replac', 1), ('mechan', 1), ('with', 1), ('chemic', 1), ('result', 1), ('ascit', 1), ('cytolog', 1), ('lavage.with', 1), ('use', 1), ('appropri', 1), ('preoper', 1), ('treatment', 1), ('take', 1), ('advantag', 1), ('minim', 1), ('invas', 1), ('natur', 1), ('surgeri', 1)]"', 'b'6'', 'b"('ia', 'ea', 'anastomosis', 'laparoscopic', 'cancer', 'outcomes', 'higher', 'rate', 'positive', 'cultures', 'equivalent', 'pretreatment', 'intracorporeal', 'colectomy', 'colon', 'technically', 'difficult', 'lack', 'consensus', 'risk', 'bacterial', 'contamination', 'cell', 'dissemination', 'study', 'underwent', 'extracorporeal', 'better', 'blood', 'loss', 'incision', 'length', 'first', 'stool', 'maximum', 'temperature', 'protein', 'postoperative', 'day', 'group', 'intraoperative', 'lavage', 'improved', 'level', 'replacing', 'mechanical', 'chemical', 'results', 'ascites', 'cytology', 'use', 'appropriate', 'preoperative', 'treatment', 'takes', 'advantage', 'minimally', 'invasive', 'nature', 'surgery')"', 'b'(14, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0'', 'b'[0.0, 0.0, 0.0, 0.0]'', 'b'1'', 'b'[1, 1, 1, 1]'', 'b'1.1198896871153945'', 'b'[0.0, 0.0, 0.0, 0.0]'', 'b'48'', 'b'0.08554855369396164'', 'b"['Adult', 'Aged', 'Aged, 80 and over', 'Anastomosis, Surgical', 'Ascites', 'Colectomy', 'Colonic Neoplasms', 'Female', 'Humans', 'Laparoscopy', 'Lymph Node Excision', 'Male', 'Middle Aged', 'Postoperative Complications', 'Surgical Stapling', 'Time Factors', 'Treatment Outcome']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'40'', 'b'Prevalence and Characteristics of Pneumonitis Following Irradiation of Breast Cancer.'', 'b'Pneumonitis is a serious complication after radiotherapy of breast cancer. This study aimed to identify its prevalence and potential risk factors.A total of 606 patients irradiated following breast-conserving surgery or mastectomy were retrospectively analyzed. In patients developing pneumonitis, radiation and clinical parameters were investigated to identify potential risk factors.Eleven patients (1.8%) developed a pneumonitis grade \xe2\x89\xa52. Mean doses to the ipsilateral lung were >7 Gy in 5 patients (45%). Of the other patients, 5 had a chronic inflammatory disease. Six patients (55%) had another malignancy (4 previous contralateral breast cancers, 1 previous ovarian and thyroid cancer, 1 synchronous carcinoma-in-situ (pTis) at the contralateral breast). Five patients (45%) received chemotherapy including taxanes and 4 patients (36%) received trastuzumab.The prevalence of pneumonitis was 1.8%. Potential risk factors included mean radiation dose to ipsilateral lung >7 Gy, systemic treatment with taxanes or trastuzumab, chronic inflammatory disease and history of another malignancy.'', 'b'947'', 'b'148'', 'b"[('patients', 16), ('pneumonitis', 8), ('breast', 6), ('potential', 6), ('risk', 6), ('cancer', 4), ('identify', 4), ('prevalence', 4), ('radiation', 4), ('mean', 4), ('ipsilateral', 4), ('lung', 4), ('gy', 4), ('chronic', 4), ('inflammatory', 4), ('disease', 4), ('another', 4), ('malignancy', 4), ('previous', 4), ('contralateral', 4), ('received', 4), ('taxanes', 4), ('serious', 2), ('complication', 2), ('radiotherapy', 2), ('study', 2), ('aimed', 2), ('total', 2), ('irradiated', 2), ('following', 2), ('surgery', 2), ('mastectomy', 2), ('retrospectively', 2), ('analyzed', 2), ('developing', 2), ('clinical', 2), ('parameters', 2), ('investigated', 2), ('developed', 2), ('grade', 2), ('doses', 2), ('six', 2), ('cancers', 2), ('ovarian', 2), ('thyroid', 2), ('synchronous', 2), ('ptis', 2), ('five', 2), ('chemotherapy', 2), ('including', 2), ('factors', 2), ('included', 2), ('dose', 2), ('systemic', 2), ('treatment', 2), ('trastuzumab', 2), ('history', 2)]"', 'b"[('.', 8), ('patient', 8), ('(', 7), (')', 7), (',', 6), ('%', 6), ('and', 5), ('pneumon', 4), ('of', 4), ('to', 4), ('a', 3), ('breast', 3), ('cancer', 3), ('potenti', 3), ('risk', 3), ('were', 3), ('the', 3), ('identifi', 2), ('preval', 2), ('or', 2), ('develop', 2), ('radiat', 2), ('1.8', 2), ('mean', 2), ('dose', 2), ('ipsilater', 2), ('lung', 2), ('>', 2), ('7', 2), ('Gy', 2), ('5', 2), ('45', 2), ('had', 2), ('chronic', 2), ('inflammatori', 2), ('diseas', 2), ('anoth', 2), ('malign', 2), ('4', 2), ('previou', 2), ('contralater', 2), ('1', 2), ('receiv', 2), ('includ', 2), ('taxan', 2), ('is', 1), ('seriou', 1), ('complic', 1), ('after', 1), ('radiotherapi', 1), ('thi', 1), ('studi', 1), ('aim', 1), ('it', 1), ('factors.a', 1), ('total', 1), ('606', 1), ('irradi', 1), ('follow', 1), ('breast-conserv', 1), ('surgeri', 1), ('mastectomi', 1), ('retrospect', 1), ('analyz', 1), ('In', 1), ('clinic', 1), ('paramet', 1), ('investig', 1), ('factors.eleven', 1), ('grade', 1), ('\xe2\x89\xa52', 1), ('in', 1), ('Of', 1), ('other', 1), ('six', 1), ('55', 1), ('ovarian', 1), ('thyroid', 1), ('synchron', 1), ('carcinoma-in-situ', 1), ('pti', 1), ('at', 1), ('five', 1), ('chemotherapi', 1), ('36', 1), ('trastuzumab.th', 1), ('wa', 1), ('factor', 1), ('system', 1), ('treatment', 1), ('with', 1), ('trastuzumab', 1), ('histori', 1)]"', 'b'8'', 'b"('patients', 'pneumonitis', 'breast', 'potential', 'risk', 'cancer', 'identify', 'prevalence', 'radiation', 'mean', 'ipsilateral', 'lung', 'gy', 'chronic', 'inflammatory', 'disease', 'another', 'malignancy', 'previous', 'contralateral', 'received', 'taxanes', 'serious', 'complication', 'radiotherapy', 'study', 'aimed', 'total', 'irradiated', 'following', 'surgery', 'mastectomy', 'retrospectively', 'analyzed', 'developing', 'clinical', 'parameters', 'investigated', 'developed', 'grade', 'doses', 'six', 'cancers', 'ovarian', 'thyroid', 'synchronous', 'ptis', 'five', 'chemotherapy', 'including', 'factors', 'included', 'dose', 'systemic', 'treatment', 'trastuzumab', 'history')"', 'b'(16, 8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.04185157649233901'', 'b'[0.0, -0.0003272281208529802, -0.00025539755773891135, -0.00019290821206335208, -0.00042300118462627374, -0.00036363259731030546]'', 'b'-2.258096538021482'', 'b'[1, -2.4657359027997265, -2.713572066704308, -3.68213122712422, -3.2972854062187906, -3.448516375942715]'', 'b'-2.457127399690391'', 'b'[0.0, 0.025819460031772195, 0.02841462682197723, 0.07671384197357434, 0.10251453901678824, 0.10721639864867515]'', 'b'85'', 'b'0.17012498103394114'', 'b"['Adult', 'Aged', 'Aged, 80 and over', 'Anti-Inflammatory Agents', 'Antineoplastic Agents', 'Antineoplastic Agents, Immunological', 'Breast Neoplasms', 'Carcinoma in Situ', 'Female', 'Humans', 'Lung', 'Mastectomy', 'Mastectomy, Segmental', 'Middle Aged', 'Neoplasms, Multiple Primary', 'Prednisolone', 'Prevalence', 'Radiation Pneumonitis', 'Retrospective Studies', 'Risk Factors', 'Trastuzumab']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'40'', 'b'Prevalence and Characteristics of Pneumonitis Following Irradiation of Breast Cancer.'', 'b'Pneumonitis is a serious complication after radiotherapy of breast cancer. This study aimed to identify its prevalence and potential risk factors.A total of 606 patients irradiated following breast-conserving surgery or mastectomy were retrospectively analyzed. In patients developing pneumonitis, radiation and clinical parameters were investigated to identify potential risk factors.Eleven patients (1.8%) developed a pneumonitis grade \xe2\x89\xa52. Mean doses to the ipsilateral lung were >7 Gy in 5 patients (45%). Of the other patients, 5 had a chronic inflammatory disease. Six patients (55%) had another malignancy (4 previous contralateral breast cancers, 1 previous ovarian and thyroid cancer, 1 synchronous carcinoma-in-situ (pTis) at the contralateral breast). Five patients (45%) received chemotherapy including taxanes and 4 patients (36%) received trastuzumab.The prevalence of pneumonitis was 1.8%. Potential risk factors included mean radiation dose to ipsilateral lung >7 Gy, systemic treatment with taxanes or trastuzumab, chronic inflammatory disease and history of another malignancy.'', 'b'947'', 'b'148'', 'b"[('patients', 16), ('pneumonitis', 8), ('breast', 6), ('potential', 6), ('risk', 6), ('cancer', 4), ('identify', 4), ('prevalence', 4), ('radiation', 4), ('mean', 4), ('ipsilateral', 4), ('lung', 4), ('gy', 4), ('chronic', 4), ('inflammatory', 4), ('disease', 4), ('another', 4), ('malignancy', 4), ('previous', 4), ('contralateral', 4), ('received', 4), ('taxanes', 4), ('serious', 2), ('complication', 2), ('radiotherapy', 2), ('study', 2), ('aimed', 2), ('total', 2), ('irradiated', 2), ('following', 2), ('surgery', 2), ('mastectomy', 2), ('retrospectively', 2), ('analyzed', 2), ('developing', 2), ('clinical', 2), ('parameters', 2), ('investigated', 2), ('developed', 2), ('grade', 2), ('doses', 2), ('six', 2), ('cancers', 2), ('ovarian', 2), ('thyroid', 2), ('synchronous', 2), ('ptis', 2), ('five', 2), ('chemotherapy', 2), ('including', 2), ('factors', 2), ('included', 2), ('dose', 2), ('systemic', 2), ('treatment', 2), ('trastuzumab', 2), ('history', 2)]"', 'b"[('.', 8), ('patient', 8), ('(', 7), (')', 7), (',', 6), ('%', 6), ('and', 5), ('pneumon', 4), ('of', 4), ('to', 4), ('a', 3), ('breast', 3), ('cancer', 3), ('potenti', 3), ('risk', 3), ('were', 3), ('the', 3), ('identifi', 2), ('preval', 2), ('or', 2), ('develop', 2), ('radiat', 2), ('1.8', 2), ('mean', 2), ('dose', 2), ('ipsilater', 2), ('lung', 2), ('>', 2), ('7', 2), ('Gy', 2), ('5', 2), ('45', 2), ('had', 2), ('chronic', 2), ('inflammatori', 2), ('diseas', 2), ('anoth', 2), ('malign', 2), ('4', 2), ('previou', 2), ('contralater', 2), ('1', 2), ('receiv', 2), ('includ', 2), ('taxan', 2), ('is', 1), ('seriou', 1), ('complic', 1), ('after', 1), ('radiotherapi', 1), ('thi', 1), ('studi', 1), ('aim', 1), ('it', 1), ('factors.a', 1), ('total', 1), ('606', 1), ('irradi', 1), ('follow', 1), ('breast-conserv', 1), ('surgeri', 1), ('mastectomi', 1), ('retrospect', 1), ('analyz', 1), ('In', 1), ('clinic', 1), ('paramet', 1), ('investig', 1), ('factors.eleven', 1), ('grade', 1), ('\xe2\x89\xa52', 1), ('in', 1), ('Of', 1), ('other', 1), ('six', 1), ('55', 1), ('ovarian', 1), ('thyroid', 1), ('synchron', 1), ('carcinoma-in-situ', 1), ('pti', 1), ('at', 1), ('five', 1), ('chemotherapi', 1), ('36', 1), ('trastuzumab.th', 1), ('wa', 1), ('factor', 1), ('system', 1), ('treatment', 1), ('with', 1), ('trastuzumab', 1), ('histori', 1)]"', 'b'8'', 'b"('patients', 'pneumonitis', 'breast', 'potential', 'risk', 'cancer', 'identify', 'prevalence', 'radiation', 'mean', 'ipsilateral', 'lung', 'gy', 'chronic', 'inflammatory', 'disease', 'another', 'malignancy', 'previous', 'contralateral', 'received', 'taxanes', 'serious', 'complication', 'radiotherapy', 'study', 'aimed', 'total', 'irradiated', 'following', 'surgery', 'mastectomy', 'retrospectively', 'analyzed', 'developing', 'clinical', 'parameters', 'investigated', 'developed', 'grade', 'doses', 'six', 'cancers', 'ovarian', 'thyroid', 'synchronous', 'ptis', 'five', 'chemotherapy', 'including', 'factors', 'included', 'dose', 'systemic', 'treatment', 'trastuzumab', 'history')"', 'b'(16, 8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.04185157649233901'', 'b'[0.0, -0.0003272281208529802, -0.00025539755773891135, -0.00019290821206335208, -0.00042300118462627374, -0.00036363259731030546]'', 'b'-2.258096538021482'', 'b'[1, -2.4657359027997265, -2.713572066704308, -3.68213122712422, -3.2972854062187906, -3.448516375942715]'', 'b'-2.457127399690391'', 'b'[0.0, 0.025819460031772195, 0.02841462682197723, 0.07671384197357434, 0.10251453901678824, 0.10721639864867515]'', 'b'85'', 'b'0.17012498103394114'', 'b"['Adult', 'Aged', 'Aged, 80 and over', 'Anti-Inflammatory Agents', 'Antineoplastic Agents', 'Antineoplastic Agents, Immunological', 'Breast Neoplasms', 'Carcinoma in Situ', 'Female', 'Humans', 'Lung', 'Mastectomy', 'Mastectomy, Segmental', 'Middle Aged', 'Neoplasms, Multiple Primary', 'Prednisolone', 'Prevalence', 'Radiation Pneumonitis', 'Retrospective Studies', 'Risk Factors', 'Trastuzumab']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'41'', 'b'The Prognostic Value of G1 Cyclins, p21 and Rb Protein in Patients With Colon Cancer.'', 'b'Cyclins D1 and E play different roles in the cell cycle. Cyclin E promotes chromosome instability, whereas cyclin D1 regulates apoptosis of cells. This study evaluated the prognostic significance of G1 cyclins, p21 and pRb in tumor proliferation.A total of 102 patients with colon cancer were operated on and staged according to TNM. Follow-up was 2 to 68 months (mean 38.3\xc2\xb116.7 months). Expression of cyclin E and D1 were evaluated using immunohistochemistry.Levels of cyclin E expression were correlated with cyclin D1 expression (p=0.038), p21 expression (p=0.047), and pRb expression (p=0.004). The 5-year survival rate along with prognosis of patients with advanced stage (III, IV) colon cancer and cyclin D1 positive tumors, were significantly worse (p=0.009). Statistically significant association was observed between tumor proliferative capacity Ki-67, cyclin D1 (p=0.009), pRb (p=0.031) and p21 (p=0.050).Cyclin D1 is highly expressed in advanced stage colon cancer patients, implying a potential prognostic value.'', 'b'877'', 'b'148'', 'b"[('cyclin', 14), ('expression', 10), ('e', 8), ('prb', 6), ('patients', 6), ('colon', 6), ('cancer', 6), ('cyclins', 4), ('evaluated', 4), ('prognostic', 4), ('tumor', 4), ('months', 4), ('advanced', 4), ('stage', 4), ('play', 2), ('different', 2), ('roles', 2), ('cell', 2), ('cycle', 2), ('promotes', 2), ('chromosome', 2), ('instability', 2), ('whereas', 2), ('regulates', 2), ('apoptosis', 2), ('cells', 2), ('study', 2), ('significance', 2), ('total', 2), ('operated', 2), ('staged', 2), ('according', 2), ('tnm', 2), ('mean', 2), ('using', 2), ('correlated', 2), ('survival', 2), ('rate', 2), ('along', 2), ('prognosis', 2), ('iii', 2), ('iv', 2), ('positive', 2), ('tumors', 2), ('significantly', 2), ('worse', 2), ('statistically', 2), ('significant', 2), ('association', 2), ('observed', 2), ('proliferative', 2), ('capacity', 2), ('highly', 2), ('expressed', 2), ('implying', 2), ('potential', 2), ('value', 2)]"', 'b"[('cyclin', 9), (',', 9), ('(', 9), (')', 9), ('D1', 7), ('and', 7), ('.', 7), ('of', 6), ('express', 6), ('E', 4), ('with', 4), ('were', 4), ('in', 3), ('the', 3), ('p21', 3), ('prb', 3), ('tumor', 3), ('patient', 3), ('colon', 3), ('cancer', 3), ('stage', 3), ('cell', 2), ('evalu', 2), ('prognost', 2), ('signific', 2), ('to', 2), ('wa', 2), ('month', 2), ('advanc', 2), ('p=0.009', 2), ('play', 1), ('differ', 1), ('role', 1), ('cycl', 1), ('promot', 1), ('chromosom', 1), ('instabl', 1), ('wherea', 1), ('regul', 1), ('apoptosi', 1), ('thi', 1), ('studi', 1), ('G1', 1), ('proliferation.a', 1), ('total', 1), ('102', 1), ('oper', 1), ('on', 1), ('accord', 1), ('tnm', 1), ('follow-up', 1), ('2', 1), ('68', 1), ('mean', 1), ('38.3\xc2\xb116.7', 1), ('use', 1), ('immunohistochemistry.level', 1), ('correl', 1), ('p=0.038', 1), ('p=0.047', 1), ('p=0.004', 1), ('5-year', 1), ('surviv', 1), ('rate', 1), ('along', 1), ('prognosi', 1), ('iii', 1), ('IV', 1), ('posit', 1), ('significantli', 1), ('wors', 1), ('statist', 1), ('associ', 1), ('observ', 1), ('between', 1), ('prolif', 1), ('capac', 1), ('ki-67', 1), ('p=0.031', 1), ('p=0.050', 1), ('.cyclin', 1), ('is', 1), ('highli', 1), ('impli', 1), ('a', 1), ('potenti', 1), ('valu', 1)]"', 'b'7'', 'b"('cyclin', 'expression', 'e', 'prb', 'patients', 'colon', 'cancer', 'cyclins', 'evaluated', 'prognostic', 'tumor', 'months', 'advanced', 'stage', 'play', 'different', 'roles', 'cell', 'cycle', 'promotes', 'chromosome', 'instability', 'whereas', 'regulates', 'apoptosis', 'cells', 'study', 'significance', 'total', 'operated', 'staged', 'according', 'tnm', 'mean', 'using', 'correlated', 'survival', 'rate', 'along', 'prognosis', 'iii', 'iv', 'positive', 'tumors', 'significantly', 'worse', 'statistically', 'significant', 'association', 'observed', 'proliferative', 'capacity', 'highly', 'expressed', 'implying', 'potential', 'value')"', 'b'(14, 10, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.04066805115900233'', 'b'[-0.0, -0.0012888424541890355, -0.0010059258179036374, -0.00047493791099583864, -0.0008332466019145397, -0.0007162997104177622]'', 'b'-2.258096538021482'', 'b'[1, -2.4657359027997265, -2.713572066704308, -3.68213122712422, -3.2972854062187906, -3.448516375942715]'', 'b'-2.3876420237858156'', 'b'[-0.03109058707003112, 0.10169424359508533, 0.11191574022623979, 0.18886864100647546, 0.20193771173015443, 0.21119964456471693]'', 'b'50'', 'b'0.09596071327564967'', 'b"['Adult', 'Aged', 'Aged, 80 and over', 'Colonic Neoplasms', 'Cyclin D1', 'Cyclin E', 'Cyclin-Dependent Kinase Inhibitor p21', 'Female', 'Follow-Up Studies', 'G1 Phase', 'Humans', 'Ki-67 Antigen', 'Male', 'Middle Aged', 'Neoplasm Proteins', 'Oncogene Proteins', 'Prognosis', 'Retinoblastoma Protein', 'Survival Rate']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'42'', 'b'Expression of Kita-Kyushu Lung Cancer Antigen-1 as Detected by a Novel Monoclonal Antibody in Gastric Cancer.'', 'b'Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is a known cancer_testis antigen. Our group has previously shown KK-LC-1 gene expression in gastric cancer. However, could not be detected the KK-LC-1 protein due to the lack of an appropriate antibody. Here, we assessed our original monoclonal antibody (Kmab34B3) and, using it, assessed the expression of KK-LC-1 in gastric cancer.We evaluated an original monoclonal antibody against KK-LC-1 (Kmab34B3), and used this antibody to compare KK-LC-1 protein expression in tumour and non-tumour stomach cells from gastric cancer patients.Kmab34B3 stained testicular germ cells, and tumour cells in nine out of 11 (82%) specimens. In non-tumorous areas, Kmab34B3 stained 13 out of 29 (45%) pyloric gland specimens. Furthermore, Kmab34B3 also stained intestinal metaplasia positive and negative areas.Kmab34B3 was able to detect KK-LC-1 protein within tumour cells and the pyloric gland where the gene has been shown to be expressed. Therefore, it might be an attractive tool for detecting KK-LC-1 expression in precancerous and cancerous stomach cells.'', 'b'934'', 'b'159'', 'b"[('cells', 10), ('expression', 8), ('antibody', 8), ('cancer', 6), ('gastric', 6), ('protein', 6), ('tumour', 6), ('stained', 6), ('shown', 4), ('gene', 4), ('assessed', 4), ('original', 4), ('monoclonal', 4), ('stomach', 4), ('specimens', 4), ('pyloric', 4), ('gland', 4), ('lung', 2), ('known', 2), ('antigen', 2), ('group', 2), ('previously', 2), ('however', 2), ('could', 2), ('detected', 2), ('due', 2), ('lack', 2), ('appropriate', 2), ('using', 2), ('evaluated', 2), ('used', 2), ('compare', 2), ('testicular', 2), ('germ', 2), ('nine', 2), ('areas', 2), ('furthermore', 2), ('also', 2), ('intestinal', 2), ('metaplasia', 2), ('positive', 2), ('negative', 2), ('able', 2), ('detect', 2), ('within', 2), ('expressed', 2), ('therefore', 2), ('might', 2), ('attractive', 2), ('tool', 2), ('detecting', 2), ('precancerous', 2), ('cancerous', 2)]"', 'b"[(',', 9), ('kk-lc-1', 8), ('.', 7), ('and', 7), ('(', 5), (')', 5), ('express', 5), ('in', 5), ('the', 5), ('cell', 5), ('cancer', 4), ('to', 4), ('of', 4), ('antibodi', 4), ('kmab34b3', 4), ('gastric', 3), ('be', 3), ('detect', 3), ('protein', 3), ('an', 3), ('tumour', 3), ('stain', 3), ('our', 2), ('ha', 2), ('shown', 2), ('gene', 2), ('assess', 2), ('origin', 2), ('monoclon', 2), ('use', 2), ('it', 2), ('stomach', 2), ('out', 2), ('%', 2), ('specimen', 2), ('pylor', 2), ('gland', 2), ('kita-kyushu', 1), ('lung', 1), ('antigen-1', 1), ('is', 1), ('a', 1), ('known', 1), ('cancer_testi', 1), ('antigen', 1), ('group', 1), ('previous', 1), ('howev', 1), ('could', 1), ('not', 1), ('due', 1), ('lack', 1), ('appropri', 1), ('here', 1), ('we', 1), ('cancer.w', 1), ('evalu', 1), ('against', 1), ('thi', 1), ('compar', 1), ('non-tumour', 1), ('from', 1), ('patients.kmab34b3', 1), ('testicular', 1), ('germ', 1), ('nine', 1), ('11', 1), ('82', 1), ('In', 1), ('non-tumor', 1), ('area', 1), ('13', 1), ('29', 1), ('45', 1), ('furthermor', 1), ('also', 1), ('intestin', 1), ('metaplasia', 1), ('posit', 1), ('neg', 1), ('areas.kmab34b3', 1), ('wa', 1), ('abl', 1), ('within', 1), ('where', 1), ('been', 1), ('therefor', 1), ('might', 1), ('attract', 1), ('tool', 1), ('for', 1), ('precancer', 1)]"', 'b'7'', 'b"('cells', 'expression', 'antibody', 'cancer', 'gastric', 'protein', 'tumour', 'stained', 'shown', 'gene', 'assessed', 'original', 'monoclonal', 'stomach', 'specimens', 'pyloric', 'gland', 'lung', 'known', 'antigen', 'group', 'previously', 'however', 'could', 'detected', 'due', 'lack', 'appropriate', 'using', 'evaluated', 'used', 'compare', 'testicular', 'germ', 'nine', 'areas', 'furthermore', 'also', 'intestinal', 'metaplasia', 'positive', 'negative', 'able', 'detect', 'within', 'expressed', 'therefore', 'might', 'attractive', 'tool', 'detecting', 'precancerous', 'cancerous')"', 'b'(10, 8, 8, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.026346573512419983'', 'b'[-0.004443495105233139, -0.0023698640561243406, -0.0018709453074665845, -0.0015799093707495604, -0.0012926531215223676, -0.0009874433567184752]'', 'b'-2.6635616461296463'', 'b'[-1.7725887222397811, -2.4011973816621555, -2.6375861597263857, -2.8066624897703196, -3.007333185232471, -3.2766661190160553]'', 'b'-2.7368531858700673'', 'b'[0.1260238289738229, 0.17071534099383065, 0.18752161904599784, 0.19954225656537392, 0.2138091246141707, 0.2329575977812977]'', 'b'14'', 'b'0.08405350243035374'', 'b"['Antibodies, Monoclonal', 'Antigens, Neoplasm', 'Gene Expression', 'Humans', 'Metaplasia', 'Precancerous Conditions', 'Pylorus', 'Stomach', 'Stomach Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'43'', 'b'Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer.'', 'b'Therapeutic targeting of receptor protein tyrosine kinases (PTKs) has proven successful in treating cancer. However, reports about PTKs in treating prostate cancer are few. Elevated expression of the erythropoietin-producing hepatocellular receptor A2 (EPHA2) receptor tyrosine kinase, a transmembrane protein, is associated with poor prognosis of certain cancer types when the enzyme is dephosphorylated. This study investigated whether EPHA2 is useful in predicting the biochemical recurrence of prostate cancer.Data from 241 patients who had undergone total prostatectomy between 2007 and 2011 were used. EPHA2 protein expression was categorized as high or low by two pathologists. The relationship was examined between EPHA2 expression level (high vs. low) and clinicopathological factors including biochemical recurrence. Correlations were examined between EPHA2, low-molecular-weight protein tyrosine phosphatase (LMW-PTP), E-cadherin, and Ki-67.EPHA2 expression was high in 121 (50.2%) and low in 120 (49.8%) patients. A log-rank test revealed early biochemical recurrence in the high-expression group. Gleason score, Ki-67 labeling index, and biochemical recurrence were more frequent in the high-expression group. Furthermore, multivariate analyses revealed that high EPHA2 expression was an independent prognostic factor for biochemical recurrence (hazard ratio=3.62, 95% confidence interval=2.39-5.61). Correlations between EPHA2 and both LMW-PTP and Ki-67 labeling index were positive, whereas EPHA2 and E-cadherin were negatively correlated.EPHA2 overexpression is predictive of aggressive prostate cancer behavior. EPHA2 may be a powerful prognostic biomarker for decision-making in postoperative follow-up after total prostatectomy, and regarding the need for palliative treatment. Additionally, it may be an important therapeutic target.'', 'b'1614'', 'b'240'', 'b"[('expression', 10), ('biochemical', 10), ('recurrence', 10), ('protein', 8), ('cancer', 8), ('high', 8), ('receptor', 6), ('tyrosine', 6), ('prostate', 6), ('low', 6), ('therapeutic', 4), ('ptks', 4), ('treating', 4), ('patients', 4), ('total', 4), ('prostatectomy', 4), ('examined', 4), ('correlations', 4), ('revealed', 4), ('group', 4), ('labeling', 4), ('index', 4), ('prognostic', 4), ('may', 4), ('targeting', 2), ('kinases', 2), ('proven', 2), ('successful', 2), ('however', 2), ('reports', 2), ('elevated', 2), ('hepatocellular', 2), ('kinase', 2), ('transmembrane', 2), ('associated', 2), ('poor', 2), ('prognosis', 2), ('certain', 2), ('types', 2), ('enzyme', 2), ('dephosphorylated', 2), ('study', 2), ('investigated', 2), ('whether', 2), ('useful', 2), ('predicting', 2), ('undergone', 2), ('used', 2), ('categorized', 2), ('two', 2), ('pathologists', 2), ('relationship', 2), ('level', 2), ('clinicopathological', 2), ('factors', 2), ('including', 2), ('phosphatase', 2), ('test', 2), ('early', 2), ('gleason', 2), ('score', 2), ('frequent', 2), ('furthermore', 2), ('multivariate', 2), ('analyses', 2), ('independent', 2), ('factor', 2), ('hazard', 2), ('confidence', 2), ('positive', 2), ('whereas', 2), ('negatively', 2), ('overexpression', 2), ('predictive', 2), ('aggressive', 2), ('behavior', 2), ('powerful', 2), ('biomarker', 2), ('postoperative', 2), ('regarding', 2), ('need', 2), ('palliative', 2), ('treatment', 2), ('additionally', 2), ('important', 2), ('target', 2)]"', 'b"[('.', 13), (',', 13), ('epha2', 9), ('and', 9), ('in', 8), ('(', 7), (')', 7), ('the', 7), ('of', 5), ('express', 5), ('biochem', 5), ('recurr', 5), ('were', 5), ('protein', 4), ('cancer', 4), ('is', 4), ('between', 4), ('wa', 4), ('high', 4), ('receptor', 3), ('tyrosin', 3), ('prostat', 3), ('low', 3), ('%', 3), ('for', 3), ('therapeut', 2), ('target', 2), ('kinas', 2), ('ptk', 2), ('treat', 2), ('a', 2), ('use', 2), ('predict', 2), ('patient', 2), ('total', 2), ('prostatectomi', 2), ('examin', 2), ('factor', 2), ('correl', 2), ('lmw-ptp', 2), ('e-cadherin', 2), ('reveal', 2), ('high-express', 2), ('group', 2), ('ki-67', 2), ('label', 2), ('index', 2), ('an', 2), ('prognost', 2), ('may', 2), ('be', 2), ('ha', 1), ('proven', 1), ('success', 1), ('howev', 1), ('report', 1), ('about', 1), ('are', 1), ('few', 1), ('elev', 1), ('erythropoietin-produc', 1), ('hepatocellular', 1), ('A2', 1), ('transmembran', 1), ('associ', 1), ('with', 1), ('poor', 1), ('prognosi', 1), ('certain', 1), ('type', 1), ('when', 1), ('enzym', 1), ('dephosphoryl', 1), ('thi', 1), ('studi', 1), ('investig', 1), ('whether', 1), ('cancer.data', 1), ('from', 1), ('241', 1), ('who', 1), ('had', 1), ('undergon', 1), ('2007', 1), ('2011', 1), ('categor', 1), ('as', 1), ('or', 1), ('by', 1), ('two', 1), ('pathologist', 1), ('relationship', 1), ('level', 1), ('vs.', 1), ('clinicopatholog', 1), ('includ', 1), ('low-molecular-weight', 1), ('phosphatas', 1), ('ki-67.epha2', 1), ('121', 1), ('50.2', 1), ('120', 1), ('49.8', 1), ('A', 1), ('log-rank', 1), ('test', 1), ('earli', 1), ('gleason', 1), ('score', 1), ('more', 1), ('frequent', 1), ('furthermor', 1), ('multivari', 1), ('analys', 1), ('that', 1), ('independ', 1), ('hazard', 1), ('ratio=3.62', 1), ('95', 1), ('confid', 1), ('interval=2.39-5.61', 1), ('both', 1), ('posit', 1), ('wherea', 1), ('neg', 1), ('correlated.epha2', 1), ('overexpress', 1), ('aggress', 1), ('behavior', 1), ('power', 1), ('biomark', 1), ('decision-mak', 1), ('postop', 1), ('follow-up', 1), ('after', 1), ('regard', 1), ('need', 1), ('palli', 1), ('treatment', 1), ('addit', 1), ('it', 1), ('import', 1)]"', 'b'13'', 'b"('expression', 'biochemical', 'recurrence', 'protein', 'cancer', 'high', 'receptor', 'tyrosine', 'prostate', 'low', 'therapeutic', 'ptks', 'treating', 'patients', 'total', 'prostatectomy', 'examined', 'correlations', 'revealed', 'group', 'labeling', 'index', 'prognostic', 'may', 'targeting', 'kinases', 'proven', 'successful', 'however', 'reports', 'elevated', 'hepatocellular', 'kinase', 'transmembrane', 'associated', 'poor', 'prognosis', 'certain', 'types', 'enzyme', 'dephosphorylated', 'study', 'investigated', 'whether', 'useful', 'predicting', 'undergone', 'used', 'categorized', 'two', 'pathologists', 'relationship', 'level', 'clinicopathological', 'factors', 'including', 'phosphatase', 'test', 'early', 'gleason', 'score', 'frequent', 'furthermore', 'multivariate', 'analyses', 'independent', 'factor', 'hazard', 'confidence', 'positive', 'whereas', 'negatively', 'overexpression', 'predictive', 'aggressive', 'behavior', 'powerful', 'biomarker', 'postoperative', 'regarding', 'need', 'palliative', 'treatment', 'additionally', 'important', 'target')"', 'b'(10, 10, 10, 8, 8, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.02218952955802505'', 'b'[-0.0808520966290949, -0.005390139775272993, -0.002994522097373885, -0.002450063534214997, -0.0021851918007863486, -0.0018102801508166372, -0.001560586336910894, -0.0011604359941132288]'', 'b'-2.8066624897703196'', 'b'[1.0, -1.70805020110221, -2.295836866004329, -2.4965075614664802, -2.6109179126442243, -2.912023005428146, -3.060443010546419, -3.3567088266895917]'', 'b'-2.802533412427141'', 'b'[-0.0808520966290949, 0.13809943990686085, 0.1856232241348204, 0.20184787059495393, 0.21109818736374558, 0.26357887227239907, 0.2770129617348847, 0.30382916805135857]'', 'b'72'', 'b'0.08455095096050973'', 'b"['Aged', 'Analysis of Variance', 'Biomarkers, Tumor', 'Cadherins', 'Ephrin-A2', 'Humans', 'Kaplan-Meier Estimate', 'Ki-67 Antigen', 'Male', 'Middle Aged', 'Neoplasm Grading', 'Neoplasm Proteins', 'Neoplasm Recurrence, Local', 'Prostatectomy', 'Prostatic Neoplasms', 'Protein Tyrosine Phosphatases', 'ROC Curve']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'44'', 'b'The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.'', 'b'The present study aimed to prospectively examine the usefulness of interferon-gamma (IFN-\xce\xb3) release (IGR) as a biomarker in non-small-cell lung cancer patients receiving immune checkpoint inhibitor treatment (ICI-Tx).IGR was measured using enzyme-linked immunosorbent assay at four time points: within 14 days before ICI-Tx (T1), and 8\xc2\xb13 (T2), 22\xc2\xb17 (T3), and 43\xc2\xb17 (T4) days after ICI-Tx.Twenty-nine patients were divided into three groups based on IFN-\xce\xb3 levels in the IGR-positive control: Group-1 (n=8) with <10 IU_ml at T1, Group-2 (n=12) with a decrease in IFN-\xce\xb3 levels to <10 IU_ml at T3 and_or T4, and Group-3 (n=9) without changes in IFN-\xce\xb3 levels. Early progression and ICI-induced interstitial pneumonitis were frequently observed in Group-1 and Group-2, respectively. Group-3 exhibited more treatment cycles than the other groups. All three groups showed clear differences in clinical outcomes.IFN-\xce\xb3 levels could be a biomarker for ICI-Tx.'', 'b'810'', 'b'138'', 'b"[('levels', 8), ('groups', 6), ('biomarker', 4), ('patients', 4), ('treatment', 4), ('days', 4), ('three', 4), ('present', 2), ('study', 2), ('aimed', 2), ('prospectively', 2), ('examine', 2), ('usefulness', 2), ('release', 2), ('igr', 2), ('lung', 2), ('cancer', 2), ('receiving', 2), ('immune', 2), ('checkpoint', 2), ('inhibitor', 2), ('measured', 2), ('using', 2), ('immunosorbent', 2), ('assay', 2), ('four', 2), ('time', 2), ('points', 2), ('within', 2), ('divided', 2), ('based', 2), ('control', 2), ('decrease', 2), ('without', 2), ('changes', 2), ('early', 2), ('progression', 2), ('interstitial', 2), ('pneumonitis', 2), ('frequently', 2), ('observed', 2), ('respectively', 2), ('exhibited', 2), ('cycles', 2), ('showed', 2), ('clear', 2), ('differences', 2), ('clinical', 2), ('could', 2)]"', 'b"[('(', 10), (')', 10), ('in', 6), (',', 6), ('and', 5), ('the', 4), ('ifn-\xce\xb3', 4), ('level', 4), ('.', 4), ('a', 3), ('ici-tx', 3), ('at', 3), ('group', 3), ('to', 2), ('use', 2), ('biomark', 2), ('patient', 2), ('treatment', 2), (':', 2), ('day', 2), ('T1', 2), ('T3', 2), ('T4', 2), ('were', 2), ('three', 2), ('group-1', 2), ('with', 2), ('<', 2), ('10', 2), ('iu_ml', 2), ('group-2', 2), ('group-3', 2), ('present', 1), ('studi', 1), ('aim', 1), ('prospect', 1), ('examin', 1), ('of', 1), ('interferon-gamma', 1), ('releas', 1), ('igr', 1), ('as', 1), ('non-small-cel', 1), ('lung', 1), ('cancer', 1), ('receiv', 1), ('immun', 1), ('checkpoint', 1), ('inhibitor', 1), ('.igr', 1), ('wa', 1), ('measur', 1), ('enzyme-link', 1), ('immunosorb', 1), ('assay', 1), ('four', 1), ('time', 1), ('point', 1), ('within', 1), ('14', 1), ('befor', 1), ('8\xc2\xb13', 1), ('T2', 1), ('22\xc2\xb17', 1), ('43\xc2\xb17', 1), ('after', 1), ('ici-tx.twenty-nin', 1), ('divid', 1), ('into', 1), ('base', 1), ('on', 1), ('igr-posit', 1), ('control', 1), ('n=8', 1), ('n=12', 1), ('decreas', 1), ('and_or', 1), ('n=9', 1), ('without', 1), ('chang', 1), ('earli', 1), ('progress', 1), ('ici-induc', 1), ('interstiti', 1), ('pneumon', 1), ('frequent', 1), ('observ', 1), ('respect', 1), ('exhibit', 1), ('more', 1), ('cycl', 1), ('than', 1), ('other', 1), ('all', 1), ('show', 1), ('clear', 1), ('differ', 1), ('clinic', 1), ('outcomes.ifn-\xce\xb3', 1), ('could', 1), ('be', 1), ('for', 1)]"', 'b'4'', 'b"('levels', 'groups', 'biomarker', 'patients', 'treatment', 'days', 'three', 'present', 'study', 'aimed', 'prospectively', 'examine', 'usefulness', 'release', 'igr', 'lung', 'cancer', 'receiving', 'immune', 'checkpoint', 'inhibitor', 'measured', 'using', 'immunosorbent', 'assay', 'four', 'time', 'points', 'within', 'divided', 'based', 'control', 'decrease', 'without', 'changes', 'early', 'progression', 'interstitial', 'pneumonitis', 'frequently', 'observed', 'respectively', 'exhibited', 'cycles', 'showed', 'clear', 'differences', 'clinical', 'could')"', 'b'(8, 6, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.02156351006987624'', 'b'[-0.10008345855698253, -0.006672230570465502, -0.003706794761369723, -0.0030328320774843194, -0.0027049583393779063, -0.0021912440502305256, -0.0018890034915780393, -0.0014046436219426444]'', 'b'-2.8066624897703196'', 'b'[1.0, -1.70805020110221, -2.295836866004329, -2.4965075614664802, -2.6109179126442243, -2.912023005428146, -3.060443010546419, -3.3567088266895917]'', 'b'-2.7234672687407793'', 'b'[-0.10008345855698253, 0.17094757151525872, 0.22977529383233694, 0.249859111065224, 0.26130969470581156, 0.31904765423894194, 0.33530887689647193, 0.3677684122419928]'', 'b'6'', 'b'0.10283514706953431'', 'b"['Adult', 'Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal', 'Antibodies, Monoclonal, Humanized', 'Antineoplastic Agents, Immunological', 'B7-H1 Antigen', 'Biomarkers, Tumor', 'Carcinoma, Non-Small-Cell Lung', 'Disease Progression', 'Female', 'Humans', 'Immunotherapy', 'Interferon-gamma', 'Latent Tuberculosis', 'Lung Diseases, Interstitial', 'Lung Neoplasms', 'Male', 'Middle Aged', 'Nivolumab', 'Prospective Studies', 'T-Lymphocytes', 'Time Factors']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'45'', 'b'Results of Tri-Modality Therapy for Rectal Cancer in Elderly Patients.'', 'b'Elderly cancer patients are more prevalent and require special attention. This study focused on the outcome of elderly (\xe2\x89\xa565 years) rectal cancer patients treated with tri-modality therapy.A total of 105 patients receiving neoadjuvant radio-chemotherapy and resection for locally advanced rectal cancers were retrospectively evaluated. Nine characteristics were analyzed for loco-regional control (LRC), metastases-free survival (MFS) and overall survival (OS) including tumor location, gender, age, performance status, radiotherapy technique, primary tumor_lymph node categories, downstaging and histological grading.The 5-year rates of LRC, MFS and OS were 91%, 78% and 87%, respectively. Radio-chemotherapy was not completed in 12 patients (11%) due to toxicity; 18 patients (17%) experienced grade 3 toxicities. A total of 29 patients (28%) had surgical complications. On multivariate analyses, MFS was significantly associated with downstaging (p=0.003) and OS with lower histological grade (p=0.013).Tri-modality therapy resulted in promising outcomes and was tolerated reasonably well by elderly patients. Prognostic factors were identified that may help personalize future treatment.'', 'b'1035'', 'b'156'', 'b"[('patients', 14), ('elderly', 6), ('mfs', 6), ('os', 6), ('cancer', 4), ('rectal', 4), ('total', 4), ('lrc', 4), ('survival', 4), ('downstaging', 4), ('histological', 4), ('grade', 4), ('prevalent', 2), ('require', 2), ('special', 2), ('attention', 2), ('study', 2), ('focused', 2), ('outcome', 2), ('years', 2), ('treated', 2), ('receiving', 2), ('neoadjuvant', 2), ('resection', 2), ('locally', 2), ('advanced', 2), ('cancers', 2), ('retrospectively', 2), ('evaluated', 2), ('nine', 2), ('characteristics', 2), ('analyzed', 2), ('control', 2), ('overall', 2), ('including', 2), ('tumor', 2), ('location', 2), ('gender', 2), ('age', 2), ('performance', 2), ('status', 2), ('radiotherapy', 2), ('technique', 2), ('primary', 2), ('node', 2), ('categories', 2), ('rates', 2), ('respectively', 2), ('completed', 2), ('due', 2), ('toxicity', 2), ('experienced', 2), ('toxicities', 2), ('surgical', 2), ('complications', 2), ('multivariate', 2), ('analyses', 2), ('significantly', 2), ('associated', 2), ('lower', 2), ('therapy', 2), ('resulted', 2), ('promising', 2), ('outcomes', 2), ('tolerated', 2), ('reasonably', 2), ('well', 2), ('prognostic', 2), ('factors', 2), ('identified', 2), ('may', 2), ('help', 2), ('personalize', 2), ('future', 2), ('treatment', 2)]"', 'b"[(',', 11), ('(', 9), (')', 9), ('and', 8), ('patient', 7), ('.', 7), ('%', 6), ('of', 4), ('were', 4), ('elderli', 3), ('cancer', 3), ('with', 3), ('mf', 3), ('OS', 3), ('wa', 3), ('outcom', 2), ('rectal', 2), ('total', 2), ('radio-chemotherapi', 2), ('for', 2), ('lrc', 2), ('surviv', 2), ('downstag', 2), ('histolog', 2), ('in', 2), ('toxic', 2), ('grade', 2), ('are', 1), ('more', 1), ('preval', 1), ('requir', 1), ('special', 1), ('attent', 1), ('thi', 1), ('studi', 1), ('focus', 1), ('on', 1), ('the', 1), ('\xe2\x89\xa565', 1), ('year', 1), ('treat', 1), ('tri-mod', 1), ('therapy.a', 1), ('105', 1), ('receiv', 1), ('neoadjuv', 1), ('resect', 1), ('local', 1), ('advanc', 1), ('retrospect', 1), ('evalu', 1), ('nine', 1), ('characterist', 1), ('analyz', 1), ('loco-region', 1), ('control', 1), ('metastases-fre', 1), ('overal', 1), ('includ', 1), ('tumor', 1), ('locat', 1), ('gender', 1), ('age', 1), ('perform', 1), ('statu', 1), ('radiotherapi', 1), ('techniqu', 1), ('primari', 1), ('tumor_lymph', 1), ('node', 1), ('categori', 1), ('grading.th', 1), ('5-year', 1), ('rate', 1), ('91', 1), ('78', 1), ('87', 1), ('respect', 1), ('not', 1), ('complet', 1), ('12', 1), ('11', 1), ('due', 1), ('to', 1), (';', 1), ('18', 1), ('17', 1), ('experienc', 1), ('3', 1), ('A', 1), ('29', 1), ('28', 1), ('had', 1), ('surgic', 1), ('complic', 1), ('On', 1), ('multivari', 1), ('analys', 1), ('significantli', 1), ('associ', 1), ('p=0.003', 1), ('lower', 1), ('p=0.013', 1), ('.tri-mod', 1), ('therapi', 1), ('result', 1), ('promis', 1), ('toler', 1), ('reason', 1), ('well', 1), ('by', 1), ('prognost', 1), ('factor', 1), ('identifi', 1), ('that', 1), ('may', 1), ('help', 1), ('person', 1), ('futur', 1), ('treatment', 1)]"', 'b'7'', 'b"('patients', 'elderly', 'mfs', 'os', 'cancer', 'rectal', 'total', 'lrc', 'survival', 'downstaging', 'histological', 'grade', 'prevalent', 'require', 'special', 'attention', 'study', 'focused', 'outcome', 'years', 'treated', 'receiving', 'neoadjuvant', 'resection', 'locally', 'advanced', 'cancers', 'retrospectively', 'evaluated', 'nine', 'characteristics', 'analyzed', 'control', 'overall', 'including', 'tumor', 'location', 'gender', 'age', 'performance', 'status', 'radiotherapy', 'technique', 'primary', 'node', 'categories', 'rates', 'respectively', 'completed', 'due', 'toxicity', 'experienced', 'toxicities', 'surgical', 'complications', 'multivariate', 'analyses', 'significantly', 'associated', 'lower', 'therapy', 'resulted', 'promising', 'outcomes', 'tolerated', 'reasonably', 'well', 'prognostic', 'factors', 'identified', 'may', 'help', 'personalize', 'future', 'treatment')"', 'b'(14, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0332809051396347'', 'b'[-0.0, -0.0, -0.023790388572273072, -0.016993134694480765, -0.008496567347240382, -0.004275144517455962, -0.0027494198125720577]'', 'b'-2.3440389678222067'', 'b'[1, 1, -0.6094379124341003, -0.9459101490553135, -1.6390573296152589, -2.4011973816621555, -2.912023005428146]'', 'b'-2.210332591731446'', 'b'[-0.10956220251152628, -0.10956220251152628, 0.07249382373741088, 0.11251785000241324, 0.19496905381889637, 0.3079639746462772, 0.40031868728948866]'', 'b'46'', 'b'0.1245498120412662'', 'b"['Age Factors', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols', 'Bevacizumab', 'Capecitabine', 'Chemoradiotherapy, Adjuvant', 'Combined Modality Therapy', 'Disease-Free Survival', 'Female', 'Fluorouracil', 'Humans', 'Karnofsky Performance Status', 'Male', 'Neoplasm Grading', 'Neoplasm Staging', 'Oxaliplatin', 'Postoperative Complications', 'Rectal Neoplasms', 'Retrospective Studies', 'Sex Factors', 'Treatment Outcome']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'46'', 'b'Is D2 Lymphadenectomy Essential for Cytology-positive Gastric Cancer? A Retrospective Analysis.'', 'b'The appropriate extent of lymphadenectomy on gastric cancer patients with positive peritoneal cytology (CY1) is uncertain. This study retrospectively compared overall survival (OS) after standard and limited lymphadenectomy.The medical records from four institutions from 2004 to 2018 were reviewed and data for 91 patients with CY1, but no other distant metastases, who underwent gastrectomy were analyzed. D2 or greater lymphadenectomy and less than D2 lymphadenectomy were performed in 51 and 40 patients, respectively.Full cohort analyses showed that patients who underwent D2 or greater lymphadenectomy had better prognostic nutritional indices and more such patients received postoperative chemotherapy. The OS in the group treated with D2 or greater lymphadenectomy was also significantly better (p=0.045). Twenty-seven pairs of patients were generated via propensity score matching, and analysis of their OS showed no significant difference between the groups according to lymphadenectomy (p=0.61).The extent of lymphadenectomy may not affect the prognoses for patients with CY1 gastric cancer.'', 'b'951'', 'b'152'', 'b"[('lymphadenectomy', 14), ('patients', 14), ('os', 6), ('greater', 6), ('extent', 4), ('gastric', 4), ('cancer', 4), ('underwent', 4), ('showed', 4), ('better', 4), ('appropriate', 2), ('positive', 2), ('peritoneal', 2), ('cytology', 2), ('uncertain', 2), ('study', 2), ('retrospectively', 2), ('compared', 2), ('overall', 2), ('survival', 2), ('standard', 2), ('limited', 2), ('medical', 2), ('records', 2), ('four', 2), ('institutions', 2), ('reviewed', 2), ('data', 2), ('distant', 2), ('metastases', 2), ('gastrectomy', 2), ('analyzed', 2), ('less', 2), ('performed', 2), ('cohort', 2), ('analyses', 2), ('prognostic', 2), ('nutritional', 2), ('indices', 2), ('received', 2), ('postoperative', 2), ('chemotherapy', 2), ('group', 2), ('treated', 2), ('also', 2), ('significantly', 2), ('pairs', 2), ('generated', 2), ('via', 2), ('propensity', 2), ('score', 2), ('matching', 2), ('analysis', 2), ('significant', 2), ('difference', 2), ('groups', 2), ('according', 2), ('may', 2), ('affect', 2), ('prognoses', 2)]"', 'b"[('lymphadenectomi', 7), ('patient', 7), ('and', 6), ('the', 5), ('.', 5), ('of', 4), ('with', 4), ('(', 4), (')', 4), ('were', 4), (',', 4), ('D2', 4), ('cy1', 3), ('OS', 3), ('or', 3), ('greater', 3), ('extent', 2), ('gastric', 2), ('cancer', 2), ('from', 2), ('to', 2), ('for', 2), ('no', 2), ('who', 2), ('underw', 2), ('in', 2), ('show', 2), ('better', 2), ('group', 2), ('appropri', 1), ('on', 1), ('posit', 1), ('periton', 1), ('cytolog', 1), ('is', 1), ('uncertain', 1), ('thi', 1), ('studi', 1), ('retrospect', 1), ('compar', 1), ('overal', 1), ('surviv', 1), ('after', 1), ('standard', 1), ('limit', 1), ('lymphadenectomy.th', 1), ('medic', 1), ('record', 1), ('four', 1), ('institut', 1), ('2004', 1), ('2018', 1), ('review', 1), ('data', 1), ('91', 1), ('but', 1), ('other', 1), ('distant', 1), ('metastas', 1), ('gastrectomi', 1), ('analyz', 1), ('less', 1), ('than', 1), ('perform', 1), ('51', 1), ('40', 1), ('respectively.ful', 1), ('cohort', 1), ('analys', 1), ('that', 1), ('had', 1), ('prognost', 1), ('nutrit', 1), ('indic', 1), ('more', 1), ('such', 1), ('receiv', 1), ('postop', 1), ('chemotherapi', 1), ('treat', 1), ('wa', 1), ('also', 1), ('significantli', 1), ('p=0.045', 1), ('twenty-seven', 1), ('pair', 1), ('gener', 1), ('via', 1), ('propens', 1), ('score', 1), ('match', 1), ('analysi', 1), ('their', 1), ('signific', 1), ('differ', 1), ('between', 1), ('accord', 1), ('p=0.61', 1), ('.the', 1), ('may', 1), ('not', 1), ('affect', 1), ('prognos', 1)]"', 'b'5'', 'b"('lymphadenectomy', 'patients', 'os', 'greater', 'extent', 'gastric', 'cancer', 'underwent', 'showed', 'better', 'appropriate', 'positive', 'peritoneal', 'cytology', 'uncertain', 'study', 'retrospectively', 'compared', 'overall', 'survival', 'standard', 'limited', 'medical', 'records', 'four', 'institutions', 'reviewed', 'data', 'distant', 'metastases', 'gastrectomy', 'analyzed', 'less', 'performed', 'cohort', 'analyses', 'prognostic', 'nutritional', 'indices', 'received', 'postoperative', 'chemotherapy', 'group', 'treated', 'also', 'significantly', 'pairs', 'generated', 'via', 'propensity', 'score', 'matching', 'analysis', 'significant', 'difference', 'groups', 'according', 'may', 'affect', 'prognoses')"', 'b'(14, 14, 6, 6, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0335228316539325'', 'b'[-0.04886782473062513, -0.015565330971179328, -0.008647406095099626, -0.004332157360382992, -0.0038284181324314817, -0.0026987209785992415, -0.0023186194323176583]'', 'b'-2.3081069585961433'', 'b'[-0.09861228866810978, -1.3025850929940455, -1.890371757896165, -2.6375861597263857, -2.7612001156935624, -3.1108738641733114, -3.2626798770413155]'', 'b'-2.1148970143358903'', 'b'[0.014456904116756998, 0.2027516809057672, 0.2942426207022389, 0.434204655229113, 0.45455422937830503, 0.5121182141002567, 0.5371088204681245]'', 'b'81'', 'b'0.14190373857619853'', 'b"['Aged', 'Aged, 80 and over', 'Analysis of Variance', 'Cause of Death', 'Female', 'Gastrectomy', 'Humans', 'Lymph Node Excision', 'Male', 'Middle Aged', 'Nutritional Status', 'Peritoneum', 'Prognosis', 'Propensity Score', 'Retrospective Studies', 'Statistics, Nonparametric', 'Stomach Neoplasms', 'Survival Rate', 'Time Factors']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'47'', 'b'Hookwire-guided Sentinel Lymph Node Biopsy Using Contrast-enhanced Ultrasonography Followed by a One-step Nucleic Acid Amplification (OSNA) Assay for Breast Cancer.'', 'b'To investigate the feasibility of hookwire-guided sentinel lymph node biopsy (SLNB) using contrast-enhanced ultrasonography (CEUS) followed by a one-step nucleic acid amplification (OSNA) assay.Clinical T1-2N0M0 breast cancer patients scheduled to undergo SLNB participated in this study. Both Sonazoid\xc2\xae and dye were used as tracers, and the most upstream sentinel lymph node (SLN) at each lymphatic flow detected by CEUS (First-SLN) was sampled under hookwire guidance, a procedure called "Sona-Hook".In each of the 50 cases, at least one First-SLN was extracted by "Sona-Hook". All contrast-enhanced SLNs (CE-SLNs) were dye-positive, and the mean number of CE-SLNs sampled per patient was lower than that of dye-positive SLNs (1.48 vs. 1.88, p<0.01). Through OSNA, qualitative assessment of tumor metastasis between First-SLNs and all SLNs completely matched together."Sona-Hook" for First-SLN followed by an OSNA assay may be a feasible minimally invasive SLNB strategy.'', 'b'836'', 'b'138'', 'b"[('slnb', 6), ('osna', 6), ('slns', 6), ('sentinel', 4), ('lymph', 4), ('node', 4), ('ceus', 4), ('followed', 4), ('sampled', 4), ('investigate', 2), ('feasibility', 2), ('biopsy', 2), ('using', 2), ('ultrasonography', 2), ('nucleic', 2), ('acid', 2), ('amplification', 2), ('breast', 2), ('cancer', 2), ('patients', 2), ('scheduled', 2), ('undergo', 2), ('participated', 2), ('study', 2), ('dye', 2), ('used', 2), ('tracers', 2), ('upstream', 2), ('sln', 2), ('lymphatic', 2), ('flow', 2), ('detected', 2), ('hookwire', 2), ('guidance', 2), ('procedure', 2), ('called', 2), ('cases', 2), ('least', 2), ('one', 2), ('extracted', 2), ('mean', 2), ('number', 2), ('per', 2), ('patient', 2), ('lower', 2), ('p', 2), ('qualitative', 2), ('assessment', 2), ('tumor', 2), ('metastasis', 2), ('completely', 2), ('matched', 2), ('together', 2), ('assay', 2), ('may', 2), ('feasible', 2), ('minimally', 2), ('invasive', 2), ('strategy', 2)]"', 'b'[(\'(\', 7), (\')\', 7), (\',\', 6), (\'of\', 5), (\'.\', 5), (\'the\', 4), (\'by\', 4), (\'and\', 4), (\'sln\', 4), (\'first-sln\', 4), (\'slnb\', 3), (\'a\', 3), (\'osna\', 3), (\'wa\', 3), (\'``\', 3), (\'sona-hook\', 3), ("\'\'", 3), (\'feasibl\', 2), (\'sentinel\', 2), (\'lymph\', 2), (\'node\', 2), (\'use\', 2), (\'contrast-enhanc\', 2), (\'ceu\', 2), (\'follow\', 2), (\'patient\', 2), (\'were\', 2), (\'at\', 2), (\'each\', 2), (\'sampl\', 2), (\'all\', 2), (\'ce-sln\', 2), (\'dye-posit\', 2), (\'To\', 1), (\'investig\', 1), (\'hookwire-guid\', 1), (\'biopsi\', 1), (\'ultrasonographi\', 1), (\'one-step\', 1), (\'nucleic\', 1), (\'acid\', 1), (\'amplif\', 1), (\'assay.clin\', 1), (\'t1-2n0m0\', 1), (\'breast\', 1), (\'cancer\', 1), (\'schedul\', 1), (\'to\', 1), (\'undergo\', 1), (\'particip\', 1), (\'in\', 1), (\'thi\', 1), (\'studi\', 1), (\'both\', 1), (\'sonazoid\xc2\xae\', 1), (\'dye\', 1), (\'as\', 1), (\'tracer\', 1), (\'most\', 1), (\'upstream\', 1), (\'lymphat\', 1), (\'flow\', 1), (\'detect\', 1), (\'under\', 1), (\'hookwir\', 1), (\'guidanc\', 1), (\'procedur\', 1), (\'call\', 1), (\'.in\', 1), (\'50\', 1), (\'case\', 1), (\'least\', 1), (\'one\', 1), (\'extract\', 1), (\'mean\', 1), (\'number\', 1), (\'per\', 1), (\'lower\', 1), (\'than\', 1), (\'that\', 1), (\'1.48\', 1), (\'vs.\', 1), (\'1.88\', 1), (\'p\', 1), (\'<\', 1), (\'0.01\', 1), (\'through\', 1), (\'qualit\', 1), (\'assess\', 1), (\'tumor\', 1), (\'metastasi\', 1), (\'between\', 1), (\'complet\', 1), (\'match\', 1), (\'togeth\', 1), (\'for\', 1), (\'an\', 1), (\'assay\', 1), (\'may\', 1), (\'be\', 1), (\'minim\', 1), (\'invas\', 1), (\'strategi\', 1)]'', 'b'5'', 'b"('slnb', 'osna', 'slns', 'sentinel', 'lymph', 'node', 'ceus', 'followed', 'sampled', 'investigate', 'feasibility', 'biopsy', 'using', 'ultrasonography', 'nucleic', 'acid', 'amplification', 'breast', 'cancer', 'patients', 'scheduled', 'undergo', 'participated', 'study', 'dye', 'used', 'tracers', 'upstream', 'sln', 'lymphatic', 'flow', 'detected', 'hookwire', 'guidance', 'procedure', 'called', 'cases', 'least', 'one', 'extracted', 'mean', 'number', 'per', 'patient', 'lower', 'p', 'qualitative', 'assessment', 'tumor', 'metastasis', 'completely', 'matched', 'together', 'assay', 'may', 'feasible', 'minimally', 'invasive', 'strategy')"', 'b'(6, 6, 6, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.027606674278167268'', 'b'[-0.17351092711179977, -0.026045936684850654, -0.008306749424465618, -0.005307089910075256, -0.004443145040993237, -0.0035380599400501706, -0.003032622805757289, -0.002768916474821873, -0.002481236841074146, -0.0021228359640301027, -0.0019579735245669, -0.001767374331909945, -0.001692485589032405]'', 'b'-2.4735180432417816'', 'b'[1.0, -0.9459101490553135, -2.1354942159291497, -2.58351893845611, -2.7612001156935624, -2.9889840465642745, -3.1431347263915326, -3.2341065045972597, -3.343805421853684, -3.499809670330265, -3.6249728132842707, -3.727387818712341, -3.770684624465665]'', 'b'-2.202210823845493'', 'b'[-0.17351092711179977, 0.1724598109629664, 0.4079973530297398, 0.4935948224676753, 0.5275417418530537, 0.5710610546962982, 0.6005123493278275, 0.6178929839516474, 0.6388515365606864, 0.6686569651893681, 0.7239552811599101, 0.744408919812857, 0.753055867747916]'', 'b'85'', 'b'0.07148538558707204'', 'b"['Adenocarcinoma, Mucinous', 'Biomarkers, Tumor', 'Breast Neoplasms', 'Carcinoma, Ductal, Breast', 'Carcinoma, Lobular', 'Contrast Media', 'Female', 'Follow-Up Studies', 'Humans', 'Image-Guided Biopsy', 'Lymphatic Metastasis', 'Nucleic Acid Amplification Techniques', 'Prognosis', 'Sentinel Lymph Node', 'Ultrasonography, Mammary']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'48'', 'b'Suppression of Carnosine on Adhesion and Extravasation of Human Colorectal Cancer Cells.'', 'b'To investigate the effect of carnosine, an active compound of dietary beef, fish and chicken, on the regulation of cell adhesion and extravasation during metastasis.Cell adhesion and extravasation abilities, and related regulating molecular mechanisms were analyzed in human colorectal cancer cells (HCT-116) and human umbilical vein cells (EA.hy926).Carnosine reduced the ability of HCT-116 cells to adhere to EA.hy926 cells. The expression levels of integrin-\xce\xb21 in HCT-116 cells, as well as of intercellular adhesion molecule-1 and E-selectin in EA.hy926 cells, were reduced after carnosine treatment. After EA.hy926 cells were treated with carnosine, phosphorylation of vascular endothelia-cadherin (VE-cadherin), protein levels of Ras homologous (RHO) and RHO-associated coiled-coil containing protein kinase, and levels of reactive oxygen species were reduced. After treating EA.hy926 cells with carnosine, phosphorylation of inhibitor of kappa B (I\xce\xbaB) and DNA binding activity of nuclear factor-\xce\xbaB (NF-\xce\xbaB) were reduced.Carnosine inhibits metastatic cell adhesion and extravasation by suppressing NF-\xce\xbaB signaling activation.'', 'b'980'', 'b'150'', 'b"[('cells', 16), ('carnosine', 8), ('adhesion', 8), ('extravasation', 6), ('reduced', 6), ('levels', 6), ('cell', 4), ('human', 4), ('phosphorylation', 4), ('protein', 4), ('investigate', 2), ('effect', 2), ('active', 2), ('compound', 2), ('dietary', 2), ('beef', 2), ('fish', 2), ('chicken', 2), ('regulation', 2), ('abilities', 2), ('related', 2), ('regulating', 2), ('molecular', 2), ('mechanisms', 2), ('analyzed', 2), ('colorectal', 2), ('cancer', 2), ('umbilical', 2), ('vein', 2), ('ability', 2), ('adhere', 2), ('expression', 2), ('well', 2), ('intercellular', 2), ('treatment', 2), ('treated', 2), ('vascular', 2), ('ras', 2), ('homologous', 2), ('rho', 2), ('containing', 2), ('kinase', 2), ('reactive', 2), ('oxygen', 2), ('species', 2), ('treating', 2), ('inhibitor', 2), ('kappa', 2), ('b', 2), ('i\xce\xbab', 2), ('dna', 2), ('binding', 2), ('activity', 2), ('nuclear', 2), ('inhibits', 2), ('metastatic', 2), ('suppressing', 2), ('signaling', 2), ('activation', 2)]"', 'b"[('of', 12), (',', 10), ('and', 10), ('cell', 10), ('(', 6), (')', 6), ('were', 5), ('ea.hy926', 5), ('the', 4), ('carnosin', 4), ('adhes', 4), ('.', 4), ('activ', 3), ('extravas', 3), ('in', 3), ('hct-116', 3), ('reduc', 3), ('level', 3), ('after', 3), ('regul', 2), ('abil', 2), ('human', 2), ('to', 2), ('as', 2), ('treat', 2), ('with', 2), ('phosphoryl', 2), ('protein', 2), ('nf-\xce\xbab', 2), ('To', 1), ('investig', 1), ('effect', 1), ('an', 1), ('compound', 1), ('dietari', 1), ('beef', 1), ('fish', 1), ('chicken', 1), ('on', 1), ('dure', 1), ('metastasis.cel', 1), ('relat', 1), ('molecular', 1), ('mechan', 1), ('analyz', 1), ('colorect', 1), ('cancer', 1), ('umbil', 1), ('vein', 1), ('.carnosin', 1), ('adher', 1), ('express', 1), ('integrin-\xce\xb21', 1), ('well', 1), ('intercellular', 1), ('molecule-1', 1), ('e-selectin', 1), ('treatment', 1), ('vascular', 1), ('endothelia-cadherin', 1), ('ve-cadherin', 1), ('ra', 1), ('homolog', 1), ('rho', 1), ('rho-associ', 1), ('coiled-coil', 1), ('contain', 1), ('kinas', 1), ('reactiv', 1), ('oxygen', 1), ('speci', 1), ('inhibitor', 1), ('kappa', 1), ('B', 1), ('i\xce\xbab', 1), ('dna', 1), ('bind', 1), ('nuclear', 1), ('factor-\xce\xbab', 1), ('reduced.carnosin', 1), ('inhibit', 1), ('metastat', 1), ('by', 1), ('suppress', 1), ('signal', 1)]"', 'b'4'', 'b"('cells', 'carnosine', 'adhesion', 'extravasation', 'reduced', 'levels', 'cell', 'human', 'phosphorylation', 'protein', 'investigate', 'effect', 'active', 'compound', 'dietary', 'beef', 'fish', 'chicken', 'regulation', 'abilities', 'related', 'regulating', 'molecular', 'mechanisms', 'analyzed', 'colorectal', 'cancer', 'umbilical', 'vein', 'ability', 'adhere', 'expression', 'well', 'intercellular', 'treatment', 'treated', 'vascular', 'ras', 'homologous', 'rho', 'containing', 'kinase', 'reactive', 'oxygen', 'species', 'treating', 'inhibitor', 'kappa', 'b', 'i\xce\xbab', 'dna', 'binding', 'activity', 'nuclear', 'inhibits', 'metastatic', 'suppressing', 'signaling', 'activation')"', 'b'(16, 8, 8, 6, 6, 6, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.01466097351672211'', 'b'[-0.00946804741805524, -0.007182656661972941, -0.006312031612036827, -0.004959453409457507]'', 'b'-3.0775374439057197'', 'b'[-2.0910424533583156, -2.367295829986474, -2.4965075614664802, -2.7376696182833684]'', 'b'-2.6620620027475224'', 'b'[0.4355579602343881, 0.4931007217592802, 0.5200151433729581, 0.5702484867392746]'', 'b'63'', 'b'0.12667681363164876'', 'b"['Apoptosis', 'Biomarkers, Tumor', 'Carnosine', 'Cell Adhesion', 'Cell Proliferation', 'Colorectal Neoplasms', 'Gene Expression Regulation, Neoplastic', 'Humans', 'NF-kappa B', 'Tumor Cells, Cultured']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'49'', 'b'Level of Melanotransferrin in Tissue and Sera Serves as a Prognostic Marker of Gastric Cancer.'', 'b'The aim of the study was to identify novel biomarkers that are vital for improving management of patients with gastric cancer (GC).An RNA-sequencing analysis was conducted using gastric tissue from patients with metastatic GC. In vitro cell functions were evaluated by siRNA-mediated knockdown assays. A total of 230 pairs of gastric tissue were subjected to expression analysis of mRNA and protein in situ. The serum levels of the candidate biomarker were determined by ELISA.MELTF was identified as a candidate biomarker. Inhibition of MELTF expression suppressed the invasion ability of GC cells. Increased tissue MELTF mRNA expression was associated with shorter survival. Furthermore, staining intensity of tissue MELTF protein was linked to recurrence rates. Serum MELTF levels gradually were increased from healthy controls to advanced GC. Patients with high serum MELTF levels had poor prognosis.Both tissue and serum MELTF levels may serve as biomarkers of GC progression.'', 'b'836'', 'b'146'', 'b"[('meltf', 12), ('gc', 10), ('tissue', 10), ('serum', 8), ('levels', 8), ('patients', 6), ('gastric', 6), ('expression', 6), ('biomarkers', 4), ('analysis', 4), ('mrna', 4), ('protein', 4), ('candidate', 4), ('biomarker', 4), ('increased', 4), ('aim', 2), ('study', 2), ('identify', 2), ('novel', 2), ('vital', 2), ('improving', 2), ('management', 2), ('cancer', 2), ('conducted', 2), ('using', 2), ('metastatic', 2), ('vitro', 2), ('cell', 2), ('functions', 2), ('evaluated', 2), ('knockdown', 2), ('assays', 2), ('total', 2), ('pairs', 2), ('subjected', 2), ('situ', 2), ('determined', 2), ('identified', 2), ('inhibition', 2), ('suppressed', 2), ('invasion', 2), ('ability', 2), ('cells', 2), ('associated', 2), ('shorter', 2), ('survival', 2), ('furthermore', 2), ('staining', 2), ('intensity', 2), ('linked', 2), ('recurrence', 2), ('rates', 2), ('gradually', 2), ('healthy', 2), ('controls', 2), ('advanced', 2), ('high', 2), ('poor', 2), ('may', 2), ('serve', 2), ('progression', 2)]"', 'b"[('of', 10), ('.', 9), ('meltf', 6), ('the', 5), ('wa', 5), ('GC', 5), ('tissu', 5), ('to', 4), ('biomark', 4), ('with', 4), ('were', 4), ('serum', 4), ('level', 4), ('patient', 3), ('gastric', 3), ('express', 3), ('identifi', 2), ('analysi', 2), ('from', 2), ('cell', 2), ('by', 2), ('mrna', 2), ('and', 2), ('protein', 2), ('candid', 2), ('as', 2), ('increas', 2), ('aim', 1), ('studi', 1), ('novel', 1), ('that', 1), ('are', 1), ('vital', 1), ('for', 1), ('improv', 1), ('manag', 1), ('cancer', 1), ('(', 1), (')', 1), ('.an', 1), ('rna-sequenc', 1), ('conduct', 1), ('use', 1), ('metastat', 1), ('In', 1), ('vitro', 1), ('function', 1), ('evalu', 1), ('sirna-medi', 1), ('knockdown', 1), ('assay', 1), ('A', 1), ('total', 1), ('230', 1), ('pair', 1), ('subject', 1), ('in', 1), ('situ', 1), ('determin', 1), ('elisa.meltf', 1), ('a', 1), ('inhibit', 1), ('suppress', 1), ('invas', 1), ('abil', 1), ('associ', 1), ('shorter', 1), ('surviv', 1), ('furthermor', 1), (',', 1), ('stain', 1), ('intens', 1), ('link', 1), ('recurr', 1), ('rate', 1), ('gradual', 1), ('healthi', 1), ('control', 1), ('advanc', 1), ('high', 1), ('had', 1), ('poor', 1), ('prognosis.both', 1), ('may', 1), ('serv', 1), ('progress', 1)]"', 'b'9'', 'b"('meltf', 'gc', 'tissue', 'serum', 'levels', 'patients', 'gastric', 'expression', 'biomarkers', 'analysis', 'mrna', 'protein', 'candidate', 'biomarker', 'increased', 'aim', 'study', 'identify', 'novel', 'vital', 'improving', 'management', 'cancer', 'conducted', 'using', 'metastatic', 'vitro', 'cell', 'functions', 'evaluated', 'knockdown', 'assays', 'total', 'pairs', 'subjected', 'situ', 'determined', 'identified', 'inhibition', 'suppressed', 'invasion', 'ability', 'cells', 'associated', 'shorter', 'survival', 'furthermore', 'staining', 'intensity', 'linked', 'recurrence', 'rates', 'gradually', 'healthy', 'controls', 'advanced', 'high', 'poor', 'may', 'serve', 'progression')"', 'b'(12, 10, 10, 8, 8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.017690627892552272'', 'b'[-0.03613462214418733, -0.009385275062957853, -0.0045968694185916014, -0.004022260741267651, -0.0037541100251831413, -0.002851222803936563, -0.002589041396678029]'', 'b'-2.8607297110405954'', 'b'[-0.791759469228055, -2.1780538303479458, -2.891820298110627, -3.0253516907351496, -3.0943445622221004, -3.3694478524670215, -3.4659081186545837]'', 'b'-2.4038849789114187'', 'b'[0.17165957549782848, 0.4905992231938659, 0.6513726943299123, 0.6814501867136156, 0.6969905965445355, 0.7589566777366952, 0.7806840248762889]'', 'b'64'', 'b'0.310083514924945'', 'b"['Adenocarcinoma', 'Adult', 'Aged', 'Aged, 80 and over', 'Apoptosis', 'Biomarkers, Tumor', 'Case-Control Studies', 'Cell Proliferation', 'Female', 'Follow-Up Studies', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Male', 'Membrane Glycoproteins', 'Middle Aged', 'Neoplasm Recurrence, Local', 'Prognosis', 'Stomach Neoplasms', 'Tumor Cells, Cultured']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'50'', 'b'Shikonin-induced Apoptosis of Colon Cancer Cells Is Reduced by Peroxiredoxin V Expression.'', 'b'Colon cancer is the second most common deadliest malignancy in the world and better understanding of its underlying mechanisms is needed to improve clinical management. Natural plant extracts are gaining attention in the development of new therapeutic strategies against various cancer types. Shikonin is a naturally extracted naphthoquinone pigment with effects against cancer, including colon cancer.In this study, we conducted a series of in vitro experiments to show the effects of Shikonin on colon cancer cell apoptosis. A colon cancer cell line with overexpression of peroxiredoxin V (PrxV) was constructed and the relationship of PrxV expression with Shikonin-induced cell apoptosis was investigated.Shikonin induced colon cancer cell apoptosis via regulation of mammalian target of rapamycin signaling. Shikonin-induced cell apoptosis was abrogated by overexpression of PrxV.According to the results obtained in this study, targeting PrxV may provide new insight for the successful management of colon cancer by inducing cell apoptosis.'', 'b'898'', 'b'148'', 'b"[('cancer', 14), ('colon', 12), ('cell', 12), ('apoptosis', 10), ('prxv', 6), ('management', 4), ('new', 4), ('shikonin', 4), ('effects', 4), ('study', 4), ('overexpression', 4), ('second', 2), ('common', 2), ('deadliest', 2), ('malignancy', 2), ('world', 2), ('better', 2), ('understanding', 2), ('underlying', 2), ('mechanisms', 2), ('needed', 2), ('improve', 2), ('clinical', 2), ('natural', 2), ('plant', 2), ('extracts', 2), ('gaining', 2), ('attention', 2), ('development', 2), ('therapeutic', 2), ('strategies', 2), ('various', 2), ('types', 2), ('naturally', 2), ('extracted', 2), ('naphthoquinone', 2), ('pigment', 2), ('including', 2), ('conducted', 2), ('series', 2), ('vitro', 2), ('experiments', 2), ('show', 2), ('line', 2), ('peroxiredoxin', 2), ('v', 2), ('constructed', 2), ('relationship', 2), ('expression', 2), ('induced', 2), ('via', 2), ('regulation', 2), ('mammalian', 2), ('target', 2), ('rapamycin', 2), ('signaling', 2), ('abrogated', 2), ('results', 2), ('obtained', 2), ('targeting', 2), ('may', 2), ('provide', 2), ('insight', 2), ('successful', 2), ('inducing', 2)]"', 'b"[('of', 10), ('cancer', 7), ('the', 7), ('colon', 6), ('cell', 6), ('.', 5), ('apoptosi', 5), ('in', 4), ('is', 3), ('to', 3), ('with', 3), (',', 3), ('prxv', 3), ('wa', 3), ('and', 2), ('manag', 2), ('natur', 2), ('extract', 2), ('new', 2), ('against', 2), ('shikonin', 2), ('a', 2), ('effect', 2), ('thi', 2), ('studi', 2), ('overexpress', 2), ('shikonin-induc', 2), ('induc', 2), ('target', 2), ('by', 2), ('second', 1), ('most', 1), ('common', 1), ('deadliest', 1), ('malign', 1), ('world', 1), ('better', 1), ('understand', 1), ('it', 1), ('underli', 1), ('mechan', 1), ('need', 1), ('improv', 1), ('clinic', 1), ('plant', 1), ('are', 1), ('gain', 1), ('attent', 1), ('develop', 1), ('therapeut', 1), ('strategi', 1), ('variou', 1), ('type', 1), ('naphthoquinon', 1), ('pigment', 1), ('includ', 1), ('cancer.in', 1), ('we', 1), ('conduct', 1), ('seri', 1), ('vitro', 1), ('experi', 1), ('show', 1), ('on', 1), ('A', 1), ('line', 1), ('peroxiredoxin', 1), ('V', 1), ('(', 1), (')', 1), ('construct', 1), ('relationship', 1), ('express', 1), ('investigated.shikonin', 1), ('via', 1), ('regul', 1), ('mammalian', 1), ('rapamycin', 1), ('signal', 1), ('abrog', 1), ('prxv.accord', 1), ('result', 1), ('obtain', 1), ('may', 1), ('provid', 1), ('insight', 1), ('for', 1), ('success', 1)]"', 'b'5'', 'b"('cancer', 'colon', 'cell', 'apoptosis', 'prxv', 'management', 'new', 'shikonin', 'effects', 'study', 'overexpression', 'second', 'common', 'deadliest', 'malignancy', 'world', 'better', 'understanding', 'underlying', 'mechanisms', 'needed', 'improve', 'clinical', 'natural', 'plant', 'extracts', 'gaining', 'attention', 'development', 'therapeutic', 'strategies', 'various', 'types', 'naturally', 'extracted', 'naphthoquinone', 'pigment', 'including', 'conducted', 'series', 'vitro', 'experiments', 'show', 'line', 'peroxiredoxin', 'v', 'constructed', 'relationship', 'expression', 'induced', 'via', 'regulation', 'mammalian', 'target', 'rapamycin', 'signaling', 'abrogated', 'results', 'obtained', 'targeting', 'may', 'provide', 'insight', 'successful', 'inducing')"', 'b'(14, 12, 12, 10, 6, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.019907494471150547'', 'b'[-0.038935808530250866, -0.008985186583904048, -0.005562258361464409, -0.0046722970236301046, -0.003407234563326763]'', 'b'-2.713572066704308'', 'b'[-0.791759469228055, -2.258096538021482, -2.7376696182833684, -2.912023005428146, -3.2626798770413155]'', 'b'-2.2148372575143678'', 'b'[0.18496677057525962, 0.5275248866833607, 0.6395602804593973, 0.6802918210502159, 0.7892868108749378]'', 'b'55'', 'b'0.15571175514797736'', 'b"['Anti-Inflammatory Agents, Non-Steroidal', 'Apoptosis', 'Biomarkers, Tumor', 'Cell Movement', 'Cell Proliferation', 'Colonic Neoplasms', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Naphthoquinones', 'Peroxiredoxins', 'Tumor Cells, Cultured']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'51'', 'b'Bis(4-hydroxy-2H-chromen-2-one) Coumarin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Aromatase Inhibition.'', 'b'The present investigation aimed to examine the therapeutic potential of the new coumarin derivative bis(4-hydroxy-2H-chromen-2-one) coumarin (4HC) against breast cancer.For this purpose, the effects of 4HC treatment on the proliferation of MCF-7 breast cancer cells and on MCF-10a non-cancerous cells were evaluated using a fluorescent assay. Cell cycle distribution and apoptosis were measured by image cytometry. The expression level of aromatase (CYP19A1) and apoptosis-related genes were determined by real-time PCR.MCF-7 mammary cancer cell proliferation was significantly decreased within 24 h after treatment with 4HC at 50 \xce\xbcM, while no effect was observed on the viability of MCF-10a non-cancerous mammary cells. 4HC also increased the percentage of the cells in the G2_M phase, inducing apoptosis. Real-time PCR revealed that 4HC induced MCF-7 mortality through an up-regulation of Bax and a down-regulation of Bcl-2, resulting in an increase in caspase-3 gene expression. The increased expression of apoptosis-related genes was accompanied by a decrease in CYP19A1 gene expression.4HC selectively inhibits proliferation of MCF-7cells in vitro. Moreover, 4HC has inhibitory effects on aromatase gene expression and promoting effects on apoptosis, in MCF-7 cells.'', 'b'1093'', 'b'179'', 'b"[('cells', 10), ('expression', 8), ('effects', 6), ('proliferation', 6), ('apoptosis', 6), ('gene', 6), ('coumarin', 4), ('breast', 4), ('treatment', 4), ('cancer', 4), ('cell', 4), ('aromatase', 4), ('genes', 4), ('mammary', 4), ('increased', 4), ('present', 2), ('investigation', 2), ('aimed', 2), ('examine', 2), ('therapeutic', 2), ('potential', 2), ('new', 2), ('derivative', 2), ('bis', 2), ('purpose', 2), ('evaluated', 2), ('using', 2), ('fluorescent', 2), ('assay', 2), ('cycle', 2), ('distribution', 2), ('measured', 2), ('image', 2), ('cytometry', 2), ('level', 2), ('determined', 2), ('significantly', 2), ('decreased', 2), ('within', 2), ('h', 2), ('\xce\xbcm', 2), ('effect', 2), ('observed', 2), ('viability', 2), ('also', 2), ('percentage', 2), ('phase', 2), ('inducing', 2), ('pcr', 2), ('revealed', 2), ('induced', 2), ('mortality', 2), ('bax', 2), ('resulting', 2), ('increase', 2), ('accompanied', 2), ('decrease', 2), ('selectively', 2), ('inhibits', 2), ('vitro', 2), ('moreover', 2), ('inhibitory', 2), ('promoting', 2)]"', 'b"[('the', 11), ('of', 10), ('cell', 7), ('.', 7), ('4hc', 6), (',', 6), ('in', 6), ('on', 5), ('and', 5), ('gene', 5), ('effect', 4), ('express', 4), ('(', 3), (')', 3), ('prolifer', 3), ('mcf-7', 3), ('were', 3), ('a', 3), ('apoptosi', 3), ('by', 3), ('wa', 3), ('increas', 3), ('coumarin', 2), ('breast', 2), ('treatment', 2), ('cancer', 2), ('mcf-10a', 2), ('non-cancer', 2), ('aromatas', 2), ('cyp19a1', 2), ('apoptosis-rel', 2), ('real-tim', 2), ('mammari', 2), ('decreas', 2), ('induc', 2), ('an', 2), ('present', 1), ('investig', 1), ('aim', 1), ('to', 1), ('examin', 1), ('therapeut', 1), ('potenti', 1), ('new', 1), ('deriv', 1), ('bi', 1), ('4-hydroxy-2h-chromen-2-on', 1), ('against', 1), ('cancer.for', 1), ('thi', 1), ('purpos', 1), ('evalu', 1), ('use', 1), ('fluoresc', 1), ('assay', 1), ('cycl', 1), ('distribut', 1), ('measur', 1), ('imag', 1), ('cytometri', 1), ('level', 1), ('determin', 1), ('pcr.mcf-7', 1), ('significantli', 1), ('within', 1), ('24', 1), ('h', 1), ('after', 1), ('with', 1), ('at', 1), ('50', 1), ('\xce\xbcM', 1), ('while', 1), ('no', 1), ('observ', 1), ('viabil', 1), ('also', 1), ('percentag', 1), ('g2_m', 1), ('phase', 1), ('pcr', 1), ('reveal', 1), ('that', 1), ('mortal', 1), ('through', 1), ('up-regul', 1), ('bax', 1), ('down-regul', 1), ('bcl-2', 1), ('result', 1), ('caspase-3', 1), ('accompani', 1), ('expression.4hc', 1), ('select', 1), ('inhibit', 1), ('mcf-7cell', 1), ('vitro', 1), ('moreov', 1), ('ha', 1), ('inhibitori', 1), ('promot', 1)]"', 'b'7'', 'b"('cells', 'expression', 'effects', 'proliferation', 'apoptosis', 'gene', 'coumarin', 'breast', 'treatment', 'cancer', 'cell', 'aromatase', 'genes', 'mammary', 'increased', 'present', 'investigation', 'aimed', 'examine', 'therapeutic', 'potential', 'new', 'derivative', 'bis', 'purpose', 'evaluated', 'using', 'fluorescent', 'assay', 'cycle', 'distribution', 'measured', 'image', 'cytometry', 'level', 'determined', 'significantly', 'decreased', 'within', 'h', '\xce\xbcm', 'effect', 'observed', 'viability', 'also', 'percentage', 'phase', 'inducing', 'pcr', 'revealed', 'induced', 'mortality', 'bax', 'resulting', 'increase', 'accompanied', 'decrease', 'selectively', 'inhibits', 'vitro', 'moreover', 'inhibitory', 'promoting')"', 'b'(10, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.011164461632492654'', 'b'[-0.04169069218878596, -0.009264598264174657, -0.007146975803791878, -0.005685094389379904, -0.0047197010025040705]'', 'b'-3.2626798770413155'', 'b'[-0.791759469228055, -2.295836866004329, -2.5553480614894135, -2.784189633918261, -2.970291913552122]'', 'b'-2.586250565749687'', 'b'[0.19805400191486033, 0.5742901685775211, 0.6392053768005962, 0.6964487581373693, 0.7430011552724494]'', 'b'75'', 'b'0.2050730994899762'', 'b"['Apoptosis', 'Aromatase', 'Biomarkers, Tumor', 'Breast Neoplasms', 'Cell Cycle', 'Cell Proliferation', 'Chromones', 'Coumarins', 'Female', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Tumor Cells, Cultured']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'52'', 'b'Evaluation and Clinical Significance of Jagged-1-activated Notch Signaling by APEX1 in Colorectal Cancer.'', 'b'Colorectal cancer (CRC) is one of the most common in the world and its prevalence is rapidly increasing. Jagged-1-activated Notch signaling by apurinic_apyrimidinic endodeoxyribonuclease 1 (APEX1) promotes CRC, and high expression of Jagged-1 is associated with poor prognosis. However, its clinical implication is unknown. The aim of this study was to investigate the clinical role of Jagged-1-activated Notch signaling by APEX1.The 5-dimethylthiazol-2-yl) 2, 5-diphenyltetrazolium bromide (MTT) assay was used to evaluate the anti-cancer efficacy of 5-fluorouracil (5-FU), oxaliplatin, and irinotecan. Tissue from CRC patients was analyzed to assess the clinical specificity of Jagged-1 activated by APEX1.The half-maximal inhibitory concentration (ICOverexpression of Jagged-1 by APEX1 might serve as a predictor of response to chemotherapy and of poor prognosis, and moreover may be a therapeutic target for chemotherapy of advanced CRC.'', 'b'813'', 'b'129'', 'b"[('crc', 8), ('clinical', 6), ('notch', 4), ('signaling', 4), ('poor', 4), ('prognosis', 4), ('chemotherapy', 4), ('colorectal', 2), ('cancer', 2), ('one', 2), ('common', 2), ('world', 2), ('prevalence', 2), ('rapidly', 2), ('increasing', 2), ('endodeoxyribonuclease', 2), ('promotes', 2), ('high', 2), ('expression', 2), ('associated', 2), ('however', 2), ('implication', 2), ('unknown', 2), ('aim', 2), ('study', 2), ('investigate', 2), ('role', 2), ('bromide', 2), ('mtt', 2), ('assay', 2), ('used', 2), ('evaluate', 2), ('efficacy', 2), ('oxaliplatin', 2), ('irinotecan', 2), ('tissue', 2), ('patients', 2), ('analyzed', 2), ('assess', 2), ('specificity', 2), ('activated', 2), ('inhibitory', 2), ('concentration', 2), ('icoverexpression', 2), ('might', 2), ('serve', 2), ('predictor', 2), ('response', 2), ('moreover', 2), ('may', 2), ('therapeutic', 2), ('target', 2), ('advanced', 2)]"', 'b"[('of', 10), ('the', 6), (',', 6), ('(', 5), (')', 5), ('and', 5), ('.', 5), ('crc', 4), ('is', 4), ('by', 4), ('to', 4), ('jagged-1', 3), ('clinic', 3), ('wa', 3), ('it', 2), ('jagged-1-activ', 2), ('notch', 2), ('signal', 2), ('apex1', 2), ('poor', 2), ('prognosi', 2), ('apex1.th', 2), ('a', 2), ('chemotherapi', 2), ('colorect', 1), ('cancer', 1), ('one', 1), ('most', 1), ('common', 1), ('in', 1), ('world', 1), ('preval', 1), ('rapidli', 1), ('increas', 1), ('apurinic_apyrimidin', 1), ('endodeoxyribonucleas', 1), ('1', 1), ('promot', 1), ('high', 1), ('express', 1), ('associ', 1), ('with', 1), ('howev', 1), ('implic', 1), ('unknown', 1), ('aim', 1), ('thi', 1), ('studi', 1), ('investig', 1), ('role', 1), ('5-dimethylthiazol-2-yl', 1), ('2', 1), ('5-diphenyltetrazolium', 1), ('bromid', 1), ('mtt', 1), ('assay', 1), ('use', 1), ('evalu', 1), ('anti-canc', 1), ('efficaci', 1), ('5-fluorouracil', 1), ('5-fu', 1), ('oxaliplatin', 1), ('irinotecan', 1), ('tissu', 1), ('from', 1), ('patient', 1), ('analyz', 1), ('assess', 1), ('specif', 1), ('activ', 1), ('half-maxim', 1), ('inhibitori', 1), ('concentr', 1), ('icoverexpress', 1), ('might', 1), ('serv', 1), ('as', 1), ('predictor', 1), ('respons', 1), ('moreov', 1), ('may', 1), ('be', 1), ('therapeut', 1), ('target', 1), ('for', 1), ('advanc', 1)]"', 'b'5'', 'b"('crc', 'clinical', 'notch', 'signaling', 'poor', 'prognosis', 'chemotherapy', 'colorectal', 'cancer', 'one', 'common', 'world', 'prevalence', 'rapidly', 'increasing', 'endodeoxyribonuclease', 'promotes', 'high', 'expression', 'associated', 'however', 'implication', 'unknown', 'aim', 'study', 'investigate', 'role', 'bromide', 'mtt', 'assay', 'used', 'evaluate', 'efficacy', 'oxaliplatin', 'irinotecan', 'tissue', 'patients', 'analyzed', 'assess', 'specificity', 'activated', 'inhibitory', 'concentration', 'icoverexpression', 'might', 'serve', 'predictor', 'response', 'moreover', 'may', 'therapeutic', 'target', 'advanced')"', 'b'(8, 6, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.00938642997173512'', 'b'[-0.043051243961979443, -0.01722049758479178, -0.00833249883135086, -0.005064852230821111]'', 'b'-3.4067192472642533'', 'b'[-0.791759469228055, -1.70805020110221, -2.4339872044851463, -2.9318256327243257]'', 'b'-2.6221083951202635'', 'b'[0.20451738041366613, 0.4412021154417558, 0.6287170616437583, 0.7573124434103983]'', 'b'54'', 'b'0.14779848410231083'', 'b"['Antineoplastic Combined Chemotherapy Protocols', 'Apoptosis', 'Biomarkers, Tumor', 'Cell Proliferation', 'Colorectal Neoplasms', 'DNA-(Apurinic or Apyrimidinic Site) Lyase', 'Female', 'Fluorouracil', 'Follow-Up Studies', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Irinotecan', 'Jagged-1 Protein', 'Male', 'Middle Aged', 'Oxaliplatin', 'Prognosis', 'Receptor, Notch1', 'Retrospective Studies', 'Survival Rate', 'Tumor Cells, Cultured']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'54'', 'b'Expression of Serpin B9 as a Prognostic Factor of Colorectal Cancer.'', 'b'Treatment of colorectal cancer (CRC) does not reflect immune interactions between tumours and macro-organisms. Serpin B9 is known as an inhibitor of Granzyme B. The aim of this study was to evaluate the impact of the expression of Serpin B9 in CRC and healthy colon tissue on prognosis.This retrospective study included 74 CRC patients in all stages. Analysis of gene expression was performed with quantitative polymerase chain reaction with reverse transcription using specific primers and master mix Xceed qPCR SG. Expression was normalized to the reference genes GAPDH, ACTB, and PSMC.Increased expression of Serpin B9 in healthy tissue was significantly associated with longer overall survival (OS). This association was found both in all patients and in the group of patients with distant metastases.The presented results support previous evidence of positive influence of the interaction between immune system and tumour on the prognosis of CRC.'', 'b'808'', 'b'144'', 'b"[('crc', 8), ('expression', 8), ('serpin', 6), ('patients', 6), ('immune', 4), ('study', 4), ('healthy', 4), ('tissue', 4), ('treatment', 2), ('colorectal', 2), ('cancer', 2), ('reflect', 2), ('interactions', 2), ('tumours', 2), ('known', 2), ('inhibitor', 2), ('granzyme', 2), ('aim', 2), ('evaluate', 2), ('impact', 2), ('colon', 2), ('retrospective', 2), ('included', 2), ('stages', 2), ('analysis', 2), ('gene', 2), ('performed', 2), ('quantitative', 2), ('polymerase', 2), ('chain', 2), ('reaction', 2), ('reverse', 2), ('transcription', 2), ('using', 2), ('specific', 2), ('primers', 2), ('master', 2), ('mix', 2), ('xceed', 2), ('qpcr', 2), ('sg', 2), ('normalized', 2), ('reference', 2), ('genes', 2), ('gapdh', 2), ('actb', 2), ('significantly', 2), ('associated', 2), ('longer', 2), ('overall', 2), ('survival', 2), ('os', 2), ('association', 2), ('found', 2), ('group', 2), ('distant', 2), ('presented', 2), ('results', 2), ('support', 2), ('previous', 2), ('evidence', 2), ('positive', 2), ('influence', 2), ('interaction', 2), ('system', 2), ('tumour', 2), ('prognosis', 2)]"', 'b"[('of', 11), ('the', 7), ('and', 6), ('.', 6), ('wa', 5), ('in', 5), ('crc', 4), ('express', 4), ('with', 4), ('serpin', 3), ('B9', 3), ('patient', 3), ('(', 2), (')', 2), ('immun', 2), ('interact', 2), ('between', 2), ('tumour', 2), ('thi', 2), ('studi', 2), ('to', 2), ('healthi', 2), ('tissu', 2), ('on', 2), ('all', 2), ('gene', 2), (',', 2), ('associ', 2), ('treatment', 1), ('colorect', 1), ('cancer', 1), ('doe', 1), ('not', 1), ('reflect', 1), ('macro-organ', 1), ('is', 1), ('known', 1), ('as', 1), ('an', 1), ('inhibitor', 1), ('granzym', 1), ('B', 1), ('aim', 1), ('evalu', 1), ('impact', 1), ('colon', 1), ('prognosis.thi', 1), ('retrospect', 1), ('includ', 1), ('74', 1), ('stage', 1), ('analysi', 1), ('perform', 1), ('quantit', 1), ('polymeras', 1), ('chain', 1), ('reaction', 1), ('revers', 1), ('transcript', 1), ('use', 1), ('specif', 1), ('primer', 1), ('master', 1), ('mix', 1), ('xceed', 1), ('qpcr', 1), ('SG', 1), ('normal', 1), ('refer', 1), ('gapdh', 1), ('actb', 1), ('psmc.increas', 1), ('significantli', 1), ('longer', 1), ('overal', 1), ('surviv', 1), ('OS', 1), ('found', 1), ('both', 1), ('group', 1), ('distant', 1), ('metastases.th', 1), ('present', 1), ('result', 1), ('support', 1), ('previou', 1), ('evid', 1), ('posit', 1), ('influenc', 1), ('system', 1), ('prognosi', 1)]"', 'b'6'', 'b"('crc', 'expression', 'serpin', 'patients', 'immune', 'study', 'healthy', 'tissue', 'treatment', 'colorectal', 'cancer', 'reflect', 'interactions', 'tumours', 'known', 'inhibitor', 'granzyme', 'aim', 'evaluate', 'impact', 'colon', 'retrospective', 'included', 'stages', 'analysis', 'gene', 'performed', 'quantitative', 'polymerase', 'chain', 'reaction', 'reverse', 'transcription', 'using', 'specific', 'primers', 'master', 'mix', 'xceed', 'qpcr', 'sg', 'normalized', 'reference', 'genes', 'gapdh', 'actb', 'significantly', 'associated', 'longer', 'overall', 'survival', 'os', 'association', 'found', 'group', 'distant', 'presented', 'results', 'support', 'previous', 'evidence', 'positive', 'influence', 'interaction', 'system', 'tumour', 'prognosis')"', 'b'(8, 8, 6, 6, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0545876179116142'', 'b'[-0.01960263183584002, -0.010861731359651431, -0.010010696374415533, -0.006211528589980757, -0.0023533500981625485]'', 'b'-1.5866893440979424'', 'b'[-1.6390573296152589, -2.258096538021482, -2.367295829986474, -2.871201010907891, -3.867534450455582]'', 'b'-1.1507234320549264'', 'b'[0.4498177234639621, 0.6376977874838549, 0.6872501136900235, 0.8560582640081289, 1.1832161352214687]'', 'b'87'', 'b'0.1601977944583808'', 'b"['Adult', 'Aged', 'Aged, 80 and over', 'Biomarkers, Tumor', 'Case-Control Studies', 'Colorectal Neoplasms', 'Female', 'Follow-Up Studies', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Lymphatic Metastasis', 'Male', 'Middle Aged', 'Prognosis', 'Retrospective Studies', 'Serpins', 'Survival Rate']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'55'', 'b'Effects of Volatile Anesthetics on Proliferation and Viability of SW480 Colon Cancer Cells '', 'b'For patients undergoing cancer surgery, the risk for cancer progression is enhanced during the perioperative period. To what extent the type of anesthetic can affect the metastatic process and finally the outcome of patients with cancer is under debate. For this reason, the aim of this study was to investigate the effects of the volatile anesthetics sevoflurane and desflurane on colon cancer cells in vitro.SW480 colon carcinoma cells were exposed for 3 or 6 h to sevoflurane (1 or 2.5 vol%) or desflurane (6 or 12 vol%). Cell cycle distribution was analyzed by flow cytometry after a 24-72 h recovery and apoptosis was detected by annexin V staining after a 0-48 h recovery. Viability was tested by measuring ATP content after 0 and 24 h recovery.Treatment with sevoflurane or desflurane caused no or only slight changes in cell-cycle distribution and apoptosis rate. Desflurane at 12vol% significantly reduced cell viability by 17\xc2\xb125% and 11\xc2\xb122% after 3 and 6 h incubation and 24 h recovery, respectively, while 2.5 vol% sevoflurane slightly increased viability.At clinically relevant concentrations, sevoflurane and desflurane had only slight effects on SW480 colon cancer cells in vitro.'', 'b'1007'', 'b'188'', 'b"[('h', 12), ('cancer', 10), ('sevoflurane', 10), ('desflurane', 10), ('colon', 6), ('cells', 6), ('vol', 6), ('recovery', 6), ('patients', 4), ('effects', 4), ('cell', 4), ('distribution', 4), ('apoptosis', 4), ('viability', 4), ('slight', 4), ('undergoing', 2), ('surgery', 2), ('risk', 2), ('progression', 2), ('enhanced', 2), ('perioperative', 2), ('period', 2), ('extent', 2), ('type', 2), ('anesthetic', 2), ('affect', 2), ('metastatic', 2), ('process', 2), ('finally', 2), ('outcome', 2), ('debate', 2), ('reason', 2), ('aim', 2), ('study', 2), ('investigate', 2), ('volatile', 2), ('anesthetics', 2), ('carcinoma', 2), ('exposed', 2), ('cycle', 2), ('analyzed', 2), ('flow', 2), ('cytometry', 2), ('detected', 2), ('annexin', 2), ('v', 2), ('staining', 2), ('tested', 2), ('measuring', 2), ('atp', 2), ('content', 2), ('caused', 2), ('changes', 2), ('rate', 2), ('significantly', 2), ('reduced', 2), ('incubation', 2), ('respectively', 2), ('slightly', 2), ('increased', 2), ('clinically', 2), ('relevant', 2), ('concentrations', 2), ('vitro', 2)]"', 'b"[('and', 9), ('the', 8), ('.', 6), ('or', 6), ('h', 6), ('%', 6), ('cancer', 5), (',', 5), ('sevofluran', 5), ('desfluran', 5), ('cell', 5), ('for', 4), ('of', 4), ('wa', 4), ('by', 4), ('after', 4), ('colon', 3), ('in', 3), ('6', 3), ('vol', 3), ('recoveri', 3), ('patient', 2), ('is', 2), ('anesthet', 2), ('with', 2), ('thi', 2), ('to', 2), ('effect', 2), ('on', 2), ('3', 2), ('(', 2), ('2.5', 2), (')', 2), ('distribut', 2), ('a', 2), ('apoptosi', 2), ('viabil', 2), ('24', 2), ('onli', 2), ('slight', 2), ('undergo', 1), ('surgeri', 1), ('risk', 1), ('progress', 1), ('enhanc', 1), ('dure', 1), ('periop', 1), ('period', 1), ('To', 1), ('what', 1), ('extent', 1), ('type', 1), ('can', 1), ('affect', 1), ('metastat', 1), ('process', 1), ('final', 1), ('outcom', 1), ('under', 1), ('debat', 1), ('reason', 1), ('aim', 1), ('studi', 1), ('investig', 1), ('volatil', 1), ('vitro.sw480', 1), ('carcinoma', 1), ('were', 1), ('expos', 1), ('1', 1), ('12', 1), ('cycl', 1), ('analyz', 1), ('flow', 1), ('cytometri', 1), ('24-72', 1), ('detect', 1), ('annexin', 1), ('V', 1), ('stain', 1), ('0-48', 1), ('test', 1), ('measur', 1), ('atp', 1), ('content', 1), ('0', 1), ('recovery.treat', 1), ('caus', 1), ('no', 1), ('chang', 1), ('cell-cycl', 1), ('rate', 1), ('at', 1), ('12vol', 1), ('significantli', 1), ('reduc', 1), ('17\xc2\xb125', 1), ('11\xc2\xb122', 1), ('incub', 1), ('respect', 1), ('while', 1), ('slightli', 1), ('increas', 1), ('viability.at', 1), ('clinic', 1), ('relev', 1), ('concentr', 1), ('had', 1), ('sw480', 1), ('vitro', 1)]"', 'b'6'', 'b"('h', 'cancer', 'sevoflurane', 'desflurane', 'colon', 'cells', 'vol', 'recovery', 'patients', 'effects', 'cell', 'distribution', 'apoptosis', 'viability', 'slight', 'undergoing', 'surgery', 'risk', 'progression', 'enhanced', 'perioperative', 'period', 'extent', 'type', 'anesthetic', 'affect', 'metastatic', 'process', 'finally', 'outcome', 'debate', 'reason', 'aim', 'study', 'investigate', 'volatile', 'anesthetics', 'carcinoma', 'exposed', 'cycle', 'analyzed', 'flow', 'cytometry', 'detected', 'annexin', 'v', 'staining', 'tested', 'measuring', 'atp', 'content', 'caused', 'changes', 'rate', 'significantly', 'reduced', 'incubation', 'respectively', 'slightly', 'increased', 'clinically', 'relevant', 'concentrations', 'vitro')"', 'b'(12, 10, 10, 10, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.01617768482506856'', 'b'[-0.06273151177100833, -0.026138129904586804, -0.010365175212922927, -0.00845580083159502, -0.006836604927672569, -0.00563720055439668, -0.004868491387888042]'', 'b'-2.7727609380946383'', 'b'[-0.6094379124341003, -1.4849066497880004, -2.4339872044851463, -2.6375861597263857, -2.8501476017100584, -3.0430512678345503, -3.189654742026425]'', 'b'-1.9512730860014074'', 'b'[0.19115480788779252, 0.46575219490012243, 0.7820898190555312, 0.8475103232270796, 0.9158106575069216, 0.9777945467633834, 1.0249012383648657]'', 'b'50'', 'b'0.15571175514797736'', 'b"['Anesthetics, Inhalation', 'Apoptosis', 'Cell Cycle', 'Cell Proliferation', 'Colonic Neoplasms', 'Desflurane', 'Humans', 'In Vitro Techniques', 'Sevoflurane', 'Tumor Cells, Cultured']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'56'', 'b'The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer.'', 'b'Carbohydrate antigen 19-9 (CA19-9) is a tumor marker for pancreatic cancer. Irreversible electroporation (IRE) is an experimental treatment modality for pancreatic cancer. The aim of this study was to evaluate whether percutaneous IRE lowers the CA19-9 level in pancreatic cancer and whether this correlates with improved overall survival.Seventy-one patients with locally advanced pancreatic cancer or local recurrence after resection were treated. Patients with missing data, metastatic disease and normal serum CA19-9 before IRE were excluded. This left 35 cases for analysis.The median CA19-9 did not decrease in the cohort after IRE treatment (282 U_ml before versus 315 U_ml after; p=0.80). The 25th percentile of patients with the best CA19-9 response had improved overall survival compared to the 25th percentile with the worst response (mean 13.1 versus 8.1 months, respectively; p=0.01).IRE did not lower the level of CA19-9 in pancreatic cancer cases. However, a response in CA19-9 was correlated with improved survival.'', 'b'881'', 'b'151'', 'b"[('pancreatic', 10), ('cancer', 10), ('ire', 8), ('improved', 6), ('patients', 6), ('response', 6), ('treatment', 4), ('whether', 4), ('level', 4), ('overall', 4), ('cases', 4), ('versus', 4), ('percentile', 4), ('survival', 4), ('carbohydrate', 2), ('antigen', 2), ('tumor', 2), ('marker', 2), ('irreversible', 2), ('electroporation', 2), ('experimental', 2), ('modality', 2), ('aim', 2), ('study', 2), ('evaluate', 2), ('percutaneous', 2), ('lowers', 2), ('correlates', 2), ('locally', 2), ('advanced', 2), ('local', 2), ('recurrence', 2), ('resection', 2), ('treated', 2), ('missing', 2), ('data', 2), ('metastatic', 2), ('disease', 2), ('normal', 2), ('serum', 2), ('excluded', 2), ('left', 2), ('median', 2), ('decrease', 2), ('cohort', 2), ('best', 2), ('compared', 2), ('worst', 2), ('mean', 2), ('months', 2), ('respectively', 2), ('lower', 2), ('however', 2), ('correlated', 2)]"', 'b"[('the', 8), ('ca19-9', 7), ('.', 7), ('with', 6), ('pancreat', 5), ('cancer', 5), ('(', 4), (')', 4), ('ire', 4), ('in', 4), ('for', 3), ('of', 3), ('thi', 3), ('improv', 3), ('patient', 3), ('after', 3), (',', 3), ('respons', 3), ('is', 2), ('a', 2), ('treatment', 2), ('wa', 2), ('to', 2), ('whether', 2), ('lower', 2), ('level', 2), ('and', 2), ('correl', 2), ('overal', 2), ('local', 2), ('were', 2), ('befor', 2), ('case', 2), ('did', 2), ('not', 2), ('u_ml', 2), ('versu', 2), (';', 2), ('25th', 2), ('percentil', 2), ('surviv', 2), ('carbohydr', 1), ('antigen', 1), ('19-9', 1), ('tumor', 1), ('marker', 1), ('irrevers', 1), ('electropor', 1), ('an', 1), ('experiment', 1), ('modal', 1), ('aim', 1), ('studi', 1), ('evalu', 1), ('percutan', 1), ('survival.seventy-on', 1), ('advanc', 1), ('or', 1), ('recurr', 1), ('resect', 1), ('treat', 1), ('miss', 1), ('data', 1), ('metastat', 1), ('diseas', 1), ('normal', 1), ('serum', 1), ('exclud', 1), ('left', 1), ('35', 1), ('analysis.th', 1), ('median', 1), ('decreas', 1), ('cohort', 1), ('282', 1), ('315', 1), ('p=0.80', 1), ('best', 1), ('had', 1), ('compar', 1), ('worst', 1), ('mean', 1), ('13.1', 1), ('8.1', 1), ('month', 1), ('respect', 1), ('p=0.01', 1), ('.ire', 1), ('howev', 1)]"', 'b'7'', 'b"('pancreatic', 'cancer', 'ire', 'improved', 'patients', 'response', 'treatment', 'whether', 'level', 'overall', 'cases', 'versus', 'percentile', 'survival', 'carbohydrate', 'antigen', 'tumor', 'marker', 'irreversible', 'electroporation', 'experimental', 'modality', 'aim', 'study', 'evaluate', 'percutaneous', 'lowers', 'correlates', 'locally', 'advanced', 'local', 'recurrence', 'resection', 'treated', 'missing', 'data', 'metastatic', 'disease', 'normal', 'serum', 'excluded', 'left', 'median', 'decrease', 'cohort', 'best', 'compared', 'worst', 'mean', 'months', 'respectively', 'lower', 'however', 'correlated')"', 'b'(10, 10, 8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.010836125090359522'', 'b'[-0.04111562887322875, -0.01827361283254611, -0.014951137772083182, -0.00888986570231973, -0.005482083849763833]'', 'b'-3.1431347263915326'', 'b'[-1.0794415416798357, -1.890371757896165, -2.0910424533583156, -2.6109179126442243, -3.0943445622221004]'', 'b'-2.145742267474991'', 'b'[0.35505534254443205, 0.6217905890407339, 0.6877962037635699, 0.85879625531796, 1.0178073810097388]'', 'b'60'', 'b'0.18489350031512233'', 'b"['Adenocarcinoma', 'Aged', 'Biomarkers, Tumor', 'CA-19-9 Antigen', 'Electroporation', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local', 'Pancreatic Neoplasms', 'Prognosis', 'Survival Rate']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'57'', 'b'Integrated Small Dense Low-density Lipoprotein Profile in Cardiovascular Disease and Cancer: A Longitudinal Study.'', 'b'Low-density lipoproteins (LDL) are a heterogeneous class of particles that differ in size and density from each other. Small dense LDL (sdLDL) particles are considered more atherogenic than larger particles. The aim of the study was to evaluate serum levels of sdLDL in patients who died from cardiovascular diseases (CVD) or cancer in a cohort of patients followed up in the De Bellis Research Hospital for 20 years.A total of 75 participants who died of cancer and 87 who died of CVD were enrolled and they were matched for age and sex with 135 healthy controls, i.e. without CVD or cancer and are still alive.Patients who died from cancer had the highest value of LDL IV subfraction (0.25\xc2\xb11.16), followed by those who died from CVD (0.17\xc2\xb10.96).The integrated profile of sdLDL between CVD and cancer suggests that therapeutic modulation of sdLDL may be associated with a risk reduction for these diseases.'', 'b'758'', 'b'150'', 'b"[('died', 10), ('cvd', 10), ('cancer', 10), ('sdldl', 8), ('ldl', 6), ('particles', 6), ('patients', 4), ('diseases', 4), ('followed', 4), ('lipoproteins', 2), ('heterogeneous', 2), ('class', 2), ('differ', 2), ('size', 2), ('density', 2), ('small', 2), ('dense', 2), ('considered', 2), ('atherogenic', 2), ('larger', 2), ('aim', 2), ('study', 2), ('evaluate', 2), ('serum', 2), ('levels', 2), ('cardiovascular', 2), ('cohort', 2), ('de', 2), ('bellis', 2), ('research', 2), ('hospital', 2), ('total', 2), ('participants', 2), ('enrolled', 2), ('matched', 2), ('age', 2), ('sex', 2), ('healthy', 2), ('controls', 2), ('without', 2), ('still', 2), ('highest', 2), ('value', 2), ('iv', 2), ('subfraction', 2), ('integrated', 2), ('profile', 2), ('suggests', 2), ('therapeutic', 2), ('modulation', 2), ('may', 2), ('associated', 2), ('risk', 2), ('reduction', 2)]"', 'b"[('of', 10), ('and', 6), ('(', 5), (')', 5), ('who', 5), ('die', 5), ('cvd', 5), ('cancer', 5), ('in', 4), ('from', 4), ('.', 4), ('sdldl', 4), ('the', 4), ('ldl', 3), ('are', 3), ('a', 3), ('particl', 3), ('for', 3), ('that', 2), ('patient', 2), ('diseas', 2), ('or', 2), ('follow', 2), ('were', 2), ('with', 2), (',', 2), ('low-dens', 1), ('lipoprotein', 1), ('heterogen', 1), ('class', 1), ('differ', 1), ('size', 1), ('densiti', 1), ('each', 1), ('other', 1), ('small', 1), ('dens', 1), ('consid', 1), ('more', 1), ('atherogen', 1), ('than', 1), ('larger', 1), ('aim', 1), ('studi', 1), ('wa', 1), ('to', 1), ('evalu', 1), ('serum', 1), ('level', 1), ('cardiovascular', 1), ('cohort', 1), ('up', 1), ('De', 1), ('belli', 1), ('research', 1), ('hospit', 1), ('20', 1), ('years.a', 1), ('total', 1), ('75', 1), ('particip', 1), ('87', 1), ('enrol', 1), ('they', 1), ('match', 1), ('age', 1), ('sex', 1), ('135', 1), ('healthi', 1), ('control', 1), ('i.e', 1), ('without', 1), ('still', 1), ('alive.pati', 1), ('had', 1), ('highest', 1), ('valu', 1), ('IV', 1), ('subfract', 1), ('0.25\xc2\xb11.16', 1), ('by', 1), ('those', 1), ('0.17\xc2\xb10.96', 1), ('.the', 1), ('integr', 1), ('profil', 1), ('between', 1), ('suggest', 1), ('therapeut', 1), ('modul', 1), ('may', 1), ('be', 1), ('associ', 1), ('risk', 1), ('reduct', 1), ('these', 1)]"', 'b'4'', 'b"('died', 'cvd', 'cancer', 'sdldl', 'ldl', 'particles', 'patients', 'diseases', 'followed', 'lipoproteins', 'heterogeneous', 'class', 'differ', 'size', 'density', 'small', 'dense', 'considered', 'atherogenic', 'larger', 'aim', 'study', 'evaluate', 'serum', 'levels', 'cardiovascular', 'cohort', 'de', 'bellis', 'research', 'hospital', 'total', 'participants', 'enrolled', 'matched', 'age', 'sex', 'healthy', 'controls', 'without', 'still', 'highest', 'value', 'iv', 'subfraction', 'integrated', 'profile', 'suggests', 'therapeutic', 'modulation', 'may', 'associated', 'risk', 'reduction')"', 'b'(10, 10, 10, 8, 6, 6, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.008173538191233507'', 'b'[-0.05607870610353548, -0.03058838514738299, -0.013458889464848516, -0.007824935735377044, -0.005801245458986429, -0.004427266271331749]'', 'b'-3.394449154672439'', 'b'[-0.791759469228055, -1.3978952727983707, -2.2188758248682006, -2.7612001156935624, -3.060443010546419, -3.330733340286331]'', 'b'-2.247317444117154'', 'b'[0.26640507947718806, 0.4703529490006883, 0.7465901115781421, 0.9290671786861647, 1.0297541048103118, 1.1206992965949851]'', 'b'10'', 'b'0.06337564134153517'', 'b"['Adult', 'Aged', 'Biomarkers', 'Cardiovascular Diseases', 'Case-Control Studies', 'Female', 'Follow-Up Studies', 'Humans', 'Lipoproteins, LDL', 'Longitudinal Studies', 'Male', 'Middle Aged', 'Neoplasms', 'Prognosis', 'Risk Factors']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'58'', 'b'Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.'', 'b'In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model.A patient CRC tumor previously established in nude mice was implanted subcutaneously in transgenic green fluorescence protein (GFP)-expressing nude mice. Harvested tumor fragments were transplanted orthotopically in non-transgenic nude mice. Mice were randomized into three groups: Group 1 (G1), untreated-control; Group 2 (G2), OXA+5-FU; Group 3 (G3), TRAB+OXA+5-FU. Tumor width, length, and mouse body weight were measured twice a week.Both treatment groups inhibited tumor growth compared to the untreated control group. The combination of TRAB, OXA and 5-FU was significantly more efficacious than OXA+5-FU and arrested tumor growth. No significant changes were observed in body-weight in any of the three groups.TRAB, OXA and 5-FU combination has clinical potential for this and other CRC patients.'', 'b'882'', 'b'142'', 'b"[('tumor', 10), ('mice', 8), ('group', 8), ('oxa', 6), ('crc', 6), ('nude', 6), ('trab', 4), ('mouse', 4), ('three', 4), ('groups', 4), ('growth', 4), ('combination', 4), ('present', 2), ('study', 2), ('aimed', 2), ('determine', 2), ('efficacy', 2), ('trabectedin', 2), ('combined', 2), ('oxaliplatinum', 2), ('colorectal', 2), ('cancer', 2), ('orthotopic', 2), ('xenograft', 2), ('pdox', 2), ('patient', 2), ('previously', 2), ('established', 2), ('implanted', 2), ('subcutaneously', 2), ('transgenic', 2), ('green', 2), ('fluorescence', 2), ('protein', 2), ('gfp', 2), ('harvested', 2), ('fragments', 2), ('transplanted', 2), ('orthotopically', 2), ('randomized', 2), ('width', 2), ('length', 2), ('body', 2), ('weight', 2), ('measured', 2), ('twice', 2), ('treatment', 2), ('inhibited', 2), ('compared', 2), ('untreated', 2), ('control', 2), ('significantly', 2), ('efficacious', 2), ('arrested', 2), ('significant', 2), ('changes', 2), ('observed', 2), ('clinical', 2), ('potential', 2), ('patients', 2)]"', 'b"[('(', 9), (')', 9), (',', 8), ('.', 6), ('group', 6), ('the', 5), ('tumor', 5), ('in', 5), ('and', 5), ('mice', 4), ('were', 4), ('of', 3), ('combin', 3), ('oxa', 3), ('5-fu', 3), ('crc', 3), ('nude', 3), ('to', 2), ('efficaci', 2), ('trab', 2), ('a', 2), ('orthotop', 2), ('mous', 2), ('patient', 2), ('wa', 2), ('three', 2), (';', 2), ('oxa+5-fu', 2), ('growth', 2), ('In', 1), ('present', 1), ('studi', 1), ('we', 1), ('aim', 1), ('determin', 1), ('trabectedin', 1), ('with', 1), ('oxaliplatinum', 1), ('+5-fluorouracil', 1), ('on', 1), ('colorect', 1), ('cancer', 1), ('patient-deriv', 1), ('xenograft', 1), ('pdox', 1), ('model.a', 1), ('previous', 1), ('establish', 1), ('implant', 1), ('subcutan', 1), ('transgen', 1), ('green', 1), ('fluoresc', 1), ('protein', 1), ('gfp', 1), ('-express', 1), ('harvest', 1), ('fragment', 1), ('transplant', 1), ('non-transgen', 1), ('random', 1), ('into', 1), (':', 1), ('1', 1), ('G1', 1), ('untreated-control', 1), ('2', 1), ('G2', 1), ('3', 1), ('G3', 1), ('trab+oxa+5-fu', 1), ('width', 1), ('length', 1), ('bodi', 1), ('weight', 1), ('measur', 1), ('twice', 1), ('week.both', 1), ('treatment', 1), ('inhibit', 1), ('compar', 1), ('untreat', 1), ('control', 1), ('significantli', 1), ('more', 1), ('than', 1), ('arrest', 1), ('No', 1), ('signific', 1), ('chang', 1), ('observ', 1), ('body-weight', 1), ('ani', 1), ('groups.trab', 1), ('ha', 1), ('clinic', 1), ('potenti', 1), ('for', 1), ('thi', 1), ('other', 1)]"', 'b'6'', 'b"('tumor', 'mice', 'group', 'oxa', 'crc', 'nude', 'trab', 'mouse', 'three', 'groups', 'growth', 'combination', 'present', 'study', 'aimed', 'determine', 'efficacy', 'trabectedin', 'combined', 'oxaliplatinum', 'colorectal', 'cancer', 'orthotopic', 'xenograft', 'pdox', 'patient', 'previously', 'established', 'implanted', 'subcutaneously', 'transgenic', 'green', 'fluorescence', 'protein', 'gfp', 'harvested', 'fragments', 'transplanted', 'orthotopically', 'randomized', 'width', 'length', 'body', 'weight', 'measured', 'twice', 'treatment', 'inhibited', 'compared', 'untreated', 'control', 'significantly', 'efficacious', 'arrested', 'significant', 'changes', 'observed', 'clinical', 'potential', 'patients')"', 'b'(10, 8, 8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.03342988990481222'', 'b'[-0.03821810092781894, -0.009247312811523384, -0.006644036928435393, -0.005354895434858376, -0.0044293579522902615, -0.003554408099296932]'', 'b'-1.9549102790337356'', 'b'[-1.1972245773362196, -2.6375861597263857, -2.9889840465642745, -3.2046926193909657, -3.394449154672439, -3.634728988229636]'', 'b'-1.2547667597161636'', 'b'[0.4118008475691091, 0.9268422028807136, 1.0723817007293739, 1.149773189805968, 1.2178536589083593, 1.3306889459148146]'', 'b'89'', 'b'0.1392903247328075'', 'b"['Animals', 'Antineoplastic Combined Chemotherapy Protocols', 'Apoptosis', 'Body Weight', 'Cell Proliferation', 'Colorectal Neoplasms', 'Disease Models, Animal', 'Fluorouracil', 'Humans', 'Mice', 'Mice, Nude', 'Oxaliplatin', 'Trabectedin', 'Tumor Cells, Cultured', 'Xenograft Model Antitumor Assays']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'59'', 'b'Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines '', 'b'Lenvatinib is a potent inhibitor of receptor tyrosine kinases, targeting vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), KIT, and RET. Here, we investigated the antiproliferative effects of lenvatinib in liver cancer cells in vitro and in vivo.Eleven hepatocellular carcinoma cell lines and two combined hepatocellular_cholangiocarcinoma cell lines were treated with 0-30 \xce\xbcM lenvatinib. Cell growth, apoptosis and the expression of FGFR1-4, FGF19, fibroblast growth factor receptor substrate (FRS)2\xce\xb1 and RET were examined. Two HCC cell lines were subcutaneously implanted on nude mice and mice were treated with 3, 10, 30 mg_kg_day of lenvatinib or vehicle for 14 consecutive days. Tumor volume was measured every 3 days. Mice were sacrificed on day 15 and tumors were processed for histological examination. Blood vessels, microvessel density, necrosis, and apoptosis were also examined.Lenvatinib dose- and time-dependently inhibited growth of all cell lines; however, sensitivity to lenvatinib varied. Apoptosis was not observed in any cell line, and expression of FGFR1, -2, -3 and -4, FGF19, FRS2\xce\xb1, and RET were observed in these cell lines. Cell lines with high expression of these factors showed higher response to lenvatinib. In mice, lenvatinib dose-dependently suppressed tumor growth. Blood vessels and microvessel density were significantly reduced and the rate of necrosis was significantly increased by lenvatinib; apoptosis was not observed.Antiproliferative effects of lenvatinib on liver cancer cells were observed in vitro and in vivo. Lenvatinib may suppress tumor formation by inhibiting angiogenesis, and via an additional direct antiproliferative effect in some liver cancer cells.'', 'b'1510'', 'b'249'', 'b"[('lenvatinib', 20), ('cell', 16), ('growth', 12), ('lines', 12), ('apoptosis', 8), ('mice', 8), ('factor', 6), ('ret', 6), ('liver', 6), ('cancer', 6), ('cells', 6), ('expression', 6), ('tumor', 6), ('observed', 6), ('receptor', 4), ('receptors', 4), ('fibroblast', 4), ('antiproliferative', 4), ('effects', 4), ('vitro', 4), ('two', 4), ('treated', 4), ('days', 4), ('blood', 4), ('vessels', 4), ('microvessel', 4), ('density', 4), ('necrosis', 4), ('significantly', 4), ('potent', 2), ('inhibitor', 2), ('tyrosine', 2), ('kinases', 2), ('targeting', 2), ('vascular', 2), ('endothelial', 2), ('kit', 2), ('investigated', 2), ('hepatocellular', 2), ('carcinoma', 2), ('combined', 2), ('\xce\xbcm', 2), ('substrate', 2), ('frs', 2), ('examined', 2), ('hcc', 2), ('subcutaneously', 2), ('implanted', 2), ('nude', 2), ('vehicle', 2), ('consecutive', 2), ('volume', 2), ('measured', 2), ('every', 2), ('sacrificed', 2), ('day', 2), ('tumors', 2), ('processed', 2), ('histological', 2), ('examination', 2), ('also', 2), ('inhibited', 2), ('however', 2), ('sensitivity', 2), ('varied', 2), ('line', 2), ('high', 2), ('factors', 2), ('showed', 2), ('higher', 2), ('response', 2), ('suppressed', 2), ('reduced', 2), ('rate', 2), ('increased', 2), ('vivo', 2), ('may', 2), ('suppress', 2), ('formation', 2), ('inhibiting', 2), ('angiogenesis', 2), ('via', 2), ('additional', 2), ('direct', 2), ('effect', 2)]"', 'b"[(',', 22), ('and', 16), ('.', 12), ('cell', 11), ('lenvatinib', 10), ('were', 10), ('of', 9), ('in', 8), ('line', 7), ('growth', 6), ('receptor', 4), ('factor', 4), ('apoptosi', 4), ('mice', 4), ('tumor', 4), ('wa', 4), ('(', 3), (')', 3), ('ret', 3), ('the', 3), ('effect', 3), ('liver', 3), ('cancer', 3), ('with', 3), ('express', 3), ('on', 3), ('day', 3), ('observ', 3), ('fibroblast', 2), ('fgfr1-4', 2), ('antiprolif', 2), ('vitro', 2), ('two', 2), ('treat', 2), ('fgf19', 2), ('examin', 2), ('3', 2), ('for', 2), ('blood', 2), ('vessel', 2), ('microvessel', 2), ('densiti', 2), ('necrosi', 2), ('inhibit', 2), (';', 2), ('to', 2), ('not', 2), ('these', 2), ('suppress', 2), ('significantli', 2), ('by', 2), ('is', 1), ('a', 1), ('potent', 1), ('inhibitor', 1), ('tyrosin', 1), ('kinas', 1), ('target', 1), ('vascular', 1), ('endotheli', 1), ('vegfr1-3', 1), ('kit', 1), ('here', 1), ('we', 1), ('investig', 1), ('vivo.eleven', 1), ('hepatocellular', 1), ('carcinoma', 1), ('combin', 1), ('hepatocellular_cholangiocarcinoma', 1), ('0-30', 1), ('\xce\xbcM', 1), ('substrat', 1), ('fr', 1), ('2\xce\xb1', 1), ('hcc', 1), ('subcutan', 1), ('implant', 1), ('nude', 1), ('10', 1), ('30', 1), ('mg_kg_day', 1), ('or', 1), ('vehicl', 1), ('14', 1), ('consecut', 1), ('volum', 1), ('measur', 1), ('everi', 1), ('sacrif', 1), ('15', 1), ('process', 1), ('histolog', 1), ('also', 1), ('examined.lenvatinib', 1), ('dose-', 1), ('time-depend', 1), ('all', 1), ('howev', 1), ('sensit', 1), ('vari', 1), ('ani', 1), ('fgfr1', 1), ('-2', 1), ('-3', 1), ('-4', 1), ('frs2\xce\xb1', 1), ('high', 1), ('show', 1), ('higher', 1), ('respons', 1), ('In', 1), ('dose-depend', 1), ('reduc', 1), ('rate', 1), ('increas', 1), ('observed.antiprolif', 1), ('vivo', 1), ('may', 1), ('format', 1), ('angiogenesi', 1), ('via', 1), ('an', 1), ('addit', 1), ('direct', 1), ('some', 1)]"', 'b'12'', 'b"('lenvatinib', 'cell', 'growth', 'lines', 'apoptosis', 'mice', 'factor', 'ret', 'liver', 'cancer', 'cells', 'expression', 'tumor', 'observed', 'receptor', 'receptors', 'fibroblast', 'antiproliferative', 'effects', 'vitro', 'two', 'treated', 'days', 'blood', 'vessels', 'microvessel', 'density', 'necrosis', 'significantly', 'potent', 'inhibitor', 'tyrosine', 'kinases', 'targeting', 'vascular', 'endothelial', 'kit', 'investigated', 'hepatocellular', 'carcinoma', 'combined', '\xce\xbcm', 'substrate', 'frs', 'examined', 'hcc', 'subcutaneously', 'implanted', 'nude', 'vehicle', 'consecutive', 'volume', 'measured', 'every', 'sacrificed', 'day', 'tumors', 'processed', 'histological', 'examination', 'also', 'inhibited', 'however', 'sensitivity', 'varied', 'line', 'high', 'factors', 'showed', 'higher', 'response', 'suppressed', 'reduced', 'rate', 'increased', 'vivo', 'may', 'suppress', 'formation', 'inhibiting', 'angiogenesis', 'via', 'additional', 'direct', 'effect')"', 'b'(20, 16, 12, 12, 8, 8, 6, 6, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.03937033284026678'', 'b'[-0.3733767935566639, -0.04228856017001677, -0.016500660893989934, -0.011931247107961953, -0.009574457555771935, -0.0034337652067619783, -0.0032906916564802292]'', 'b'-1.760009940032921'', 'b'[1.0, -1.1972245773362196, -2.1570004211501135, -2.481240089335692, -2.7013019741124937, -3.74493212836325, -3.787491742782046]'', 'b'-1.0948163988321302'', 'b'[-0.3733767935566639, 0.4556601321813506, 0.8364104136934001, 0.9621393808014862, 1.047471794406752, 1.4788100290667632, 1.4956160972352768]'', 'b'83'', 'b'0.12726973459428803'', 'b"['Animals', 'Antineoplastic Agents', 'Apoptosis', 'Biomarkers, Tumor', 'Carcinoma, Hepatocellular', 'Cell Proliferation', 'Female', 'Humans', 'In Vitro Techniques', 'Liver Neoplasms', 'Mice', 'Mice, Inbred BALB C', 'Mice, Nude', 'Phenylurea Compounds', 'Quinolines', 'Tumor Cells, Cultured', 'Xenograft Model Antitumor Assays']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'60'', 'b'Identification of Matrix Metalloproteinase 11 as a Prognostic Biomarker in Pancreatic Cancer.'', 'b"The aim of this study was to investigate matrix metalloproteinase 11 (MMP11) as a promising biomarker in human pancreatic cancer.A consecutive eliminating method was used to select biomarker candidates in pancreatic cancer. mRNA and protein expression levels of candidates were determined in tissues and whole blood samples of healthy donors and pancreatic cancer patients. The prognostic value of MMP11 was determined using various data-sets and Liptak's Z analysis.Analysis using Gene Expression Omnibus (GEO) database showed significantly higher MMP11 mRNA expression in pancreatic cancer tissues compared to that in various normal tissues. MMP11 protein was specifically expressed in pancreatic cancer tissues, but not in various normal or other cancer tissues. Secreted MMP11 levels could be measured using easily accessible techniques and whole blood samples of pancreatic cancer. In addition, high levels of MMP11 were associated with poor prognosis of pancreatic cancer patients.MMP11 may be a promising prognostic biomarker for pancreatic cancer patients."', 'b'914'', 'b'151'', 'b"[('pancreatic', 16), ('cancer', 16), ('tissues', 10), ('biomarker', 6), ('expression', 6), ('levels', 6), ('using', 6), ('various', 6), ('promising', 4), ('candidates', 4), ('mrna', 4), ('protein', 4), ('determined', 4), ('whole', 4), ('blood', 4), ('samples', 4), ('patients', 4), ('prognostic', 4), ('normal', 4), ('aim', 2), ('study', 2), ('investigate', 2), ('matrix', 2), ('metalloproteinase', 2), ('human', 2), ('consecutive', 2), ('eliminating', 2), ('method', 2), ('used', 2), ('select', 2), ('healthy', 2), ('donors', 2), ('value', 2), ('liptak', 2), ('z', 2), ('gene', 2), ('omnibus', 2), ('geo', 2), ('database', 2), ('showed', 2), ('significantly', 2), ('higher', 2), ('compared', 2), ('specifically', 2), ('expressed', 2), ('secreted', 2), ('could', 2), ('measured', 2), ('easily', 2), ('accessible', 2), ('techniques', 2), ('addition', 2), ('high', 2), ('associated', 2), ('poor', 2), ('prognosis', 2), ('may', 2)]"', 'b'[(\'pancreat\', 8), (\'cancer\', 8), (\'of\', 7), (\'in\', 7), (\'mmp11\', 6), (\'.\', 6), (\'and\', 5), (\'tissu\', 5), (\'wa\', 4), (\'use\', 4), (\'express\', 4), (\'to\', 3), (\'biomark\', 3), (\'level\', 3), (\'variou\', 3), (\'the\', 2), (\'(\', 2), (\')\', 2), (\'a\', 2), (\'promis\', 2), (\'candid\', 2), (\'mrna\', 2), (\'protein\', 2), (\'were\', 2), (\'determin\', 2), (\'whole\', 2), (\'blood\', 2), (\'sampl\', 2), (\'patient\', 2), (\'prognost\', 2), (\'normal\', 2), (\',\', 2), (\'be\', 2), (\'aim\', 1), (\'thi\', 1), (\'studi\', 1), (\'investig\', 1), (\'matrix\', 1), (\'metalloproteinas\', 1), (\'11\', 1), (\'as\', 1), (\'human\', 1), (\'cancer.a\', 1), (\'consecut\', 1), (\'elimin\', 1), (\'method\', 1), (\'select\', 1), (\'healthi\', 1), (\'donor\', 1), (\'valu\', 1), (\'data-set\', 1), (\'liptak\', 1), ("\'s", 1), (\'Z\', 1), (\'analysis.analysi\', 1), (\'gene\', 1), (\'omnibu\', 1), (\'geo\', 1), (\'databas\', 1), (\'show\', 1), (\'significantli\', 1), (\'higher\', 1), (\'compar\', 1), (\'that\', 1), (\'specif\', 1), (\'but\', 1), (\'not\', 1), (\'or\', 1), (\'other\', 1), (\'secret\', 1), (\'could\', 1), (\'measur\', 1), (\'easili\', 1), (\'access\', 1), (\'techniqu\', 1), (\'In\', 1), (\'addit\', 1), (\'high\', 1), (\'associ\', 1), (\'with\', 1), (\'poor\', 1), (\'prognosi\', 1), (\'patients.mmp11\', 1), (\'may\', 1), (\'for\', 1)]'', 'b'6'', 'b"('pancreatic', 'cancer', 'tissues', 'biomarker', 'expression', 'levels', 'using', 'various', 'promising', 'candidates', 'mrna', 'protein', 'determined', 'whole', 'blood', 'samples', 'patients', 'prognostic', 'normal', 'aim', 'study', 'investigate', 'matrix', 'metalloproteinase', 'human', 'consecutive', 'eliminating', 'method', 'used', 'select', 'healthy', 'donors', 'value', 'liptak', 'z', 'gene', 'omnibus', 'geo', 'database', 'showed', 'significantly', 'higher', 'compared', 'specifically', 'expressed', 'secreted', 'could', 'measured', 'easily', 'accessible', 'techniques', 'addition', 'high', 'associated', 'poor', 'prognosis', 'may')"', 'b'(16, 16, 10, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.03964691927757325'', 'b'[-0.0, -0.0, -0.017476094173944343, -0.011053182125928821]'', 'b'-1.7212954278522306'', 'b'[1, 1, -2.1354942159291497, -2.6109179126442243]'', 'b'-1.0373097253898822'', 'b'[-0.3948829987776275, -0.3948829987776275, 0.8583622545862989, 1.0677811945593414]'', 'b'56'', 'b'0.18489350031512233'', 'b"['Animals', 'Apoptosis', 'Biomarkers, Tumor', 'Case-Control Studies', 'Cell Proliferation', 'Follow-Up Studies', 'Humans', 'Matrix Metalloproteinase 11', 'Mice', 'Mice, Inbred BALB C', 'Mice, Nude', 'Pancreatic Neoplasms', 'Prognosis', 'Survival Rate', 'Tumor Cells, Cultured', 'Xenograft Model Antitumor Assays']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'61'', 'b'Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer.'', 'b'The presence of ascites in ovarian cancer patients is considered a negative prognostic factor. The underlying mechanisms are not clearly understood.The amount of ascites was evaluated, preferably, using diffusion-weighted MRI at primary diagnosis in a retrospective cohort of 214 women with ovarian cancer, in an ordinal manner (amount of ascites: none, limited, moderate, abundant). In a prospective cohort comprising 45 women with ovarian cancer, IL-10 (interleukin), VEGF (vascular endothelial growth factor), TGF-\xce\xb2 (transforming growth factor) and CCL-2 [chemokine (C-C) motif ligand 2] were measured at diagnosis (and at interval debulking, when available).Gradually increasing amounts of ascites were correlated significantly, even after correction for FIGO stage, with reduced survival (p<0.0001) and stronger immunosuppression (IL10 and VEGF). Neoadjuvant chemotherapy reduced immunosuppression, which was observed as a reduction in CCL-2, IL-10 and VEGF.The amount of ascites is an independent predictor of survival and correlates with increased immunosuppression.'', 'b'930'', 'b'144'', 'b"[('ascites', 10), ('ovarian', 6), ('cancer', 6), ('factor', 6), ('amount', 6), ('immunosuppression', 6), ('diagnosis', 4), ('cohort', 4), ('women', 4), ('vegf', 4), ('growth', 4), ('reduced', 4), ('survival', 4), ('presence', 2), ('patients', 2), ('considered', 2), ('negative', 2), ('prognostic', 2), ('underlying', 2), ('mechanisms', 2), ('clearly', 2), ('evaluated', 2), ('preferably', 2), ('using', 2), ('mri', 2), ('primary', 2), ('retrospective', 2), ('ordinal', 2), ('manner', 2), ('none', 2), ('limited', 2), ('moderate', 2), ('abundant', 2), ('prospective', 2), ('comprising', 2), ('interleukin', 2), ('vascular', 2), ('endothelial', 2), ('transforming', 2), ('chemokine', 2), ('motif', 2), ('ligand', 2), ('measured', 2), ('interval', 2), ('debulking', 2), ('available', 2), ('increasing', 2), ('amounts', 2), ('correlated', 2), ('significantly', 2), ('even', 2), ('correction', 2), ('figo', 2), ('stage', 2), ('p', 2), ('stronger', 2), ('neoadjuvant', 2), ('chemotherapy', 2), ('observed', 2), ('reduction', 2), ('independent', 2), ('predictor', 2), ('correlates', 2), ('increased', 2)]"', 'b"[(',', 14), ('(', 8), (')', 8), ('of', 7), ('and', 6), ('ascit', 5), ('in', 4), ('a', 4), ('.', 4), ('amount', 4), ('with', 4), ('ovarian', 3), ('cancer', 3), ('factor', 3), ('at', 3), ('immunosuppress', 3), ('the', 2), ('is', 2), ('wa', 2), ('diagnosi', 2), ('cohort', 2), ('women', 2), ('an', 2), ('il-10', 2), ('vegf', 2), ('growth', 2), ('ccl-2', 2), ('were', 2), ('increas', 2), ('correl', 2), ('reduc', 2), ('surviv', 2), ('presenc', 1), ('patient', 1), ('consid', 1), ('neg', 1), ('prognost', 1), ('underli', 1), ('mechan', 1), ('are', 1), ('not', 1), ('clearli', 1), ('understood.th', 1), ('evalu', 1), ('prefer', 1), ('use', 1), ('diffusion-weight', 1), ('mri', 1), ('primari', 1), ('retrospect', 1), ('214', 1), ('ordin', 1), ('manner', 1), (':', 1), ('none', 1), ('limit', 1), ('moder', 1), ('abund', 1), ('In', 1), ('prospect', 1), ('compris', 1), ('45', 1), ('interleukin', 1), ('vascular', 1), ('endotheli', 1), ('tgf-\xce\xb2', 1), ('transform', 1), ('[', 1), ('chemokin', 1), ('c-c', 1), ('motif', 1), ('ligand', 1), ('2', 1), (']', 1), ('measur', 1), ('interv', 1), ('debulk', 1), ('when', 1), ('avail', 1), ('.gradual', 1), ('significantli', 1), ('even', 1), ('after', 1), ('correct', 1), ('for', 1), ('figo', 1), ('stage', 1), ('p', 1), ('<', 1), ('0.0001', 1), ('stronger', 1), ('il10', 1), ('neoadjuv', 1), ('chemotherapi', 1), ('which', 1), ('observ', 1), ('as', 1), ('reduct', 1), ('vegf.th', 1), ('independ', 1), ('predictor', 1)]"', 'b'4'', 'b"('ascites', 'ovarian', 'cancer', 'factor', 'amount', 'immunosuppression', 'diagnosis', 'cohort', 'women', 'vegf', 'growth', 'reduced', 'survival', 'presence', 'patients', 'considered', 'negative', 'prognostic', 'underlying', 'mechanisms', 'clearly', 'evaluated', 'preferably', 'using', 'mri', 'primary', 'retrospective', 'ordinal', 'manner', 'none', 'limited', 'moderate', 'abundant', 'prospective', 'comprising', 'interleukin', 'vascular', 'endothelial', 'transforming', 'chemokine', 'motif', 'ligand', 'measured', 'interval', 'debulking', 'available', 'increasing', 'amounts', 'correlated', 'significantly', 'even', 'correction', 'figo', 'stage', 'p', 'stronger', 'neoadjuvant', 'chemotherapy', 'observed', 'reduction', 'independent', 'predictor', 'correlates', 'increased')"', 'b'(10, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.007116889976200232'', 'b'[-0.02599602549846624, -0.01808419165110695, -0.014854871713409278, -0.009453100181260452, -0.007998777076451151, -0.006708651741539675]'', 'b'-3.4067192472642533'', 'b'[-1.7725887222397811, -2.1354942159291497, -2.332204510175204, -2.784189633918261, -2.951243718581427, -3.1271343850450917]'', 'b'-1.988110177131836'', 'b'[0.7372841859462247, 0.8882297934259415, 0.970048766626441, 1.158045835454472, 1.2275297113668977, 1.300689043372204]'', 'b'89'', 'b'0.17055052382944416'', 'b"['Adenocarcinoma, Clear Cell', 'Adenocarcinoma, Mucinous', 'Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols', 'Ascites', 'Cystadenocarcinoma, Serous', 'Endometrial Neoplasms', 'Female', 'Follow-Up Studies', 'Humans', 'Immunosuppression', 'Middle Aged', 'Neoadjuvant Therapy', 'Neoplasm Invasiveness', 'Ovarian Neoplasms', 'Prognosis', 'Prospective Studies', 'Retrospective Studies', 'Survival Rate', 'Young Adult']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'61'', 'b'Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer.'', 'b'The presence of ascites in ovarian cancer patients is considered a negative prognostic factor. The underlying mechanisms are not clearly understood.The amount of ascites was evaluated, preferably, using diffusion-weighted MRI at primary diagnosis in a retrospective cohort of 214 women with ovarian cancer, in an ordinal manner (amount of ascites: none, limited, moderate, abundant). In a prospective cohort comprising 45 women with ovarian cancer, IL-10 (interleukin), VEGF (vascular endothelial growth factor), TGF-\xce\xb2 (transforming growth factor) and CCL-2 [chemokine (C-C) motif ligand 2] were measured at diagnosis (and at interval debulking, when available).Gradually increasing amounts of ascites were correlated significantly, even after correction for FIGO stage, with reduced survival (p<0.0001) and stronger immunosuppression (IL10 and VEGF). Neoadjuvant chemotherapy reduced immunosuppression, which was observed as a reduction in CCL-2, IL-10 and VEGF.The amount of ascites is an independent predictor of survival and correlates with increased immunosuppression.'', 'b'930'', 'b'144'', 'b"[('ascites', 10), ('ovarian', 6), ('cancer', 6), ('factor', 6), ('amount', 6), ('immunosuppression', 6), ('diagnosis', 4), ('cohort', 4), ('women', 4), ('vegf', 4), ('growth', 4), ('reduced', 4), ('survival', 4), ('presence', 2), ('patients', 2), ('considered', 2), ('negative', 2), ('prognostic', 2), ('underlying', 2), ('mechanisms', 2), ('clearly', 2), ('evaluated', 2), ('preferably', 2), ('using', 2), ('mri', 2), ('primary', 2), ('retrospective', 2), ('ordinal', 2), ('manner', 2), ('none', 2), ('limited', 2), ('moderate', 2), ('abundant', 2), ('prospective', 2), ('comprising', 2), ('interleukin', 2), ('vascular', 2), ('endothelial', 2), ('transforming', 2), ('chemokine', 2), ('motif', 2), ('ligand', 2), ('measured', 2), ('interval', 2), ('debulking', 2), ('available', 2), ('increasing', 2), ('amounts', 2), ('correlated', 2), ('significantly', 2), ('even', 2), ('correction', 2), ('figo', 2), ('stage', 2), ('p', 2), ('stronger', 2), ('neoadjuvant', 2), ('chemotherapy', 2), ('observed', 2), ('reduction', 2), ('independent', 2), ('predictor', 2), ('correlates', 2), ('increased', 2)]"', 'b"[(',', 14), ('(', 8), (')', 8), ('of', 7), ('and', 6), ('ascit', 5), ('in', 4), ('a', 4), ('.', 4), ('amount', 4), ('with', 4), ('ovarian', 3), ('cancer', 3), ('factor', 3), ('at', 3), ('immunosuppress', 3), ('the', 2), ('is', 2), ('wa', 2), ('diagnosi', 2), ('cohort', 2), ('women', 2), ('an', 2), ('il-10', 2), ('vegf', 2), ('growth', 2), ('ccl-2', 2), ('were', 2), ('increas', 2), ('correl', 2), ('reduc', 2), ('surviv', 2), ('presenc', 1), ('patient', 1), ('consid', 1), ('neg', 1), ('prognost', 1), ('underli', 1), ('mechan', 1), ('are', 1), ('not', 1), ('clearli', 1), ('understood.th', 1), ('evalu', 1), ('prefer', 1), ('use', 1), ('diffusion-weight', 1), ('mri', 1), ('primari', 1), ('retrospect', 1), ('214', 1), ('ordin', 1), ('manner', 1), (':', 1), ('none', 1), ('limit', 1), ('moder', 1), ('abund', 1), ('In', 1), ('prospect', 1), ('compris', 1), ('45', 1), ('interleukin', 1), ('vascular', 1), ('endotheli', 1), ('tgf-\xce\xb2', 1), ('transform', 1), ('[', 1), ('chemokin', 1), ('c-c', 1), ('motif', 1), ('ligand', 1), ('2', 1), (']', 1), ('measur', 1), ('interv', 1), ('debulk', 1), ('when', 1), ('avail', 1), ('.gradual', 1), ('significantli', 1), ('even', 1), ('after', 1), ('correct', 1), ('for', 1), ('figo', 1), ('stage', 1), ('p', 1), ('<', 1), ('0.0001', 1), ('stronger', 1), ('il10', 1), ('neoadjuv', 1), ('chemotherapi', 1), ('which', 1), ('observ', 1), ('as', 1), ('reduct', 1), ('vegf.th', 1), ('independ', 1), ('predictor', 1)]"', 'b'4'', 'b"('ascites', 'ovarian', 'cancer', 'factor', 'amount', 'immunosuppression', 'diagnosis', 'cohort', 'women', 'vegf', 'growth', 'reduced', 'survival', 'presence', 'patients', 'considered', 'negative', 'prognostic', 'underlying', 'mechanisms', 'clearly', 'evaluated', 'preferably', 'using', 'mri', 'primary', 'retrospective', 'ordinal', 'manner', 'none', 'limited', 'moderate', 'abundant', 'prospective', 'comprising', 'interleukin', 'vascular', 'endothelial', 'transforming', 'chemokine', 'motif', 'ligand', 'measured', 'interval', 'debulking', 'available', 'increasing', 'amounts', 'correlated', 'significantly', 'even', 'correction', 'figo', 'stage', 'p', 'stronger', 'neoadjuvant', 'chemotherapy', 'observed', 'reduction', 'independent', 'predictor', 'correlates', 'increased')"', 'b'(10, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.007116889976200232'', 'b'[-0.02599602549846624, -0.01808419165110695, -0.014854871713409278, -0.009453100181260452, -0.007998777076451151, -0.006708651741539675]'', 'b'-3.4067192472642533'', 'b'[-1.7725887222397811, -2.1354942159291497, -2.332204510175204, -2.784189633918261, -2.951243718581427, -3.1271343850450917]'', 'b'-1.988110177131836'', 'b'[0.7372841859462247, 0.8882297934259415, 0.970048766626441, 1.158045835454472, 1.2275297113668977, 1.300689043372204]'', 'b'89'', 'b'0.17055052382944416'', 'b"['Adenocarcinoma, Clear Cell', 'Adenocarcinoma, Mucinous', 'Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols', 'Ascites', 'Cystadenocarcinoma, Serous', 'Endometrial Neoplasms', 'Female', 'Follow-Up Studies', 'Humans', 'Immunosuppression', 'Middle Aged', 'Neoadjuvant Therapy', 'Neoplasm Invasiveness', 'Ovarian Neoplasms', 'Prognosis', 'Prospective Studies', 'Retrospective Studies', 'Survival Rate', 'Young Adult']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'62'', 'b'Efficacy of Afatinib and Lapatinib Against '', 'b'Trastuzumab is the only clinically approved targeted therapy for HER2 gene-amplified gastric cancer at present. However, the clinical significance of multi-targeting tyrosine kinase inhibitors (TKIs) in HER2-positive gastric cancer remains unclear.We examined the anti-tumor activity of lapatinib and afatinib, that are reversible and irreversible TKIs, in HER2 gene-amplified trastuzumab-sensitive and - resistant gastric cancer cells (GLM-1 and GLM-1HerR2) in vitro and in vivo.Afatinib inhibited the growth of GLM-1 and GLM-1HerR2 cells in vitro more efficiently than lapatinib by inducing GAfatinib could be a potential new molecular-targeted therapy for trastuzumab-sensitive and trastuzumab-resistant HER2 gene-amplified gastric cancers.'', 'b'649'', 'b'95'', 'b"[('gastric', 8), ('cancer', 6), ('therapy', 4), ('tkis', 4), ('lapatinib', 4), ('cells', 4), ('vitro', 4), ('trastuzumab', 2), ('clinically', 2), ('approved', 2), ('targeted', 2), ('present', 2), ('however', 2), ('clinical', 2), ('significance', 2), ('tyrosine', 2), ('kinase', 2), ('inhibitors', 2), ('remains', 2), ('examined', 2), ('activity', 2), ('afatinib', 2), ('reversible', 2), ('irreversible', 2), ('resistant', 2), ('inhibited', 2), ('growth', 2), ('efficiently', 2), ('inducing', 2), ('gafatinib', 2), ('could', 2), ('potential', 2), ('new', 2), ('cancers', 2)]"', 'b"[('and', 7), ('in', 5), ('the', 4), ('gastric', 4), ('cancer', 4), ('her2', 3), ('gene-amplifi', 3), (',', 3), ('of', 3), ('clinic', 2), ('therapi', 2), ('for', 2), ('.', 2), ('(', 2), ('tki', 2), (')', 2), ('lapatinib', 2), ('trastuzumab-sensit', 2), ('cell', 2), ('glm-1', 2), ('glm-1herr2', 2), ('vitro', 2), ('trastuzumab', 1), ('is', 1), ('onli', 1), ('approv', 1), ('target', 1), ('at', 1), ('present', 1), ('howev', 1), ('signific', 1), ('multi-target', 1), ('tyrosin', 1), ('kinas', 1), ('inhibitor', 1), ('her2-posit', 1), ('remain', 1), ('unclear.w', 1), ('examin', 1), ('anti-tumor', 1), ('activ', 1), ('afatinib', 1), ('that', 1), ('are', 1), ('revers', 1), ('irrevers', 1), ('-', 1), ('resist', 1), ('vivo.afatinib', 1), ('inhibit', 1), ('growth', 1), ('more', 1), ('effici', 1), ('than', 1), ('by', 1), ('induc', 1), ('gafatinib', 1), ('could', 1), ('be', 1), ('a', 1), ('potenti', 1), ('new', 1), ('molecular-target', 1), ('trastuzumab-resist', 1)]"', 'b'2'', 'b"('gastric', 'cancer', 'therapy', 'tkis', 'lapatinib', 'cells', 'vitro', 'trastuzumab', 'clinically', 'approved', 'targeted', 'present', 'however', 'clinical', 'significance', 'tyrosine', 'kinase', 'inhibitors', 'remains', 'examined', 'activity', 'afatinib', 'reversible', 'irreversible', 'resistant', 'inhibited', 'growth', 'efficiently', 'inducing', 'gafatinib', 'could', 'potential', 'new', 'cancers')"', 'b'(8, 6, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.011450530642627023'', 'b'[-0.0, -0.04698409453555929, -0.021142842541001683, -0.012813843964243442, -0.011127811863685094, -0.009396818907111857, -0.0070476141803338934, -0.0063112962808960235, -0.005563905931842547, -0.005220454948395476, -0.004340704344523188, -0.0038294359226157485]'', 'b'-2.898599985096005'', 'b'[1, -1.1972245773362196, -1.9957322735539909, -2.4965075614664802, -2.6375861597263857, -2.8066624897703196, -3.0943445622221004, -3.2046926193909657, -3.330733340286331, -3.394449154672439, -3.59511985013459, -3.7361984483944957]'', 'b'-1.637398392202962'', 'b'[-0.41593640797545983, 0.5062546144967396, 0.8439090642749464, 1.0556653254901174, 1.1153213772684056, 1.186816461738992, 1.308464796933333, 1.3551262288818684, 1.4084234111947693, 1.4353660798135128, 1.5449298829035156, 1.631058710962554]'', 'b'33'', 'b'0.15621439723178948'', 'b"['Afatinib', 'Animals', 'Antineoplastic Combined Chemotherapy Protocols', 'Apoptosis', 'Biomarkers, Tumor', 'Cell Cycle', 'Cell Movement', 'Cell Proliferation', 'Drug Resistance, Neoplasm', 'Drug Synergism', 'Gene Amplification', 'Humans', 'Lapatinib', 'Male', 'Mice', 'Mice, Nude', 'Receptor, ErbB-2', 'Signal Transduction', 'Stomach Neoplasms', 'Trastuzumab', 'Tumor Cells, Cultured', 'Xenograft Model Antitumor Assays']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'63'', 'b'Double-negative T Cells Inhibit Proliferation and Invasion of Human Pancreatic Cancer Cells in Co-culture.'', 'b'Double-negative T (DNT) cells are phenotypically CD3DNT cells were isolated from human peripheral blood. The effect of DNT cells on proliferation and invasion of the human pancreatic cell line Panc-1 was assessed. Expression of Nrf2 and Fas in Panc-1 cells co-cultured with DNT cells was analyzed with RT-PCR. The supernatants of Panc-1 and DNT co-cultures were analyzed with ELISA for IFN-r and FasL levels.The isolated DNT cell phenotype was CD4DNT cells inhibited proliferation and invasion of human pancreatic cancer cells. The INF-r, Fas_FasL pathway and Nrf2 may be involved in the anti-cancer effect of DNT cells against human pancreatic cancer.'', 'b'553'', 'b'100'', 'b"[('cells', 16), ('dnt', 12), ('human', 8), ('pancreatic', 6), ('isolated', 4), ('effect', 4), ('proliferation', 4), ('invasion', 4), ('cell', 4), ('analyzed', 4), ('cancer', 4), ('phenotypically', 2), ('peripheral', 2), ('blood', 2), ('line', 2), ('assessed', 2), ('expression', 2), ('fas', 2), ('supernatants', 2), ('elisa', 2), ('fasl', 2), ('phenotype', 2), ('inhibited', 2), ('pathway', 2), ('may', 2), ('involved', 2)]"', 'b"[('cell', 10), ('dnt', 6), ('of', 6), ('and', 6), ('.', 5), ('the', 5), ('human', 4), ('pancreat', 3), ('panc-1', 3), ('wa', 3), ('with', 3), ('phenotyp', 2), ('were', 2), ('isol', 2), ('effect', 2), ('prolifer', 2), ('invas', 2), ('nrf2', 2), ('in', 2), ('co-cultur', 2), ('analyz', 2), ('cancer', 2), ('double-neg', 1), ('T', 1), ('(', 1), (')', 1), ('are', 1), ('cd3dnt', 1), ('from', 1), ('peripher', 1), ('blood', 1), ('on', 1), ('line', 1), ('assess', 1), ('express', 1), ('fa', 1), ('rt-pcr', 1), ('supernat', 1), ('elisa', 1), ('for', 1), ('ifn-r', 1), ('fasl', 1), ('levels.th', 1), ('cd4dnt', 1), ('inhibit', 1), ('inf-r', 1), (',', 1), ('fas_fasl', 1), ('pathway', 1), ('may', 1), ('be', 1), ('involv', 1), ('anti-canc', 1), ('against', 1)]"', 'b'5'', 'b"('cells', 'dnt', 'human', 'pancreatic', 'isolated', 'effect', 'proliferation', 'invasion', 'cell', 'analyzed', 'cancer', 'phenotypically', 'peripheral', 'blood', 'line', 'assessed', 'expression', 'fas', 'supernatants', 'elisa', 'fasl', 'phenotype', 'inhibited', 'pathway', 'may', 'involved')"', 'b'(16, 12, 8, 6, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.045545308864005825'', 'b'[-0.44333538216357427, -0.0281293383965574, -0.012344821689073379, -0.017486903592995606, -0.006025687554432507, -0.009253612228968826]'', 'b'-1.4849066497880004'', 'b'[1.0, -1.7725887222397811, -2.6109179126442243, -2.2771447329921766, -3.3567088266895917, -2.9415818076696905]'', 'b'-0.8115663839857273'', 'b'[-0.44333538216357427, 0.7977879680928655, 1.1925586948268225, 1.0552355759479957, 1.577665330865303, 1.4018432554801705]'', 'b'60'', 'b'0.14928913743861227'', 'b"['Apoptosis', 'CD4-Positive T-Lymphocytes', 'CD8-Positive T-Lymphocytes', 'Cell Proliferation', 'Coculture Techniques', 'Fas Ligand Protein', 'Humans', 'Lymphocyte Activation', 'NF-E2-Related Factor 2', 'Pancreatic Neoplasms', 'Receptors, Antigen, T-Cell, alpha-beta', 'Receptors, Interferon', 'Tumor Cells, Cultured', 'fas Receptor']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'64'', 'b'Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer.'', 'b'Gastric cancer (GC) exhibits heterogeneous clinical and molecular features, requiring the development of new biomarkers to further understand this disease. Our transcriptomic analysis detected overexpression of melanoma-associated antigen A6 (MAGEA6) in metastatic GC, leading us to determine the clinical significance of MAGEA6 in GC.Fourteen GC cell lines and 230 pairs of surgically resected gastric tissues were subjected to mRNA expression analysis. Polymerase chain reaction array analysis was performed to identify coordinately expressed cancer-related genes, and immunohistochemistry (IHC) was used to detected MAGEA6 expression in situ.MAGEA6 mRNA levels were positively correlated with the expression of matrix metallopeptidase 9 mRNA. MAGEA6 mRNA levels were higher in GC tissues compared with those in normal adjacent tissues. Patients with high MAGEA6 expression had significantly worse prognosis. MAGEA6 protein levels in primary lesions predicted the likelihood of recurrence.Overexpression of MAGEA6 in GC tissues represents a promising biomarker for assessing the malignant phenotype of GC.'', 'b'959'', 'b'149'', 'b"[('gc', 12), ('tissues', 8), ('mrna', 8), ('expression', 8), ('analysis', 6), ('levels', 6), ('gastric', 4), ('clinical', 4), ('detected', 4), ('cancer', 2), ('exhibits', 2), ('heterogeneous', 2), ('molecular', 2), ('features', 2), ('requiring', 2), ('development', 2), ('new', 2), ('biomarkers', 2), ('understand', 2), ('disease', 2), ('transcriptomic', 2), ('overexpression', 2), ('antigen', 2), ('metastatic', 2), ('leading', 2), ('us', 2), ('determine', 2), ('significance', 2), ('cell', 2), ('lines', 2), ('pairs', 2), ('surgically', 2), ('resected', 2), ('subjected', 2), ('polymerase', 2), ('chain', 2), ('reaction', 2), ('array', 2), ('performed', 2), ('identify', 2), ('coordinately', 2), ('expressed', 2), ('genes', 2), ('immunohistochemistry', 2), ('ihc', 2), ('used', 2), ('positively', 2), ('correlated', 2), ('matrix', 2), ('metallopeptidase', 2), ('higher', 2), ('compared', 2), ('normal', 2), ('adjacent', 2), ('patients', 2), ('high', 2), ('significantly', 2), ('worse', 2), ('prognosis', 2), ('protein', 2), ('primary', 2), ('lesions', 2), ('predicted', 2), ('likelihood', 2), ('represents', 2), ('promising', 2), ('biomarker', 2), ('assessing', 2), ('malignant', 2), ('phenotype', 2)]"', 'b"[('of', 8), ('magea6', 7), ('in', 7), ('GC', 6), ('.', 6), ('the', 5), ('to', 5), ('express', 5), ('tissu', 4), ('mrna', 4), ('(', 3), (')', 3), ('and', 3), (',', 3), ('analysi', 3), ('were', 3), ('level', 3), ('with', 3), ('gastric', 2), ('clinic', 2), ('biomark', 2), ('detect', 2), ('wa', 2), ('cancer', 1), ('exhibit', 1), ('heterogen', 1), ('molecular', 1), ('featur', 1), ('requir', 1), ('develop', 1), ('new', 1), ('further', 1), ('understand', 1), ('thi', 1), ('diseas', 1), ('our', 1), ('transcriptom', 1), ('overexpress', 1), ('melanoma-associ', 1), ('antigen', 1), ('A6', 1), ('metastat', 1), ('lead', 1), ('us', 1), ('determin', 1), ('signific', 1), ('gc.fourteen', 1), ('cell', 1), ('line', 1), ('230', 1), ('pair', 1), ('surgic', 1), ('resect', 1), ('subject', 1), ('polymeras', 1), ('chain', 1), ('reaction', 1), ('array', 1), ('perform', 1), ('identifi', 1), ('coordin', 1), ('cancer-rel', 1), ('gene', 1), ('immunohistochemistri', 1), ('ihc', 1), ('use', 1), ('situ.magea6', 1), ('posit', 1), ('correl', 1), ('matrix', 1), ('metallopeptidas', 1), ('9', 1), ('higher', 1), ('compar', 1), ('those', 1), ('normal', 1), ('adjac', 1), ('patient', 1), ('high', 1), ('had', 1), ('significantli', 1), ('wors', 1), ('prognosi', 1), ('protein', 1), ('primari', 1), ('lesion', 1), ('predict', 1), ('likelihood', 1), ('recurrence.overexpress', 1), ('repres', 1), ('a', 1), ('promis', 1), ('for', 1), ('assess', 1), ('malign', 1), ('phenotyp', 1)]"', 'b'6'', 'b"('gc', 'tissues', 'mrna', 'expression', 'analysis', 'levels', 'gastric', 'clinical', 'detected', 'cancer', 'exhibits', 'heterogeneous', 'molecular', 'features', 'requiring', 'development', 'new', 'biomarkers', 'understand', 'disease', 'transcriptomic', 'overexpression', 'antigen', 'metastatic', 'leading', 'us', 'determine', 'significance', 'cell', 'lines', 'pairs', 'surgically', 'resected', 'subjected', 'polymerase', 'chain', 'reaction', 'array', 'performed', 'identify', 'coordinately', 'expressed', 'genes', 'immunohistochemistry', 'ihc', 'used', 'positively', 'correlated', 'matrix', 'metallopeptidase', 'higher', 'compared', 'normal', 'adjacent', 'patients', 'high', 'significantly', 'worse', 'prognosis', 'protein', 'primary', 'lesions', 'predicted', 'likelihood', 'represents', 'promising', 'biomarker', 'assessing', 'malignant', 'phenotype')"', 'b'(12, 8, 8, 8, 6, 6, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.018653830618778525'', 'b'[-0.08051261846884804, -0.017483865189953776, -0.007872684375380894, -0.00652604099538153]'', 'b'-2.3440389678222067'', 'b'[-0.791759469228055, -2.332204510175204, -3.1431347263915326, -3.330733340286331]'', 'b'-1.2388836663045368'', 'b'[0.38247976839033615, 1.1417265790365525, 1.5589291819613225, 1.651974176577842]'', 'b'49'', 'b'0.310083514924945'', 'b"['Adenocarcinoma', 'Adenocarcinoma, Mucinous', 'Adult', 'Aged', 'Aged, 80 and over', 'Antigens, Neoplasm', 'Biomarkers, Tumor', 'Carcinoma, Signet Ring Cell', 'Case-Control Studies', 'Female', 'Follow-Up Studies', 'Gastrectomy', 'Humans', 'Liver Neoplasms', 'Lymphatic Metastasis', 'Male', 'Middle Aged', 'Neoplasm Invasiveness', 'Neoplasm Proteins', 'Neoplasm Recurrence, Local', 'Prognosis', 'Stomach Neoplasms', 'Survival Rate']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'64'', 'b'Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer.'', 'b'Gastric cancer (GC) exhibits heterogeneous clinical and molecular features, requiring the development of new biomarkers to further understand this disease. Our transcriptomic analysis detected overexpression of melanoma-associated antigen A6 (MAGEA6) in metastatic GC, leading us to determine the clinical significance of MAGEA6 in GC.Fourteen GC cell lines and 230 pairs of surgically resected gastric tissues were subjected to mRNA expression analysis. Polymerase chain reaction array analysis was performed to identify coordinately expressed cancer-related genes, and immunohistochemistry (IHC) was used to detected MAGEA6 expression in situ.MAGEA6 mRNA levels were positively correlated with the expression of matrix metallopeptidase 9 mRNA. MAGEA6 mRNA levels were higher in GC tissues compared with those in normal adjacent tissues. Patients with high MAGEA6 expression had significantly worse prognosis. MAGEA6 protein levels in primary lesions predicted the likelihood of recurrence.Overexpression of MAGEA6 in GC tissues represents a promising biomarker for assessing the malignant phenotype of GC.'', 'b'959'', 'b'149'', 'b"[('gc', 12), ('tissues', 8), ('mrna', 8), ('expression', 8), ('analysis', 6), ('levels', 6), ('gastric', 4), ('clinical', 4), ('detected', 4), ('cancer', 2), ('exhibits', 2), ('heterogeneous', 2), ('molecular', 2), ('features', 2), ('requiring', 2), ('development', 2), ('new', 2), ('biomarkers', 2), ('understand', 2), ('disease', 2), ('transcriptomic', 2), ('overexpression', 2), ('antigen', 2), ('metastatic', 2), ('leading', 2), ('us', 2), ('determine', 2), ('significance', 2), ('cell', 2), ('lines', 2), ('pairs', 2), ('surgically', 2), ('resected', 2), ('subjected', 2), ('polymerase', 2), ('chain', 2), ('reaction', 2), ('array', 2), ('performed', 2), ('identify', 2), ('coordinately', 2), ('expressed', 2), ('genes', 2), ('immunohistochemistry', 2), ('ihc', 2), ('used', 2), ('positively', 2), ('correlated', 2), ('matrix', 2), ('metallopeptidase', 2), ('higher', 2), ('compared', 2), ('normal', 2), ('adjacent', 2), ('patients', 2), ('high', 2), ('significantly', 2), ('worse', 2), ('prognosis', 2), ('protein', 2), ('primary', 2), ('lesions', 2), ('predicted', 2), ('likelihood', 2), ('represents', 2), ('promising', 2), ('biomarker', 2), ('assessing', 2), ('malignant', 2), ('phenotype', 2)]"', 'b"[('of', 8), ('magea6', 7), ('in', 7), ('GC', 6), ('.', 6), ('the', 5), ('to', 5), ('express', 5), ('tissu', 4), ('mrna', 4), ('(', 3), (')', 3), ('and', 3), (',', 3), ('analysi', 3), ('were', 3), ('level', 3), ('with', 3), ('gastric', 2), ('clinic', 2), ('biomark', 2), ('detect', 2), ('wa', 2), ('cancer', 1), ('exhibit', 1), ('heterogen', 1), ('molecular', 1), ('featur', 1), ('requir', 1), ('develop', 1), ('new', 1), ('further', 1), ('understand', 1), ('thi', 1), ('diseas', 1), ('our', 1), ('transcriptom', 1), ('overexpress', 1), ('melanoma-associ', 1), ('antigen', 1), ('A6', 1), ('metastat', 1), ('lead', 1), ('us', 1), ('determin', 1), ('signific', 1), ('gc.fourteen', 1), ('cell', 1), ('line', 1), ('230', 1), ('pair', 1), ('surgic', 1), ('resect', 1), ('subject', 1), ('polymeras', 1), ('chain', 1), ('reaction', 1), ('array', 1), ('perform', 1), ('identifi', 1), ('coordin', 1), ('cancer-rel', 1), ('gene', 1), ('immunohistochemistri', 1), ('ihc', 1), ('use', 1), ('situ.magea6', 1), ('posit', 1), ('correl', 1), ('matrix', 1), ('metallopeptidas', 1), ('9', 1), ('higher', 1), ('compar', 1), ('those', 1), ('normal', 1), ('adjac', 1), ('patient', 1), ('high', 1), ('had', 1), ('significantli', 1), ('wors', 1), ('prognosi', 1), ('protein', 1), ('primari', 1), ('lesion', 1), ('predict', 1), ('likelihood', 1), ('recurrence.overexpress', 1), ('repres', 1), ('a', 1), ('promis', 1), ('for', 1), ('assess', 1), ('malign', 1), ('phenotyp', 1)]"', 'b'6'', 'b"('gc', 'tissues', 'mrna', 'expression', 'analysis', 'levels', 'gastric', 'clinical', 'detected', 'cancer', 'exhibits', 'heterogeneous', 'molecular', 'features', 'requiring', 'development', 'new', 'biomarkers', 'understand', 'disease', 'transcriptomic', 'overexpression', 'antigen', 'metastatic', 'leading', 'us', 'determine', 'significance', 'cell', 'lines', 'pairs', 'surgically', 'resected', 'subjected', 'polymerase', 'chain', 'reaction', 'array', 'performed', 'identify', 'coordinately', 'expressed', 'genes', 'immunohistochemistry', 'ihc', 'used', 'positively', 'correlated', 'matrix', 'metallopeptidase', 'higher', 'compared', 'normal', 'adjacent', 'patients', 'high', 'significantly', 'worse', 'prognosis', 'protein', 'primary', 'lesions', 'predicted', 'likelihood', 'represents', 'promising', 'biomarker', 'assessing', 'malignant', 'phenotype')"', 'b'(12, 8, 8, 8, 6, 6, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.018653830618778525'', 'b'[-0.08051261846884804, -0.017483865189953776, -0.007872684375380894, -0.00652604099538153]'', 'b'-2.3440389678222067'', 'b'[-0.791759469228055, -2.332204510175204, -3.1431347263915326, -3.330733340286331]'', 'b'-1.2388836663045368'', 'b'[0.38247976839033615, 1.1417265790365525, 1.5589291819613225, 1.651974176577842]'', 'b'49'', 'b'0.310083514924945'', 'b"['Adenocarcinoma', 'Adenocarcinoma, Mucinous', 'Adult', 'Aged', 'Aged, 80 and over', 'Antigens, Neoplasm', 'Biomarkers, Tumor', 'Carcinoma, Signet Ring Cell', 'Case-Control Studies', 'Female', 'Follow-Up Studies', 'Gastrectomy', 'Humans', 'Liver Neoplasms', 'Lymphatic Metastasis', 'Male', 'Middle Aged', 'Neoplasm Invasiveness', 'Neoplasm Proteins', 'Neoplasm Recurrence, Local', 'Prognosis', 'Stomach Neoplasms', 'Survival Rate']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'65'', 'b'Cytoplasmic Mineralocorticoid Receptor Expression Predicts Dismal Local Relapse-free Survival in Non-triple-negative Breast Cancer.'', 'b'The aim of the study was to investigate the prognostic role of androgen receptor (AR), mineralocorticoid receptor (MR) and glucocorticoid receptor \xce\xb2 (GR\xce\xb2) expression in HER-2 negative breast cancer patients.The study population (n=152) was enriched with triple-negative breast cancers (TNBC) (n=96; 63.2%). The median follow-up time was 100 months. AR, MR and GR\xce\xb2 immunocytochemical staining was compared with that of epithelial-mesenchymal transition (EMT) markers (vimentin, SIP1, ZEB1).High expression of cytoplasmic MR was associated with dismal local relapse-free survival (RR=13.923; 95%CI=1.071-181.045; p=0.044) in tumours with non-TNBC phenotype. AR and GR\xce\xb2 were more frequently expressed in ER+_PR+_HER2- tumours, while cytoplasmic MR was more often expressed in TNBC tumours (for all, p<0.0005). GR\xce\xb2 and AR were associated with decreased vimentin expression (p<0.005), indicating their association with attenuated EMT.Cytoplasmic MR expression is a strong predictor of local recurrence in non-metastatic breast cancer patients with non-TNBC tumour phenotype.'', 'b'927'', 'b'143'', 'b"[('mr', 10), ('ar', 8), ('gr\xce\xb2', 8), ('expression', 8), ('receptor', 6), ('breast', 6), ('tumours', 6), ('study', 4), ('cancer', 4), ('tnbc', 4), ('vimentin', 4), ('cytoplasmic', 4), ('associated', 4), ('local', 4), ('phenotype', 4), ('expressed', 4), ('p', 4), ('aim', 2), ('investigate', 2), ('prognostic', 2), ('role', 2), ('androgen', 2), ('mineralocorticoid', 2), ('glucocorticoid', 2), ('\xce\xb2', 2), ('negative', 2), ('population', 2), ('enriched', 2), ('cancers', 2), ('median', 2), ('time', 2), ('months', 2), ('immunocytochemical', 2), ('staining', 2), ('compared', 2), ('transition', 2), ('emt', 2), ('markers', 2), ('dismal', 2), ('survival', 2), ('frequently', 2), ('often', 2), ('decreased', 2), ('indicating', 2), ('association', 2), ('attenuated', 2), ('strong', 2), ('predictor', 2), ('recurrence', 2), ('patients', 2), ('tumour', 2)]"', 'b"[('(', 11), (')', 11), (',', 7), ('with', 7), ('wa', 6), ('express', 6), ('of', 5), ('MR', 5), ('in', 5), ('.', 5), ('the', 4), ('AR', 4), ('and', 4), ('gr\xce\xb2', 4), ('tumour', 4), ('receptor', 3), ('breast', 3), ('cancer', 3), (';', 3), ('associ', 3), ('studi', 2), ('tnbc', 2), ('%', 2), ('vimentin', 2), ('cytoplasm', 2), ('local', 2), ('non-tnbc', 2), ('phenotyp', 2), ('were', 2), ('more', 2), ('p', 2), ('<', 2), ('aim', 1), ('to', 1), ('investig', 1), ('prognost', 1), ('role', 1), ('androgen', 1), ('mineralocorticoid', 1), ('glucocorticoid', 1), ('\xce\xb2', 1), ('her-2', 1), ('neg', 1), ('patients.th', 1), ('popul', 1), ('n=152', 1), ('enrich', 1), ('triple-neg', 1), ('n=96', 1), ('63.2', 1), ('median', 1), ('follow-up', 1), ('time', 1), ('100', 1), ('month', 1), ('immunocytochem', 1), ('stain', 1), ('compar', 1), ('that', 1), ('epithelial-mesenchym', 1), ('transit', 1), ('emt', 1), ('marker', 1), ('sip1', 1), ('zeb1', 1), ('.high', 1), ('dismal', 1), ('relapse-fre', 1), ('surviv', 1), ('rr=13.923', 1), ('95', 1), ('ci=1.071-181.045', 1), ('p=0.044', 1), ('frequent', 1), ('er+_pr+_her2-', 1), ('while', 1), ('often', 1), ('for', 1), ('all', 1), ('0.0005', 1), ('decreas', 1), ('0.005', 1), ('indic', 1), ('their', 1), ('attenu', 1), ('emt.cytoplasm', 1), ('is', 1), ('a', 1), ('strong', 1), ('predictor', 1), ('recurr', 1), ('non-metastat', 1), ('patient', 1)]"', 'b'5'', 'b"('mr', 'ar', 'gr\xce\xb2', 'expression', 'receptor', 'breast', 'tumours', 'study', 'cancer', 'tnbc', 'vimentin', 'cytoplasmic', 'associated', 'local', 'phenotype', 'expressed', 'p', 'aim', 'investigate', 'prognostic', 'role', 'androgen', 'mineralocorticoid', 'glucocorticoid', '\xce\xb2', 'negative', 'population', 'enriched', 'cancers', 'median', 'time', 'months', 'immunocytochemical', 'staining', 'compared', 'transition', 'emt', 'markers', 'dismal', 'survival', 'frequently', 'often', 'decreased', 'indicating', 'association', 'attenuated', 'strong', 'predictor', 'recurrence', 'patients', 'tumour')"', 'b'(10, 8, 8, 8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.018029139662329084'', 'b'[-0.08372815229129454, -0.018168505050943785, -0.008175036676503027, -0.0067766751397327725]'', 'b'-2.3440389678222067'', 'b'[-0.791759469228055, -2.332204510175204, -3.1431347263915326, -3.330733340286331]'', 'b'-1.1973951678695678'', 'b'[0.39775534450560673, 1.186434743842658, 1.6188002250487885, 1.7154186346390083]'', 'b'85'', 'b'0.11609928372430872'', 'b"['Biomarkers, Tumor', 'Breast Neoplasms', 'Cytoplasm', 'Female', 'Follow-Up Studies', 'Humans', 'Neoplasm Metastasis', 'Neoplasm Recurrence, Local', 'Prognosis', 'Receptor, ErbB-2', 'Receptors, Androgen', 'Receptors, Estrogen', 'Receptors, Glucocorticoid', 'Receptors, Mineralocorticoid', 'Receptors, Progesterone', 'Retrospective Studies', 'Survival Rate']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'66'', 'b'Clonal Evolution of MEK_MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.'', 'b'The aim of this study was to examine clonal heterogeneity, to test the utility of liquid biopsy in monitoring disease progression and to evaluate the usefulness of ex vivo drug screening in a BRAF L597Q-mutated colorectal cancer (CRC) patient developing metastases during adjuvant therapy.Next generation sequencing (NGS) and droplet digital PCR (ddPCR) were performed in samples from tumor tissues and liquid biopsies. Live cancer cells from a metastatic lesion were used in ex vivo drug sensitivity assays.We found evidence of continued dependence of MEK_MAPK pathway activation, but different activating mutations in primary tumor and metastases. Liquid biopsy based BRAF L597Q ddPCR testing was a sensitive personalized biomarker predicting the rise of clinically aggressive metastatic disease. Ex vivo drug sensitivity assays with BRAF L597Q mutated cells showed response to MEK_MAPK targeted therapies.The rare BRAF L597Q mutation may be associated with aggressive tumor behavior in CRC. Liquid biopsy can be used to capture clinically relevant tumor features.'', 'b'912'', 'b'155'', 'b"[('liquid', 8), ('braf', 8), ('tumor', 8), ('biopsy', 6), ('ex', 6), ('vivo', 6), ('drug', 6), ('disease', 4), ('cancer', 4), ('crc', 4), ('metastases', 4), ('ddpcr', 4), ('cells', 4), ('metastatic', 4), ('used', 4), ('sensitivity', 4), ('clinically', 4), ('aggressive', 4), ('aim', 2), ('study', 2), ('examine', 2), ('clonal', 2), ('heterogeneity', 2), ('test', 2), ('utility', 2), ('monitoring', 2), ('progression', 2), ('evaluate', 2), ('usefulness', 2), ('screening', 2), ('colorectal', 2), ('patient', 2), ('developing', 2), ('adjuvant', 2), ('generation', 2), ('sequencing', 2), ('ngs', 2), ('droplet', 2), ('digital', 2), ('pcr', 2), ('performed', 2), ('samples', 2), ('tissues', 2), ('biopsies', 2), ('live', 2), ('lesion', 2), ('found', 2), ('evidence', 2), ('continued', 2), ('dependence', 2), ('pathway', 2), ('activation', 2), ('different', 2), ('activating', 2), ('mutations', 2), ('primary', 2), ('based', 2), ('testing', 2), ('sensitive', 2), ('personalized', 2), ('biomarker', 2), ('predicting', 2), ('rise', 2), ('assays', 2), ('mutated', 2), ('showed', 2), ('response', 2), ('targeted', 2), ('rare', 2), ('mutation', 2), ('may', 2), ('associated', 2), ('behavior', 2), ('capture', 2), ('relevant', 2), ('features', 2)]"', 'b"[('of', 6), ('in', 6), ('to', 5), ('.', 5), ('the', 4), ('liquid', 4), ('biopsi', 4), ('and', 4), ('braf', 4), ('tumor', 4), ('use', 3), ('vivo', 3), ('drug', 3), ('a', 3), ('(', 3), (')', 3), ('sensit', 3), ('mutat', 3), ('l597q', 3), ('wa', 2), (',', 2), ('test', 2), ('diseas', 2), ('ex', 2), ('cancer', 2), ('crc', 2), ('metastas', 2), ('ddpcr', 2), ('were', 2), ('from', 2), ('cell', 2), ('metastat', 2), ('mek_mapk', 2), ('activ', 2), ('clinic', 2), ('aggress', 2), ('with', 2), ('be', 2), ('aim', 1), ('thi', 1), ('studi', 1), ('examin', 1), ('clonal', 1), ('heterogen', 1), ('util', 1), ('monitor', 1), ('progress', 1), ('evalu', 1), ('screen', 1), ('l597q-mutat', 1), ('colorect', 1), ('patient', 1), ('develop', 1), ('dure', 1), ('adjuv', 1), ('therapy.next', 1), ('gener', 1), ('sequenc', 1), ('ng', 1), ('droplet', 1), ('digit', 1), ('pcr', 1), ('perform', 1), ('sampl', 1), ('tissu', 1), ('live', 1), ('lesion', 1), ('assays.w', 1), ('found', 1), ('evid', 1), ('continu', 1), ('depend', 1), ('pathway', 1), ('but', 1), ('differ', 1), ('primari', 1), ('base', 1), ('person', 1), ('biomark', 1), ('predict', 1), ('rise', 1), ('Ex', 1), ('assay', 1), ('show', 1), ('respons', 1), ('target', 1), ('therapies.th', 1), ('rare', 1), ('may', 1), ('associ', 1), ('behavior', 1), ('can', 1), ('captur', 1), ('relev', 1), ('featur', 1)]"', 'b'5'', 'b"('liquid', 'braf', 'tumor', 'biopsy', 'ex', 'vivo', 'drug', 'disease', 'cancer', 'crc', 'metastases', 'ddpcr', 'cells', 'metastatic', 'used', 'sensitivity', 'clinically', 'aggressive', 'aim', 'study', 'examine', 'clonal', 'heterogeneity', 'test', 'utility', 'monitoring', 'progression', 'evaluate', 'usefulness', 'screening', 'colorectal', 'patient', 'developing', 'adjuvant', 'generation', 'sequencing', 'ngs', 'droplet', 'digital', 'pcr', 'performed', 'samples', 'tissues', 'biopsies', 'live', 'lesion', 'found', 'evidence', 'continued', 'dependence', 'pathway', 'activation', 'different', 'activating', 'mutations', 'primary', 'based', 'testing', 'sensitive', 'personalized', 'biomarker', 'predicting', 'rise', 'assays', 'mutated', 'showed', 'response', 'targeted', 'rare', 'mutation', 'may', 'associated', 'behavior', 'capture', 'relevant', 'features')"', 'b'(8, 8, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.033643219162781006'', 'b'[-0.26064846181664303, -0.018190602530480073]'', 'b'-1.6855773452501515'', 'b'[0.3068528194400547, -2.367295829986474]'', 'b'-0.8317209712836852'', 'b'[-0.1599614307823007, 1.2488135879450597]'', 'b'30'', 'b'0.07861139543647958'', 'b"['Aged', 'Antineoplastic Combined Chemotherapy Protocols', 'Biomarkers, Tumor', 'Capecitabine', 'Clonal Evolution', 'Colorectal Neoplasms', 'Drug Resistance, Neoplasm', 'Female', 'High-Throughput Nucleotide Sequencing', 'Humans', 'Lung Neoplasms', 'MAP Kinase Kinase 1', 'Mitogen-Activated Protein Kinases', 'Mutation', 'Oxaliplatin', 'Prognosis']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'66'', 'b'Clonal Evolution of MEK_MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case.'', 'b'The aim of this study was to examine clonal heterogeneity, to test the utility of liquid biopsy in monitoring disease progression and to evaluate the usefulness of ex vivo drug screening in a BRAF L597Q-mutated colorectal cancer (CRC) patient developing metastases during adjuvant therapy.Next generation sequencing (NGS) and droplet digital PCR (ddPCR) were performed in samples from tumor tissues and liquid biopsies. Live cancer cells from a metastatic lesion were used in ex vivo drug sensitivity assays.We found evidence of continued dependence of MEK_MAPK pathway activation, but different activating mutations in primary tumor and metastases. Liquid biopsy based BRAF L597Q ddPCR testing was a sensitive personalized biomarker predicting the rise of clinically aggressive metastatic disease. Ex vivo drug sensitivity assays with BRAF L597Q mutated cells showed response to MEK_MAPK targeted therapies.The rare BRAF L597Q mutation may be associated with aggressive tumor behavior in CRC. Liquid biopsy can be used to capture clinically relevant tumor features.'', 'b'912'', 'b'155'', 'b"[('liquid', 8), ('braf', 8), ('tumor', 8), ('biopsy', 6), ('ex', 6), ('vivo', 6), ('drug', 6), ('disease', 4), ('cancer', 4), ('crc', 4), ('metastases', 4), ('ddpcr', 4), ('cells', 4), ('metastatic', 4), ('used', 4), ('sensitivity', 4), ('clinically', 4), ('aggressive', 4), ('aim', 2), ('study', 2), ('examine', 2), ('clonal', 2), ('heterogeneity', 2), ('test', 2), ('utility', 2), ('monitoring', 2), ('progression', 2), ('evaluate', 2), ('usefulness', 2), ('screening', 2), ('colorectal', 2), ('patient', 2), ('developing', 2), ('adjuvant', 2), ('generation', 2), ('sequencing', 2), ('ngs', 2), ('droplet', 2), ('digital', 2), ('pcr', 2), ('performed', 2), ('samples', 2), ('tissues', 2), ('biopsies', 2), ('live', 2), ('lesion', 2), ('found', 2), ('evidence', 2), ('continued', 2), ('dependence', 2), ('pathway', 2), ('activation', 2), ('different', 2), ('activating', 2), ('mutations', 2), ('primary', 2), ('based', 2), ('testing', 2), ('sensitive', 2), ('personalized', 2), ('biomarker', 2), ('predicting', 2), ('rise', 2), ('assays', 2), ('mutated', 2), ('showed', 2), ('response', 2), ('targeted', 2), ('rare', 2), ('mutation', 2), ('may', 2), ('associated', 2), ('behavior', 2), ('capture', 2), ('relevant', 2), ('features', 2)]"', 'b"[('of', 6), ('in', 6), ('to', 5), ('.', 5), ('the', 4), ('liquid', 4), ('biopsi', 4), ('and', 4), ('braf', 4), ('tumor', 4), ('use', 3), ('vivo', 3), ('drug', 3), ('a', 3), ('(', 3), (')', 3), ('sensit', 3), ('mutat', 3), ('l597q', 3), ('wa', 2), (',', 2), ('test', 2), ('diseas', 2), ('ex', 2), ('cancer', 2), ('crc', 2), ('metastas', 2), ('ddpcr', 2), ('were', 2), ('from', 2), ('cell', 2), ('metastat', 2), ('mek_mapk', 2), ('activ', 2), ('clinic', 2), ('aggress', 2), ('with', 2), ('be', 2), ('aim', 1), ('thi', 1), ('studi', 1), ('examin', 1), ('clonal', 1), ('heterogen', 1), ('util', 1), ('monitor', 1), ('progress', 1), ('evalu', 1), ('screen', 1), ('l597q-mutat', 1), ('colorect', 1), ('patient', 1), ('develop', 1), ('dure', 1), ('adjuv', 1), ('therapy.next', 1), ('gener', 1), ('sequenc', 1), ('ng', 1), ('droplet', 1), ('digit', 1), ('pcr', 1), ('perform', 1), ('sampl', 1), ('tissu', 1), ('live', 1), ('lesion', 1), ('assays.w', 1), ('found', 1), ('evid', 1), ('continu', 1), ('depend', 1), ('pathway', 1), ('but', 1), ('differ', 1), ('primari', 1), ('base', 1), ('person', 1), ('biomark', 1), ('predict', 1), ('rise', 1), ('Ex', 1), ('assay', 1), ('show', 1), ('respons', 1), ('target', 1), ('therapies.th', 1), ('rare', 1), ('may', 1), ('associ', 1), ('behavior', 1), ('can', 1), ('captur', 1), ('relev', 1), ('featur', 1)]"', 'b'5'', 'b"('liquid', 'braf', 'tumor', 'biopsy', 'ex', 'vivo', 'drug', 'disease', 'cancer', 'crc', 'metastases', 'ddpcr', 'cells', 'metastatic', 'used', 'sensitivity', 'clinically', 'aggressive', 'aim', 'study', 'examine', 'clonal', 'heterogeneity', 'test', 'utility', 'monitoring', 'progression', 'evaluate', 'usefulness', 'screening', 'colorectal', 'patient', 'developing', 'adjuvant', 'generation', 'sequencing', 'ngs', 'droplet', 'digital', 'pcr', 'performed', 'samples', 'tissues', 'biopsies', 'live', 'lesion', 'found', 'evidence', 'continued', 'dependence', 'pathway', 'activation', 'different', 'activating', 'mutations', 'primary', 'based', 'testing', 'sensitive', 'personalized', 'biomarker', 'predicting', 'rise', 'assays', 'mutated', 'showed', 'response', 'targeted', 'rare', 'mutation', 'may', 'associated', 'behavior', 'capture', 'relevant', 'features')"', 'b'(8, 8, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.033643219162781006'', 'b'[-0.26064846181664303, -0.018190602530480073]'', 'b'-1.6855773452501515'', 'b'[0.3068528194400547, -2.367295829986474]'', 'b'-0.8317209712836852'', 'b'[-0.1599614307823007, 1.2488135879450597]'', 'b'30'', 'b'0.07861139543647958'', 'b"['Aged', 'Antineoplastic Combined Chemotherapy Protocols', 'Biomarkers, Tumor', 'Capecitabine', 'Clonal Evolution', 'Colorectal Neoplasms', 'Drug Resistance, Neoplasm', 'Female', 'High-Throughput Nucleotide Sequencing', 'Humans', 'Lung Neoplasms', 'MAP Kinase Kinase 1', 'Mitogen-Activated Protein Kinases', 'Mutation', 'Oxaliplatin', 'Prognosis']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'67'', 'b'Association of Genetic Ancestry With DNA Methylation Changes in Prostate Cancer Disparity.'', 'b'We hypothesized that ancestry-mediated methylated DNA changes may drive racial and ethnic disparity in prostate cancer (PCa). To test this hypothesis, we analyzed genetic ancestry and association with DNA methylation changes in PCa disparity.Pyrosequencing and ancestry informative markers were used for DNA methylation and genetic ancestry testing, respectively.Using Spearman rho rank correlation test, the data demonstrated significant (p<0.05) and variable association between African-American ancestry and DNA methylation for all genes investigated in prostate tissues.Genetic ancestry influences DNA methylation and this modifying factor must be considered in epigenetic association studies in populations of admixed patients.'', 'b'639'', 'b'94'', 'b"[('dna', 10), ('ancestry', 10), ('methylation', 8), ('association', 6), ('changes', 4), ('prostate', 4), ('pca', 4), ('test', 4), ('genetic', 4), ('hypothesized', 2), ('methylated', 2), ('may', 2), ('drive', 2), ('racial', 2), ('ethnic', 2), ('disparity', 2), ('cancer', 2), ('hypothesis', 2), ('analyzed', 2), ('informative', 2), ('markers', 2), ('used', 2), ('testing', 2), ('spearman', 2), ('rho', 2), ('rank', 2), ('correlation', 2), ('data', 2), ('demonstrated', 2), ('significant', 2), ('p', 2), ('variable', 2), ('genes', 2), ('investigated', 2), ('influences', 2), ('modifying', 2), ('factor', 2), ('must', 2), ('considered', 2), ('epigenetic', 2), ('studies', 2), ('populations', 2), ('admixed', 2), ('patients', 2)]"', 'b"[('and', 7), ('methyl', 5), ('dna', 5), ('in', 5), ('ancestri', 5), ('test', 3), (',', 3), ('associ', 3), ('chang', 2), ('prostat', 2), ('(', 2), ('pca', 2), (')', 2), ('.', 2), ('thi', 2), ('genet', 2), ('for', 2), ('We', 1), ('hypothes', 1), ('that', 1), ('ancestry-medi', 1), ('may', 1), ('drive', 1), ('racial', 1), ('ethnic', 1), ('dispar', 1), ('cancer', 1), ('To', 1), ('hypothesi', 1), ('we', 1), ('analyz', 1), ('with', 1), ('disparity.pyrosequenc', 1), ('inform', 1), ('marker', 1), ('were', 1), ('use', 1), ('respectively.us', 1), ('spearman', 1), ('rho', 1), ('rank', 1), ('correl', 1), ('the', 1), ('data', 1), ('demonstr', 1), ('signific', 1), ('p', 1), ('<', 1), ('0.05', 1), ('variabl', 1), ('between', 1), ('african-american', 1), ('all', 1), ('gene', 1), ('investig', 1), ('tissues.genet', 1), ('influenc', 1), ('modifi', 1), ('factor', 1), ('must', 1), ('be', 1), ('consid', 1), ('epigenet', 1), ('studi', 1), ('popul', 1), ('of', 1), ('admix', 1), ('patient', 1)]"', 'b'2'', 'b"('dna', 'ancestry', 'methylation', 'association', 'changes', 'prostate', 'pca', 'test', 'genetic', 'hypothesized', 'methylated', 'may', 'drive', 'racial', 'ethnic', 'disparity', 'cancer', 'hypothesis', 'analyzed', 'informative', 'markers', 'used', 'testing', 'spearman', 'rho', 'rank', 'correlation', 'data', 'demonstrated', 'significant', 'p', 'variable', 'genes', 'investigated', 'influences', 'modifying', 'factor', 'must', 'considered', 'epigenetic', 'studies', 'populations', 'admixed', 'patients')"', 'b'(10, 10, 8, 6, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.019053577907792853'', 'b'[-0.0, -0.0, -0.0, -0.5337194436318432, -0.05398733092062216]'', 'b'-2.2188758248682006'', 'b'[1, 1, 1, 1.0, -1.3025850929940455]'', 'b'-1.0569380849211099'', 'b'[-0.5275274733839221, -0.5275274733839221, -0.5275274733839221, -0.5337194436318432, 0.7032309246773891]'', 'b'31'', 'b'0.05544777820228863'', 'b"['Adolescent', 'Adult', 'African Americans', 'Aged', 'Aged, 80 and over', 'Biomarkers, Tumor', 'Case-Control Studies', 'DNA Methylation', 'European Continental Ancestry Group', 'Follow-Up Studies', 'Gene Expression Regulation, Neoplastic', 'Healthcare Disparities', 'Humans', 'Male', 'Middle Aged', 'Prognosis', 'Prostatic Neoplasms', 'Young Adult']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'68'', 'b'Prognostic significance of neutrophil-lymphocyte ratio (NLR) in patients with ovarian cancer: A systematic review and meta-analysis.'', 'b'The prognostic role of neutrophil to lymphocyte ratio (NLR) in patients with ovarian cancer remains inconsistent. This meta-analysis was conducted to evaluate the predictive value of this biomarker for prognoses in ovarian cancer patients.We systematically searched PubMed, Web of Science, and Embase for eligible studies embracing multivariate results. The Newcastle-Ottawa Scale were used to assess the study quality. Pooled hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated.Ten studies involving 2919 patients were included in this meta-analysis. In multivariate analysis, the group with higher NLR had worse overall survival (OS) (HR\xe2\x80\x8a=\xe2\x80\x8a1.34, 95% CI\xe2\x80\x8a=\xe2\x80\x8a1.16-1.54) and shorter PFS (HR\xe2\x80\x8a=\xe2\x80\x8a1.36, 95% CI\xe2\x80\x8a=\xe2\x80\x8a1.17-1.57) than the control group. Furthermore, PLR values higher than the cut-off were associated with not only poorer OS (HR\xe2\x80\x8a=\xe2\x80\x8a1.97, 95% CI\xe2\x80\x8a=\xe2\x80\x8a1.61-2.40) but also more unfavorable PFS (HR\xe2\x80\x8a=\xe2\x80\x8a1.79, 95% CI\xe2\x80\x8a=\xe2\x80\x8a1.46-2.20). Univariate analysis also indicated the same results. Additionally, subgroup analysis showed that when the cut-off values for NLR and PLR were higher, their predictive effects became stronger.This comprehensive meta-analysis suggested that the values of inflammatory marker of NLR was associated with ovarian cancer survival. Therefore, inflammatory markers can potentially serve as prognostic biomarkers.'', 'b'1150'', 'b'198'', 'b"[('nlr', 8), ('hr', 8), ('ci', 8), ('ovarian', 6), ('cancer', 6), ('analysis', 6), ('higher', 6), ('values', 6), ('prognostic', 4), ('patients', 4), ('predictive', 4), ('studies', 4), ('multivariate', 4), ('results', 4), ('group', 4), ('survival', 4), ('os', 4), ('pfs', 4), ('plr', 4), ('associated', 4), ('also', 4), ('inflammatory', 4), ('role', 2), ('neutrophil', 2), ('lymphocyte', 2), ('ratio', 2), ('remains', 2), ('inconsistent', 2), ('conducted', 2), ('evaluate', 2), ('value', 2), ('biomarker', 2), ('prognoses', 2), ('systematically', 2), ('searched', 2), ('pubmed', 2), ('web', 2), ('science', 2), ('embase', 2), ('eligible', 2), ('embracing', 2), ('scale', 2), ('used', 2), ('assess', 2), ('study', 2), ('quality', 2), ('pooled', 2), ('hazard', 2), ('ratios', 2), ('hrs', 2), ('confidence', 2), ('intervals', 2), ('cis', 2), ('involving', 2), ('included', 2), ('worse', 2), ('overall', 2), ('shorter', 2), ('control', 2), ('furthermore', 2), ('poorer', 2), ('unfavorable', 2), ('univariate', 2), ('indicated', 2), ('additionally', 2), ('subgroup', 2), ('showed', 2), ('effects', 2), ('became', 2), ('comprehensive', 2), ('suggested', 2), ('marker', 2), ('therefore', 2), ('markers', 2), ('potentially', 2), ('serve', 2), ('biomarkers', 2)]"', 'b"[(',', 12), ('the', 10), ('.', 9), ('(', 8), (')', 8), ('=', 8), ('of', 5), ('were', 5), ('95', 5), ('%', 5), ('nlr', 4), ('with', 4), ('valu', 4), ('and', 4), ('HR', 4), ('CI', 4), ('to', 3), ('in', 3), ('ovarian', 3), ('cancer', 3), ('thi', 3), ('meta-analysi', 3), ('for', 3), ('studi', 3), ('analysi', 3), ('higher', 3), ('prognost', 2), ('ratio', 2), ('patient', 2), ('wa', 2), ('predict', 2), ('biomark', 2), ('multivari', 2), ('result', 2), ('group', 2), ('surviv', 2), ('OS', 2), ('pf', 2), ('than', 2), ('plr', 2), ('cut-off', 2), ('associ', 2), ('also', 2), ('that', 2), ('inflammatori', 2), ('marker', 2), ('role', 1), ('neutrophil', 1), ('lymphocyt', 1), ('remain', 1), ('inconsist', 1), ('conduct', 1), ('evalu', 1), ('prognos', 1), ('patients.w', 1), ('systemat', 1), ('search', 1), ('pubm', 1), ('web', 1), ('scienc', 1), ('embas', 1), ('elig', 1), ('embrac', 1), ('newcastle-ottawa', 1), ('scale', 1), ('use', 1), ('assess', 1), ('qualiti', 1), ('pool', 1), ('hazard', 1), ('hr', 1), ('confid', 1), ('interv', 1), ('ci', 1), ('calculated.ten', 1), ('involv', 1), ('2919', 1), ('includ', 1), ('In', 1), ('had', 1), ('wors', 1), ('overal', 1), ('1.34', 1), ('1.16-1.54', 1), ('shorter', 1), ('1.36', 1), ('1.17-1.57', 1), ('control', 1), ('furthermor', 1), ('not', 1), ('onli', 1), ('poorer', 1), ('1.97', 1), ('1.61-2.40', 1), ('but', 1), ('more', 1), ('unfavor', 1), ('1.79', 1), ('1.46-2.20', 1), ('univari', 1), ('indic', 1), ('same', 1), ('addit', 1), ('subgroup', 1), ('show', 1), ('when', 1), ('their', 1), ('effect', 1), ('becam', 1), ('stronger.thi', 1), ('comprehens', 1), ('suggest', 1), ('therefor', 1), ('can', 1), ('potenti', 1), ('serv', 1), ('as', 1)]"', 'b'9'', 'b"('nlr', 'hr', 'ci', 'ovarian', 'cancer', 'analysis', 'higher', 'values', 'prognostic', 'patients', 'predictive', 'studies', 'multivariate', 'results', 'group', 'survival', 'os', 'pfs', 'plr', 'associated', 'also', 'inflammatory', 'role', 'neutrophil', 'lymphocyte', 'ratio', 'remains', 'inconsistent', 'conducted', 'evaluate', 'value', 'biomarker', 'prognoses', 'systematically', 'searched', 'pubmed', 'web', 'science', 'embase', 'eligible', 'embracing', 'scale', 'used', 'assess', 'study', 'quality', 'pooled', 'hazard', 'ratios', 'hrs', 'confidence', 'intervals', 'cis', 'involving', 'included', 'worse', 'overall', 'shorter', 'control', 'furthermore', 'poorer', 'unfavorable', 'univariate', 'indicated', 'additionally', 'subgroup', 'showed', 'effects', 'became', 'comprehensive', 'suggested', 'marker', 'therefore', 'markers', 'potentially', 'serve', 'biomarkers')"', 'b'(8, 8, 8, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.005049805817345496'', 'b'[-0.041999195094127514, -0.015599701034961647, -0.00974981314685103, -0.00853108650349465, -0.0077998505174808235, -0.006499875431234019]'', 'b'-3.5108595065168497'', 'b'[-1.5649493574615367, -2.5553480614894135, -3.0253516907351496, -3.1588830833596715, -3.2484952420493594, -3.4308167988433134]'', 'b'-1.6133534471501287'', 'b'[0.8544459738939355, 1.3951933029826276, 1.6518103665379429, 1.7247171096683047, 1.7736444106312883, 1.8731900728687945]'', 'b'81'', 'b'0.22616628915507284'', 'b"['Female', 'Humans', 'Lymphocyte Count', 'Neutrophils', 'Observational Studies as Topic', 'Ovarian Neoplasms', 'Prognosis', 'Survival Analysis']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'69'', 'b'Surgical Management of Dysplasia and Cancer in Inflammatory Bowel Disease.'', 'b'Patients with inflammatory bowel disease are at an increased risk of cancer secondary to long-standing intestinal inflammation. Surgical options must take into account the significant risk of synchronous disease at other colonic sites. Ileal pouch anal anastomosis is a viable option for patients with ulcerative colitis, but this should be restricted to early cancers that are unlikely to require preoperative or postoperative radiation treatment.'', 'b'385'', 'b'64'', 'b"[('patients', 4), ('disease', 4), ('risk', 4), ('inflammatory', 2), ('bowel', 2), ('increased', 2), ('cancer', 2), ('secondary', 2), ('intestinal', 2), ('inflammation', 2), ('surgical', 2), ('options', 2), ('must', 2), ('take', 2), ('account', 2), ('significant', 2), ('synchronous', 2), ('colonic', 2), ('sites', 2), ('ileal', 2), ('pouch', 2), ('anal', 2), ('anastomosis', 2), ('viable', 2), ('option', 2), ('ulcerative', 2), ('colitis', 2), ('restricted', 2), ('early', 2), ('cancers', 2), ('unlikely', 2), ('require', 2), ('preoperative', 2), ('postoperative', 2), ('radiation', 2), ('treatment', 2)]"', 'b"[('to', 3), ('.', 3), ('patient', 2), ('with', 2), ('diseas', 2), ('are', 2), ('at', 2), ('risk', 2), ('of', 2), ('cancer', 2), ('option', 2), ('inflammatori', 1), ('bowel', 1), ('an', 1), ('increas', 1), ('secondari', 1), ('long-stand', 1), ('intestin', 1), ('inflamm', 1), ('surgic', 1), ('must', 1), ('take', 1), ('into', 1), ('account', 1), ('the', 1), ('signific', 1), ('synchron', 1), ('other', 1), ('colon', 1), ('site', 1), ('ileal', 1), ('pouch', 1), ('anal', 1), ('anastomosi', 1), ('is', 1), ('a', 1), ('viabl', 1), ('for', 1), ('ulcer', 1), ('coliti', 1), (',', 1), ('but', 1), ('thi', 1), ('should', 1), ('be', 1), ('restrict', 1), ('earli', 1), ('that', 1), ('unlik', 1), ('requir', 1), ('preoper', 1), ('or', 1), ('postop', 1), ('radiat', 1), ('treatment', 1)]"', 'b'3'', 'b"('patients', 'disease', 'risk', 'inflammatory', 'bowel', 'increased', 'cancer', 'secondary', 'intestinal', 'inflammation', 'surgical', 'options', 'must', 'take', 'account', 'significant', 'synchronous', 'colonic', 'sites', 'ileal', 'pouch', 'anal', 'anastomosis', 'viable', 'option', 'ulcerative', 'colitis', 'restricted', 'early', 'cancers', 'unlikely', 'require', 'preoperative', 'postoperative', 'radiation', 'treatment')"', 'b'(4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.004868165136562963'', 'b'[-0.04246681402307998, -0.015773388065715422, -0.009858367541072138, -0.008626071598438121, -0.007886694032857711, -0.006572245027381425]'', 'b'-3.5108595065168497'', 'b'[-1.5649493574615367, -2.5553480614894135, -3.0253516907351496, -3.1588830833596715, -3.2484952420493594, -3.4308167988433134]'', 'b'-1.5553213902586336'', 'b'[0.8639593731451487, 1.4107273815896153, 1.6702016188631823, 1.7439201054819522, 1.7933921628866143, 1.8940461662685886]'', 'b'40'', 'b'0.16800939925001895'', 'b"['Anastomosis, Surgical', 'Cell Transformation, Neoplastic', 'Colectomy', 'Colitis, Ulcerative', 'Colorectal Neoplasms', 'Comorbidity', 'Crohn Disease', 'Female', 'Humans', 'Incidence', 'Inflammatory Bowel Diseases', 'Male', 'Precancerous Conditions', 'Prognosis', 'Risk Assessment', 'Surgical Stomas', 'Survival Analysis']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'70'', 'b'Wheat Bran for Colon Cancer Prevention: The Synergy between Phytochemical Alkylresorcinol C21 and Intestinal Microbial Metabolite Butyrate.'', 'b'There is convincing evidence that consuming whole grains (WGs) may decrease the risk of colorectal cancer (CRC). Wheat bran (WB) is a rich source of dietary fiber and phytochemicals with health-promoting properties. However, the active components especially the interaction between different components in WG wheat have not been fully explored. Here, we investigated whether one of the major WB phytochemicals, alkylresorcinol (AR) C21, and the major active intestinal microbial metabolite of fiber, butyrate, could synergistically suppress human colon cancer cells. Our results demonstrated for the first time that the combination of C21 and butyrate synergistically inhibited the growth of human colon cancer cells and induced apoptosis. Further mechanistic studies demonstrated that the cotreatment of C21 and butyrate induced significant up-regulations in cleaved Poly(ADP-ribose) polymerase (PARP), cleaved caspase 3, p53 upregulated modulator of apoptosis (PUMA), cytochrome C, lipid-conjugated membrane-bound form of microtubule-associated protein 1'', 'b'914'', 'b'143'', 'b"[('cancer', 6), ('butyrate', 6), ('wheat', 4), ('wb', 4), ('fiber', 4), ('phytochemicals', 4), ('active', 4), ('components', 4), ('major', 4), ('synergistically', 4), ('human', 4), ('colon', 4), ('cells', 4), ('demonstrated', 4), ('induced', 4), ('apoptosis', 4), ('cleaved', 4), ('convincing', 2), ('evidence', 2), ('consuming', 2), ('whole', 2), ('grains', 2), ('wgs', 2), ('may', 2), ('decrease', 2), ('risk', 2), ('colorectal', 2), ('crc', 2), ('bran', 2), ('rich', 2), ('source', 2), ('dietary', 2), ('properties', 2), ('however', 2), ('especially', 2), ('interaction', 2), ('different', 2), ('wg', 2), ('fully', 2), ('explored', 2), ('investigated', 2), ('whether', 2), ('one', 2), ('alkylresorcinol', 2), ('ar', 2), ('intestinal', 2), ('microbial', 2), ('metabolite', 2), ('could', 2), ('suppress', 2), ('results', 2), ('first', 2), ('time', 2), ('combination', 2), ('inhibited', 2), ('growth', 2), ('mechanistic', 2), ('studies', 2), ('cotreatment', 2), ('significant', 2), ('poly', 2), ('polymerase', 2), ('parp', 2), ('caspase', 2), ('upregulated', 2), ('modulator', 2), ('puma', 2), ('cytochrome', 2), ('c', 2), ('form', 2), ('protein', 2)]"', 'b"[(',', 10), ('the', 9), ('of', 9), ('(', 7), (')', 7), ('.', 5), ('and', 5), ('that', 3), ('cancer', 3), ('c21', 3), ('butyr', 3), ('is', 2), ('wheat', 2), ('WB', 2), ('fiber', 2), ('phytochem', 2), ('activ', 2), ('compon', 2), ('in', 2), ('major', 2), ('synergist', 2), ('human', 2), ('colon', 2), ('cell', 2), ('demonstr', 2), ('induc', 2), ('apoptosi', 2), ('cleav', 2), ('there', 1), ('convinc', 1), ('evid', 1), ('consum', 1), ('whole', 1), ('grain', 1), ('wg', 1), ('may', 1), ('decreas', 1), ('risk', 1), ('colorect', 1), ('crc', 1), ('bran', 1), ('a', 1), ('rich', 1), ('sourc', 1), ('dietari', 1), ('with', 1), ('health-promot', 1), ('properti', 1), ('howev', 1), ('especi', 1), ('interact', 1), ('between', 1), ('differ', 1), ('WG', 1), ('have', 1), ('not', 1), ('been', 1), ('fulli', 1), ('explor', 1), ('here', 1), ('we', 1), ('investig', 1), ('whether', 1), ('one', 1), ('alkylresorcinol', 1), ('AR', 1), ('intestin', 1), ('microbi', 1), ('metabolit', 1), ('could', 1), ('suppress', 1), ('our', 1), ('result', 1), ('for', 1), ('first', 1), ('time', 1), ('combin', 1), ('inhibit', 1), ('growth', 1), ('further', 1), ('mechanist', 1), ('studi', 1), ('cotreat', 1), ('signific', 1), ('up-regul', 1), ('poli', 1), ('adp-ribos', 1), ('polymeras', 1), ('parp', 1), ('caspas', 1), ('3', 1), ('p53', 1), ('upregul', 1), ('modul', 1), ('puma', 1), ('cytochrom', 1), ('C', 1), ('lipid-conjug', 1), ('membrane-bound', 1), ('form', 1), ('microtubule-associ', 1), ('protein', 1), ('1', 1)]"', 'b'6'', 'b"('cancer', 'butyrate', 'wheat', 'wb', 'fiber', 'phytochemicals', 'active', 'components', 'major', 'synergistically', 'human', 'colon', 'cells', 'demonstrated', 'induced', 'apoptosis', 'cleaved', 'convincing', 'evidence', 'consuming', 'whole', 'grains', 'wgs', 'may', 'decrease', 'risk', 'colorectal', 'crc', 'bran', 'rich', 'source', 'dietary', 'properties', 'however', 'especially', 'interaction', 'different', 'wg', 'fully', 'explored', 'investigated', 'whether', 'one', 'alkylresorcinol', 'ar', 'intestinal', 'microbial', 'metabolite', 'could', 'suppress', 'results', 'first', 'time', 'combination', 'inhibited', 'growth', 'mechanistic', 'studies', 'cotreatment', 'significant', 'poly', 'polymerase', 'parp', 'caspase', 'upregulated', 'modulator', 'puma', 'cytochrome', 'c', 'form', 'protein')"', 'b'(6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.010668562663886232'', 'b'[-0.11162217935120047, -0.06976386209450029, -0.021465803721384707, -0.015503080465444508, -0.010073516443146682]'', 'b'-2.6888794541139363'', 'b'[-0.6094379124341003, -1.0794415416798357, -2.258096538021482, -2.58351893845611, -3.0253516907351496]'', 'b'-1.1474591580740292'', 'b'[0.3401339398257017, 0.6024480868226149, 1.2602682837967938, 1.4418900715278546, 1.7066520801636402]'', 'b'50'', 'b'0.1272412677025107'', 'b"['Animals', 'Autophagy', 'Butyrates', 'Caspase 3', 'Cell Line, Tumor', 'Colonic Neoplasms', 'Dietary Fiber', 'Gastrointestinal Microbiome', 'Humans', 'Intestines', 'Male', 'Mice', 'Phytochemicals', 'Poly(ADP-ribose) Polymerases', 'Resorcinols']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'71'', 'b'Smoking and gastrointestinal cancer patients-is smoking cessation an attainable goal?'', 'b'Negative consequences of tobacco use during cancer treatment are well-documented but more in-depth, patient-level data are needed to understand patient beliefs about continued smoking (vs cessation) during gastrointestinal (GI) cancer treatment.We conducted semi-structured interviews with 10 patients who were active smokers being treated for GI cancers and 5 caregivers of such patients. All interviews were audio-recorded, transcribed verbatim, and uploaded to NVivo. We consensus coded data inductively using conventional content analysis and iteratively developed our codebook. We developed data matrices to categorize the themes regarding patient perspectives on smoking as well as presumed barriers to smoking cessation during active therapy.Our interviews revealed three consistent themes: (a) Smoking cessation is not necessarily desired by many patients who have received a cancer diagnosis; (b) Failure in past quit attempts may lead to feelings of hopeless about future attempts, especially during cancer treatment; (c) Patients perceived little to no access to smoking cessation treatment at the time of their cancer diagnosis.Well-designed systemic changes that promote the positive and efficacious effects of quitting smoking during cancer treatment, and that provide barrier-free access to such treatments may be helpful in promoting tobacco-free behavior during cancer treatment.'', 'b'1206'', 'b'191'', 'b"[('cancer', 14), ('smoking', 12), ('treatment', 10), ('cessation', 8), ('patients', 8), ('data', 6), ('interviews', 6), ('patient', 4), ('gi', 4), ('active', 4), ('developed', 4), ('themes', 4), ('attempts', 4), ('may', 4), ('access', 4), ('negative', 2), ('consequences', 2), ('tobacco', 2), ('use', 2), ('needed', 2), ('understand', 2), ('beliefs', 2), ('continued', 2), ('vs', 2), ('gastrointestinal', 2), ('conducted', 2), ('smokers', 2), ('treated', 2), ('cancers', 2), ('caregivers', 2), ('transcribed', 2), ('verbatim', 2), ('uploaded', 2), ('nvivo', 2), ('consensus', 2), ('coded', 2), ('inductively', 2), ('using', 2), ('conventional', 2), ('content', 2), ('analysis', 2), ('iteratively', 2), ('codebook', 2), ('matrices', 2), ('categorize', 2), ('regarding', 2), ('perspectives', 2), ('well', 2), ('presumed', 2), ('barriers', 2), ('revealed', 2), ('three', 2), ('consistent', 2), ('necessarily', 2), ('desired', 2), ('many', 2), ('received', 2), ('diagnosis', 2), ('b', 2), ('failure', 2), ('past', 2), ('quit', 2), ('lead', 2), ('feelings', 2), ('hopeless', 2), ('future', 2), ('especially', 2), ('c', 2), ('perceived', 2), ('little', 2), ('time', 2), ('systemic', 2), ('changes', 2), ('promote', 2), ('positive', 2), ('efficacious', 2), ('effects', 2), ('quitting', 2), ('provide', 2), ('treatments', 2), ('helpful', 2), ('promoting', 2), ('behavior', 2)]"', 'b"[('cancer', 8), ('to', 8), ('dure', 6), ('treatment', 6), ('patient', 6), ('smoke', 6), ('of', 5), (',', 5), ('(', 5), (')', 5), ('and', 5), ('cessat', 4), ('.', 4), ('data', 3), ('interview', 3), ('the', 3), ('use', 2), ('are', 2), ('about', 2), ('GI', 2), ('who', 2), ('were', 2), ('activ', 2), ('be', 2), ('such', 2), ('We', 2), ('develop', 2), ('theme', 2), ('as', 2), ('a', 2), (';', 2), ('in', 2), ('quit', 2), ('attempt', 2), ('may', 2), ('access', 2), ('that', 2), ('promot', 2), ('neg', 1), ('consequ', 1), ('tobacco', 1), ('well-docu', 1), ('but', 1), ('more', 1), ('in-depth', 1), ('patient-level', 1), ('need', 1), ('understand', 1), ('belief', 1), ('continu', 1), ('vs', 1), ('gastrointestin', 1), ('treatment.w', 1), ('conduct', 1), ('semi-structur', 1), ('with', 1), ('10', 1), ('smoker', 1), ('treat', 1), ('for', 1), ('5', 1), ('caregiv', 1), ('all', 1), ('audio-record', 1), ('transcrib', 1), ('verbatim', 1), ('upload', 1), ('nvivo', 1), ('consensu', 1), ('code', 1), ('induct', 1), ('convent', 1), ('content', 1), ('analysi', 1), ('iter', 1), ('our', 1), ('codebook', 1), ('matric', 1), ('categor', 1), ('regard', 1), ('perspect', 1), ('on', 1), ('well', 1), ('presum', 1), ('barrier', 1), ('therapy.our', 1), ('reveal', 1), ('three', 1), ('consist', 1), (':', 1), ('is', 1), ('not', 1), ('necessarili', 1), ('desir', 1), ('by', 1), ('mani', 1), ('have', 1), ('receiv', 1), ('diagnosi', 1), ('b', 1), ('failur', 1), ('past', 1), ('lead', 1), ('feel', 1), ('hopeless', 1), ('futur', 1), ('especi', 1), ('c', 1), ('perceiv', 1), ('littl', 1), ('no', 1), ('at', 1), ('time', 1), ('their', 1), ('diagnosis.well-design', 1), ('system', 1), ('chang', 1), ('posit', 1), ('efficaci', 1), ('effect', 1), ('provid', 1), ('barrier-fre', 1), ('help', 1), ('tobacco-fre', 1), ('behavior', 1)]"', 'b'4'', 'b"('cancer', 'smoking', 'treatment', 'cessation', 'patients', 'data', 'interviews', 'patient', 'gi', 'active', 'developed', 'themes', 'attempts', 'may', 'access', 'negative', 'consequences', 'tobacco', 'use', 'needed', 'understand', 'beliefs', 'continued', 'vs', 'gastrointestinal', 'conducted', 'smokers', 'treated', 'cancers', 'caregivers', 'transcribed', 'verbatim', 'uploaded', 'nvivo', 'consensus', 'coded', 'inductively', 'using', 'conventional', 'content', 'analysis', 'iteratively', 'codebook', 'matrices', 'categorize', 'regarding', 'perspectives', 'well', 'presumed', 'barriers', 'revealed', 'three', 'consistent', 'necessarily', 'desired', 'many', 'received', 'diagnosis', 'b', 'failure', 'past', 'quit', 'lead', 'feelings', 'hopeless', 'future', 'especially', 'c', 'perceived', 'little', 'time', 'systemic', 'changes', 'promote', 'positive', 'efficacious', 'effects', 'quitting', 'provide', 'treatments', 'helpful', 'promoting', 'behavior')"', 'b'(14, 12, 10, 8, 8, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.007898887792480927'', 'b'[-0.03167150487792878, -0.014400545583063319, -0.010473124060409685, -0.00778407869354774, -0.007024656381982106]'', 'b'-2.951243718581427'', 'b'[-1.890371757896165, -2.6888794541139363, -3.007333185232471, -3.3040650932041693, -3.4067192472642533]'', 'b'-1.21220023502962'', 'b'[1.0776765303235296, 1.548853245853206, 1.732289544695968, 1.9032135993637995, 1.9623446323571214]'', 'b'74'', 'b'0.08338060094605644'', 'b"['Attitude to Health', 'Female', 'Gastrointestinal Neoplasms', 'Health Knowledge, Attitudes, Practice', 'Health Services Accessibility', 'Humans', 'Interviews as Topic', 'Male', 'Middle Aged', 'Smoking', 'Smoking Cessation']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'72'', 'b'EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.'', 'b'Despite effective therapeutic strategies for treating hormone receptor-positive (HR+) breast cancer, resistance to endocrine therapy that is either de novo or acquired still occurs. We investigated epidermal growth factor receptor (EGFR) as a therapeutic target for overcoming endocrine resistance in HR+ breast cancer models.Using clinical data from 2,166 patients who had HR+ breast tumors and received tamoxifen, we analyzed survival rates. Levels of mRNA and protein expression were analyzed by real-time PCR and western blotting, respectively. Cell viability was analyzed by MTT assays and anchorage-independent growth by soft agar colony-formation assays. Efficacy of tamoxifen and_or gefitinib was analyzed using orthotopic xenograft mouse models.EGFR expression was significantly associated with more advanced stage and higher grade. EGFR expression was different in luminal A-like (Lum A, 1.3%) versus luminal B-like (Lum B, 11.4%) subtypes. On multivariate analyses for survival Lum B subtype EGFR+ tumors showed a hazard ratio (HR) of 5.22 (95% CI, 1.29-21.15, P = 0.020) for overall survival (OS) and HR of 2.91 (95% CI, 1.35-6.28, P = 0.006) for disease-free survival (DFS). Levels of EGFR inversely correlated with ER-\xce\xb1 expression. Basal ER-\xce\xb1 level was completely blocked by TGFA or EGF treatment. With TGFA pretreatment, ER+ breast cancer cells were resistant to 4-hydroxytamoxifen (4-OHT). Conversely, downregulation of ER-\xce\xb1 by TGFA was reversed by gefitinib with recovered sensitivity to 4-OHT. Tumorigenicity of EGFR and ER+ breast cancer cells were significantly decreased by combined tamoxifen and gefitinib.Aberrant EGFR expression was associated with poor prognosis in ER+ breast cancers, especially the Lum B subtype. Loss of ER by EGFR activation induced tamoxifen resistance. Therefore, EGFR could be a therapeutic target for overcoming recurrence of ER+ breast cancer with high EGFR expression.'', 'b'1644'', 'b'277'', 'b"[('egfr', 16), ('breast', 14), ('expression', 12), ('cancer', 10), ('tamoxifen', 8), ('analyzed', 8), ('survival', 8), ('lum', 8), ('therapeutic', 6), ('resistance', 6), ('b', 6), ('tgfa', 6), ('endocrine', 4), ('growth', 4), ('target', 4), ('overcoming', 4), ('tumors', 4), ('levels', 4), ('assays', 4), ('gefitinib', 4), ('significantly', 4), ('associated', 4), ('luminal', 4), ('subtype', 4), ('hr', 4), ('ci', 4), ('p', 4), ('cells', 4), ('despite', 2), ('effective', 2), ('strategies', 2), ('treating', 2), ('hormone', 2), ('therapy', 2), ('either', 2), ('de', 2), ('novo', 2), ('acquired', 2), ('still', 2), ('occurs', 2), ('investigated', 2), ('epidermal', 2), ('factor', 2), ('receptor', 2), ('clinical', 2), ('data', 2), ('patients', 2), ('received', 2), ('rates', 2), ('mrna', 2), ('protein', 2), ('pcr', 2), ('western', 2), ('blotting', 2), ('respectively', 2), ('cell', 2), ('viability', 2), ('mtt', 2), ('soft', 2), ('agar', 2), ('efficacy', 2), ('using', 2), ('orthotopic', 2), ('xenograft', 2), ('mouse', 2), ('advanced', 2), ('stage', 2), ('higher', 2), ('grade', 2), ('different', 2), ('versus', 2), ('subtypes', 2), ('multivariate', 2), ('analyses', 2), ('showed', 2), ('hazard', 2), ('ratio', 2), ('overall', 2), ('os', 2), ('dfs', 2), ('inversely', 2), ('correlated', 2), ('basal', 2), ('level', 2), ('completely', 2), ('blocked', 2), ('egf', 2), ('treatment', 2), ('pretreatment', 2), ('resistant', 2), ('conversely', 2), ('downregulation', 2), ('reversed', 2), ('recovered', 2), ('sensitivity', 2), ('tumorigenicity', 2), ('decreased', 2), ('combined', 2), ('poor', 2), ('prognosis', 2), ('cancers', 2), ('especially', 2), ('loss', 2), ('er', 2), ('activation', 2), ('induced', 2), ('therefore', 2), ('could', 2), ('recurrence', 2), ('high', 2)]"', 'b"[('.', 14), (',', 13), ('(', 10), (')', 10), ('of', 9), ('egfr', 8), ('and', 8), ('by', 8), ('breast', 7), ('wa', 7), ('for', 6), ('cancer', 6), ('express', 6), ('with', 6), ('resist', 4), ('tamoxifen', 4), ('analyz', 4), ('surviv', 4), ('lum', 4), ('%', 4), ('er+', 4), ('therapeut', 3), ('hr+', 3), ('to', 3), ('a', 3), ('in', 3), ('level', 3), ('were', 3), ('cell', 3), ('B', 3), ('subtyp', 3), ('er-\xce\xb1', 3), ('tgfa', 3), ('endocrin', 2), ('or', 2), ('growth', 2), ('target', 2), ('overcom', 2), ('tumor', 2), ('assay', 2), ('gefitinib', 2), ('significantli', 2), ('associ', 2), ('lumin', 2), ('HR', 2), ('95', 2), ('CI', 2), ('P', 2), ('=', 2), ('4-oht', 2), ('despit', 1), ('effect', 1), ('strategi', 1), ('treat', 1), ('hormon', 1), ('receptor-posit', 1), ('therapi', 1), ('that', 1), ('is', 1), ('either', 1), ('de', 1), ('novo', 1), ('acquir', 1), ('still', 1), ('occur', 1), ('We', 1), ('investig', 1), ('epiderm', 1), ('factor', 1), ('receptor', 1), ('as', 1), ('models.us', 1), ('clinic', 1), ('data', 1), ('from', 1), ('2,166', 1), ('patient', 1), ('who', 1), ('had', 1), ('receiv', 1), ('we', 1), ('rate', 1), ('mrna', 1), ('protein', 1), ('real-tim', 1), ('pcr', 1), ('western', 1), ('blot', 1), ('respect', 1), ('viabil', 1), ('mtt', 1), ('anchorage-independ', 1), ('soft', 1), ('agar', 1), ('colony-form', 1), ('efficaci', 1), ('and_or', 1), ('use', 1), ('orthotop', 1), ('xenograft', 1), ('mous', 1), ('models.egfr', 1), ('more', 1), ('advanc', 1), ('stage', 1), ('higher', 1), ('grade', 1), ('differ', 1), ('a-lik', 1), ('A', 1), ('1.3', 1), ('versu', 1), ('b-like', 1), ('11.4', 1), ('On', 1), ('multivari', 1), ('analys', 1), ('egfr+', 1), ('show', 1), ('hazard', 1), ('ratio', 1), ('5.22', 1), ('1.29-21.15', 1), ('0.020', 1), ('overal', 1), ('OS', 1), ('2.91', 1), ('1.35-6.28', 1), ('0.006', 1), ('disease-fre', 1), ('df', 1), ('invers', 1), ('correl', 1), ('basal', 1), ('complet', 1), ('block', 1), ('egf', 1), ('treatment', 1), ('pretreat', 1), ('4-hydroxytamoxifen', 1), ('convers', 1), ('downregul', 1), ('revers', 1), ('recov', 1), ('sensit', 1), ('tumorigen', 1), ('decreas', 1), ('combin', 1), ('gefitinib.aberr', 1), ('poor', 1), ('prognosi', 1), ('especi', 1), ('the', 1), ('loss', 1), ('ER', 1), ('activ', 1), ('induc', 1), ('therefor', 1), ('could', 1), ('be', 1), ('recurr', 1), ('high', 1)]"', 'b'14'', 'b"('egfr', 'breast', 'expression', 'cancer', 'tamoxifen', 'analyzed', 'survival', 'lum', 'therapeutic', 'resistance', 'b', 'tgfa', 'endocrine', 'growth', 'target', 'overcoming', 'tumors', 'levels', 'assays', 'gefitinib', 'significantly', 'associated', 'luminal', 'subtype', 'hr', 'ci', 'p', 'cells', 'despite', 'effective', 'strategies', 'treating', 'hormone', 'therapy', 'either', 'de', 'novo', 'acquired', 'still', 'occurs', 'investigated', 'epidermal', 'factor', 'receptor', 'clinical', 'data', 'patients', 'received', 'rates', 'mrna', 'protein', 'pcr', 'western', 'blotting', 'respectively', 'cell', 'viability', 'mtt', 'soft', 'agar', 'efficacy', 'using', 'orthotopic', 'xenograft', 'mouse', 'advanced', 'stage', 'higher', 'grade', 'different', 'versus', 'subtypes', 'multivariate', 'analyses', 'showed', 'hazard', 'ratio', 'overall', 'os', 'dfs', 'inversely', 'correlated', 'basal', 'level', 'completely', 'blocked', 'egf', 'treatment', 'pretreatment', 'resistant', 'conversely', 'downregulation', 'reversed', 'recovered', 'sensitivity', 'tumorigenicity', 'decreased', 'combined', 'poor', 'prognosis', 'cancers', 'especially', 'loss', 'er', 'activation', 'induced', 'therefore', 'could', 'recurrence', 'high')"', 'b'(16, 14, 12, 10, 8, 8, 8, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.007596034773862866'', 'b'[-0.03232897474720671, -0.014694666622552975, -0.010687030270947617, -0.007943063039217824, -0.007168130059781939]'', 'b'-2.951243718581427'', 'b'[-1.890371757896165, -2.6888794541139363, -3.007333185232471, -3.3040650932041693, -3.4067192472642533]'', 'b'-1.1657229954494213'', 'b'[1.1000480548294418, 1.5804874866574607, 1.7676703431972605, 1.9420854017539875, 2.0024241446073128]'', 'b'81'', 'b'0.2524145992407703'', 'b"['Adult', 'Aged', 'Animals', 'Antineoplastic Agents', 'Breast Neoplasms', 'Cell Line, Tumor', 'Drug Resistance, Neoplasm', 'Estrogen Receptor alpha', 'Female', 'Humans', 'Mice', 'Mice, Nude', 'Middle Aged', 'Neoplasm Grading', 'Neoplasm Staging', 'Proportional Hazards Models', 'Receptor, ErbB-2', 'Receptors, Estrogen', 'Survival Rate', 'Tamoxifen']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'73'', 'b'Anaplastic Thyroid Cancer: A Rare Entity Presented Clinically Only with Fever and Elevated CRP.'', 'b'Anaplastic thyroid carcinoma (ATC) is a rare but almost invariably lethal disease. In this manuscript, we present a case where the dominant manifestation of ATC beside the goitre was elevated CRP values and a persistent low-grade fever. The patient underwent surgical removal of the tumour, chemotherapy and radiotherapy treatment. She is still alive and healthy 11 months after the surgery. We aim to demonstrate that ATC can be present with no specific symptoms or findings and to raise awareness towards an earlier diagnosis.'', 'b'446'', 'b'83'', 'b"[('atc', 6), ('present', 4), ('anaplastic', 2), ('thyroid', 2), ('carcinoma', 2), ('rare', 2), ('almost', 2), ('invariably', 2), ('lethal', 2), ('disease', 2), ('manuscript', 2), ('case', 2), ('dominant', 2), ('manifestation', 2), ('beside', 2), ('goitre', 2), ('elevated', 2), ('crp', 2), ('values', 2), ('persistent', 2), ('fever', 2), ('patient', 2), ('underwent', 2), ('surgical', 2), ('removal', 2), ('tumour', 2), ('chemotherapy', 2), ('radiotherapy', 2), ('treatment', 2), ('still', 2), ('alive', 2), ('healthy', 2), ('months', 2), ('surgery', 2), ('aim', 2), ('demonstrate', 2), ('specific', 2), ('symptoms', 2), ('findings', 2), ('raise', 2), ('awareness', 2), ('towards', 2), ('earlier', 2), ('diagnosis', 2)]"', 'b"[('.', 5), ('the', 5), ('and', 4), ('atc', 3), ('a', 3), ('is', 2), (',', 2), ('present', 2), ('of', 2), ('to', 2), ('anaplast', 1), ('thyroid', 1), ('carcinoma', 1), ('(', 1), (')', 1), ('rare', 1), ('but', 1), ('almost', 1), ('invari', 1), ('lethal', 1), ('diseas', 1), ('In', 1), ('thi', 1), ('manuscript', 1), ('we', 1), ('case', 1), ('where', 1), ('domin', 1), ('manifest', 1), ('besid', 1), ('goitr', 1), ('wa', 1), ('elev', 1), ('crp', 1), ('valu', 1), ('persist', 1), ('low-grad', 1), ('fever', 1), ('patient', 1), ('underw', 1), ('surgic', 1), ('remov', 1), ('tumour', 1), ('chemotherapi', 1), ('radiotherapi', 1), ('treatment', 1), ('she', 1), ('still', 1), ('aliv', 1), ('healthi', 1), ('11', 1), ('month', 1), ('after', 1), ('surgeri', 1), ('We', 1), ('aim', 1), ('demonstr', 1), ('that', 1), ('can', 1), ('be', 1), ('with', 1), ('no', 1), ('specif', 1), ('symptom', 1), ('or', 1), ('find', 1), ('rais', 1), ('awar', 1), ('toward', 1), ('an', 1), ('earlier', 1), ('diagnosi', 1)]"', 'b'5'', 'b"('atc', 'present', 'anaplastic', 'thyroid', 'carcinoma', 'rare', 'almost', 'invariably', 'lethal', 'disease', 'manuscript', 'case', 'dominant', 'manifestation', 'beside', 'goitre', 'elevated', 'crp', 'values', 'persistent', 'fever', 'patient', 'underwent', 'surgical', 'removal', 'tumour', 'chemotherapy', 'radiotherapy', 'treatment', 'still', 'alive', 'healthy', 'months', 'surgery', 'aim', 'demonstrate', 'specific', 'symptoms', 'findings', 'raise', 'awareness', 'towards', 'earlier', 'diagnosis')"', 'b'(6, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.006120800350079092'', 'b'[-0.2968087926064561, -0.015621515400339793]'', 'b'-3.1271343850450917'', 'b'[0.3068528194400547, -2.6375861597263857]'', 'b'-1.1867150448011585'', 'b'[-0.18215322969177905, 1.5657175269277757]'', 'b'22'', 'b'0.11258160868873397'', 'b"['C-Reactive Protein', 'Female', 'Fever', 'Humans', 'Thyroid Carcinoma, Anaplastic', 'Thyroid Neoplasms', 'Treatment Outcome']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'74'', 'b'The association of matrix metalloproteinas-2 promoter polymorphisms with lung cancer susceptibility in Taiwan.'', 'b'Matrix metalloproteinases-2 (MMP2) has been reported to be overexpressed in various types of cancer. However, the contribution of various genotypes of MMP2 to lung cancer is controversial and not yet been examined in Taiwan. Therefore, in the current study, we investigated the association of MMP2 genotypes with lung cancer risk among Taiwanese. In this hospital-based, case-control study, 358 lung cancer patients and 716 age- and gender-matched healthy controls were recruited, and the genotypic distributions of MMP2-1306 and MMP2- 735 were determined. Then, their association with lung cancer was evaluated, and their interaction with personal smoking status was also examined via stratification analysis. The results showed that the percentages of variant CT and TT at MMP2-1306 were 17.3% and 1.7% among the lung cancer patients, respectively, much lower than those of 28.7% and 2.4%, respectively, among the healthy controls (P for trend = 0.0001). The allelic frequency distribution analysis showed that the variant T allele at MMP2-1306 conferred a statistically significantly lower lung cancer risk than the wild-type C allele (adjusted odds ratio = 0.54, 95% confidence interval = 0.41-0.72, P = 0.0001). There was an obvious effect of MMP2-1306 genotype on lung cancer risk among the subpopulations of ever smokers but not nonsmokers. As for the genotypes of MMP2-735, there was no such differential distribution in the aspects of genotypic or allelic frequencies, or combinative effects with smoking status. The genotypes of MMP2-1306 may act as a biomarker in determining personal susceptibility to lung cancer in Taiwan. The contribution of MMP2 genotypes alone and its joint effects with personal cigarette smoking habit on lung cancer susceptibility should be taken into consideration of the clinical practices for early detection and prediction of lung cancer in Taiwan.'', 'b'1605'', 'b'285'', 'b"[('cancer', 22), ('lung', 20), ('genotypes', 10), ('among', 8), ('taiwan', 6), ('risk', 6), ('personal', 6), ('smoking', 6), ('various', 4), ('contribution', 4), ('examined', 4), ('study', 4), ('association', 4), ('patients', 4), ('healthy', 4), ('controls', 4), ('genotypic', 4), ('status', 4), ('analysis', 4), ('showed', 4), ('variant', 4), ('respectively', 4), ('lower', 4), ('p', 4), ('allelic', 4), ('distribution', 4), ('allele', 4), ('effects', 4), ('susceptibility', 4), ('matrix', 2), ('reported', 2), ('overexpressed', 2), ('types', 2), ('however', 2), ('controversial', 2), ('yet', 2), ('therefore', 2), ('current', 2), ('investigated', 2), ('taiwanese', 2), ('recruited', 2), ('distributions', 2), ('determined', 2), ('evaluated', 2), ('interaction', 2), ('also', 2), ('via', 2), ('stratification', 2), ('results', 2), ('percentages', 2), ('ct', 2), ('tt', 2), ('much', 2), ('trend', 2), ('frequency', 2), ('conferred', 2), ('statistically', 2), ('significantly', 2), ('c', 2), ('adjusted', 2), ('odds', 2), ('ratio', 2), ('confidence', 2), ('interval', 2), ('obvious', 2), ('effect', 2), ('genotype', 2), ('subpopulations', 2), ('ever', 2), ('smokers', 2), ('nonsmokers', 2), ('differential', 2), ('aspects', 2), ('frequencies', 2), ('combinative', 2), ('may', 2), ('act', 2), ('biomarker', 2), ('determining', 2), ('alone', 2), ('joint', 2), ('cigarette', 2), ('habit', 2), ('taken', 2), ('consideration', 2), ('clinical', 2), ('practices', 2), ('early', 2), ('detection', 2), ('prediction', 2)]"', 'b"[('the', 17), (',', 16), ('of', 15), ('cancer', 11), ('.', 11), ('and', 11), ('lung', 10), ('genotyp', 8), ('in', 7), ('with', 5), ('mmp2-1306', 5), ('%', 5), ('mmp2', 4), ('among', 4), ('wa', 4), ('=', 4), ('allel', 4), ('(', 3), (')', 3), ('to', 3), ('taiwan', 3), ('risk', 3), ('were', 3), ('distribut', 3), ('person', 3), ('smoke', 3), ('for', 3), ('effect', 3), ('been', 2), ('be', 2), ('variou', 2), ('contribut', 2), ('not', 2), ('examin', 2), ('studi', 2), ('associ', 2), ('patient', 2), ('healthi', 2), ('control', 2), ('determin', 2), ('their', 2), ('statu', 2), ('analysi', 2), ('show', 2), ('that', 2), ('variant', 2), ('at', 2), ('respect', 2), ('lower', 2), ('than', 2), ('P', 2), ('0.0001', 2), ('frequenc', 2), ('a', 2), ('there', 2), ('on', 2), ('or', 2), ('suscept', 2), ('matrix', 1), ('metalloproteinases-2', 1), ('ha', 1), ('report', 1), ('overexpress', 1), ('type', 1), ('howev', 1), ('is', 1), ('controversi', 1), ('yet', 1), ('therefor', 1), ('current', 1), ('we', 1), ('investig', 1), ('taiwanes', 1), ('In', 1), ('thi', 1), ('hospital-bas', 1), ('case-control', 1), ('358', 1), ('716', 1), ('age-', 1), ('gender-match', 1), ('recruit', 1), ('mmp2-', 1), ('735', 1), ('then', 1), ('evalu', 1), ('interact', 1), ('also', 1), ('via', 1), ('stratif', 1), ('result', 1), ('percentag', 1), ('CT', 1), ('TT', 1), ('17.3', 1), ('1.7', 1), ('much', 1), ('those', 1), ('28.7', 1), ('2.4', 1), ('trend', 1), ('T', 1), ('confer', 1), ('statist', 1), ('significantli', 1), ('wild-typ', 1), ('C', 1), ('adjust', 1), ('odd', 1), ('ratio', 1), ('0.54', 1), ('95', 1), ('confid', 1), ('interv', 1), ('0.41-0.72', 1), ('an', 1), ('obviou', 1), ('subpopul', 1), ('ever', 1), ('smoker', 1), ('but', 1), ('nonsmok', 1), ('As', 1), ('mmp2-735', 1), ('no', 1), ('such', 1), ('differenti', 1), ('aspect', 1), ('combin', 1), ('may', 1), ('act', 1), ('as', 1), ('biomark', 1), ('alon', 1), ('it', 1), ('joint', 1), ('cigarett', 1), ('habit', 1), ('should', 1), ('taken', 1), ('into', 1), ('consider', 1), ('clinic', 1), ('practic', 1), ('earli', 1), ('detect', 1), ('predict', 1)]"', 'b'11'', 'b"('cancer', 'lung', 'genotypes', 'among', 'taiwan', 'risk', 'personal', 'smoking', 'various', 'contribution', 'examined', 'study', 'association', 'patients', 'healthy', 'controls', 'genotypic', 'status', 'analysis', 'showed', 'variant', 'respectively', 'lower', 'p', 'allelic', 'distribution', 'allele', 'effects', 'susceptibility', 'matrix', 'reported', 'overexpressed', 'types', 'however', 'controversial', 'yet', 'therefore', 'current', 'investigated', 'taiwanese', 'recruited', 'distributions', 'determined', 'evaluated', 'interaction', 'also', 'via', 'stratification', 'results', 'percentages', 'ct', 'tt', 'much', 'trend', 'frequency', 'conferred', 'statistically', 'significantly', 'c', 'adjusted', 'odds', 'ratio', 'confidence', 'interval', 'obvious', 'effect', 'genotype', 'subpopulations', 'ever', 'smokers', 'nonsmokers', 'differential', 'aspects', 'frequencies', 'combinative', 'may', 'act', 'biomarker', 'determining', 'alone', 'joint', 'cigarette', 'habit', 'taken', 'consideration', 'clinical', 'practices', 'early', 'detection', 'prediction')"', 'b'(22, 20, 10, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.009933331352021325'', 'b'[-0.19980490096574602, -0.02750810943699946, -0.022414015096814375, -0.01592574756878916, -0.011638046300269003, -0.009455912618968564, -0.008770701559623017, -0.00694214866276106, -0.006430621919189192]'', 'b'-2.6018680771243066'', 'b'[-0.09861228866810978, -2.0910424533583156, -2.295836866004329, -2.6375861597263857, -2.951243718581427, -3.1588830833596715, -3.2341065045972597, -3.477336814478207, -3.5538768916005408]'', 'b'-0.947657983958485'', 'b'[0.0591096557140117, 1.2654537421766325, 1.389390898709989, 1.5962101920879082, 1.7860289740918929, 1.9116878342263708, 1.9572114245062107, 2.1243366422607726, 2.171095670536507]'', 'b'4'', 'b'0.18418453037182622'', 'b"['Case-Control Studies', 'Genetic Predisposition to Disease', 'Genotype', 'Humans', 'Lung Neoplasms', 'Matrix Metalloproteinase 2', 'Polymorphism, Single Nucleotide', 'Risk Factors', 'Taiwan']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'75'', 'b'Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells.'', 'b'Although Taxol has improved the survival of cancer patients as a first-line chemotherapeutic agent, an increasing number of patients develop resistance to Taxol after prolonged treatment. The potential mechanisms of cancer cell resistance to Taxol are not completely clear. It has been reported that microRNAs (miRNAs) are involved in regulating the sensitivity of cancer cells to various chemotherapeutic agents. In this study, we aimed to explore the role of miR-129-5p in regulating the sensitivity of breast cancer cells to Taxol. Cell apoptosis and autophagy, and the sensitivity of MCF-7 cells to Taxol were assessed with a series of in vitro assays. Our results showed that the inhibition of autophagy increased the Taxol-induced apoptosis and the sensitivity of MCF-7 cells to Taxol. Up-regulation of miR-129-5p also inhibited autophagy and induced apoptosis. Furthermore, miR-129-5p overexpression increased the sensitivity of MCF-7 cells to Taxol. High mobility group box 1 (HMGB1), a target gene of miR-129-5p and a regulator of autophagy, was negatively regulated by miR-129-5p. We found that interference of HMGB1 enhanced the chemosensitivity of Taxol by inhibiting autophagy and inducing apoptosis in MCF-7 cells. Taken together, our findings suggested that miR-129-5p increased the chemosensitivity of MCF-7 cells to Taxol through suppressing autophagy and enhancing apoptosis by inhibiting HMGB1. Using miR-129-5p_HMGB1_autophagy-based therapeutic strategies may be a potential treatment for overcoming Taxol resistance in breast cancer.'', 'b'1333'', 'b'222'', 'b"[('taxol', 20), ('cells', 14), ('autophagy', 12), ('cancer', 10), ('sensitivity', 10), ('apoptosis', 10), ('resistance', 6), ('increased', 6), ('patients', 4), ('chemotherapeutic', 4), ('treatment', 4), ('potential', 4), ('cell', 4), ('regulating', 4), ('breast', 4), ('chemosensitivity', 4), ('inhibiting', 4), ('although', 2), ('improved', 2), ('survival', 2), ('agent', 2), ('increasing', 2), ('number', 2), ('develop', 2), ('prolonged', 2), ('mechanisms', 2), ('completely', 2), ('clear', 2), ('reported', 2), ('micrornas', 2), ('mirnas', 2), ('involved', 2), ('various', 2), ('agents', 2), ('study', 2), ('aimed', 2), ('explore', 2), ('role', 2), ('assessed', 2), ('series', 2), ('vitro', 2), ('assays', 2), ('results', 2), ('showed', 2), ('inhibition', 2), ('also', 2), ('inhibited', 2), ('induced', 2), ('furthermore', 2), ('overexpression', 2), ('high', 2), ('mobility', 2), ('group', 2), ('box', 2), ('target', 2), ('gene', 2), ('regulator', 2), ('negatively', 2), ('regulated', 2), ('found', 2), ('interference', 2), ('enhanced', 2), ('inducing', 2), ('taken', 2), ('together', 2), ('findings', 2), ('suggested', 2), ('suppressing', 2), ('enhancing', 2), ('using', 2), ('therapeutic', 2), ('strategies', 2), ('may', 2), ('overcoming', 2)]"', 'b"[('of', 17), ('the', 12), ('.', 12), ('taxol', 10), ('to', 9), ('cell', 9), (',', 7), ('and', 7), ('mir-129-5p', 6), ('autophagi', 6), ('cancer', 5), ('a', 5), ('in', 5), ('sensit', 5), ('apoptosi', 5), ('mcf-7', 5), ('increas', 4), ('that', 4), ('regul', 4), ('inhibit', 4), ('resist', 3), ('hmgb1', 3), ('by', 3), ('ha', 2), ('patient', 2), ('chemotherapeut', 2), ('agent', 2), ('treatment', 2), ('potenti', 2), ('are', 2), ('(', 2), (')', 2), ('breast', 2), ('our', 2), ('induc', 2), ('enhanc', 2), ('chemosensit', 2), ('although', 1), ('improv', 1), ('surviv', 1), ('as', 1), ('first-lin', 1), ('an', 1), ('number', 1), ('develop', 1), ('after', 1), ('prolong', 1), ('mechan', 1), ('not', 1), ('complet', 1), ('clear', 1), ('It', 1), ('been', 1), ('report', 1), ('microrna', 1), ('mirna', 1), ('involv', 1), ('variou', 1), ('In', 1), ('thi', 1), ('studi', 1), ('we', 1), ('aim', 1), ('explor', 1), ('role', 1), ('were', 1), ('assess', 1), ('with', 1), ('seri', 1), ('vitro', 1), ('assay', 1), ('result', 1), ('show', 1), ('taxol-induc', 1), ('up-regul', 1), ('also', 1), ('furthermor', 1), ('overexpress', 1), ('high', 1), ('mobil', 1), ('group', 1), ('box', 1), ('1', 1), ('target', 1), ('gene', 1), ('wa', 1), ('neg', 1), ('We', 1), ('found', 1), ('interfer', 1), ('taken', 1), ('togeth', 1), ('find', 1), ('suggest', 1), ('through', 1), ('suppress', 1), ('use', 1), ('mir-129-5p_hmgb1_autophagy-bas', 1), ('therapeut', 1), ('strategi', 1), ('may', 1), ('be', 1), ('for', 1), ('overcom', 1)]"', 'b'12'', 'b"('taxol', 'cells', 'autophagy', 'cancer', 'sensitivity', 'apoptosis', 'resistance', 'increased', 'patients', 'chemotherapeutic', 'treatment', 'potential', 'cell', 'regulating', 'breast', 'chemosensitivity', 'inhibiting', 'although', 'improved', 'survival', 'agent', 'increasing', 'number', 'develop', 'prolonged', 'mechanisms', 'completely', 'clear', 'reported', 'micrornas', 'mirnas', 'involved', 'various', 'agents', 'study', 'aimed', 'explore', 'role', 'assessed', 'series', 'vitro', 'assays', 'results', 'showed', 'inhibition', 'also', 'inhibited', 'induced', 'furthermore', 'overexpression', 'high', 'mobility', 'group', 'box', 'target', 'gene', 'regulator', 'negatively', 'regulated', 'found', 'interference', 'enhanced', 'inducing', 'taken', 'together', 'findings', 'suggested', 'suppressing', 'enhancing', 'using', 'therapeutic', 'strategies', 'may', 'overcoming')"', 'b'(20, 14, 12, 10, 10, 10, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.008953442877168585'', 'b'[-0.15415177585940273, -0.04110714022917406, -0.018685063740533664]'', 'b'-2.6635616461296463'', 'b'[-0.3862943611198906, -1.70805020110221, -2.4965075614664802]'', 'b'-0.9300738348891177'', 'b'[0.2381918470844182, 1.0531958870276625, 1.5393642961859397]'', 'b'77'', 'b'0.2561806806548928'', 'b"['Antineoplastic Agents, Phytogenic', 'Apoptosis', 'Autophagy', 'Breast Neoplasms', 'Drug Resistance, Neoplasm', 'Female', 'Gene Expression Regulation, Neoplastic', 'HMGB1 Protein', 'Humans', 'MCF-7 Cells', 'MicroRNAs', 'Paclitaxel', 'Up-Regulation']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'77'', 'b'Dysregulation of miR-195-5p_-218-5p_BIRC5 axis predicts a poor prognosis in patients with gastric cancer.'', 'b'MicroRNAs (miRNAs) function by negatively regulating their target genes. Aberrant expression of baculoviral IAP repeat containing 5 (BIRC5) is associated with the tumor growth and metastasis, however, the clinical significance of miRNAs_BIRC5 axis in gastric cancer (GC) remains unknown. The association of BIRC5 or miR-195-5p_-218-5p expression levels with the clinicopathological characteristics and prognosis in patients with GC was analysed by using a tissue microarray and TCGA dataset. Pearson correlation analysis was used for analysing the correlation of BIRC5 with miR-195-5p_-218-5p expression in GC tissues. Cox proportional hazard regression model was conducted to assess whether BIRC5 or miR-195-5p_-218-5p was an independent prognostic factor in patients with GC. We found that BIRC5 expression levels were increased in GC tissues as compared with the adjacent normal tissues, and acted as an independent prognostic factor of tumor recurrence in patients with GC. Increased expression of BIRC5 was traceable to the dysregulation of miR-195-5p_-218-5p rather than its genetic and epigenetic alterations in GC tissues. MiR-195-5p_-218-5p displayed a negative correlation with BIRC5 expression, and acted as independent prognostic factors of poor prognosis in patients with GC. In conclusion, dysregulation of miR-195-5p_-218-5p_BIRC5 axis predicts a poor prognosis in patients with gastric cancer.'', 'b'1215'', 'b'195'', 'b"[('gc', 16), ('expression', 12), ('patients', 10), ('tissues', 8), ('prognosis', 6), ('correlation', 6), ('independent', 6), ('prognostic', 6), ('tumor', 4), ('axis', 4), ('gastric', 4), ('cancer', 4), ('levels', 4), ('factor', 4), ('increased', 4), ('acted', 4), ('dysregulation', 4), ('poor', 4), ('micrornas', 2), ('mirnas', 2), ('function', 2), ('negatively', 2), ('regulating', 2), ('target', 2), ('genes', 2), ('aberrant', 2), ('baculoviral', 2), ('iap', 2), ('repeat', 2), ('containing', 2), ('associated', 2), ('growth', 2), ('metastasis', 2), ('however', 2), ('clinical', 2), ('significance', 2), ('remains', 2), ('unknown', 2), ('association', 2), ('clinicopathological', 2), ('characteristics', 2), ('analysed', 2), ('using', 2), ('tissue', 2), ('microarray', 2), ('tcga', 2), ('dataset', 2), ('pearson', 2), ('analysis', 2), ('used', 2), ('analysing', 2), ('cox', 2), ('proportional', 2), ('hazard', 2), ('regression', 2), ('model', 2), ('conducted', 2), ('assess', 2), ('whether', 2), ('found', 2), ('compared', 2), ('adjacent', 2), ('normal', 2), ('recurrence', 2), ('traceable', 2), ('rather', 2), ('genetic', 2), ('epigenetic', 2), ('alterations', 2), ('displayed', 2), ('negative', 2), ('factors', 2), ('conclusion', 2), ('predicts', 2)]"', 'b"[('with', 10), ('.', 9), ('of', 9), ('in', 9), ('GC', 8), ('birc5', 7), ('the', 7), ('express', 6), ('and', 6), (',', 5), ('mir-195-5p_-218-5p', 5), ('patient', 5), ('wa', 5), ('tissu', 5), ('(', 3), (')', 3), ('prognosi', 3), ('a', 3), ('correl', 3), ('independ', 3), ('prognost', 3), ('factor', 3), ('as', 3), ('by', 2), ('neg', 2), ('associ', 2), ('tumor', 2), ('axi', 2), ('gastric', 2), ('cancer', 2), ('or', 2), ('level', 2), ('analys', 2), ('use', 2), ('to', 2), ('an', 2), ('increas', 2), ('act', 2), ('dysregul', 2), ('poor', 2), ('microrna', 1), ('mirna', 1), ('function', 1), ('regul', 1), ('their', 1), ('target', 1), ('gene', 1), ('aberr', 1), ('baculovir', 1), ('iap', 1), ('repeat', 1), ('contain', 1), ('5', 1), ('is', 1), ('growth', 1), ('metastasi', 1), ('howev', 1), ('clinic', 1), ('signific', 1), ('mirnas_birc5', 1), ('remain', 1), ('unknown', 1), ('clinicopatholog', 1), ('characterist', 1), ('microarray', 1), ('tcga', 1), ('dataset', 1), ('pearson', 1), ('analysi', 1), ('for', 1), ('cox', 1), ('proport', 1), ('hazard', 1), ('regress', 1), ('model', 1), ('conduct', 1), ('assess', 1), ('whether', 1), ('We', 1), ('found', 1), ('that', 1), ('were', 1), ('compar', 1), ('adjac', 1), ('normal', 1), ('recurr', 1), ('traceabl', 1), ('rather', 1), ('than', 1), ('it', 1), ('genet', 1), ('epigenet', 1), ('alter', 1), ('display', 1), ('In', 1), ('conclus', 1), ('mir-195-5p_-218-5p_birc5', 1), ('predict', 1)]"', 'b'9'', 'b"('gc', 'expression', 'patients', 'tissues', 'prognosis', 'correlation', 'independent', 'prognostic', 'tumor', 'axis', 'gastric', 'cancer', 'levels', 'factor', 'increased', 'acted', 'dysregulation', 'poor', 'micrornas', 'mirnas', 'function', 'negatively', 'regulating', 'target', 'genes', 'aberrant', 'baculoviral', 'iap', 'repeat', 'containing', 'associated', 'growth', 'metastasis', 'however', 'clinical', 'significance', 'remains', 'unknown', 'association', 'clinicopathological', 'characteristics', 'analysed', 'using', 'tissue', 'microarray', 'tcga', 'dataset', 'pearson', 'analysis', 'used', 'analysing', 'cox', 'proportional', 'hazard', 'regression', 'model', 'conducted', 'assess', 'whether', 'found', 'compared', 'adjacent', 'normal', 'recurrence', 'traceable', 'rather', 'genetic', 'epigenetic', 'alterations', 'displayed', 'negative', 'factors', 'conclusion', 'predicts')"', 'b'(16, 12, 10, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.019296488870887668'', 'b'[-0.02556319837158678, -0.02130266530965565, -0.015587316080235843, -0.009235245553943911]'', 'b'-1.8076800420510515'', 'b'[-2.2188758248682006, -2.4011973816621555, -2.713572066704308, -3.2456340097683265]'', 'b'-0.5780425466247726'', 'b'[1.4180390718256015, 1.5345571249191114, 1.7341895259189735, 2.0922010486792577]'', 'b'75'', 'b'0.2561806806548928'', 'b"['Gene Expression Regulation, Neoplastic', 'Humans', 'MicroRNAs', 'Neoplasm Recurrence, Local', 'Prognosis', 'Stomach Neoplasms', 'Survivin']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'78'', 'b'Socio-demographic characteristics are related to the advanced clinical stage of oral cancer.'', 'b'Social determinants may be associated with the onset and progression of the clinical stage of oral cancer.To evaluate the impact of socio-demographic characteristics on the prevalence of advanced clinical stage of oral cancer.Information about 51,116 cases of oral cancer, from all Brazilian states, between 2000 and 2012, was obtained from the Cancer Registry Information System. The clinical stage of oral cancer (dependent variable) was classified as initial (stages I and II) or advanced (stages III and IV). The relationship between the clinical stage of oral cancer and the following independent variables was analyzed: sex, age, schooling, marital status, family history of cancer, and origin of referral. Analyses on frequency distribution and multivariate binary logistic regression model were performed (\xce\xb1<0.05).Compared to individuals with no schooling, those who attended elementary to high school (OR=2.461) and college education (OR = 3.050) had a higher prevalence of advanced cases of oral cancer. Individuals without a partner (OR = 14,209) demonstrated a higher prevalence compared to married individuals. Subjects aged 20-44 years (OR = 4.081) and 45-64 years (OR = 14.875) had a higher prevalence compared to those aged 15-19 years. The variables gender, family history of cancer and origin of referral integrated the binary model of logistic regression, but did not present statistical significance.Socioeconomic factors may be related to the advanced clinical stage of oral cancer.'', 'b'1282'', 'b'222'', 'b"[('cancer', 16), ('oral', 14), ('clinical', 10), ('stage', 10), ('prevalence', 8), ('advanced', 8), ('individuals', 6), ('higher', 6), ('years', 6), ('may', 4), ('cases', 4), ('stages', 4), ('variables', 4), ('schooling', 4), ('family', 4), ('history', 4), ('origin', 4), ('referral', 4), ('binary', 4), ('logistic', 4), ('regression', 4), ('model', 4), ('compared', 4), ('aged', 4), ('social', 2), ('determinants', 2), ('associated', 2), ('onset', 2), ('progression', 2), ('evaluate', 2), ('impact', 2), ('characteristics', 2), ('brazilian', 2), ('states', 2), ('obtained', 2), ('registry', 2), ('information', 2), ('system', 2), ('dependent', 2), ('variable', 2), ('classified', 2), ('initial', 2), ('ii', 2), ('iii', 2), ('iv', 2), ('relationship', 2), ('following', 2), ('independent', 2), ('analyzed', 2), ('sex', 2), ('age', 2), ('marital', 2), ('status', 2), ('analyses', 2), ('frequency', 2), ('distribution', 2), ('multivariate', 2), ('performed', 2), ('\xce\xb1', 2), ('attended', 2), ('elementary', 2), ('high', 2), ('school', 2), ('college', 2), ('education', 2), ('without', 2), ('partner', 2), ('demonstrated', 2), ('married', 2), ('subjects', 2), ('gender', 2), ('integrated', 2), ('present', 2), ('statistical', 2), ('factors', 2), ('related', 2)]"', 'b"[('of', 16), ('the', 12), (',', 11), ('and', 10), ('(', 9), (')', 9), ('cancer', 8), ('stage', 7), ('oral', 7), ('.', 7), ('clinic', 5), ('to', 5), ('preval', 4), ('advanc', 4), ('OR', 4), ('=', 4), ('a', 4), ('wa', 3), ('variabl', 3), ('age', 3), ('school', 3), ('individu', 3), ('higher', 3), ('year', 3), ('may', 2), ('be', 2), ('with', 2), ('on', 2), ('case', 2), ('from', 2), ('between', 2), ('famili', 2), ('histori', 2), ('origin', 2), ('referr', 2), ('binari', 2), ('logist', 2), ('regress', 2), ('model', 2), ('those', 2), ('had', 2), ('compar', 2), ('social', 1), ('determin', 1), ('associ', 1), ('onset', 1), ('progress', 1), ('cancer.to', 1), ('evalu', 1), ('impact', 1), ('socio-demograph', 1), ('characterist', 1), ('cancer.inform', 1), ('about', 1), ('51,116', 1), ('all', 1), ('brazilian', 1), ('state', 1), ('2000', 1), ('2012', 1), ('obtain', 1), ('registri', 1), ('inform', 1), ('system', 1), ('depend', 1), ('classifi', 1), ('as', 1), ('initi', 1), ('I', 1), ('II', 1), ('or', 1), ('iii', 1), ('IV', 1), ('relationship', 1), ('follow', 1), ('independ', 1), ('analyz', 1), (':', 1), ('sex', 1), ('marit', 1), ('statu', 1), ('analys', 1), ('frequenc', 1), ('distribut', 1), ('multivari', 1), ('were', 1), ('perform', 1), ('\xce\xb1', 1), ('<', 1), ('0.05', 1), ('.compar', 1), ('no', 1), ('who', 1), ('attend', 1), ('elementari', 1), ('high', 1), ('or=2.461', 1), ('colleg', 1), ('educ', 1), ('3.050', 1), ('without', 1), ('partner', 1), ('14,209', 1), ('demonstr', 1), ('marri', 1), ('subject', 1), ('20-44', 1), ('4.081', 1), ('45-64', 1), ('14.875', 1), ('15-19', 1), ('gender', 1), ('integr', 1), ('but', 1), ('did', 1), ('not', 1), ('present', 1), ('statist', 1), ('significance.socioeconom', 1), ('factor', 1), ('relat', 1)]"', 'b'7'', 'b"('cancer', 'oral', 'clinical', 'stage', 'prevalence', 'advanced', 'individuals', 'higher', 'years', 'may', 'cases', 'stages', 'variables', 'schooling', 'family', 'history', 'origin', 'referral', 'binary', 'logistic', 'regression', 'model', 'compared', 'aged', 'social', 'determinants', 'associated', 'onset', 'progression', 'evaluate', 'impact', 'characteristics', 'brazilian', 'states', 'obtained', 'registry', 'information', 'system', 'dependent', 'variable', 'classified', 'initial', 'ii', 'iii', 'iv', 'relationship', 'following', 'independent', 'analyzed', 'sex', 'age', 'marital', 'status', 'analyses', 'frequency', 'distribution', 'multivariate', 'performed', '\xce\xb1', 'attended', 'elementary', 'high', 'school', 'college', 'education', 'without', 'partner', 'demonstrated', 'married', 'subjects', 'gender', 'integrated', 'present', 'statistical', 'factors', 'related')"', 'b'(16, 14, 10, 10, 8, 8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.009088739569975652'', 'b'[-0.06501297954762546, -0.0204877894137775, -0.01599046978636293, -0.013379780841650611, -0.01024389470688875, -0.00910568418390111, -0.007450105241373637, -0.007049561948826668, -0.0065560926124088, -0.0062364043963060835, -0.005850078460251725, -0.0050876254463952985, -0.00482955748896945, -0.004509193168541346]'', 'b'-2.5145260669691587'', 'b'[-1.3025850929940455, -2.4657359027997265, -2.713572066704308, -2.891820298110627, -3.1588830833596715, -3.2766661190160553, -3.477336814478207, -3.5325994931532563, -3.605170185988091, -3.663439094112067, -3.727387818712341, -3.875197323201151, -3.927253685157205, -4.003946305945459]'', 'b'-0.7678901181704874'', 'b'[0.8468493800986368, 1.6165592936496431, 1.7790429779758994, 1.8959041692856895, 2.0709930046277476, 2.1482126536211377, 2.2797742200257725, 2.3160049439661137, 2.3635829622832984, 2.4217488932447275, 2.464022764611671, 2.582737378983067, 2.617431847580271, 2.6901305321663673]'', 'b'40'', 'b'0.08711724891521684'', 'b"['Adolescent', 'Adult', 'Brazil', 'Humans', 'Marital Status', 'Mouth Neoplasms', 'Prevalence', 'Socioeconomic Factors', 'Young Adult']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'79'', 'b'Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo.'', 'b'Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide and new improvements are urgently needed. Several miRNA-targeted therapeutics have reached clinical development. MicroRNA-143 (miR-143) was found to significantly suppress the migration and invasion of NSCLC. It might be of great potential for NSCLC treatment. However, the therapeutic effect of miR-143 against NSCLC in vivo has not been explored until now.The cationic liposome_pVAX-miR-143 complex (CL-pVAX-miR-143) was prepared and its biodistribution was assessed. The tumor suppression effects of CL-pVAX-miR-143 were evaluated in early-stage and advanced experimental lung cancer metastasis mice models by systemic delivery, respectively, and also in subcutaneous tumor models by intratumoral injection. The toxicity of CL-pVAX-miR-143 was assessed by H&E analysis and biochemical measurements. The preliminary mechanism of CL-pVAX-miR-143 on tumor suppression was explored by immunochemistry and western blotting.The assays on the stability and safety of CL-pVAX-miR-143 showed that it mainly accumulated in the lung after systemic administration. The intratumoral delivery of CL-pVAX-miR-143 effectively inhibited A549 subcutaneous tumor growth. Notably, systemic delivery of CL-pVAX-miR-143 significantly inhibited tumor metastasis and prolonged survival dose dependently in early-stage experimental lung cancer metastasis models. More importantly, same results were shown in advanced mice models with metastasis. CL-pVAX-miR-143 treatment did not induce obvious acute toxicity. The preliminary mechanism on inhibiting tumor metastasis might be induced by targeting CD44v3.Our results suggested that CL-pVAX-miR-143 might be a promising strategy for clinical treatment of non-small cell lung cancer, especially for advanced NSCLC with metastasis.'', 'b'1613'', 'b'240'', 'b"[('tumor', 12), ('metastasis', 12), ('lung', 10), ('nsclc', 10), ('cancer', 8), ('models', 8), ('might', 6), ('treatment', 6), ('advanced', 6), ('systemic', 6), ('delivery', 6), ('cell', 4), ('clinical', 4), ('significantly', 4), ('explored', 4), ('assessed', 4), ('suppression', 4), ('experimental', 4), ('mice', 4), ('subcutaneous', 4), ('intratumoral', 4), ('toxicity', 4), ('preliminary', 4), ('mechanism', 4), ('inhibited', 4), ('results', 4), ('remains', 2), ('leading', 2), ('cause', 2), ('deaths', 2), ('worldwide', 2), ('new', 2), ('improvements', 2), ('urgently', 2), ('needed', 2), ('several', 2), ('therapeutics', 2), ('reached', 2), ('development', 2), ('found', 2), ('suppress', 2), ('migration', 2), ('invasion', 2), ('great', 2), ('potential', 2), ('however', 2), ('therapeutic', 2), ('effect', 2), ('vivo', 2), ('cationic', 2), ('complex', 2), ('prepared', 2), ('biodistribution', 2), ('effects', 2), ('evaluated', 2), ('respectively', 2), ('also', 2), ('injection', 2), ('h', 2), ('e', 2), ('analysis', 2), ('biochemical', 2), ('measurements', 2), ('immunochemistry', 2), ('western', 2), ('assays', 2), ('stability', 2), ('safety', 2), ('showed', 2), ('mainly', 2), ('accumulated', 2), ('administration', 2), ('effectively', 2), ('growth', 2), ('notably', 2), ('prolonged', 2), ('survival', 2), ('dose', 2), ('dependently', 2), ('importantly', 2), ('shown', 2), ('induce', 2), ('obvious', 2), ('acute', 2), ('inhibiting', 2), ('induced', 2), ('targeting', 2), ('suggested', 2), ('promising', 2), ('strategy', 2), ('especially', 2)]"', 'b"[('.', 13), ('of', 11), ('the', 10), ('and', 9), ('cl-pvax-mir-143', 9), (',', 6), ('in', 6), ('tumor', 6), ('metastasi', 6), ('lung', 5), ('nsclc', 5), ('wa', 5), ('by', 5), ('cancer', 4), ('model', 4), ('(', 3), (')', 3), ('suppress', 3), ('might', 3), ('be', 3), ('for', 3), ('treatment', 3), ('effect', 3), ('advanc', 3), ('system', 3), ('deliveri', 3), ('on', 3), ('inhibit', 3), ('non-smal', 2), ('cell', 2), ('therapeut', 2), ('clinic', 2), ('mir-143', 2), ('significantli', 2), ('not', 2), ('explor', 2), ('it', 2), ('assess', 2), ('were', 2), ('early-stag', 2), ('experiment', 2), ('mice', 2), ('subcutan', 2), ('intratumor', 2), ('toxic', 2), ('preliminari', 2), ('mechan', 2), ('that', 2), ('result', 2), ('with', 2), ('induc', 2), ('remain', 1), ('lead', 1), ('caus', 1), ('cancer-rel', 1), ('death', 1), ('worldwid', 1), ('new', 1), ('improv', 1), ('are', 1), ('urgent', 1), ('need', 1), ('sever', 1), ('mirna-target', 1), ('have', 1), ('reach', 1), ('develop', 1), ('microrna-143', 1), ('found', 1), ('to', 1), ('migrat', 1), ('invas', 1), ('It', 1), ('great', 1), ('potenti', 1), ('howev', 1), ('against', 1), ('vivo', 1), ('ha', 1), ('been', 1), ('until', 1), ('now.th', 1), ('cation', 1), ('liposome_pvax-mir-143', 1), ('complex', 1), ('prepar', 1), ('biodistribut', 1), ('evalu', 1), ('respect', 1), ('also', 1), ('inject', 1), ('H', 1), ('&', 1), ('E', 1), ('analysi', 1), ('biochem', 1), ('measur', 1), ('immunochemistri', 1), ('western', 1), ('blotting.th', 1), ('assay', 1), ('stabil', 1), ('safeti', 1), ('show', 1), ('mainli', 1), ('accumul', 1), ('after', 1), ('administr', 1), ('a549', 1), ('growth', 1), ('notabl', 1), ('prolong', 1), ('surviv', 1), ('dose', 1), ('depend', 1), ('more', 1), ('importantli', 1), ('same', 1), ('shown', 1), ('did', 1), ('obviou', 1), ('acut', 1), ('target', 1), ('cd44v3.our', 1), ('suggest', 1), ('a', 1), ('promis', 1), ('strategi', 1), ('especi', 1)]"', 'b'13'', 'b"('tumor', 'metastasis', 'lung', 'nsclc', 'cancer', 'models', 'might', 'treatment', 'advanced', 'systemic', 'delivery', 'cell', 'clinical', 'significantly', 'explored', 'assessed', 'suppression', 'experimental', 'mice', 'subcutaneous', 'intratumoral', 'toxicity', 'preliminary', 'mechanism', 'inhibited', 'results', 'remains', 'leading', 'cause', 'deaths', 'worldwide', 'new', 'improvements', 'urgently', 'needed', 'several', 'therapeutics', 'reached', 'development', 'found', 'suppress', 'migration', 'invasion', 'great', 'potential', 'however', 'therapeutic', 'effect', 'vivo', 'cationic', 'complex', 'prepared', 'biodistribution', 'effects', 'evaluated', 'respectively', 'also', 'injection', 'h', 'e', 'analysis', 'biochemical', 'measurements', 'immunochemistry', 'western', 'assays', 'stability', 'safety', 'showed', 'mainly', 'accumulated', 'administration', 'effectively', 'growth', 'notably', 'prolonged', 'survival', 'dose', 'dependently', 'importantly', 'shown', 'induce', 'obvious', 'acute', 'inhibiting', 'induced', 'targeting', 'suggested', 'promising', 'strategy', 'especially')"', 'b'(12, 12, 10, 10, 8, 8, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0'', 'b'[-0.0, -0.0, -0.0, -0.0, -0.0]'', 'b'1'', 'b'[1, 1, 1, 1, 1]'', 'b'0.3053816495511819'', 'b'[-0.6718697821126605, -0.6718697821126605, -0.6718697821126605, -0.6718697821126605, -0.6718697821126605]'', 'b'75'', 'b'0.14165087424314754'', 'b"['A549 Cells', 'Animals', 'Carcinoma, Non-Small-Cell Lung', 'Cations', 'Cell Line, Tumor', 'Cell Movement', 'Cell Proliferation', 'Female', 'Humans', 'Liposomes', 'Lung Neoplasms', 'Mice', 'Mice, Inbred BALB C', 'Mice, Nude', 'MicroRNAs', 'Tissue Distribution']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'80'', 'b"The duration of endocrine therapy and breast cancer patients' survival: A nationwide population-based cohort study."', 'b"As research progressed, the recommended duration of endocrine therapy for breast cancer patients has been extended from 5 to 10 years. This study aimed to investigate how the duration of endocrine medication and therapy affect survival rate in the real world. By using the National Health Insurance Research Database (NHIRD), this study examined 1002 breast cancer patients newly diagnosed between 2000 and 2005 as research subjects, and conducted follow-up until 2013. Among these subjects, 51 used aromatase inhibitors (AIs), 561 used tamoxifen, and 390 alternated between the use of tamoxifen and AIs. The mean follow-up period in this study was 9.63 years, and the mean duration of taking endocrine medication was 4.04 years. The tamoxifen group had the longest follow-up period (9.87 years), shortest endocrine therapy duration (3.29 years), and best survival rate (86.1%). Patients were divided into 3 groups based on the duration of endocrine therapy: under 2 years, 2 to 5 years, and over 5 years. It was found that patients who received medication for less than 2 years showed the lowest survival rate with statistically significant differences (P\xe2\x80\x8a<\xe2\x80\x8a.001). Therefore, the extension of endocrine therapy duration is critical in improving breast cancer patients' survival rate."', 'b'1086'', 'b'199'', 'b"[('years', 18), ('duration', 12), ('endocrine', 12), ('therapy', 10), ('patients', 10), ('survival', 8), ('rate', 8), ('research', 6), ('breast', 6), ('cancer', 6), ('study', 6), ('medication', 6), ('tamoxifen', 6), ('subjects', 4), ('used', 4), ('ais', 4), ('mean', 4), ('period', 4), ('progressed', 2), ('recommended', 2), ('extended', 2), ('aimed', 2), ('investigate', 2), ('affect', 2), ('real', 2), ('world', 2), ('using', 2), ('national', 2), ('health', 2), ('insurance', 2), ('database', 2), ('nhird', 2), ('examined', 2), ('newly', 2), ('diagnosed', 2), ('conducted', 2), ('among', 2), ('aromatase', 2), ('inhibitors', 2), ('alternated', 2), ('use', 2), ('taking', 2), ('group', 2), ('longest', 2), ('shortest', 2), ('best', 2), ('divided', 2), ('groups', 2), ('based', 2), ('found', 2), ('received', 2), ('less', 2), ('showed', 2), ('lowest', 2), ('statistically', 2), ('significant', 2), ('differences', 2), ('p', 2), ('therefore', 2), ('extension', 2), ('critical', 2), ('improving', 2)]"', 'b'[(\',\', 12), (\'the\', 12), (\'year\', 9), (\'.\', 9), (\'and\', 8), (\'durat\', 6), (\'of\', 6), (\'endocrin\', 6), (\'(\', 6), (\')\', 6), (\'therapi\', 5), (\'patient\', 5), (\'surviv\', 4), (\'rate\', 4), (\'use\', 4), (\'research\', 3), (\'breast\', 3), (\'cancer\', 3), (\'5\', 3), (\'to\', 3), (\'thi\', 3), (\'studi\', 3), (\'medic\', 3), (\'in\', 3), (\'follow-up\', 3), (\'tamoxifen\', 3), (\'wa\', 3), (\'2\', 3), (\'for\', 2), (\'between\', 2), (\'subject\', 2), (\'ai\', 2), (\'mean\', 2), (\'period\', 2), (\'group\', 2), (\'As\', 1), (\'progress\', 1), (\'recommend\', 1), (\'ha\', 1), (\'been\', 1), (\'extend\', 1), (\'from\', 1), (\'10\', 1), (\'aim\', 1), (\'investig\', 1), (\'how\', 1), (\'affect\', 1), (\'real\', 1), (\'world\', 1), (\'By\', 1), (\'nation\', 1), (\'health\', 1), (\'insur\', 1), (\'databas\', 1), (\'nhird\', 1), (\'examin\', 1), (\'1002\', 1), (\'newli\', 1), (\'diagnos\', 1), (\'2000\', 1), (\'2005\', 1), (\'as\', 1), (\'conduct\', 1), (\'until\', 1), (\'2013\', 1), (\'among\', 1), (\'these\', 1), (\'51\', 1), (\'aromatas\', 1), (\'inhibitor\', 1), (\'561\', 1), (\'390\', 1), (\'altern\', 1), (\'9.63\', 1), (\'take\', 1), (\'4.04\', 1), (\'had\', 1), (\'longest\', 1), (\'9.87\', 1), (\'shortest\', 1), (\'3.29\', 1), (\'best\', 1), (\'86.1\', 1), (\'%\', 1), (\'were\', 1), (\'divid\', 1), (\'into\', 1), (\'3\', 1), (\'base\', 1), (\'on\', 1), (\':\', 1), (\'under\', 1), (\'over\', 1), (\'It\', 1), (\'found\', 1), (\'that\', 1), (\'who\', 1), (\'receiv\', 1), (\'less\', 1), (\'than\', 1), (\'show\', 1), (\'lowest\', 1), (\'with\', 1), (\'statist\', 1), (\'signific\', 1), (\'differ\', 1), (\'P\', 1), (\'<\', 1), (\'.001\', 1), (\'therefor\', 1), (\'extens\', 1), (\'is\', 1), (\'critic\', 1), (\'improv\', 1), ("\'", 1)]'', 'b'9'', 'b"('years', 'duration', 'endocrine', 'therapy', 'patients', 'survival', 'rate', 'research', 'breast', 'cancer', 'study', 'medication', 'tamoxifen', 'subjects', 'used', 'ais', 'mean', 'period', 'progressed', 'recommended', 'extended', 'aimed', 'investigate', 'affect', 'real', 'world', 'using', 'national', 'health', 'insurance', 'database', 'nhird', 'examined', 'newly', 'diagnosed', 'conducted', 'among', 'aromatase', 'inhibitors', 'alternated', 'use', 'taking', 'group', 'longest', 'shortest', 'best', 'divided', 'groups', 'based', 'found', 'received', 'less', 'showed', 'lowest', 'statistically', 'significant', 'differences', 'p', 'therefore', 'extension', 'critical', 'improving')"', 'b'(18, 12, 12, 10, 10, 8, 8, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.022090808001044685'', 'b'[-0.6772317252540457, -0.0620513701117644, -0.03126682379359552, -0.02166084939249829, -0.015519923032135311, -0.0113486851681813, -0.00853991924463066, -0.007595545398540291, -0.006799821594883689, -0.006253240582288748, -0.009405685293895797]'', 'b'-1.578838469622204'', 'b'[1.0, -1.3978952727983707, -2.0910424533583156, -2.4657359027997265, -2.8066624897703196, -3.1271343850450917, -3.4188406077965983, -3.543294782270004, -3.653960350157523, -3.74493212836325, -3.343805421853684]'', 'b'-0.4597530488252421'', 'b'[-0.6772317252540457, 0.9541544864488731, 1.438365630549807, 1.7091178890310617, 1.960163361828748, 2.200309544097201, 2.4233196841702966, 2.5298460996394185, 2.6088592420642387, 2.693065579744776, 2.4217101741123237]'', 'b'88'', 'b'0.1766670460820435'', 'b"['Antineoplastic Agents, Hormonal', 'Breast Neoplasms', 'Drug Administration Schedule', 'Female', 'Humans', 'Middle Aged', 'Retrospective Studies', 'Survival Rate', 'Taiwan']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'81'', 'b'Osimertinib or EGFR-TKIs_chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.'', 'b'The aim of this meta-analysis is to investigate the impact of Osimertinib on treatment efficacy in advanced nonsmall cell lung cancer (NSCLC).Trials comparing Osimertinib against epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)_chemotherapy in patients with NSCLC with an epidermal growth factor receptor (EGFR) mutation were included, and the pooled data for progression-free survival (PFS), overall survival (OS), overall response rate (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed.Analysis results based on 6 eligible trials showed that Osimertinib significantly improved the overall PFS (hazard ratio [HR]\xe2\x80\x8a=\xe2\x80\x8a0.38, 95% confidence interval [CI]\xe2\x80\x8a=\xe2\x80\x8a0.29-0.50), improved the OS (HR\xe2\x80\x8a=\xe2\x80\x8a0.66, 95% CI\xe2\x80\x8a=\xe2\x80\x8a0.48-0.89), increased the ORR (odds ratio [OR]\xe2\x80\x8a=\xe2\x80\x8a1.76, 95% CI\xe2\x80\x8a=\xe2\x80\x8a1.14-2.72), increased the overall DCR (OR\xe2\x80\x8a=\xe2\x80\x8a1.18, 95% CI\xe2\x80\x8a=\xe2\x80\x8a1.02-1.37), and reduced the grade 3 or greater AEs (relative ratio [RR]\xe2\x80\x8a=\xe2\x80\x8a0.50, 95% CI\xe2\x80\x8a=\xe2\x80\x8a0.33-0.75) in all subgroups except in the ORR in the Exon 19 deletion (Ex19del) and_or L858R subgroup. Compared to patients with Ex19del and_or L858R mutation, patients with the T790M mutation had the benefits of a greater PFS (41.7%), a greater ORR (80.0%), a greater DCR (71.2%), and fewer grade 3 or greater AEs (70.7%) (each P\xe2\x80\x8a<\xe2\x80\x8a.05). Race, sex, age, EGFR mutation, and smoking history may significantly predict additional benefits from Osimertinib, but there were no significant differences between subgroups stratified by these clinical characteristics.Osimertinib showed greater treatment benefit for patients with NSCLC with EGFR mutation than EGFR-TKIs_chemotherapy, especially for T790M mutation-positive patients.'', 'b'1436'', 'b'250'', 'b"[('greater', 12), ('patients', 10), ('mutation', 10), ('ci', 10), ('osimertinib', 8), ('overall', 8), ('orr', 8), ('nsclc', 6), ('egfr', 6), ('pfs', 6), ('dcr', 6), ('aes', 6), ('ratio', 6), ('treatment', 4), ('epidermal', 4), ('growth', 4), ('factor', 4), ('receptor', 4), ('survival', 4), ('os', 4), ('rate', 4), ('showed', 4), ('significantly', 4), ('improved', 4), ('hr', 4), ('increased', 4), ('grade', 4), ('subgroups', 4), ('benefits', 4), ('aim', 2), ('investigate', 2), ('impact', 2), ('efficacy', 2), ('advanced', 2), ('nonsmall', 2), ('cell', 2), ('lung', 2), ('cancer', 2), ('comparing', 2), ('tyrosine', 2), ('kinase', 2), ('inhibitors', 2), ('included', 2), ('pooled', 2), ('data', 2), ('response', 2), ('disease', 2), ('control', 2), ('adverse', 2), ('events', 2), ('results', 2), ('based', 2), ('eligible', 2), ('trials', 2), ('hazard', 2), ('confidence', 2), ('interval', 2), ('odds', 2), ('reduced', 2), ('relative', 2), ('rr', 2), ('except', 2), ('exon', 2), ('deletion', 2), ('subgroup', 2), ('compared', 2), ('fewer', 2), ('p', 2), ('race', 2), ('sex', 2), ('age', 2), ('smoking', 2), ('history', 2), ('may', 2), ('predict', 2), ('additional', 2), ('significant', 2), ('differences', 2), ('stratified', 2), ('clinical', 2), ('benefit', 2), ('especially', 2)]"', 'b"[(',', 24), ('(', 19), (')', 19), ('the', 12), ('=', 10), ('%', 9), ('with', 6), ('greater', 6), ('in', 5), ('patient', 5), ('mutat', 5), ('and', 5), ('95', 5), ('CI', 5), ('osimertinib', 4), ('overal', 4), ('orr', 4), ('[', 4), (']', 4), ('of', 3), ('nsclc', 3), ('egfr', 3), ('were', 3), ('for', 3), ('pf', 3), ('dcr', 3), ('ae', 3), ('ratio', 3), ('subgroup', 3), ('.', 3), ('benefit', 3), ('a', 3), ('to', 2), ('on', 2), ('treatment', 2), ('compar', 2), ('epiderm', 2), ('growth', 2), ('factor', 2), ('receptor', 2), ('surviv', 2), ('OS', 2), ('rate', 2), ('show', 2), ('significantli', 2), ('improv', 2), ('HR', 2), ('increas', 2), ('OR', 2), ('grade', 2), ('3', 2), ('or', 2), ('ex19del', 2), ('and_or', 2), ('l858r', 2), ('t790m', 2), ('aim', 1), ('thi', 1), ('meta-analysi', 1), ('is', 1), ('investig', 1), ('impact', 1), ('efficaci', 1), ('advanc', 1), ('nonsmal', 1), ('cell', 1), ('lung', 1), ('cancer', 1), ('.trial', 1), ('against', 1), ('tyrosin', 1), ('kinas', 1), ('inhibitor', 1), ('egfr-tki', 1), ('_chemotherapi', 1), ('an', 1), ('includ', 1), ('pool', 1), ('data', 1), ('progression-fre', 1), ('respons', 1), ('diseas', 1), ('control', 1), ('advers', 1), ('event', 1), ('analyzed.analysi', 1), ('result', 1), ('base', 1), ('6', 1), ('elig', 1), ('trial', 1), ('that', 1), ('hazard', 1), ('0.38', 1), ('confid', 1), ('interv', 1), ('0.29-0.50', 1), ('0.66', 1), ('0.48-0.89', 1), ('odd', 1), ('1.76', 1), ('1.14-2.72', 1), ('1.18', 1), ('1.02-1.37', 1), ('reduc', 1), ('rel', 1), ('RR', 1), ('0.50', 1), ('0.33-0.75', 1), ('all', 1), ('except', 1), ('exon', 1), ('19', 1), ('delet', 1), ('had', 1), ('41.7', 1), ('80.0', 1), ('71.2', 1), ('fewer', 1), ('70.7', 1), ('each', 1), ('P', 1), ('<', 1), ('.05', 1), ('race', 1), ('sex', 1), ('age', 1), ('smoke', 1), ('histori', 1), ('may', 1), ('predict', 1), ('addit', 1), ('from', 1), ('but', 1), ('there', 1), ('no', 1), ('signific', 1), ('differ', 1), ('between', 1), ('stratifi', 1), ('by', 1), ('these', 1), ('clinic', 1), ('characteristics.osimertinib', 1), ('than', 1), ('egfr-tkis_chemotherapi', 1), ('especi', 1), ('mutation-posit', 1)]"', 'b'3'', 'b"('greater', 'patients', 'mutation', 'ci', 'osimertinib', 'overall', 'orr', 'nsclc', 'egfr', 'pfs', 'dcr', 'aes', 'ratio', 'treatment', 'epidermal', 'growth', 'factor', 'receptor', 'survival', 'os', 'rate', 'showed', 'significantly', 'improved', 'hr', 'increased', 'grade', 'subgroups', 'benefits', 'aim', 'investigate', 'impact', 'efficacy', 'advanced', 'nonsmall', 'cell', 'lung', 'cancer', 'comparing', 'tyrosine', 'kinase', 'inhibitors', 'included', 'pooled', 'data', 'response', 'disease', 'control', 'adverse', 'events', 'results', 'based', 'eligible', 'trials', 'hazard', 'confidence', 'interval', 'odds', 'reduced', 'relative', 'rr', 'except', 'exon', 'deletion', 'subgroup', 'compared', 'fewer', 'p', 'race', 'sex', 'age', 'smoking', 'history', 'may', 'predict', 'additional', 'significant', 'differences', 'stratified', 'clinical', 'benefit', 'especially')"', 'b'(12, 10, 10, 10, 8, 8, 8, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.011647511453129644'', 'b'[-0.08103631523749417, -0.04319941994670556, -0.02640814046871255, -0.019590538814407785, -0.015509176561406164, -0.01306035920960519, -0.01200710443463703, -0.010947654043345528, -0.009544108653173023, -0.00845955085167609, -0.007370697771757385, -0.006691321575522632]'', 'b'-2.169685580677429'', 'b'[-1.1972245773362196, -1.8332133440562162, -2.332204510175204, -2.6375861597263857, -2.871201010907891, -3.0430512678345503, -3.1271343850450917, -3.219507705176107, -3.3567088266895917, -3.477336814478207, -3.6151205168412597, -3.718498871295094]'', 'b'-0.6014602160850082'', 'b'[0.8731680143318425, 1.3462938027304112, 1.7244971605812087, 1.9635258934616522, 2.1374382442300006, 2.265370531116332, 2.3279654068276137, 2.3967318451384236, 2.498869913201251, 2.5886702697225688, 2.6912420345497443, 2.7867472333179832]'', 'b'72'', 'b'0.2524145992407703'', 'b"['Acrylamides', 'Aniline Compounds', 'Antineoplastic Agents', 'Carcinoma, Non-Small-Cell Lung', 'ErbB Receptors', 'Humans', 'Lung Neoplasms', 'Mutation', 'Protein Kinase Inhibitors']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'82'', 'b'Timescale of tumor volume of a young breast cancer patient with luminal B subtype: A case report.'', 'b"It is largely unknown about the tumor growth of breast cancer naturally. We devised and analyzed an appropriate mathematical tool of the equations that describe how fast tumors grow without treatment on the basis of the ellipsoid shape of solid breast cancer.A 31-year-old woman presented with a painless palpable lump in her left breast for 5 months.Infiltrated ductal breast cancer (histologic grade II) of luminal B INTERVENTIONS:: The patient did not receive any therapy due to her private reasons for 2 years, the analysis of the tumor volume growth was done regarding the growth rate of the tumor in the absence of intervention.After 2 years of diagnosis of breast cancer, the tumor mass occupied the whole left breast with skin implanted and nipple abnormality. As this case indicated that the tumor's early growth rate was very slow. When the tumor volume reached 300 cm, its fast growth began without treatment. Later growth approached the maximum, when the tumor volume was more than 800 cm.The tumor growth is segmental without therapy. Early diagnosis and treatment is the key to good prognosis for every breast cancer patient."', 'b'955'', 'b'185'', 'b"[('tumor', 16), ('growth', 14), ('breast', 14), ('cancer', 8), ('without', 6), ('treatment', 6), ('volume', 6), ('fast', 4), ('left', 4), ('patient', 4), ('therapy', 4), ('years', 4), ('rate', 4), ('diagnosis', 4), ('early', 4), ('largely', 2), ('unknown', 2), ('naturally', 2), ('devised', 2), ('analyzed', 2), ('appropriate', 2), ('mathematical', 2), ('tool', 2), ('equations', 2), ('describe', 2), ('tumors', 2), ('grow', 2), ('basis', 2), ('ellipsoid', 2), ('shape', 2), ('solid', 2), ('woman', 2), ('presented', 2), ('painless', 2), ('palpable', 2), ('lump', 2), ('ductal', 2), ('histologic', 2), ('grade', 2), ('ii', 2), ('luminal', 2), ('b', 2), ('interventions', 2), ('receive', 2), ('due', 2), ('private', 2), ('reasons', 2), ('analysis', 2), ('done', 2), ('regarding', 2), ('absence', 2), ('mass', 2), ('occupied', 2), ('whole', 2), ('skin', 2), ('implanted', 2), ('nipple', 2), ('abnormality', 2), ('case', 2), ('indicated', 2), ('slow', 2), ('reached', 2), ('cm', 2), ('began', 2), ('later', 2), ('approached', 2), ('maximum', 2), ('segmental', 2), ('key', 2), ('good', 2), ('prognosis', 2), ('every', 2)]"', 'b'[(\'the\', 17), (\'of\', 10), (\'tumor\', 9), (\'growth\', 7), (\'breast\', 7), (\'.\', 6), (\'cancer\', 4), (\',\', 4), (\'is\', 3), (\'and\', 3), (\'without\', 3), (\'treatment\', 3), (\'for\', 3), (\'volum\', 3), (\'wa\', 3), (\'that\', 2), (\'fast\', 2), (\'with\', 2), (\'in\', 2), (\'her\', 2), (\'left\', 2), (\':\', 2), (\'patient\', 2), (\'therapi\', 2), (\'to\', 2), (\'2\', 2), (\'year\', 2), (\'rate\', 2), (\'diagnosi\', 2), (\'earli\', 2), (\'when\', 2), (\'It\', 1), (\'larg\', 1), (\'unknown\', 1), (\'about\', 1), (\'natur\', 1), (\'We\', 1), (\'devis\', 1), (\'analyz\', 1), (\'an\', 1), (\'appropri\', 1), (\'mathemat\', 1), (\'tool\', 1), (\'equat\', 1), (\'describ\', 1), (\'how\', 1), (\'grow\', 1), (\'on\', 1), (\'basi\', 1), (\'ellipsoid\', 1), (\'shape\', 1), (\'solid\', 1), (\'cancer.a\', 1), (\'31-year-old\', 1), (\'woman\', 1), (\'present\', 1), (\'a\', 1), (\'painless\', 1), (\'palpabl\', 1), (\'lump\', 1), (\'5\', 1), (\'months.infiltr\', 1), (\'ductal\', 1), (\'(\', 1), (\'histolog\', 1), (\'grade\', 1), (\'II\', 1), (\')\', 1), (\'lumin\', 1), (\'B\', 1), (\'intervent\', 1), (\'did\', 1), (\'not\', 1), (\'receiv\', 1), (\'ani\', 1), (\'due\', 1), (\'privat\', 1), (\'reason\', 1), (\'analysi\', 1), (\'done\', 1), (\'regard\', 1), (\'absenc\', 1), (\'intervention.aft\', 1), (\'mass\', 1), (\'occupi\', 1), (\'whole\', 1), (\'skin\', 1), (\'implant\', 1), (\'nippl\', 1), (\'abnorm\', 1), (\'As\', 1), (\'thi\', 1), (\'case\', 1), (\'indic\', 1), ("\'s", 1), (\'veri\', 1), (\'slow\', 1), (\'reach\', 1), (\'300\', 1), (\'cm\', 1), (\'it\', 1), (\'began\', 1), (\'later\', 1), (\'approach\', 1), (\'maximum\', 1), (\'more\', 1), (\'than\', 1), (\'800\', 1), (\'cm.the\', 1), (\'segment\', 1), (\'key\', 1), (\'good\', 1), (\'prognosi\', 1), (\'everi\', 1)]'', 'b'6'', 'b"('tumor', 'growth', 'breast', 'cancer', 'without', 'treatment', 'volume', 'fast', 'left', 'patient', 'therapy', 'years', 'rate', 'diagnosis', 'early', 'largely', 'unknown', 'naturally', 'devised', 'analyzed', 'appropriate', 'mathematical', 'tool', 'equations', 'describe', 'tumors', 'grow', 'basis', 'ellipsoid', 'shape', 'solid', 'woman', 'presented', 'painless', 'palpable', 'lump', 'ductal', 'histologic', 'grade', 'ii', 'luminal', 'b', 'interventions', 'receive', 'due', 'private', 'reasons', 'analysis', 'done', 'regarding', 'absence', 'mass', 'occupied', 'whole', 'skin', 'implanted', 'nipple', 'abnormality', 'case', 'indicated', 'slow', 'reached', 'cm', 'began', 'later', 'approached', 'maximum', 'segmental', 'key', 'good', 'prognosis', 'every')"', 'b'(16, 14, 14, 8, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.004746260368507203'', 'b'[-0.0, -0.188597701450166, -0.04191060032225911, -0.02901503099233323, -0.019343353994888818, -0.01371619646910298, -0.011606012396933292, -0.009797283192216417, -0.008829407993502866]'', 'b'-3.0163830207523885'', 'b'[1, -0.3862943611198906, -1.890371757896165, -2.258096538021482, -2.6635616461296463, -3.007333185232471, -3.174387269895637, -3.343805421853684, -3.4543472962535073]'', 'b'-0.7945679249137482'', 'b'[-0.7494280164585349, 0.2914169143614869, 1.4260790737021056, 1.7034872668937155, 2.009366416523487, 2.268704504918601, 2.394728570459939, 2.52253606663283, 2.622986380169313]'', 'b'85'', 'b'0.26661648705756474'', 'b"['Adult', 'Biomarkers, Tumor', 'Breast Neoplasms', 'Carcinoma, Ductal, Breast', 'Female', 'Humans', 'Neoplasm Grading', 'Receptor, ErbB-2', 'Tumor Burden']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'83'', 'b'Radiotherapy combined with cytokine-induced killer cell therapy for liver metastasis from rectal cancer: A case report.'', 'b"Colorectal cancer is the most common type of cancer leading to death; approximately 10% to 25% of rectal cancer patients present with synchronous colorectal liver metastases. However, the management of synchronous colorectal liver metastases is difficult, especially for patients unable to tolerate chemotherapy or surgery. To date, the optimum treatment of colorectal liver metastasis patients remains controversial, and the curative effect is unsatisfactory. Therefore, we established a novel therapeutic approach to treat colorectal liver metastases employing radiotherapy plus immunotherapy.A 56-year-old man presented with mucous bloody defecation occurring >20 times a day and accompanied by fatigue and poor appetite. After 4 months, he was admitted to the hospital due to increased fecal blood volume.Highly differentiated adenocarcinoma was diagnosed based on rectal biopsy, and abdominal computed tomography (CT) showed multiple metastatic tumors in the liver.The patient underwent 1 cycle of chemotherapy, which was terminated owing to severe gastrointestinal reactions. Several days later, he was administered cytokine-induced killer (CIK) cell therapy plus adjuvant radiotherapy.Dynamic changes in the patient's tumor markers returned to normal levels, and abdominal CT and abdominal magnetic resonance imaging (MRI) revealed no metastatic liver tumors.Sequent therapy provided a curative effect for liver metastasis in a rectal cancer patient. Radiation may have activated the body to produce distant effects, eliminating the live metastasis. CIK cell-immunotherapy and radiotherapy may have synergistic therapeutic effects and could be combined for successful treatment of liver metastasis from rectal cancer."', 'b'1491'', 'b'234'', 'b"[('liver', 14), ('colorectal', 10), ('cancer', 10), ('rectal', 8), ('metastasis', 8), ('patients', 6), ('metastases', 6), ('abdominal', 6), ('patient', 6), ('synchronous', 4), ('chemotherapy', 4), ('treatment', 4), ('curative', 4), ('effect', 4), ('therapeutic', 4), ('radiotherapy', 4), ('plus', 4), ('ct', 4), ('metastatic', 4), ('cik', 4), ('therapy', 4), ('may', 4), ('effects', 4), ('common', 2), ('type', 2), ('leading', 2), ('death', 2), ('approximately', 2), ('present', 2), ('however', 2), ('management', 2), ('difficult', 2), ('especially', 2), ('unable', 2), ('tolerate', 2), ('surgery', 2), ('date', 2), ('optimum', 2), ('remains', 2), ('controversial', 2), ('unsatisfactory', 2), ('therefore', 2), ('established', 2), ('novel', 2), ('approach', 2), ('treat', 2), ('employing', 2), ('man', 2), ('presented', 2), ('mucous', 2), ('bloody', 2), ('defecation', 2), ('occurring', 2), ('times', 2), ('day', 2), ('accompanied', 2), ('fatigue', 2), ('poor', 2), ('appetite', 2), ('months', 2), ('admitted', 2), ('hospital', 2), ('due', 2), ('increased', 2), ('fecal', 2), ('blood', 2), ('differentiated', 2), ('adenocarcinoma', 2), ('diagnosed', 2), ('based', 2), ('biopsy', 2), ('computed', 2), ('tomography', 2), ('showed', 2), ('multiple', 2), ('tumors', 2), ('underwent', 2), ('cycle', 2), ('terminated', 2), ('owing', 2), ('severe', 2), ('gastrointestinal', 2), ('reactions', 2), ('several', 2), ('days', 2), ('later', 2), ('administered', 2), ('killer', 2), ('cell', 2), ('adjuvant', 2), ('changes', 2), ('tumor', 2), ('markers', 2), ('returned', 2), ('normal', 2), ('levels', 2), ('magnetic', 2), ('resonance', 2), ('imaging', 2), ('mri', 2), ('revealed', 2), ('provided', 2), ('radiation', 2), ('activated', 2), ('body', 2), ('produce', 2), ('distant', 2), ('eliminating', 2), ('live', 2), ('synergistic', 2), ('could', 2), ('combined', 2), ('successful', 2)]"', 'b'[(\',\', 11), (\'the\', 9), (\'to\', 9), (\'.\', 8), (\'and\', 8), (\'liver\', 7), (\'of\', 6), (\'patient\', 6), (\'colorect\', 5), (\'cancer\', 5), (\'rectal\', 4), (\'metastasi\', 4), (\'effect\', 4), (\'a\', 4), (\'wa\', 4), (\'is\', 3), (\'metastas\', 3), (\'for\', 3), (\'abdomin\', 3), (\'(\', 3), (\')\', 3), (\'in\', 3), (\'%\', 2), (\'present\', 2), (\'with\', 2), (\'synchron\', 2), (\'chemotherapi\', 2), (\'treatment\', 2), (\'cur\', 2), (\'therapeut\', 2), (\'radiotherapi\', 2), (\'plu\', 2), (\'day\', 2), (\'he\', 2), (\'CT\', 2), (\'metastat\', 2), (\'tumor\', 2), (\'sever\', 2), (\'cik\', 2), (\'therapi\', 2), (\'may\', 2), (\'have\', 2), (\'most\', 1), (\'common\', 1), (\'type\', 1), (\'lead\', 1), (\'death\', 1), (\';\', 1), (\'approxim\', 1), (\'10\', 1), (\'25\', 1), (\'howev\', 1), (\'manag\', 1), (\'difficult\', 1), (\'especi\', 1), (\'unabl\', 1), (\'toler\', 1), (\'or\', 1), (\'surgeri\', 1), (\'To\', 1), (\'date\', 1), (\'optimum\', 1), (\'remain\', 1), (\'controversi\', 1), (\'unsatisfactori\', 1), (\'therefor\', 1), (\'we\', 1), (\'establish\', 1), (\'novel\', 1), (\'approach\', 1), (\'treat\', 1), (\'employ\', 1), (\'immunotherapy.a\', 1), (\'56-year-old\', 1), (\'man\', 1), (\'mucou\', 1), (\'bloodi\', 1), (\'defec\', 1), (\'occur\', 1), (\'>\', 1), (\'20\', 1), (\'time\', 1), (\'accompani\', 1), (\'by\', 1), (\'fatigu\', 1), (\'poor\', 1), (\'appetit\', 1), (\'after\', 1), (\'4\', 1), (\'month\', 1), (\'admit\', 1), (\'hospit\', 1), (\'due\', 1), (\'increas\', 1), (\'fecal\', 1), (\'blood\', 1), (\'volume.highli\', 1), (\'differenti\', 1), (\'adenocarcinoma\', 1), (\'diagnos\', 1), (\'base\', 1), (\'on\', 1), (\'biopsi\', 1), (\'comput\', 1), (\'tomographi\', 1), (\'show\', 1), (\'multipl\', 1), (\'liver.th\', 1), (\'underw\', 1), (\'1\', 1), (\'cycl\', 1), (\'which\', 1), (\'termin\', 1), (\'owe\', 1), (\'gastrointestin\', 1), (\'reaction\', 1), (\'later\', 1), (\'administ\', 1), (\'cytokine-induc\', 1), (\'killer\', 1), (\'cell\', 1), (\'adjuv\', 1), (\'radiotherapy.dynam\', 1), (\'chang\', 1), ("\'s", 1), (\'marker\', 1), (\'return\', 1), (\'normal\', 1), (\'level\', 1), (\'magnet\', 1), (\'reson\', 1), (\'imag\', 1), (\'mri\', 1), (\'reveal\', 1), (\'no\', 1), (\'tumors.sequ\', 1), (\'provid\', 1), (\'radiat\', 1), (\'activ\', 1), (\'bodi\', 1), (\'produc\', 1), (\'distant\', 1), (\'elimin\', 1), (\'live\', 1), (\'cell-immunotherapi\', 1), (\'synergist\', 1), (\'could\', 1), (\'be\', 1), (\'combin\', 1), (\'success\', 1), (\'from\', 1)]'', 'b'8'', 'b"('liver', 'colorectal', 'cancer', 'rectal', 'metastasis', 'patients', 'metastases', 'abdominal', 'patient', 'synchronous', 'chemotherapy', 'treatment', 'curative', 'effect', 'therapeutic', 'radiotherapy', 'plus', 'ct', 'metastatic', 'cik', 'therapy', 'may', 'effects', 'common', 'type', 'leading', 'death', 'approximately', 'present', 'however', 'management', 'difficult', 'especially', 'unable', 'tolerate', 'surgery', 'date', 'optimum', 'remains', 'controversial', 'unsatisfactory', 'therefore', 'established', 'novel', 'approach', 'treat', 'employing', 'man', 'presented', 'mucous', 'bloody', 'defecation', 'occurring', 'times', 'day', 'accompanied', 'fatigue', 'poor', 'appetite', 'months', 'admitted', 'hospital', 'due', 'increased', 'fecal', 'blood', 'differentiated', 'adenocarcinoma', 'diagnosed', 'based', 'biopsy', 'computed', 'tomography', 'showed', 'multiple', 'tumors', 'underwent', 'cycle', 'terminated', 'owing', 'severe', 'gastrointestinal', 'reactions', 'several', 'days', 'later', 'administered', 'killer', 'cell', 'adjuvant', 'changes', 'tumor', 'markers', 'returned', 'normal', 'levels', 'magnetic', 'resonance', 'imaging', 'mri', 'revealed', 'provided', 'radiation', 'activated', 'body', 'produce', 'distant', 'eliminating', 'live', 'synergistic', 'could', 'combined', 'successful')"', 'b'(14, 10, 10, 8, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.016116890219120713'', 'b'[-0.040223321170719764, -0.01398423795523395, -0.01701097312503385, -0.005643781896121944, -0.005334533573046769, -0.00512395987937387, -0.008078981320626568]'', 'b'-1.7408400239252009'', 'b'[-1.9444389791664407, -3.007333185232471, -2.817712325956905, -3.927253685157205, -3.9836066217083363, -4.0238805208462765, -3.574710978503383]'', 'b'-0.43488237709713606'', 'b'[1.4860240775616862, 2.3130394580129394, 2.1809073036172935, 3.0587097284680422, 3.102599756735923, 3.1339667569279737, 2.8013622525308524]'', 'b'59'', 'b'0.12726973459428803'', 'b"['Combined Modality Therapy', 'Cytokine-Induced Killer Cells', 'Humans', 'Immunotherapy', 'Liver Neoplasms', 'Male', 'Middle Aged', 'Radiotherapy, Adjuvant', 'Rectal Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'83'', 'b'Radiotherapy combined with cytokine-induced killer cell therapy for liver metastasis from rectal cancer: A case report.'', 'b"Colorectal cancer is the most common type of cancer leading to death; approximately 10% to 25% of rectal cancer patients present with synchronous colorectal liver metastases. However, the management of synchronous colorectal liver metastases is difficult, especially for patients unable to tolerate chemotherapy or surgery. To date, the optimum treatment of colorectal liver metastasis patients remains controversial, and the curative effect is unsatisfactory. Therefore, we established a novel therapeutic approach to treat colorectal liver metastases employing radiotherapy plus immunotherapy.A 56-year-old man presented with mucous bloody defecation occurring >20 times a day and accompanied by fatigue and poor appetite. After 4 months, he was admitted to the hospital due to increased fecal blood volume.Highly differentiated adenocarcinoma was diagnosed based on rectal biopsy, and abdominal computed tomography (CT) showed multiple metastatic tumors in the liver.The patient underwent 1 cycle of chemotherapy, which was terminated owing to severe gastrointestinal reactions. Several days later, he was administered cytokine-induced killer (CIK) cell therapy plus adjuvant radiotherapy.Dynamic changes in the patient's tumor markers returned to normal levels, and abdominal CT and abdominal magnetic resonance imaging (MRI) revealed no metastatic liver tumors.Sequent therapy provided a curative effect for liver metastasis in a rectal cancer patient. Radiation may have activated the body to produce distant effects, eliminating the live metastasis. CIK cell-immunotherapy and radiotherapy may have synergistic therapeutic effects and could be combined for successful treatment of liver metastasis from rectal cancer."', 'b'1491'', 'b'234'', 'b"[('liver', 14), ('colorectal', 10), ('cancer', 10), ('rectal', 8), ('metastasis', 8), ('patients', 6), ('metastases', 6), ('abdominal', 6), ('patient', 6), ('synchronous', 4), ('chemotherapy', 4), ('treatment', 4), ('curative', 4), ('effect', 4), ('therapeutic', 4), ('radiotherapy', 4), ('plus', 4), ('ct', 4), ('metastatic', 4), ('cik', 4), ('therapy', 4), ('may', 4), ('effects', 4), ('common', 2), ('type', 2), ('leading', 2), ('death', 2), ('approximately', 2), ('present', 2), ('however', 2), ('management', 2), ('difficult', 2), ('especially', 2), ('unable', 2), ('tolerate', 2), ('surgery', 2), ('date', 2), ('optimum', 2), ('remains', 2), ('controversial', 2), ('unsatisfactory', 2), ('therefore', 2), ('established', 2), ('novel', 2), ('approach', 2), ('treat', 2), ('employing', 2), ('man', 2), ('presented', 2), ('mucous', 2), ('bloody', 2), ('defecation', 2), ('occurring', 2), ('times', 2), ('day', 2), ('accompanied', 2), ('fatigue', 2), ('poor', 2), ('appetite', 2), ('months', 2), ('admitted', 2), ('hospital', 2), ('due', 2), ('increased', 2), ('fecal', 2), ('blood', 2), ('differentiated', 2), ('adenocarcinoma', 2), ('diagnosed', 2), ('based', 2), ('biopsy', 2), ('computed', 2), ('tomography', 2), ('showed', 2), ('multiple', 2), ('tumors', 2), ('underwent', 2), ('cycle', 2), ('terminated', 2), ('owing', 2), ('severe', 2), ('gastrointestinal', 2), ('reactions', 2), ('several', 2), ('days', 2), ('later', 2), ('administered', 2), ('killer', 2), ('cell', 2), ('adjuvant', 2), ('changes', 2), ('tumor', 2), ('markers', 2), ('returned', 2), ('normal', 2), ('levels', 2), ('magnetic', 2), ('resonance', 2), ('imaging', 2), ('mri', 2), ('revealed', 2), ('provided', 2), ('radiation', 2), ('activated', 2), ('body', 2), ('produce', 2), ('distant', 2), ('eliminating', 2), ('live', 2), ('synergistic', 2), ('could', 2), ('combined', 2), ('successful', 2)]"', 'b'[(\',\', 11), (\'the\', 9), (\'to\', 9), (\'.\', 8), (\'and\', 8), (\'liver\', 7), (\'of\', 6), (\'patient\', 6), (\'colorect\', 5), (\'cancer\', 5), (\'rectal\', 4), (\'metastasi\', 4), (\'effect\', 4), (\'a\', 4), (\'wa\', 4), (\'is\', 3), (\'metastas\', 3), (\'for\', 3), (\'abdomin\', 3), (\'(\', 3), (\')\', 3), (\'in\', 3), (\'%\', 2), (\'present\', 2), (\'with\', 2), (\'synchron\', 2), (\'chemotherapi\', 2), (\'treatment\', 2), (\'cur\', 2), (\'therapeut\', 2), (\'radiotherapi\', 2), (\'plu\', 2), (\'day\', 2), (\'he\', 2), (\'CT\', 2), (\'metastat\', 2), (\'tumor\', 2), (\'sever\', 2), (\'cik\', 2), (\'therapi\', 2), (\'may\', 2), (\'have\', 2), (\'most\', 1), (\'common\', 1), (\'type\', 1), (\'lead\', 1), (\'death\', 1), (\';\', 1), (\'approxim\', 1), (\'10\', 1), (\'25\', 1), (\'howev\', 1), (\'manag\', 1), (\'difficult\', 1), (\'especi\', 1), (\'unabl\', 1), (\'toler\', 1), (\'or\', 1), (\'surgeri\', 1), (\'To\', 1), (\'date\', 1), (\'optimum\', 1), (\'remain\', 1), (\'controversi\', 1), (\'unsatisfactori\', 1), (\'therefor\', 1), (\'we\', 1), (\'establish\', 1), (\'novel\', 1), (\'approach\', 1), (\'treat\', 1), (\'employ\', 1), (\'immunotherapy.a\', 1), (\'56-year-old\', 1), (\'man\', 1), (\'mucou\', 1), (\'bloodi\', 1), (\'defec\', 1), (\'occur\', 1), (\'>\', 1), (\'20\', 1), (\'time\', 1), (\'accompani\', 1), (\'by\', 1), (\'fatigu\', 1), (\'poor\', 1), (\'appetit\', 1), (\'after\', 1), (\'4\', 1), (\'month\', 1), (\'admit\', 1), (\'hospit\', 1), (\'due\', 1), (\'increas\', 1), (\'fecal\', 1), (\'blood\', 1), (\'volume.highli\', 1), (\'differenti\', 1), (\'adenocarcinoma\', 1), (\'diagnos\', 1), (\'base\', 1), (\'on\', 1), (\'biopsi\', 1), (\'comput\', 1), (\'tomographi\', 1), (\'show\', 1), (\'multipl\', 1), (\'liver.th\', 1), (\'underw\', 1), (\'1\', 1), (\'cycl\', 1), (\'which\', 1), (\'termin\', 1), (\'owe\', 1), (\'gastrointestin\', 1), (\'reaction\', 1), (\'later\', 1), (\'administ\', 1), (\'cytokine-induc\', 1), (\'killer\', 1), (\'cell\', 1), (\'adjuv\', 1), (\'radiotherapy.dynam\', 1), (\'chang\', 1), ("\'s", 1), (\'marker\', 1), (\'return\', 1), (\'normal\', 1), (\'level\', 1), (\'magnet\', 1), (\'reson\', 1), (\'imag\', 1), (\'mri\', 1), (\'reveal\', 1), (\'no\', 1), (\'tumors.sequ\', 1), (\'provid\', 1), (\'radiat\', 1), (\'activ\', 1), (\'bodi\', 1), (\'produc\', 1), (\'distant\', 1), (\'elimin\', 1), (\'live\', 1), (\'cell-immunotherapi\', 1), (\'synergist\', 1), (\'could\', 1), (\'be\', 1), (\'combin\', 1), (\'success\', 1), (\'from\', 1)]'', 'b'8'', 'b"('liver', 'colorectal', 'cancer', 'rectal', 'metastasis', 'patients', 'metastases', 'abdominal', 'patient', 'synchronous', 'chemotherapy', 'treatment', 'curative', 'effect', 'therapeutic', 'radiotherapy', 'plus', 'ct', 'metastatic', 'cik', 'therapy', 'may', 'effects', 'common', 'type', 'leading', 'death', 'approximately', 'present', 'however', 'management', 'difficult', 'especially', 'unable', 'tolerate', 'surgery', 'date', 'optimum', 'remains', 'controversial', 'unsatisfactory', 'therefore', 'established', 'novel', 'approach', 'treat', 'employing', 'man', 'presented', 'mucous', 'bloody', 'defecation', 'occurring', 'times', 'day', 'accompanied', 'fatigue', 'poor', 'appetite', 'months', 'admitted', 'hospital', 'due', 'increased', 'fecal', 'blood', 'differentiated', 'adenocarcinoma', 'diagnosed', 'based', 'biopsy', 'computed', 'tomography', 'showed', 'multiple', 'tumors', 'underwent', 'cycle', 'terminated', 'owing', 'severe', 'gastrointestinal', 'reactions', 'several', 'days', 'later', 'administered', 'killer', 'cell', 'adjuvant', 'changes', 'tumor', 'markers', 'returned', 'normal', 'levels', 'magnetic', 'resonance', 'imaging', 'mri', 'revealed', 'provided', 'radiation', 'activated', 'body', 'produce', 'distant', 'eliminating', 'live', 'synergistic', 'could', 'combined', 'successful')"', 'b'(14, 10, 10, 8, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.016116890219120713'', 'b'[-0.040223321170719764, -0.01398423795523395, -0.01701097312503385, -0.005643781896121944, -0.005334533573046769, -0.00512395987937387, -0.008078981320626568]'', 'b'-1.7408400239252009'', 'b'[-1.9444389791664407, -3.007333185232471, -2.817712325956905, -3.927253685157205, -3.9836066217083363, -4.0238805208462765, -3.574710978503383]'', 'b'-0.43488237709713606'', 'b'[1.4860240775616862, 2.3130394580129394, 2.1809073036172935, 3.0587097284680422, 3.102599756735923, 3.1339667569279737, 2.8013622525308524]'', 'b'59'', 'b'0.12726973459428803'', 'b"['Combined Modality Therapy', 'Cytokine-Induced Killer Cells', 'Humans', 'Immunotherapy', 'Liver Neoplasms', 'Male', 'Middle Aged', 'Radiotherapy, Adjuvant', 'Rectal Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'84'', 'b'Long-term effects of radiation prior to surgery and chemotherapy on survival of esophageal cancer undergoing surgery.'', 'b'Esophageal cancer (EC) is one of the most common cancers in the world, with continuously growing diagnoses and morbidity. Because it is still unclear how to choose the best treatment for EC patients, a multimodal treatment is necessary to improve the prospect of the malignancy, including a sequence of surgery, chemotherapy, and radiotherapy, whether alone or combination. Therefore, this paper aims to analyze the effect of the sequence of chemotherapy, radiotherapy, and surgery on the prognosis and survival rate of patients with EC.The Surveillance, Epidemiology, and End Results (SEER) database was used to extract a dataset of patients who were diagnosed with EC from 1973 to 2015, with follow-up data for 6 years after diagnosis. The data were analyzed using correlation analysis, logistic regression Cox regression, and Kaplan-Meier analysis.EC patients who had radiation prior to surgery and chemotherapy had a better prognosis than the cases without chemotherapy. Based on univariate logistic regression, the odds radios of vital status recoded for "radiation prior to surgery combined with chemotherapy" is the lowest one among the 8 groups classified by radiation sequence with surgery and chemotherapy (P\xe2\x80\x8a<\xe2\x80\x8a.001). Further, radiation prior to surgery and chemotherapy is an independent prognostic factor for better survival among EC patients.In conclusion, in the treatment of EC, administering radiation prior to surgery and chemotherapy is better than no radiotherapy, perioperative radiotherapy, postoperative radiotherapy, and other combinations without chemotherapy.'', 'b'1354'', 'b'231'', 'b"[('chemotherapy', 18), ('surgery', 14), ('ec', 10), ('radiotherapy', 10), ('radiation', 10), ('patients', 8), ('prior', 8), ('treatment', 6), ('sequence', 6), ('regression', 6), ('better', 6), ('one', 4), ('prognosis', 4), ('survival', 4), ('data', 4), ('logistic', 4), ('without', 4), ('among', 4), ('esophageal', 2), ('cancer', 2), ('common', 2), ('cancers', 2), ('world', 2), ('continuously', 2), ('growing', 2), ('diagnoses', 2), ('morbidity', 2), ('still', 2), ('unclear', 2), ('choose', 2), ('best', 2), ('multimodal', 2), ('necessary', 2), ('improve', 2), ('prospect', 2), ('malignancy', 2), ('including', 2), ('whether', 2), ('alone', 2), ('combination', 2), ('therefore', 2), ('paper', 2), ('aims', 2), ('analyze', 2), ('effect', 2), ('rate', 2), ('surveillance', 2), ('epidemiology', 2), ('end', 2), ('results', 2), ('seer', 2), ('database', 2), ('used', 2), ('extract', 2), ('dataset', 2), ('diagnosed', 2), ('years', 2), ('diagnosis', 2), ('analyzed', 2), ('using', 2), ('correlation', 2), ('analysis', 2), ('cox', 2), ('cases', 2), ('based', 2), ('univariate', 2), ('odds', 2), ('radios', 2), ('vital', 2), ('status', 2), ('recoded', 2), ('combined', 2), ('lowest', 2), ('groups', 2), ('classified', 2), ('p', 2), ('independent', 2), ('prognostic', 2), ('factor', 2), ('conclusion', 2), ('administering', 2), ('perioperative', 2), ('postoperative', 2), ('combinations', 2)]"', 'b'[(\',\', 21), (\'the\', 14), (\'and\', 11), (\'of\', 9), (\'to\', 9), (\'chemotherapi\', 9), (\'surgeri\', 7), (\'is\', 6), (\'with\', 6), (\'.\', 6), (\'EC\', 5), (\'radiotherapi\', 5), (\'radiat\', 5), (\'for\', 4), (\'patient\', 4), (\'a\', 4), (\'prior\', 4), (\'(\', 3), (\')\', 3), (\'treatment\', 3), (\'sequenc\', 3), (\'combin\', 3), (\'regress\', 3), (\'better\', 3), (\'cancer\', 2), (\'one\', 2), (\'in\', 2), (\'diagnos\', 2), (\'analyz\', 2), (\'on\', 2), (\'prognosi\', 2), (\'surviv\', 2), (\'use\', 2), (\'who\', 2), (\'were\', 2), (\'data\', 2), (\'logist\', 2), (\'had\', 2), (\'than\', 2), (\'without\', 2), (\'among\', 2), (\'esophag\', 1), (\'most\', 1), (\'common\', 1), (\'world\', 1), (\'continu\', 1), (\'grow\', 1), (\'morbid\', 1), (\'becaus\', 1), (\'it\', 1), (\'still\', 1), (\'unclear\', 1), (\'how\', 1), (\'choos\', 1), (\'best\', 1), (\'multimod\', 1), (\'necessari\', 1), (\'improv\', 1), (\'prospect\', 1), (\'malign\', 1), (\'includ\', 1), (\'whether\', 1), (\'alon\', 1), (\'or\', 1), (\'therefor\', 1), (\'thi\', 1), (\'paper\', 1), (\'aim\', 1), (\'effect\', 1), (\'rate\', 1), (\'ec.th\', 1), (\'surveil\', 1), (\'epidemiolog\', 1), (\'end\', 1), (\'result\', 1), (\'seer\', 1), (\'databas\', 1), (\'wa\', 1), (\'extract\', 1), (\'dataset\', 1), (\'from\', 1), (\'1973\', 1), (\'2015\', 1), (\'follow-up\', 1), (\'6\', 1), (\'year\', 1), (\'after\', 1), (\'diagnosi\', 1), (\'correl\', 1), (\'analysi\', 1), (\'cox\', 1), (\'kaplan-mei\', 1), (\'analysis.ec\', 1), (\'case\', 1), (\'base\', 1), (\'univari\', 1), (\'odd\', 1), (\'radio\', 1), (\'vital\', 1), (\'statu\', 1), (\'recod\', 1), (\'``\', 1), ("\'\'", 1), (\'lowest\', 1), (\'8\', 1), (\'group\', 1), (\'classifi\', 1), (\'by\', 1), (\'P\', 1), (\'<\', 1), (\'.001\', 1), (\'further\', 1), (\'an\', 1), (\'independ\', 1), (\'prognost\', 1), (\'factor\', 1), (\'patients.in\', 1), (\'conclus\', 1), (\'administ\', 1), (\'no\', 1), (\'periop\', 1), (\'postop\', 1), (\'other\', 1)]'', 'b'6'', 'b"('chemotherapy', 'surgery', 'ec', 'radiotherapy', 'radiation', 'patients', 'prior', 'treatment', 'sequence', 'regression', 'better', 'one', 'prognosis', 'survival', 'data', 'logistic', 'without', 'among', 'esophageal', 'cancer', 'common', 'cancers', 'world', 'continuously', 'growing', 'diagnoses', 'morbidity', 'still', 'unclear', 'choose', 'best', 'multimodal', 'necessary', 'improve', 'prospect', 'malignancy', 'including', 'whether', 'alone', 'combination', 'therefore', 'paper', 'aims', 'analyze', 'effect', 'rate', 'surveillance', 'epidemiology', 'end', 'results', 'seer', 'database', 'used', 'extract', 'dataset', 'diagnosed', 'years', 'diagnosis', 'analyzed', 'using', 'correlation', 'analysis', 'cox', 'cases', 'based', 'univariate', 'odds', 'radios', 'vital', 'status', 'recoded', 'combined', 'lowest', 'groups', 'classified', 'p', 'independent', 'prognostic', 'factor', 'conclusion', 'administering', 'perioperative', 'postoperative', 'combinations')"', 'b'(18, 14, 10, 10, 10, 8, 8, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.006753965087549438'', 'b'[-0.07167794185129729, -0.049278585022766885, -0.035838970925648646, -0.02920212445793593, -0.020748877904322897, -0.01416483284137371, -0.01259096252566552, -0.01004089416603706, -0.009223612082754974, -0.007900804375005205, -0.007388715202551163, -0.007061780901553324, -0.006035408895274222]'', 'b'-2.5553480614894135'', 'b'[-1.3978952727983707, -1.7725887222397811, -2.0910424533583156, -2.295836866004329, -2.6375861597263857, -3.0253516907351496, -3.1431347263915326, -3.3694478524670215, -3.4543472962535073, -3.6151205168412597, -3.68213122712422, -3.727387818712341, -3.8903491282217537]'', 'b'-0.6040556057842822'', 'b'[1.1021808168562948, 1.3976106249486524, 1.6486978131845251, 1.8101694751967519, 2.079624221231198, 2.3998016551953207, 2.4932307678461654, 2.6727492734835754, 2.7400941135390013, 2.8847983595586806, 2.9382716493692382, 2.9743855605277805, 3.122819748647521]'', 'b'22'', 'b'0.21624495693494633'', 'b"['Adult', 'Aged', 'Chemotherapy, Adjuvant', 'Combined Modality Therapy', 'Esophageal Neoplasms', 'Esophagectomy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Prognosis', 'Radiotherapy, Adjuvant', 'SEER Program', 'Survival Rate', 'Treatment Outcome']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'85'', 'b'Ovarian cancer metastasis to the breast 18 years after the initial diagnosis: A case report.'', 'b'Ovarian cancer often metastasizes, but it is unusual to transfer to the breast as an isolated mass. In particular, it is rare for patients to have breast metastases after 18 years of diagnosis of ovarian cancer. Therefore, accurate identification of ovarian cancer mammary gland metastasis can contribute to the treatment of the disease.This case report shows that an 82-year-old woman was diagnosed with breast metastases from ovarian cancer diagnosed 18 years ago. The patient underwent total uterine attachment, omentum, pelvic lymphadenectomy, pelvic floor tumor reduction, and chemotherapy 18 years ago.The pathological examination revealed metastatic adenocarcinoma. Immunohistochemical (IHC) staining results were negative for estrogen receptor (ER), progesterone receptor (PR), human epidermal receptor-2 (Her-2), and thyroid transcription factor-1 (TTF-1); and positive for cytokeratin (CK) 5_6, CK7, and CA125.The patient underwent breast-conserving surgery and sentinel lymph node biopsy because of breast mass in November, 2018.Currently, she has been followed for more than 1 month without any signs of recurrence.Breast metastatic tumors should be distinguished from primary breast tumors to avoid any unnecessary surgery. The correct diagnosis is very important: surgical treatment of patients with secondary breast cancer may be diagnostic and palliative.'', 'b'1183'', 'b'189'', 'b"[('breast', 12), ('cancer', 10), ('ovarian', 8), ('years', 6), ('mass', 4), ('patients', 4), ('metastases', 4), ('diagnosis', 4), ('treatment', 4), ('diagnosed', 4), ('patient', 4), ('underwent', 4), ('pelvic', 4), ('metastatic', 4), ('receptor', 4), ('surgery', 4), ('tumors', 4), ('often', 2), ('metastasizes', 2), ('unusual', 2), ('transfer', 2), ('isolated', 2), ('particular', 2), ('rare', 2), ('therefore', 2), ('accurate', 2), ('identification', 2), ('mammary', 2), ('gland', 2), ('metastasis', 2), ('contribute', 2), ('case', 2), ('report', 2), ('shows', 2), ('woman', 2), ('ago', 2), ('total', 2), ('uterine', 2), ('attachment', 2), ('omentum', 2), ('lymphadenectomy', 2), ('floor', 2), ('tumor', 2), ('reduction', 2), ('chemotherapy', 2), ('pathological', 2), ('examination', 2), ('revealed', 2), ('adenocarcinoma', 2), ('immunohistochemical', 2), ('ihc', 2), ('staining', 2), ('results', 2), ('negative', 2), ('estrogen', 2), ('er', 2), ('progesterone', 2), ('pr', 2), ('human', 2), ('epidermal', 2), ('thyroid', 2), ('transcription', 2), ('positive', 2), ('cytokeratin', 2), ('ck', 2), ('sentinel', 2), ('lymph', 2), ('node', 2), ('biopsy', 2), ('november', 2), ('followed', 2), ('month', 2), ('without', 2), ('signs', 2), ('distinguished', 2), ('primary', 2), ('avoid', 2), ('unnecessary', 2), ('correct', 2), ('important', 2), ('surgical', 2), ('secondary', 2), ('may', 2), ('diagnostic', 2), ('palliative', 2)]"', 'b"[(',', 14), ('of', 7), ('breast', 6), ('.', 6), ('and', 6), ('(', 6), (')', 6), ('cancer', 5), ('to', 5), ('the', 5), ('ovarian', 4), ('for', 4), ('patient', 4), ('metastas', 3), ('is', 3), ('18', 3), ('year', 3), ('tumor', 3), ('it', 2), ('an', 2), ('mass', 2), ('diagnosi', 2), ('treatment', 2), ('diagnos', 2), ('with', 2), ('from', 2), ('underw', 2), ('pelvic', 2), ('metastat', 2), ('receptor', 2), ('surgeri', 2), ('ani', 2), ('be', 2), ('often', 1), ('but', 1), ('unusu', 1), ('transfer', 1), ('as', 1), ('isol', 1), ('In', 1), ('particular', 1), ('rare', 1), ('have', 1), ('after', 1), ('therefor', 1), ('accur', 1), ('identif', 1), ('mammari', 1), ('gland', 1), ('metastasi', 1), ('can', 1), ('contribut', 1), ('disease.thi', 1), ('case', 1), ('report', 1), ('show', 1), ('that', 1), ('82-year-old', 1), ('woman', 1), ('wa', 1), ('ago', 1), ('total', 1), ('uterin', 1), ('attach', 1), ('omentum', 1), ('lymphadenectomi', 1), ('floor', 1), ('reduct', 1), ('chemotherapi', 1), ('ago.th', 1), ('patholog', 1), ('examin', 1), ('reveal', 1), ('adenocarcinoma', 1), ('immunohistochem', 1), ('ihc', 1), ('stain', 1), ('result', 1), ('were', 1), ('neg', 1), ('estrogen', 1), ('ER', 1), ('progesteron', 1), ('PR', 1), ('human', 1), ('epiderm', 1), ('receptor-2', 1), ('her-2', 1), ('thyroid', 1), ('transcript', 1), ('factor-1', 1), ('ttf-1', 1), (';', 1), ('posit', 1), ('cytokeratin', 1), ('CK', 1), ('5_6', 1), ('ck7', 1), ('ca125.th', 1), ('breast-conserv', 1), ('sentinel', 1), ('lymph', 1), ('node', 1), ('biopsi', 1), ('becaus', 1), ('in', 1), ('novemb', 1), ('2018.current', 1), ('she', 1), ('ha', 1), ('been', 1), ('follow', 1), ('more', 1), ('than', 1), ('1', 1), ('month', 1), ('without', 1), ('sign', 1), ('recurrence.breast', 1), ('should', 1), ('distinguish', 1), ('primari', 1), ('avoid', 1), ('unnecessari', 1), ('correct', 1), ('veri', 1), ('import', 1), (':', 1), ('surgic', 1), ('secondari', 1), ('may', 1), ('diagnost', 1), ('palli', 1)]"', 'b'6'', 'b"('breast', 'cancer', 'ovarian', 'years', 'mass', 'patients', 'metastases', 'diagnosis', 'treatment', 'diagnosed', 'patient', 'underwent', 'pelvic', 'metastatic', 'receptor', 'surgery', 'tumors', 'often', 'metastasizes', 'unusual', 'transfer', 'isolated', 'particular', 'rare', 'therefore', 'accurate', 'identification', 'mammary', 'gland', 'metastasis', 'contribute', 'case', 'report', 'shows', 'woman', 'ago', 'total', 'uterine', 'attachment', 'omentum', 'lymphadenectomy', 'floor', 'tumor', 'reduction', 'chemotherapy', 'pathological', 'examination', 'revealed', 'adenocarcinoma', 'immunohistochemical', 'ihc', 'staining', 'results', 'negative', 'estrogen', 'er', 'progesterone', 'pr', 'human', 'epidermal', 'thyroid', 'transcription', 'positive', 'cytokeratin', 'ck', 'sentinel', 'lymph', 'node', 'biopsy', 'november', 'followed', 'month', 'without', 'signs', 'distinguished', 'primary', 'avoid', 'unnecessary', 'correct', 'important', 'surgical', 'secondary', 'may', 'diagnostic', 'palliative')"', 'b'(12, 10, 8, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.00603090679227594'', 'b'[-0.20185381852722106, -0.050463454631805266, -0.025378097606915957, -0.0198072956932027, -0.016573451498394093, -0.013313100383955914, -0.011769552513352328, -0.009784326788208562, -0.008597485647653915]'', 'b'-2.6109179126442243'', 'b'[-0.3862943611198906, -1.7725887222397811, -2.4657359027997265, -2.713572066704308, -2.891820298110627, -3.1108738641733114, -3.2341065045972597, -3.4188406077965983, -3.5538768916005408]'', 'b'-0.582609495217316'', 'b'[0.3118999674703328, 1.4312152090495498, 2.002421965252112, 2.2036894967111227, 2.348444729187593, 2.5263379381694113, 2.6264150574345937, 2.7764374607087983, 2.902668529061133]'', 'b'82'', 'b'0.26661648705756474'', 'b"['Adenocarcinoma', 'Aged, 80 and over', 'Breast', 'Breast Neoplasms', 'Female', 'Humans', 'Neoplasm Metastasis', 'Ovarian Neoplasms', 'Time Factors']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'85'', 'b'Ovarian cancer metastasis to the breast 18 years after the initial diagnosis: A case report.'', 'b'Ovarian cancer often metastasizes, but it is unusual to transfer to the breast as an isolated mass. In particular, it is rare for patients to have breast metastases after 18 years of diagnosis of ovarian cancer. Therefore, accurate identification of ovarian cancer mammary gland metastasis can contribute to the treatment of the disease.This case report shows that an 82-year-old woman was diagnosed with breast metastases from ovarian cancer diagnosed 18 years ago. The patient underwent total uterine attachment, omentum, pelvic lymphadenectomy, pelvic floor tumor reduction, and chemotherapy 18 years ago.The pathological examination revealed metastatic adenocarcinoma. Immunohistochemical (IHC) staining results were negative for estrogen receptor (ER), progesterone receptor (PR), human epidermal receptor-2 (Her-2), and thyroid transcription factor-1 (TTF-1); and positive for cytokeratin (CK) 5_6, CK7, and CA125.The patient underwent breast-conserving surgery and sentinel lymph node biopsy because of breast mass in November, 2018.Currently, she has been followed for more than 1 month without any signs of recurrence.Breast metastatic tumors should be distinguished from primary breast tumors to avoid any unnecessary surgery. The correct diagnosis is very important: surgical treatment of patients with secondary breast cancer may be diagnostic and palliative.'', 'b'1183'', 'b'189'', 'b"[('breast', 12), ('cancer', 10), ('ovarian', 8), ('years', 6), ('mass', 4), ('patients', 4), ('metastases', 4), ('diagnosis', 4), ('treatment', 4), ('diagnosed', 4), ('patient', 4), ('underwent', 4), ('pelvic', 4), ('metastatic', 4), ('receptor', 4), ('surgery', 4), ('tumors', 4), ('often', 2), ('metastasizes', 2), ('unusual', 2), ('transfer', 2), ('isolated', 2), ('particular', 2), ('rare', 2), ('therefore', 2), ('accurate', 2), ('identification', 2), ('mammary', 2), ('gland', 2), ('metastasis', 2), ('contribute', 2), ('case', 2), ('report', 2), ('shows', 2), ('woman', 2), ('ago', 2), ('total', 2), ('uterine', 2), ('attachment', 2), ('omentum', 2), ('lymphadenectomy', 2), ('floor', 2), ('tumor', 2), ('reduction', 2), ('chemotherapy', 2), ('pathological', 2), ('examination', 2), ('revealed', 2), ('adenocarcinoma', 2), ('immunohistochemical', 2), ('ihc', 2), ('staining', 2), ('results', 2), ('negative', 2), ('estrogen', 2), ('er', 2), ('progesterone', 2), ('pr', 2), ('human', 2), ('epidermal', 2), ('thyroid', 2), ('transcription', 2), ('positive', 2), ('cytokeratin', 2), ('ck', 2), ('sentinel', 2), ('lymph', 2), ('node', 2), ('biopsy', 2), ('november', 2), ('followed', 2), ('month', 2), ('without', 2), ('signs', 2), ('distinguished', 2), ('primary', 2), ('avoid', 2), ('unnecessary', 2), ('correct', 2), ('important', 2), ('surgical', 2), ('secondary', 2), ('may', 2), ('diagnostic', 2), ('palliative', 2)]"', 'b"[(',', 14), ('of', 7), ('breast', 6), ('.', 6), ('and', 6), ('(', 6), (')', 6), ('cancer', 5), ('to', 5), ('the', 5), ('ovarian', 4), ('for', 4), ('patient', 4), ('metastas', 3), ('is', 3), ('18', 3), ('year', 3), ('tumor', 3), ('it', 2), ('an', 2), ('mass', 2), ('diagnosi', 2), ('treatment', 2), ('diagnos', 2), ('with', 2), ('from', 2), ('underw', 2), ('pelvic', 2), ('metastat', 2), ('receptor', 2), ('surgeri', 2), ('ani', 2), ('be', 2), ('often', 1), ('but', 1), ('unusu', 1), ('transfer', 1), ('as', 1), ('isol', 1), ('In', 1), ('particular', 1), ('rare', 1), ('have', 1), ('after', 1), ('therefor', 1), ('accur', 1), ('identif', 1), ('mammari', 1), ('gland', 1), ('metastasi', 1), ('can', 1), ('contribut', 1), ('disease.thi', 1), ('case', 1), ('report', 1), ('show', 1), ('that', 1), ('82-year-old', 1), ('woman', 1), ('wa', 1), ('ago', 1), ('total', 1), ('uterin', 1), ('attach', 1), ('omentum', 1), ('lymphadenectomi', 1), ('floor', 1), ('reduct', 1), ('chemotherapi', 1), ('ago.th', 1), ('patholog', 1), ('examin', 1), ('reveal', 1), ('adenocarcinoma', 1), ('immunohistochem', 1), ('ihc', 1), ('stain', 1), ('result', 1), ('were', 1), ('neg', 1), ('estrogen', 1), ('ER', 1), ('progesteron', 1), ('PR', 1), ('human', 1), ('epiderm', 1), ('receptor-2', 1), ('her-2', 1), ('thyroid', 1), ('transcript', 1), ('factor-1', 1), ('ttf-1', 1), (';', 1), ('posit', 1), ('cytokeratin', 1), ('CK', 1), ('5_6', 1), ('ck7', 1), ('ca125.th', 1), ('breast-conserv', 1), ('sentinel', 1), ('lymph', 1), ('node', 1), ('biopsi', 1), ('becaus', 1), ('in', 1), ('novemb', 1), ('2018.current', 1), ('she', 1), ('ha', 1), ('been', 1), ('follow', 1), ('more', 1), ('than', 1), ('1', 1), ('month', 1), ('without', 1), ('sign', 1), ('recurrence.breast', 1), ('should', 1), ('distinguish', 1), ('primari', 1), ('avoid', 1), ('unnecessari', 1), ('correct', 1), ('veri', 1), ('import', 1), (':', 1), ('surgic', 1), ('secondari', 1), ('may', 1), ('diagnost', 1), ('palli', 1)]"', 'b'6'', 'b"('breast', 'cancer', 'ovarian', 'years', 'mass', 'patients', 'metastases', 'diagnosis', 'treatment', 'diagnosed', 'patient', 'underwent', 'pelvic', 'metastatic', 'receptor', 'surgery', 'tumors', 'often', 'metastasizes', 'unusual', 'transfer', 'isolated', 'particular', 'rare', 'therefore', 'accurate', 'identification', 'mammary', 'gland', 'metastasis', 'contribute', 'case', 'report', 'shows', 'woman', 'ago', 'total', 'uterine', 'attachment', 'omentum', 'lymphadenectomy', 'floor', 'tumor', 'reduction', 'chemotherapy', 'pathological', 'examination', 'revealed', 'adenocarcinoma', 'immunohistochemical', 'ihc', 'staining', 'results', 'negative', 'estrogen', 'er', 'progesterone', 'pr', 'human', 'epidermal', 'thyroid', 'transcription', 'positive', 'cytokeratin', 'ck', 'sentinel', 'lymph', 'node', 'biopsy', 'november', 'followed', 'month', 'without', 'signs', 'distinguished', 'primary', 'avoid', 'unnecessary', 'correct', 'important', 'surgical', 'secondary', 'may', 'diagnostic', 'palliative')"', 'b'(12, 10, 8, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.00603090679227594'', 'b'[-0.20185381852722106, -0.050463454631805266, -0.025378097606915957, -0.0198072956932027, -0.016573451498394093, -0.013313100383955914, -0.011769552513352328, -0.009784326788208562, -0.008597485647653915]'', 'b'-2.6109179126442243'', 'b'[-0.3862943611198906, -1.7725887222397811, -2.4657359027997265, -2.713572066704308, -2.891820298110627, -3.1108738641733114, -3.2341065045972597, -3.4188406077965983, -3.5538768916005408]'', 'b'-0.582609495217316'', 'b'[0.3118999674703328, 1.4312152090495498, 2.002421965252112, 2.2036894967111227, 2.348444729187593, 2.5263379381694113, 2.6264150574345937, 2.7764374607087983, 2.902668529061133]'', 'b'82'', 'b'0.26661648705756474'', 'b"['Adenocarcinoma', 'Aged, 80 and over', 'Breast', 'Breast Neoplasms', 'Female', 'Humans', 'Neoplasm Metastasis', 'Ovarian Neoplasms', 'Time Factors']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'86'', 'b'Expression of estrogen receptor beta and overall survival in non-small cell lung cancer patients: Protocol for a systematic review and meta-analysis of cohort studies.'', 'b'Lung cancer is the leading cause of cancer-related deaths among males and the second leading cause among females worldwide. Numerous studies have linked estrogen status to lung cancer outcome. However, there are studies with conflicting results about the effect of ER\xce\xb2 on survival of lung cancer. The aim of this meta-analysis is to evaluate the prognostic impact of estrogen receptor beta expression on survival among NSCLC patients.We will search 15 electronic databases, including PubMed, Web of Science, EMBASE, Cochrane Library, and CNKI from inception to June 1, 2019. We will include all cohort studies comparing overall survival of NSCLC patients with high or low estrogen receptor beta expression. The database searches will be supplemented by searching through citations and references. Two reviewers will independently screen search results to identify eligible articles, complete data collection, and conduct quality assessment. All disagreements will be resolved by an independent third reviewer. Methodological quality of the included studies will be assessed using the Newcastle- Ottawa scale. Discrepancies will be resolved by consensus or by consulting a third author. Meta-analyses will be performed, and findings will be reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) and the meta-analysis of observational studies in epidemiology (MOOSE) guidelines.The results will be submitted to a peer-reviewed journal for publication.This review will provide a comprehensive evaluation of the evidence on the prognostic impact of ER\xce\xb2 expression among NSCLC patients and will help clinicians find potential treatments based on estrogen signaling.'', 'b'1464'', 'b'245'', 'b"[('studies', 10), ('among', 8), ('estrogen', 8), ('lung', 6), ('cancer', 6), ('results', 6), ('survival', 6), ('expression', 6), ('nsclc', 6), ('leading', 4), ('cause', 4), ('er\xce\xb2', 4), ('prognostic', 4), ('impact', 4), ('receptor', 4), ('beta', 4), ('search', 4), ('patients', 4), ('quality', 4), ('resolved', 4), ('third', 4), ('deaths', 2), ('males', 2), ('second', 2), ('females', 2), ('worldwide', 2), ('numerous', 2), ('linked', 2), ('status', 2), ('outcome', 2), ('however', 2), ('conflicting', 2), ('effect', 2), ('aim', 2), ('evaluate', 2), ('electronic', 2), ('databases', 2), ('including', 2), ('pubmed', 2), ('web', 2), ('science', 2), ('embase', 2), ('cochrane', 2), ('library', 2), ('cnki', 2), ('inception', 2), ('june', 2), ('include', 2), ('cohort', 2), ('comparing', 2), ('overall', 2), ('high', 2), ('low', 2), ('database', 2), ('searches', 2), ('supplemented', 2), ('searching', 2), ('citations', 2), ('references', 2), ('two', 2), ('reviewers', 2), ('independently', 2), ('screen', 2), ('identify', 2), ('eligible', 2), ('articles', 2), ('complete', 2), ('data', 2), ('collection', 2), ('conduct', 2), ('assessment', 2), ('disagreements', 2), ('independent', 2), ('reviewer', 2), ('methodological', 2), ('included', 2), ('assessed', 2), ('using', 2), ('ottawa', 2), ('scale', 2), ('discrepancies', 2), ('consensus', 2), ('consulting', 2), ('author', 2), ('performed', 2), ('findings', 2), ('reported', 2), ('according', 2), ('preferred', 2), ('reporting', 2), ('items', 2), ('systematic', 2), ('reviews', 2), ('prisma', 2), ('observational', 2), ('epidemiology', 2), ('moose', 2), ('submitted', 2), ('journal', 2), ('review', 2), ('provide', 2), ('comprehensive', 2), ('evaluation', 2), ('evidence', 2), ('help', 2), ('clinicians', 2), ('find', 2), ('potential', 2), ('treatments', 2), ('based', 2), ('signaling', 2)]"', 'b"[('the', 12), ('will', 12), ('of', 11), ('.', 11), (',', 10), ('and', 8), ('be', 7), ('to', 6), ('studi', 5), ('among', 4), ('estrogen', 4), ('on', 4), ('search', 4), ('by', 4), ('review', 4), ('lung', 3), ('cancer', 3), ('result', 3), ('surviv', 3), ('express', 3), ('nsclc', 3), ('includ', 3), ('a', 3), ('is', 2), ('lead', 2), ('caus', 2), ('with', 2), ('er\xce\xb2', 2), ('meta-analysi', 2), ('evalu', 2), ('prognost', 2), ('impact', 2), ('receptor', 2), ('beta', 2), ('databas', 2), ('all', 2), ('patient', 2), ('or', 2), ('independ', 2), ('qualiti', 2), ('assess', 2), ('resolv', 2), ('third', 2), ('meta-analys', 2), ('find', 2), ('report', 2), ('for', 2), ('(', 2), (')', 2), ('cancer-rel', 1), ('death', 1), ('male', 1), ('second', 1), ('femal', 1), ('worldwid', 1), ('numer', 1), ('have', 1), ('link', 1), ('statu', 1), ('outcom', 1), ('howev', 1), ('there', 1), ('are', 1), ('conflict', 1), ('about', 1), ('effect', 1), ('aim', 1), ('thi', 1), ('patients.w', 1), ('15', 1), ('electron', 1), ('pubm', 1), ('web', 1), ('scienc', 1), ('embas', 1), ('cochran', 1), ('librari', 1), ('cnki', 1), ('from', 1), ('incept', 1), ('june', 1), ('1', 1), ('2019', 1), ('We', 1), ('cohort', 1), ('compar', 1), ('overal', 1), ('high', 1), ('low', 1), ('supplement', 1), ('through', 1), ('citat', 1), ('refer', 1), ('two', 1), ('screen', 1), ('identifi', 1), ('elig', 1), ('articl', 1), ('complet', 1), ('data', 1), ('collect', 1), ('conduct', 1), ('disagr', 1), ('an', 1), ('methodolog', 1), ('use', 1), ('newcastle-', 1), ('ottawa', 1), ('scale', 1), ('discrep', 1), ('consensu', 1), ('consult', 1), ('author', 1), ('perform', 1), ('accord', 1), ('prefer', 1), ('item', 1), ('systemat', 1), ('prisma', 1), ('observ', 1), ('in', 1), ('epidemiolog', 1), ('moos', 1), ('guidelines.th', 1), ('submit', 1), ('peer-review', 1), ('journal', 1), ('publication.thi', 1), ('provid', 1), ('comprehens', 1), ('evid', 1), ('help', 1), ('clinician', 1), ('potenti', 1), ('treatment', 1), ('base', 1), ('signal', 1)]"', 'b'11'', 'b"('studies', 'among', 'estrogen', 'lung', 'cancer', 'results', 'survival', 'expression', 'nsclc', 'leading', 'cause', 'er\xce\xb2', 'prognostic', 'impact', 'receptor', 'beta', 'search', 'patients', 'quality', 'resolved', 'third', 'deaths', 'males', 'second', 'females', 'worldwide', 'numerous', 'linked', 'status', 'outcome', 'however', 'conflicting', 'effect', 'aim', 'evaluate', 'electronic', 'databases', 'including', 'pubmed', 'web', 'science', 'embase', 'cochrane', 'library', 'cnki', 'inception', 'june', 'include', 'cohort', 'comparing', 'overall', 'high', 'low', 'database', 'searches', 'supplemented', 'searching', 'citations', 'references', 'two', 'reviewers', 'independently', 'screen', 'identify', 'eligible', 'articles', 'complete', 'data', 'collection', 'conduct', 'assessment', 'disagreements', 'independent', 'reviewer', 'methodological', 'included', 'assessed', 'using', 'ottawa', 'scale', 'discrepancies', 'consensus', 'consulting', 'author', 'performed', 'findings', 'reported', 'according', 'preferred', 'reporting', 'items', 'systematic', 'reviews', 'prisma', 'observational', 'epidemiology', 'moose', 'submitted', 'journal', 'review', 'provide', 'comprehensive', 'evaluation', 'evidence', 'help', 'clinicians', 'find', 'potential', 'treatments', 'based', 'signaling')"', 'b'(10, 8, 8, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0015446431599033608'', 'b'[-0.02281670878010067, -0.017112531585075502, -0.011252075562789371]'', 'b'-3.9126548857360524'', 'b'[-2.58351893845611, -2.871201010907891, -3.290459441148391]'', 'b'-0.8219371624587936'', 'b'[2.122106372878604, 2.3584088633405758, 2.702788373570963]'', 'b'68'', 'b'0.1940986333074194'', 'b"['Adult', 'Carcinoma, Non-Small-Cell Lung', 'Cohort Studies', 'Estrogen Receptor beta', 'Female', 'Humans', 'Lung Neoplasms', 'Male', 'Meta-Analysis as Topic', 'Middle Aged', 'Research Design', 'Survival Analysis', 'Systematic Reviews as Topic']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'87'', 'b'Prognostic value and clinicopathological roles of phenotypes of tumour-associated macrophages in colorectal cancer.'', 'b'The role of tumour-associated macrophages (TAMs) in predicting the prognosis of colorectal cancer (CRC) remains controversial. This is especially so because the prognostic significance and clinicopathological relevance of different subtypes of TAMs in the immune microenvironment of CRC have not yet been established.To assess the clinicopathological and prognostic value of pan-macrophages, M1-macrophages or M2-macrophages in patients with CRC.Comprehensive searched on the Medline_PubMed, Web of Science (WoS) and Google Scholar databases was conducted to identify relevant studies published up to April 2019. The association between overall survival (OS), cancer-specific survival (CSS) or disease-free survival (DFS) and TAMs was analysed by meta-analysis.A total of 3749 patients from 17 studies were included. The pooled hazard ratios (HRs) indicated that high-density pan-macrophages improved OS (HR 0.67, P\xe2\x80\x89=\xe2\x80\x890.02). The pooled HR for M2-macrophages showed that high M2-macrophages infiltration was significantly associated with shorter OS (HR 2.93, P\xe2\x80\x89<\xe2\x80\x890.0001) and DFS (HR 2.04, P\xe2\x80\x89=\xe2\x80\x890.02). The pooled odds ratios (ORs) revealed that high-density TAMs was associated with high CD8+\xe2\x80\x89T cell infiltration (OR 2.04, P\xe2\x80\x89=\xe2\x80\x890.007), no distant metastasis (NDM) (OR 0.38, P\xe2\x80\x89<\xe2\x80\x890.0001), microsatellite instability-high (MSI-H) (OR 0.38, P\xe2\x80\x89=\xe2\x80\x890.001), no lymph node metastasis (NLNM) (OR 0.54, P\xe2\x80\x89=\xe2\x80\x890.0002) and non-mucinous cancer (OR 0.39, P\xe2\x80\x89<\xe2\x80\x890.00001).Unlike other solid tumours, high-density CD68+\xe2\x80\x89macrophage infiltration can be a good prognostic marker for CRC. However, when macrophages act as targets of combination therapy in CRC treatment, this might be more effective for CRC patients with high CD8+\xe2\x80\x89T cell infiltrate, NDM, MSI-H, NLNM and non-mucinous cancer.'', 'b'1505'', 'b'257'', 'b"[('p', 16), ('crc', 10), ('tams', 8), ('hr', 8), ('cancer', 6), ('prognostic', 6), ('patients', 6), ('survival', 6), ('os', 6), ('pooled', 6), ('high', 6), ('infiltration', 6), ('macrophages', 4), ('clinicopathological', 4), ('studies', 4), ('dfs', 4), ('ratios', 4), ('associated', 4), ('cell', 4), ('metastasis', 4), ('ndm', 4), ('nlnm', 4), ('role', 2), ('predicting', 2), ('prognosis', 2), ('colorectal', 2), ('remains', 2), ('controversial', 2), ('especially', 2), ('significance', 2), ('relevance', 2), ('different', 2), ('subtypes', 2), ('immune', 2), ('microenvironment', 2), ('yet', 2), ('assess', 2), ('value', 2), ('searched', 2), ('web', 2), ('science', 2), ('wos', 2), ('google', 2), ('scholar', 2), ('databases', 2), ('conducted', 2), ('identify', 2), ('relevant', 2), ('published', 2), ('april', 2), ('association', 2), ('overall', 2), ('css', 2), ('analysed', 2), ('total', 2), ('included', 2), ('hazard', 2), ('hrs', 2), ('indicated', 2), ('improved', 2), ('showed', 2), ('significantly', 2), ('shorter', 2), ('odds', 2), ('ors', 2), ('revealed', 2), ('distant', 2), ('microsatellite', 2), ('lymph', 2), ('node', 2), ('solid', 2), ('tumours', 2), ('macrophage', 2), ('good', 2), ('marker', 2), ('however', 2), ('act', 2), ('targets', 2), ('combination', 2), ('therapy', 2), ('treatment', 2), ('might', 2), ('effective', 2), ('infiltrate', 2)]"', 'b"[(',', 20), ('(', 19), (')', 19), ('the', 10), ('of', 9), ('P', 8), ('.', 7), ('and', 7), ('crc', 5), ('=', 5), ('OR', 5), ('tam', 4), ('in', 4), ('with', 4), ('wa', 4), ('HR', 4), ('infiltr', 4), ('macrophag', 3), ('cancer', 3), ('prognost', 3), ('or', 3), ('m2-macrophag', 3), ('patient', 3), ('associ', 3), ('surviv', 3), ('OS', 3), ('pool', 3), ('that', 3), ('high-dens', 3), ('for', 3), ('high', 3), ('<', 3), ('thi', 2), ('clinicopatholog', 2), ('relev', 2), ('pan-macrophag', 2), ('to', 2), ('studi', 2), ('df', 2), ('ratio', 2), ('0.02', 2), ('0.0001', 2), ('2.04', 2), ('cd8+', 2), ('T', 2), ('cell', 2), ('no', 2), ('metastasi', 2), ('ndm', 2), ('0.38', 2), ('msi-h', 2), ('nlnm', 2), ('non-mucin', 2), ('be', 2), ('role', 1), ('tumour-associ', 1), ('predict', 1), ('prognosi', 1), ('colorect', 1), ('remain', 1), ('controversi', 1), ('is', 1), ('especi', 1), ('so', 1), ('becaus', 1), ('signific', 1), ('differ', 1), ('subtyp', 1), ('immun', 1), ('microenviron', 1), ('have', 1), ('not', 1), ('yet', 1), ('been', 1), ('established.to', 1), ('assess', 1), ('valu', 1), ('m1-macrophag', 1), ('crc.comprehens', 1), ('search', 1), ('on', 1), ('medline_pubm', 1), ('web', 1), ('scienc', 1), ('wo', 1), ('googl', 1), ('scholar', 1), ('databas', 1), ('conduct', 1), ('identifi', 1), ('publish', 1), ('up', 1), ('april', 1), ('2019', 1), ('between', 1), ('overal', 1), ('cancer-specif', 1), ('css', 1), ('disease-fre', 1), ('analys', 1), ('by', 1), ('meta-analysis.a', 1), ('total', 1), ('3749', 1), ('from', 1), ('17', 1), ('were', 1), ('includ', 1), ('hazard', 1), ('hr', 1), ('indic', 1), ('improv', 1), ('0.67', 1), ('show', 1), ('significantli', 1), ('shorter', 1), ('2.93', 1), ('odd', 1), ('reveal', 1), ('0.007', 1), ('distant', 1), ('microsatellit', 1), ('instability-high', 1), ('0.001', 1), ('lymph', 1), ('node', 1), ('0.54', 1), ('0.0002', 1), ('0.39', 1), ('0.00001', 1), ('.unlik', 1), ('other', 1), ('solid', 1), ('tumour', 1), ('cd68+', 1), ('can', 1), ('a', 1), ('good', 1), ('marker', 1), ('howev', 1), ('when', 1), ('act', 1), ('as', 1), ('target', 1), ('combin', 1), ('therapi', 1), ('treatment', 1), ('might', 1), ('more', 1), ('effect', 1)]"', 'b'7'', 'b"('p', 'crc', 'tams', 'hr', 'cancer', 'prognostic', 'patients', 'survival', 'os', 'pooled', 'high', 'infiltration', 'macrophages', 'clinicopathological', 'studies', 'dfs', 'ratios', 'associated', 'cell', 'metastasis', 'ndm', 'nlnm', 'role', 'predicting', 'prognosis', 'colorectal', 'remains', 'controversial', 'especially', 'significance', 'relevance', 'different', 'subtypes', 'immune', 'microenvironment', 'yet', 'assess', 'value', 'searched', 'web', 'science', 'wos', 'google', 'scholar', 'databases', 'conducted', 'identify', 'relevant', 'published', 'april', 'association', 'overall', 'css', 'analysed', 'total', 'included', 'hazard', 'hrs', 'indicated', 'improved', 'showed', 'significantly', 'shorter', 'odds', 'ors', 'revealed', 'distant', 'microsatellite', 'lymph', 'node', 'solid', 'tumours', 'macrophage', 'good', 'marker', 'however', 'act', 'targets', 'combination', 'therapy', 'treatment', 'might', 'effective', 'infiltrate')"', 'b'(16, 10, 8, 8, 6, 6, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0073025209226277405'', 'b'[-0.41301023096995937, -0.01552557329324389, -0.013729225970058647, -0.011951340592640981, -0.010581123199854117, -0.004772541932662629]'', 'b'-2.295836866004329'', 'b'[0.3068528194400547, -2.979681653901961, -3.102643365036796, -3.241326752570746, -3.3630986247883623, -4.1647859739235145]'', 'b'-0.4526657122212913'', 'b'[-0.25346670766144047, 2.4749777260881154, 2.5771119577171464, 2.692304899444829, 2.793450829248431, 3.4784077476951496]'', 'b'68'', 'b'0.19509701586433517'', 'b"['Animals', 'Colorectal Neoplasms', 'Disease-Free Survival', 'Humans', 'Lymphatic Metastasis', 'Macrophages', 'Microsatellite Instability', 'Odds Ratio', 'Phenotype', 'Prognosis', 'Proportional Hazards Models', 'Tumor Microenvironment']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'88'', 'b'The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.'', 'b'Breast cancer has, due to its high incidence, the highest mortality of cancer in women. The most common molecular type of breast cancer is the luminal subtype, which expresses estrogen and progesterone receptors and is typically treated with surgery and adjuvant endocrine therapy (ET). Estrogen receptor alpha (ER\xce\xb1), encoded by the estrogen receptor-1 (ESR1) gene, is expressed in approximately 70% of all breast cancers, and ET represents a major treatment modality in ER\xce\xb1-positive cancers. However, resistance to different ET evolves frequently, leading to disease progression or recurrence in ER+ breast cancer. Acquired mutations in the Ligand Binding Domain (LBD) of the ER\xce\xb1 referred as ESR1 mutations; could be selected by ET itself leading to resistance over the course of ET therapy.The goal of this review is to estimate the effect of Aromatase Inhibitors (AIs), Tamoxifen (TAM) and Fulvestrant (FUL) on the development of ESR1 mutations in hormone-sensitive advanced breast cancer.A systematic review of qualitative studies published between January 1st, 2007 and March 1st, 2019 was conducted using the PubMed and Thomas Reuters Web of Science databases. Search terms included ESR1 mutations, estrogen receptor, breast cancer, recurrent, metastatic disease, aromatase inhibitors, fulvestrant and tamoxifen. Only full-text studies in English concerning the development of ESR1 mutations and their outcomes on disease progression were included. Selection of studies was performed using predefined data fields, taking study quality indicators into consideration. Inclusion criteria of the study populations were: Ghoncheh et al. (2016) [1] female patients above 18\xe2\x80\xafyears; Nielsen et al. (2011) [2] Estrogen-receptor positive (ER+) breast cancer in the advanced setting; Reinert et al. (2017) [3] previous exposure to endocrine therapy including SERDs (preferably Fulvestrant), SERMs (preferably Tamoxifen) or Aromatase Inhibitors.The current review enrolled 16 articles, including 4 multicentre double blinded RCTs and 12 cohorts and comprising a total of 2632 patients. The overall incidence rate of the ESR1 mutation was 24% (95% CI: 18%-31%). We observed that D538G was the most frequent ESR1 mutation. Several studies showed that prior endocrine therapy (AIs, TAM, FUL) could result in an ESR1 mutation and therapy resistance leading to disease progression or recurrence. Different mechanisms had been implied to explain the underlying ET resistance. One of the key findings of this work is the significant difference in ESR1 mutation incidence between patients with and without AI therapy (OR: 9.34, 95% CI: 3.28-26.62, P\xe2\x80\xaf\xe2\x89\xa4.001).ESR1 mutations are not uncommon phenomenon in patients with hormone-sensitive advanced breast cancer. There is a significant higher incidence rate of ESR1 mutations in patients with previous AI-containing therapeutic regimens, compared to those who received non-AI containing regimes. These ESR1 mutations could lead to the development of complete endocrine resistance to AI, whereas only partial resistance is seen in case of TAM or FUL.'', 'b'2631'', 'b'451'', 'b"[('et', 18), ('breast', 16), ('mutations', 16), ('cancer', 14), ('resistance', 12), ('therapy', 10), ('patients', 10), ('incidence', 8), ('estrogen', 8), ('endocrine', 8), ('disease', 8), ('studies', 8), ('mutation', 8), ('leading', 6), ('progression', 6), ('could', 6), ('review', 6), ('aromatase', 6), ('tamoxifen', 6), ('tam', 6), ('fulvestrant', 6), ('ful', 6), ('development', 6), ('advanced', 6), ('al', 6), ('receptor', 4), ('er\xce\xb1', 4), ('cancers', 4), ('different', 4), ('recurrence', 4), ('inhibitors', 4), ('ais', 4), ('using', 4), ('included', 4), ('study', 4), ('previous', 4), ('including', 4), ('preferably', 4), ('rate', 4), ('ci', 4), ('significant', 4), ('ai', 4), ('due', 2), ('high', 2), ('highest', 2), ('mortality', 2), ('women', 2), ('common', 2), ('molecular', 2), ('type', 2), ('luminal', 2), ('subtype', 2), ('expresses', 2), ('progesterone', 2), ('receptors', 2), ('typically', 2), ('treated', 2), ('surgery', 2), ('adjuvant', 2), ('alpha', 2), ('encoded', 2), ('gene', 2), ('expressed', 2), ('approximately', 2), ('represents', 2), ('major', 2), ('treatment', 2), ('modality', 2), ('however', 2), ('evolves', 2), ('frequently', 2), ('acquired', 2), ('ligand', 2), ('binding', 2), ('domain', 2), ('lbd', 2), ('referred', 2), ('selected', 2), ('course', 2), ('goal', 2), ('estimate', 2), ('effect', 2), ('systematic', 2), ('qualitative', 2), ('published', 2), ('january', 2), ('march', 2), ('conducted', 2), ('pubmed', 2), ('thomas', 2), ('reuters', 2), ('web', 2), ('science', 2), ('databases', 2), ('search', 2), ('terms', 2), ('recurrent', 2), ('metastatic', 2), ('english', 2), ('concerning', 2), ('outcomes', 2), ('selection', 2), ('performed', 2), ('predefined', 2), ('data', 2), ('fields', 2), ('taking', 2), ('quality', 2), ('indicators', 2), ('consideration', 2), ('inclusion', 2), ('criteria', 2), ('populations', 2), ('ghoncheh', 2), ('female', 2), ('years', 2), ('nielsen', 2), ('positive', 2), ('setting', 2), ('reinert', 2), ('exposure', 2), ('serds', 2), ('serms', 2), ('current', 2), ('enrolled', 2), ('articles', 2), ('multicentre', 2), ('double', 2), ('blinded', 2), ('rcts', 2), ('cohorts', 2), ('comprising', 2), ('total', 2), ('overall', 2), ('observed', 2), ('frequent', 2), ('several', 2), ('showed', 2), ('prior', 2), ('result', 2), ('mechanisms', 2), ('implied', 2), ('explain', 2), ('underlying', 2), ('one', 2), ('key', 2), ('findings', 2), ('work', 2), ('difference', 2), ('without', 2), ('p', 2), ('uncommon', 2), ('phenomenon', 2), ('higher', 2), ('therapeutic', 2), ('regimens', 2), ('compared', 2), ('received', 2), ('containing', 2), ('regimes', 2), ('lead', 2), ('complete', 2), ('whereas', 2), ('partial', 2), ('seen', 2), ('case', 2)]"', 'b"[(',', 26), ('the', 20), ('of', 20), ('.', 19), ('(', 16), (')', 16), ('in', 13), ('and', 13), ('mutat', 12), ('to', 11), ('esr1', 11), ('cancer', 9), ('breast', 8), ('is', 7), ('ET', 6), ('%', 6), ('resist', 6), ('studi', 6), ('therapi', 5), ('patient', 5), ('incid', 4), ('estrogen', 4), ('with', 4), ('endocrin', 4), ('lead', 4), ('diseas', 4), ('or', 4), ('wa', 4), ('includ', 4), (':', 4), ('receptor', 3), ('a', 3), ('differ', 3), ('progress', 3), ('recurr', 3), (';', 3), ('could', 3), ('review', 3), ('aromatas', 3), ('tamoxifen', 3), ('tam', 3), ('fulvestr', 3), ('ful', 3), ('develop', 3), ('advanc', 3), ('et', 3), ('al', 3), ('[', 3), (']', 3), ('most', 2), ('express', 2), ('er\xce\xb1', 2), ('by', 2), ('frequent', 2), ('er+', 2), ('select', 2), ('thi', 2), ('inhibitor', 2), ('ai', 2), ('on', 2), ('hormone-sensit', 2), ('between', 2), ('1st', 2), ('use', 2), ('onli', 2), ('were', 2), ('18', 2), ('previou', 2), ('prefer', 2), ('rate', 2), ('95', 2), ('CI', 2), ('that', 2), ('signific', 2), ('AI', 2), ('ha', 1), ('due', 1), ('it', 1), ('high', 1), ('highest', 1), ('mortal', 1), ('women', 1), ('common', 1), ('molecular', 1), ('type', 1), ('lumin', 1), ('subtyp', 1), ('which', 1), ('progesteron', 1), ('typic', 1), ('treat', 1), ('surgeri', 1), ('adjuv', 1), ('alpha', 1), ('encod', 1), ('receptor-1', 1), ('gene', 1), ('approxim', 1), ('70', 1), ('all', 1), ('repres', 1), ('major', 1), ('treatment', 1), ('modal', 1), ('er\xce\xb1-posit', 1), ('howev', 1), ('evolv', 1), ('acquir', 1), ('ligand', 1), ('bind', 1), ('domain', 1), ('lbd', 1), ('refer', 1), ('as', 1), ('be', 1), ('itself', 1), ('over', 1), ('cours', 1), ('therapy.th', 1), ('goal', 1), ('estim', 1), ('effect', 1), ('cancer.a', 1), ('systemat', 1), ('qualit', 1), ('publish', 1), ('januari', 1), ('2007', 1), ('march', 1), ('2019', 1), ('conduct', 1), ('pubm', 1), ('thoma', 1), ('reuter', 1), ('web', 1), ('scienc', 1), ('databas', 1), ('search', 1), ('term', 1), ('metastat', 1), ('full-text', 1), ('english', 1), ('concern', 1), ('their', 1), ('outcom', 1), ('perform', 1), ('predefin', 1), ('data', 1), ('field', 1), ('take', 1), ('qualiti', 1), ('indic', 1), ('into', 1), ('consider', 1), ('inclus', 1), ('criteria', 1), ('popul', 1), ('ghoncheh', 1), ('2016', 1), ('1', 1), ('femal', 1), ('abov', 1), ('year', 1), ('nielsen', 1), ('2011', 1), ('2', 1), ('estrogen-receptor', 1), ('posit', 1), ('set', 1), ('reinert', 1), ('2017', 1), ('3', 1), ('exposur', 1), ('serd', 1), ('serm', 1), ('inhibitors.th', 1), ('current', 1), ('enrol', 1), ('16', 1), ('articl', 1), ('4', 1), ('multicentr', 1), ('doubl', 1), ('blind', 1), ('rct', 1), ('12', 1), ('cohort', 1), ('compris', 1), ('total', 1), ('2632', 1), ('overal', 1), ('24', 1), ('-31', 1), ('We', 1), ('observ', 1), ('d538g', 1), ('sever', 1), ('show', 1), ('prior', 1), ('result', 1), ('an', 1), ('mechan', 1), ('had', 1), ('been', 1), ('impli', 1), ('explain', 1), ('underli', 1), ('one', 1), ('key', 1), ('find', 1), ('work', 1), ('without', 1), ('OR', 1), ('9.34', 1), ('3.28-26.62', 1), ('P', 1), ('\xe2\x89\xa4.001', 1), ('.esr1', 1), ('are', 1), ('not', 1), ('uncommon', 1), ('phenomenon', 1), ('there', 1), ('higher', 1), ('ai-contain', 1), ('therapeut', 1), ('regimen', 1), ('compar', 1), ('those', 1), ('who', 1), ('receiv', 1), ('non-ai', 1), ('contain', 1), ('regim', 1), ('these', 1), ('complet', 1), ('wherea', 1), ('partial', 1), ('seen', 1), ('case', 1)]"', 'b'19'', 'b"('et', 'breast', 'mutations', 'cancer', 'resistance', 'therapy', 'patients', 'incidence', 'estrogen', 'endocrine', 'disease', 'studies', 'mutation', 'leading', 'progression', 'could', 'review', 'aromatase', 'tamoxifen', 'tam', 'fulvestrant', 'ful', 'development', 'advanced', 'al', 'receptor', 'er\xce\xb1', 'cancers', 'different', 'recurrence', 'inhibitors', 'ais', 'using', 'included', 'study', 'previous', 'including', 'preferably', 'rate', 'ci', 'significant', 'ai', 'due', 'high', 'highest', 'mortality', 'women', 'common', 'molecular', 'type', 'luminal', 'subtype', 'expresses', 'progesterone', 'receptors', 'typically', 'treated', 'surgery', 'adjuvant', 'alpha', 'encoded', 'gene', 'expressed', 'approximately', 'represents', 'major', 'treatment', 'modality', 'however', 'evolves', 'frequently', 'acquired', 'ligand', 'binding', 'domain', 'lbd', 'referred', 'selected', 'course', 'goal', 'estimate', 'effect', 'systematic', 'qualitative', 'published', 'january', 'march', 'conducted', 'pubmed', 'thomas', 'reuters', 'web', 'science', 'databases', 'search', 'terms', 'recurrent', 'metastatic', 'english', 'concerning', 'outcomes', 'selection', 'performed', 'predefined', 'data', 'fields', 'taking', 'quality', 'indicators', 'consideration', 'inclusion', 'criteria', 'populations', 'ghoncheh', 'female', 'years', 'nielsen', 'positive', 'setting', 'reinert', 'exposure', 'serds', 'serms', 'current', 'enrolled', 'articles', 'multicentre', 'double', 'blinded', 'rcts', 'cohorts', 'comprising', 'total', 'overall', 'observed', 'frequent', 'several', 'showed', 'prior', 'result', 'mechanisms', 'implied', 'explain', 'underlying', 'one', 'key', 'findings', 'work', 'difference', 'without', 'p', 'uncommon', 'phenomenon', 'higher', 'therapeutic', 'regimens', 'compared', 'received', 'containing', 'regimes', 'lead', 'complete', 'whereas', 'partial', 'seen', 'case')"', 'b'(18, 16, 16, 14, 12, 10, 10, 8, 8, 8, 8, 8, 8, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.005949323843016752'', 'b'[-0.06459620421167851, -0.032298102105839256, -0.022098701440837386, -0.013544365399222913, -0.009127724508171963, -0.002281853540316789, -0.0022218047629400314, -0.0021543159651566967]'', 'b'-2.4339872044851463'', 'b'[-1.5649493574615367, -2.258096538021482, -2.6375861597263857, -3.1271343850450917, -3.5217885770490405, -4.91350300563827, -4.940171252720432, -4.976350909297934]'', 'b'-0.44889792138647633'', 'b'[1.3141672475817665, 1.896238046296359, 2.2149147045945727, 2.626013147338548, 2.9574242634744143, 4.148400864645962, 4.170916487232797, 4.223929091576299]'', 'b'80'', 'b'0.1766670460820435'', 'b"['Antineoplastic Agents, Hormonal', 'Aromatase Inhibitors', 'Breast Neoplasms', 'Drug Resistance, Neoplasm', 'Estrogen Receptor alpha', 'Female', 'Fulvestrant', 'Humans', 'Mutation', 'Non-Randomized Controlled Trials as Topic', 'Randomized Controlled Trials as Topic', 'Tamoxifen']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'89'', 'b'Targeted blockade of interleukin 9 inhibits tumor growth in murine model of pancreatic cancer.'', 'b'Interleukin 9 (IL-9) has been implicated in the pathogenesis of several tumor types, but the role of anti-IL-9 in pancreatic cancer remains unclear.We aimed to explore the mechanism and effects of blockading IL-9 in a pancreatic cancer mouse model.Panc02 cells were injected subcutaneously into mice to establish a mouse model. The mice were randomly categorized into 3 groups - the control group, the immunoglobulin G (IgG) group and the anti-IL-9 group - corresponding to intravenous tail injection of phosphate-buffered saline (PBS), IgG isotype antibody and anti-IL-9 antibody, respectively. Then, the expression of IL-9, interleukin-9 receptor (IL-9r), Janus kinase 1 (Jak1), Jak3, and signal transducer and activator of transcription 3 (Stat3) mRNA was tested with quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Interleukin 9 in the tumor tissue was detected using enzyme-linked immunosorbent assay (ELISA). Western blotting and immunocytochemistry were performed to detect STAT3 and phosphorylation signal transducers and activators of transcription-3 (pSTAT3). Matrix metalloproteinase 2 (MMP2), MMP9 and vascular endothelial growth factor (VEGF) levels were assessed using immunocytochemistry.Tumor weight in the anti-IL-9 group was significantly lower than in the other groups (p < 0.05). There was a remarkable survival benefit in the anti-IL-9 group compared to the other groups (p < 0.05). The concentration of IL-9 in tumor tissue was significantly downregulated in the anti-IL-9-treated mice (p < 0.05). The expression of Jak1 and Jak3 mRNA and pSTAT3, MMP2 and MMP9 proteins in the anti-IL-9 group was lower than that of the PBS or IgG groups (p < 0.05), but the STAT3 and VEGF protein levels showed no significant difference (p < 0.05).Anti-IL-9 antibody could effectively restrain the growth of pancreatic cancer in mice, and this effect may partly occur by blocking the STAT3 pathway.'', 'b'1645'', 'b'284'', 'b"[('group', 12), ('p', 10), ('mice', 8), ('groups', 8), ('tumor', 6), ('pancreatic', 6), ('cancer', 6), ('igg', 6), ('antibody', 6), ('interleukin', 4), ('mouse', 4), ('pbs', 4), ('expression', 4), ('signal', 4), ('mrna', 4), ('tissue', 4), ('using', 4), ('growth', 4), ('vegf', 4), ('levels', 4), ('significantly', 4), ('lower', 4), ('implicated', 2), ('pathogenesis', 2), ('several', 2), ('types', 2), ('role', 2), ('remains', 2), ('aimed', 2), ('explore', 2), ('mechanism', 2), ('effects', 2), ('blockading', 2), ('cells', 2), ('injected', 2), ('subcutaneously', 2), ('establish', 2), ('model', 2), ('randomly', 2), ('categorized', 2), ('control', 2), ('immunoglobulin', 2), ('g', 2), ('corresponding', 2), ('intravenous', 2), ('tail', 2), ('injection', 2), ('saline', 2), ('isotype', 2), ('respectively', 2), ('receptor', 2), ('janus', 2), ('kinase', 2), ('transducer', 2), ('activator', 2), ('transcription', 2), ('tested', 2), ('quantitative', 2), ('polymerase', 2), ('chain', 2), ('reaction', 2), ('detected', 2), ('immunosorbent', 2), ('assay', 2), ('elisa', 2), ('western', 2), ('blotting', 2), ('immunocytochemistry', 2), ('performed', 2), ('detect', 2), ('phosphorylation', 2), ('transducers', 2), ('activators', 2), ('matrix', 2), ('metalloproteinase', 2), ('vascular', 2), ('endothelial', 2), ('factor', 2), ('assessed', 2), ('weight', 2), ('remarkable', 2), ('survival', 2), ('benefit', 2), ('compared', 2), ('concentration', 2), ('downregulated', 2), ('proteins', 2), ('protein', 2), ('showed', 2), ('significant', 2), ('difference', 2), ('could', 2), ('effectively', 2), ('restrain', 2), ('effect', 2), ('may', 2), ('partly', 2), ('occur', 2), ('blocking', 2), ('pathway', 2)]"', 'b"[('the', 21), ('(', 16), (')', 16), ('and', 14), (',', 13), ('in', 11), ('of', 11), ('group', 10), ('.', 9), ('anti-il-9', 6), ('wa', 6), ('to', 5), ('p', 5), ('<', 5), ('0.05', 5), ('il-9', 4), ('were', 4), ('mice', 4), ('stat3', 4), ('tumor', 3), ('pancreat', 3), ('cancer', 3), ('effect', 3), ('a', 3), ('igg', 3), ('antibodi', 3), ('interleukin', 2), ('9', 2), ('but', 2), ('mous', 2), ('inject', 2), ('into', 2), ('3', 2), ('-', 2), ('pb', 2), ('express', 2), ('jak1', 2), ('jak3', 2), ('signal', 2), ('transduc', 2), ('activ', 2), ('mrna', 2), ('tissu', 2), ('detect', 2), ('use', 2), ('pstat3', 2), ('mmp2', 2), ('mmp9', 2), ('growth', 2), ('vegf', 2), ('level', 2), ('significantli', 2), ('lower', 2), ('than', 2), ('other', 2), ('protein', 2), ('ha', 1), ('been', 1), ('implic', 1), ('pathogenesi', 1), ('sever', 1), ('type', 1), ('role', 1), ('remain', 1), ('unclear.w', 1), ('aim', 1), ('explor', 1), ('mechan', 1), ('blockad', 1), ('model.panc02', 1), ('cell', 1), ('subcutan', 1), ('establish', 1), ('model', 1), ('randomli', 1), ('categor', 1), ('control', 1), ('immunoglobulin', 1), ('G', 1), ('correspond', 1), ('intraven', 1), ('tail', 1), ('phosphate-buff', 1), ('salin', 1), ('isotyp', 1), ('respect', 1), ('then', 1), ('interleukin-9', 1), ('receptor', 1), ('il-9r', 1), ('janu', 1), ('kinas', 1), ('1', 1), ('transcript', 1), ('test', 1), ('with', 1), ('quantit', 1), ('reverse-transcript', 1), ('polymeras', 1), ('chain', 1), ('reaction', 1), ('qrt-pcr', 1), ('enzyme-link', 1), ('immunosorb', 1), ('assay', 1), ('elisa', 1), ('western', 1), ('blot', 1), ('immunocytochemistri', 1), ('perform', 1), ('phosphoryl', 1), ('transcription-3', 1), ('matrix', 1), ('metalloproteinas', 1), ('2', 1), ('vascular', 1), ('endotheli', 1), ('factor', 1), ('assess', 1), ('immunocytochemistry.tumor', 1), ('weight', 1), ('there', 1), ('remark', 1), ('surviv', 1), ('benefit', 1), ('compar', 1), ('concentr', 1), ('downregul', 1), ('anti-il-9-tr', 1), ('that', 1), ('or', 1), ('show', 1), ('no', 1), ('signific', 1), ('differ', 1), ('.anti-il-9', 1), ('could', 1), ('restrain', 1), ('thi', 1), ('may', 1), ('partli', 1), ('occur', 1), ('by', 1), ('block', 1), ('pathway', 1)]"', 'b'9'', 'b"('group', 'p', 'mice', 'groups', 'tumor', 'pancreatic', 'cancer', 'igg', 'antibody', 'interleukin', 'mouse', 'pbs', 'expression', 'signal', 'mrna', 'tissue', 'using', 'growth', 'vegf', 'levels', 'significantly', 'lower', 'implicated', 'pathogenesis', 'several', 'types', 'role', 'remains', 'aimed', 'explore', 'mechanism', 'effects', 'blockading', 'cells', 'injected', 'subcutaneously', 'establish', 'model', 'randomly', 'categorized', 'control', 'immunoglobulin', 'g', 'corresponding', 'intravenous', 'tail', 'injection', 'saline', 'isotype', 'respectively', 'receptor', 'janus', 'kinase', 'transducer', 'activator', 'transcription', 'tested', 'quantitative', 'polymerase', 'chain', 'reaction', 'detected', 'immunosorbent', 'assay', 'elisa', 'western', 'blotting', 'immunocytochemistry', 'performed', 'detect', 'phosphorylation', 'transducers', 'activators', 'matrix', 'metalloproteinase', 'vascular', 'endothelial', 'factor', 'assessed', 'weight', 'remarkable', 'survival', 'benefit', 'compared', 'concentration', 'downregulated', 'proteins', 'protein', 'showed', 'significant', 'difference', 'could', 'effectively', 'restrain', 'effect', 'may', 'partly', 'occur', 'blocking', 'pathway')"', 'b'(12, 10, 8, 8, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.005543556675053523'', 'b'[-0.065638067681506, -0.032819033840753, -0.02245512841735731, -0.013762820642896417, -0.00927494434629976, -0.0023182950277148623, -0.0022572872638276288, -0.0021883845446798965]'', 'b'-2.4339872044851463'', 'b'[-1.5649493574615367, -2.258096538021482, -2.6375861597263857, -3.1271343850450917, -3.5217885770490405, -4.91350300563827, -4.940171252720432, -4.976350909297934]'', 'b'-0.41828132644697347'', 'b'[1.3353632739614656, 1.9268222141223692, 2.2506387652830115, 2.6683677593918063, 3.0051241607438945, 4.2146513470542954, 4.237526546959421, 4.290726751011671]'', 'b'61'', 'b'0.17055052382944416'', 'b"['Animals', 'Disease Models, Animal', 'Interleukin-9', 'Matrix Metalloproteinase 2', 'Mice', 'Pancreatic Neoplasms', 'Random Allocation', 'STAT3 Transcription Factor', 'Vascular Endothelial Growth Factor A']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'90'', 'b'A qualitative transcriptional signature for predicting microsatellite instability status of right-sided Colon Cancer.'', 'b'Microsatellite instability (MSI) accounts for about 15% of colorectal cancer and is associated with prognosis. Today, MSI is usually detected by polymerase chain reaction amplification of specific microsatellite markers. However, the instability is identified by comparing the length of microsatellite repeats in tumor and normal samples. In this work, we developed a qualitative transcriptional signature to individually predict MSI status for right-sided colon cancer (RCC) based on tumor samples.Using RCC samples, based on the relative expression orderings (REOs) of gene pairs, we extracted a signature consisting of 10 gene pairs (10-GPS) to predict MSI status for RCC through a feature selection process. A sample is predicted as MSI when the gene expression orderings of at least 7 gene pairs vote for MSI; otherwise the microsatellite stability (MSS). The classification performance reached the largest F-score in the training dataset. This signature was verified in four independent datasets of RCCs with the F-scores of 1, 0.9630, 0.9412 and 0.8798, respectively. Additionally, the hierarchical clustering analyses and molecular features also supported the correctness of the reclassifications of the MSI status by 10-GPS.The qualitative transcriptional signature can be used to classify MSI status of RCC samples at the individualized level.'', 'b'1158'', 'b'196'', 'b"[('msi', 16), ('microsatellite', 8), ('signature', 8), ('status', 8), ('rcc', 8), ('gene', 8), ('samples', 6), ('pairs', 6), ('instability', 4), ('cancer', 4), ('tumor', 4), ('qualitative', 4), ('transcriptional', 4), ('predict', 4), ('based', 4), ('expression', 4), ('orderings', 4), ('accounts', 2), ('colorectal', 2), ('associated', 2), ('prognosis', 2), ('today', 2), ('usually', 2), ('detected', 2), ('polymerase', 2), ('chain', 2), ('reaction', 2), ('amplification', 2), ('specific', 2), ('markers', 2), ('however', 2), ('identified', 2), ('comparing', 2), ('length', 2), ('repeats', 2), ('normal', 2), ('work', 2), ('developed', 2), ('individually', 2), ('colon', 2), ('relative', 2), ('reos', 2), ('extracted', 2), ('consisting', 2), ('feature', 2), ('selection', 2), ('process', 2), ('sample', 2), ('predicted', 2), ('least', 2), ('vote', 2), ('otherwise', 2), ('stability', 2), ('mss', 2), ('classification', 2), ('performance', 2), ('reached', 2), ('largest', 2), ('training', 2), ('dataset', 2), ('verified', 2), ('four', 2), ('independent', 2), ('datasets', 2), ('rccs', 2), ('respectively', 2), ('additionally', 2), ('hierarchical', 2), ('clustering', 2), ('analyses', 2), ('molecular', 2), ('features', 2), ('also', 2), ('supported', 2), ('correctness', 2), ('reclassifications', 2), ('used', 2), ('classify', 2), ('individualized', 2), ('level', 2)]"', 'b"[('the', 14), ('of', 11), (',', 9), ('msi', 8), ('.', 8), ('(', 5), (')', 5), ('rcc', 5), ('microsatellit', 4), ('for', 4), ('and', 4), ('is', 4), ('sampl', 4), ('signatur', 4), ('statu', 4), ('gene', 4), ('by', 3), ('in', 3), ('a', 3), ('to', 3), ('predict', 3), ('pair', 3), ('instabl', 2), ('cancer', 2), ('with', 2), ('tumor', 2), ('thi', 2), ('we', 2), ('qualit', 2), ('transcript', 2), ('individu', 2), ('base', 2), ('on', 2), ('express', 2), ('order', 2), ('featur', 2), ('at', 2), ('f-score', 2), ('dataset', 2), ('account', 1), ('about', 1), ('15', 1), ('%', 1), ('colorect', 1), ('associ', 1), ('prognosi', 1), ('today', 1), ('usual', 1), ('detect', 1), ('polymeras', 1), ('chain', 1), ('reaction', 1), ('amplif', 1), ('specif', 1), ('marker', 1), ('howev', 1), ('identifi', 1), ('compar', 1), ('length', 1), ('repeat', 1), ('normal', 1), ('In', 1), ('work', 1), ('develop', 1), ('right-sid', 1), ('colon', 1), ('samples.us', 1), ('rel', 1), ('reo', 1), ('extract', 1), ('consist', 1), ('10', 1), ('10-gp', 1), ('through', 1), ('select', 1), ('process', 1), ('A', 1), ('as', 1), ('when', 1), ('least', 1), ('7', 1), ('vote', 1), (';', 1), ('otherwis', 1), ('stabil', 1), ('mss', 1), ('classif', 1), ('perform', 1), ('reach', 1), ('largest', 1), ('train', 1), ('wa', 1), ('verifi', 1), ('four', 1), ('independ', 1), ('1', 1), ('0.9630', 1), ('0.9412', 1), ('0.8798', 1), ('respect', 1), ('addit', 1), ('hierarch', 1), ('cluster', 1), ('analys', 1), ('molecular', 1), ('also', 1), ('support', 1), ('correct', 1), ('reclassif', 1), ('10-gps.the', 1), ('can', 1), ('be', 1), ('use', 1), ('classifi', 1), ('level', 1)]"', 'b'8'', 'b"('msi', 'microsatellite', 'signature', 'status', 'rcc', 'gene', 'samples', 'pairs', 'instability', 'cancer', 'tumor', 'qualitative', 'transcriptional', 'predict', 'based', 'expression', 'orderings', 'accounts', 'colorectal', 'associated', 'prognosis', 'today', 'usually', 'detected', 'polymerase', 'chain', 'reaction', 'amplification', 'specific', 'markers', 'however', 'identified', 'comparing', 'length', 'repeats', 'normal', 'work', 'developed', 'individually', 'colon', 'relative', 'reos', 'extracted', 'consisting', 'feature', 'selection', 'process', 'sample', 'predicted', 'least', 'vote', 'otherwise', 'stability', 'mss', 'classification', 'performance', 'reached', 'largest', 'training', 'dataset', 'verified', 'four', 'independent', 'datasets', 'rccs', 'respectively', 'additionally', 'hierarchical', 'clustering', 'analyses', 'molecular', 'features', 'also', 'supported', 'correctness', 'reclassifications', 'used', 'classify', 'individualized', 'level')"', 'b'(16, 8, 8, 8, 8, 8, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.00121700562540536'', 'b'[-0.08666581076717451, -0.02888860358905817, -0.015204528204767457, -0.011711596049618177, -0.009122716922860475, -0.007602264102383728]'', 'b'-3.875197323201151'', 'b'[-1.3025850929940455, -2.4011973816621555, -3.0430512678345503, -3.3040650932041693, -3.5538768916005408, -3.7361984483944957]'', 'b'-0.6178139393877988'', 'b'[1.1288959317756435, 2.081017178937673, 2.637285053329596, 2.8634948013005936, 3.0799962217728685, 3.238006677171684]'', 'b'95'', 'b'0.11827650652285465'', 'b"['Algorithms', 'Cluster Analysis', 'Colonic Neoplasms', 'Computational Biology', 'Humans', 'Microsatellite Instability', 'Transcriptome']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'91'', 'b'The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study.'', 'b'The aim was to evaluate the prognostic biomarker potential of the soluble urokinase-type plasminogen activator receptor (suPAR) in plasma samples collected pre- and postoperatively from patients resected for colorectal cancer (CRC).Patients with CRC were recruited prospectively at six centers from 2006 to 2008. Preoperative plasma samples were available from 494 patients and from 328 of these patients at 6 months postoperatively. Determinations of intact soluble uPAR (suPAR) suPAR(I-III) and the cleaved forms suPAR(I-III)\xe2\x80\x89+\xe2\x80\x89(II-III) and uPAR(I) were performed. Clinical data were retrieved retrospectively.In a multivariable model based on preoperative plasma samples suPAR(I-III)\xe2\x80\x89+\xe2\x80\x89(II-III) and uPAR(I) showed an independent statistically significant association to long term survival. When including the change in biomarker level between the pre- and postoperatively samples the hazard ratios were 3.06 (95% confidence interval [CI], 1.78-5.28; P\xe2\x80\x89<\xe2\x80\x89.0001) and 2.24 (95% CI, 1.59-3.16; P\xe2\x80\x89<\xe2\x80\x89.0001) for suPAR(I-III)\xe2\x80\x89+\xe2\x80\x89(II-III) and uPAR(I), respectively. A one-unit decrease in biomarker levels between the pre- and postoperative levels resulted in a 55% and 34% reduction in the risk estimate of death for suPAR(I-III)\xe2\x80\x89+\xe2\x80\x89(II-III) and uPAR(I), respectively.This study validates previously findings regarding the prognostic significance of suPAR in preoperative samples. The inclusion of postoperative samples added further prognostic information.'', 'b'1249'', 'b'202'', 'b"[('supar', 16), ('samples', 12), ('upar', 10), ('prognostic', 6), ('biomarker', 6), ('plasma', 6), ('postoperatively', 6), ('patients', 6), ('preoperative', 6), ('soluble', 4), ('crc', 4), ('ci', 4), ('p', 4), ('levels', 4), ('postoperative', 4), ('aim', 2), ('evaluate', 2), ('potential', 2), ('plasminogen', 2), ('activator', 2), ('receptor', 2), ('collected', 2), ('resected', 2), ('colorectal', 2), ('cancer', 2), ('recruited', 2), ('prospectively', 2), ('six', 2), ('centers', 2), ('available', 2), ('months', 2), ('determinations', 2), ('intact', 2), ('cleaved', 2), ('forms', 2), ('performed', 2), ('clinical', 2), ('data', 2), ('retrieved', 2), ('multivariable', 2), ('model', 2), ('based', 2), ('showed', 2), ('independent', 2), ('statistically', 2), ('significant', 2), ('association', 2), ('long', 2), ('term', 2), ('survival', 2), ('including', 2), ('change', 2), ('level', 2), ('hazard', 2), ('ratios', 2), ('confidence', 2), ('interval', 2), ('respectively', 2), ('decrease', 2), ('resulted', 2), ('reduction', 2), ('risk', 2), ('estimate', 2), ('death', 2), ('study', 2), ('validates', 2), ('previously', 2), ('findings', 2), ('regarding', 2), ('significance', 2), ('inclusion', 2), ('added', 2), ('information', 2)]"', 'b"[('(', 18), (')', 18), ('the', 11), ('and', 11), ('supar', 8), ('.', 7), ('of', 6), ('in', 6), ('sampl', 6), ('postop', 5), ('were', 5), ('upar', 5), ('i-iii', 5), ('from', 4), ('+', 4), ('ii-iii', 4), ('I', 4), ('%', 4), (',', 4), ('to', 3), ('prognost', 3), ('biomark', 3), ('plasma', 3), ('pre-', 3), ('patient', 3), ('for', 3), ('preoper', 3), ('level', 3), ('solubl', 2), ('crc', 2), ('at', 2), ('a', 2), ('signific', 2), ('between', 2), ('95', 2), ('CI', 2), (';', 2), ('P', 2), ('<', 2), ('.0001', 2), ('aim', 1), ('wa', 1), ('evalu', 1), ('potenti', 1), ('urokinase-typ', 1), ('plasminogen', 1), ('activ', 1), ('receptor', 1), ('collect', 1), ('resect', 1), ('colorect', 1), ('cancer', 1), ('.patient', 1), ('with', 1), ('recruit', 1), ('prospect', 1), ('six', 1), ('center', 1), ('2006', 1), ('2008', 1), ('avail', 1), ('494', 1), ('328', 1), ('these', 1), ('6', 1), ('month', 1), ('determin', 1), ('intact', 1), ('cleav', 1), ('form', 1), ('perform', 1), ('clinic', 1), ('data', 1), ('retriev', 1), ('retrospectively.in', 1), ('multivari', 1), ('model', 1), ('base', 1), ('on', 1), ('show', 1), ('an', 1), ('independ', 1), ('statist', 1), ('associ', 1), ('long', 1), ('term', 1), ('surviv', 1), ('when', 1), ('includ', 1), ('chang', 1), ('hazard', 1), ('ratio', 1), ('3.06', 1), ('confid', 1), ('interv', 1), ('[', 1), (']', 1), ('1.78-5.28', 1), ('2.24', 1), ('1.59-3.16', 1), ('respect', 1), ('A', 1), ('one-unit', 1), ('decreas', 1), ('result', 1), ('55', 1), ('34', 1), ('reduct', 1), ('risk', 1), ('estim', 1), ('death', 1), ('respectively.thi', 1), ('studi', 1), ('valid', 1), ('previous', 1), ('find', 1), ('regard', 1), ('inclus', 1), ('ad', 1), ('further', 1), ('inform', 1)]"', 'b'7'', 'b"('supar', 'samples', 'upar', 'prognostic', 'biomarker', 'plasma', 'postoperatively', 'patients', 'preoperative', 'soluble', 'crc', 'ci', 'p', 'levels', 'postoperative', 'aim', 'evaluate', 'potential', 'plasminogen', 'activator', 'receptor', 'collected', 'resected', 'colorectal', 'cancer', 'recruited', 'prospectively', 'six', 'centers', 'available', 'months', 'determinations', 'intact', 'cleaved', 'forms', 'performed', 'clinical', 'data', 'retrieved', 'multivariable', 'model', 'based', 'showed', 'independent', 'statistically', 'significant', 'association', 'long', 'term', 'survival', 'including', 'change', 'level', 'hazard', 'ratios', 'confidence', 'interval', 'respectively', 'decrease', 'resulted', 'reduction', 'risk', 'estimate', 'death', 'study', 'validates', 'previously', 'findings', 'regarding', 'significance', 'inclusion', 'added', 'information')"', 'b'(16, 12, 10, 6, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.00656953769358427'', 'b'[-0.10888414073510774, -0.05149816102081764, -0.03258685599828514, -0.019552113598971084, -0.010729818438459741, -0.004805447920231818]'', 'b'-2.109060958860994'', 'b'[-1.0794415416798357, -1.8332133440562162, -2.295836866004329, -2.8066624897703196, -3.4067192472642533, -4.214935757608986]'', 'b'-0.31036444246761596'', 'b'[0.9402725179167113, 1.604920971621216, 2.0199808443970078, 2.4694282725282135, 2.9973852775040375, 3.72685638573756]'', 'b'60'', 'b'0.08062839917834955'', 'b"['Adult', 'Aged', 'Aged, 80 and over', 'Biomarkers, Tumor', 'Colorectal Neoplasms', 'Denmark', 'Female', 'Humans', 'Male', 'Middle Aged', 'Prognosis', 'Proportional Hazards Models', 'Prospective Studies', 'Receptors, Urokinase Plasminogen Activator', 'Retrospective Studies']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'92'', 'b'The Role of Mitochondrial Calcium Signaling in the Pathophysiology of Cancer Cells.'', 'b'The pioneering work of Richard Altman on the presence of mitochondria in cells set in motion a field of research dedicated to uncovering the secrets of the mitochondria. Despite limitations in studying the structure and function of the mitochondria, advances in our understanding of this organelle prompted the development of potential treatments for various diseases, from neurodegenerative conditions to muscular dystrophy and cancer. As the powerhouses of the cell, the mitochondria represent the essence of cellular life and as such, a selective advantage for cancer cells. Much of the function of the mitochondria relies on Ca'', 'b'536'', 'b'96'', 'b"[('mitochondria', 10), ('cells', 4), ('function', 4), ('cancer', 4), ('pioneering', 2), ('work', 2), ('richard', 2), ('altman', 2), ('presence', 2), ('set', 2), ('motion', 2), ('field', 2), ('research', 2), ('dedicated', 2), ('uncovering', 2), ('secrets', 2), ('despite', 2), ('limitations', 2), ('studying', 2), ('structure', 2), ('advances', 2), ('understanding', 2), ('organelle', 2), ('prompted', 2), ('development', 2), ('potential', 2), ('treatments', 2), ('various', 2), ('diseases', 2), ('neurodegenerative', 2), ('conditions', 2), ('muscular', 2), ('dystrophy', 2), ('powerhouses', 2), ('cell', 2), ('represent', 2), ('essence', 2), ('cellular', 2), ('life', 2), ('selective', 2), ('advantage', 2), ('much', 2), ('relies', 2), ('ca', 2)]"', 'b"[('the', 13), ('of', 11), ('mitochondria', 5), ('in', 4), (',', 4), ('cell', 3), ('.', 3), ('and', 3), ('on', 2), ('a', 2), ('to', 2), ('function', 2), ('for', 2), ('cancer', 2), ('pioneer', 1), ('work', 1), ('richard', 1), ('altman', 1), ('presenc', 1), ('set', 1), ('motion', 1), ('field', 1), ('research', 1), ('dedic', 1), ('uncov', 1), ('secret', 1), ('despit', 1), ('limit', 1), ('studi', 1), ('structur', 1), ('advanc', 1), ('our', 1), ('understand', 1), ('thi', 1), ('organel', 1), ('prompt', 1), ('develop', 1), ('potenti', 1), ('treatment', 1), ('variou', 1), ('diseas', 1), ('from', 1), ('neurodegen', 1), ('condit', 1), ('muscular', 1), ('dystrophi', 1), ('As', 1), ('powerhous', 1), ('repres', 1), ('essenc', 1), ('cellular', 1), ('life', 1), ('as', 1), ('such', 1), ('select', 1), ('advantag', 1), ('much', 1), ('reli', 1), ('Ca', 1)]"', 'b'4'', 'b"('mitochondria', 'cells', 'function', 'cancer', 'pioneering', 'work', 'richard', 'altman', 'presence', 'set', 'motion', 'field', 'research', 'dedicated', 'uncovering', 'secrets', 'despite', 'limitations', 'studying', 'structure', 'advances', 'understanding', 'organelle', 'prompted', 'development', 'potential', 'treatments', 'various', 'diseases', 'neurodegenerative', 'conditions', 'muscular', 'dystrophy', 'powerhouses', 'cell', 'represent', 'essence', 'cellular', 'life', 'selective', 'advantage', 'much', 'relies', 'ca')"', 'b'(10, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.006028405526961738'', 'b'[-0.11106760236515659, -0.05252120470975112, -0.03322820599870962, -0.019936923599225772, -0.010940994658111705, -0.004899153389984568]'', 'b'-2.109060958860994'', 'b'[-1.0794415416798357, -1.8332133440562162, -2.295836866004329, -2.8066624897703196, -3.4067192472642533, -4.214935757608986]'', 'b'-0.2847997542005692'', 'b'[0.9591278714218208, 1.636803746437007, 2.0597365887216412, 2.518029703231364, 3.0563775610523707, 3.799529492204132]'', 'b'93'', 'b'0.08171924792244156'', 'b"['Apoptosis', 'Calcium', 'Calcium Signaling', 'Homeostasis', 'Humans', 'Mitochondria', 'Neoplasms']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'93'', 'b'Calcium Signaling and the Regulation of Chemosensitivity in Cancer Cells: Role of the Transient Receptor Potential Channels.'', 'b'Cancer cells acquire the ability to modify the calcium signaling network by altering the expression and functions of cation channels, pumps or transporters. Calcium signaling pathways are involved in proliferation, angiogenesis, invasion, immune evasion, disruption of cell death pathways, ECM remodelling, epithelial-mesenchymal transition (EMT) and drug resistance. Among cation channels, a pivotal role is played by the Transient Receptor Potential non-selective cation-permeable receptors localized in plasma membrane, endoplasmic reticulum, mitochondria and lysosomes. Several findings indicate that the dysregulation in calcium signaling induced by TRP channels is responsible for cancer growth, metastasis and chemoresistance. Drug resistance represents a major limitation in the application of current therapeutic regimens and several efforts are spent to overcome it. Here we describe the ability of Transient Receptor Potential Channels to modify, by altering the intracellular calcium influx, the cancer cell sensitivity to chemotherapeutic drugs.'', 'b'920'', 'b'139'', 'b"[('calcium', 8), ('channels', 8), ('cancer', 6), ('signaling', 6), ('ability', 4), ('modify', 4), ('altering', 4), ('cation', 4), ('pathways', 4), ('cell', 4), ('drug', 4), ('resistance', 4), ('transient', 4), ('receptor', 4), ('potential', 4), ('several', 4), ('cells', 2), ('acquire', 2), ('network', 2), ('expression', 2), ('functions', 2), ('pumps', 2), ('transporters', 2), ('involved', 2), ('proliferation', 2), ('angiogenesis', 2), ('invasion', 2), ('immune', 2), ('evasion', 2), ('disruption', 2), ('death', 2), ('ecm', 2), ('remodelling', 2), ('transition', 2), ('emt', 2), ('among', 2), ('pivotal', 2), ('role', 2), ('played', 2), ('receptors', 2), ('localized', 2), ('plasma', 2), ('membrane', 2), ('endoplasmic', 2), ('reticulum', 2), ('mitochondria', 2), ('lysosomes', 2), ('findings', 2), ('indicate', 2), ('dysregulation', 2), ('induced', 2), ('trp', 2), ('responsible', 2), ('growth', 2), ('metastasis', 2), ('chemoresistance', 2), ('represents', 2), ('major', 2), ('limitation', 2), ('application', 2), ('current', 2), ('therapeutic', 2), ('regimens', 2), ('efforts', 2), ('spent', 2), ('overcome', 2), ('describe', 2), ('intracellular', 2), ('influx', 2), ('sensitivity', 2), ('chemotherapeutic', 2), ('drugs', 2)]"', 'b"[(',', 13), ('the', 9), ('.', 6), ('and', 5), ('to', 4), ('calcium', 4), ('by', 4), ('of', 4), ('channel', 4), ('in', 4), ('cancer', 3), ('cell', 3), ('signal', 3), ('drug', 3), ('receptor', 3), ('abil', 2), ('modifi', 2), ('alter', 2), ('cation', 2), ('pathway', 2), ('are', 2), ('resist', 2), ('a', 2), ('is', 2), ('transient', 2), ('potenti', 2), ('sever', 2), ('acquir', 1), ('network', 1), ('express', 1), ('function', 1), ('pump', 1), ('or', 1), ('transport', 1), ('involv', 1), ('prolifer', 1), ('angiogenesi', 1), ('invas', 1), ('immun', 1), ('evas', 1), ('disrupt', 1), ('death', 1), ('ecm', 1), ('remodel', 1), ('epithelial-mesenchym', 1), ('transit', 1), ('(', 1), ('emt', 1), (')', 1), ('among', 1), ('pivot', 1), ('role', 1), ('play', 1), ('non-select', 1), ('cation-perm', 1), ('local', 1), ('plasma', 1), ('membran', 1), ('endoplasm', 1), ('reticulum', 1), ('mitochondria', 1), ('lysosom', 1), ('find', 1), ('indic', 1), ('that', 1), ('dysregul', 1), ('induc', 1), ('trp', 1), ('respons', 1), ('for', 1), ('growth', 1), ('metastasi', 1), ('chemoresist', 1), ('repres', 1), ('major', 1), ('limit', 1), ('applic', 1), ('current', 1), ('therapeut', 1), ('regimen', 1), ('effort', 1), ('spent', 1), ('overcom', 1), ('it', 1), ('here', 1), ('we', 1), ('describ', 1), ('intracellular', 1), ('influx', 1), ('sensit', 1), ('chemotherapeut', 1)]"', 'b'6'', 'b"('calcium', 'channels', 'cancer', 'signaling', 'ability', 'modify', 'altering', 'cation', 'pathways', 'cell', 'drug', 'resistance', 'transient', 'receptor', 'potential', 'several', 'cells', 'acquire', 'network', 'expression', 'functions', 'pumps', 'transporters', 'involved', 'proliferation', 'angiogenesis', 'invasion', 'immune', 'evasion', 'disruption', 'death', 'ecm', 'remodelling', 'transition', 'emt', 'among', 'pivotal', 'role', 'played', 'receptors', 'localized', 'plasma', 'membrane', 'endoplasmic', 'reticulum', 'mitochondria', 'lysosomes', 'findings', 'indicate', 'dysregulation', 'induced', 'trp', 'responsible', 'growth', 'metastasis', 'chemoresistance', 'represents', 'major', 'limitation', 'application', 'current', 'therapeutic', 'regimens', 'efforts', 'spent', 'overcome', 'describe', 'intracellular', 'influx', 'sensitivity', 'chemotherapeutic', 'drugs')"', 'b'(8, 8, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.002546070884632287'', 'b'[-0.15095143709060302, -0.06499677953036209, -0.039747097805851755, -0.01945070743690618, -0.01498661064810804, -0.013644526112456572, -0.011148576213836468, -0.010507853442926327, -0.00962298157404832, -0.009051319302322678, -0.006624516300975293]'', 'b'-2.8781214537524646'', 'b'[-0.791759469228055, -1.6390573296152589, -2.1354942159291497, -2.8501476017100584, -3.1108738641733114, -3.2046926193909657, -3.4067192472642533, -3.4659081186545837, -3.5538768916005408, -3.6151205168412597, -3.927253685157205]'', 'b'-0.3541818930653439'', 'b'[0.7171033782604079, 1.491468270468778, 1.9522330416804323, 2.6055571961845208, 2.8439087780421857, 2.9296763125543515, 3.114365671716069, 3.168475146499966, 3.2488947252092717, 3.3048826215451106, 3.590229535643709]'', 'b'92'', 'b'0.08171924792244156'', 'b"['Antineoplastic Agents', 'Calcium', 'Calcium Signaling', 'Drug Resistance, Neoplasm', 'Humans', 'Neoplasms', 'Transient Receptor Potential Channels']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'94'', 'b'Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer.'', 'b'To investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer.Peripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) platform was applied to identify, enumerate and characterize CTCs based on cell size, aneuploidy of chromosome 8 (Chr8) and vimentin expression. Quantification and analysis of CTCs were performed on patients before chemotherapy administration and after two cycles of therapy.Before treatment, CTCs were detected in 60 (98.4%) patients, small cell CTCs (\xe2\x89\xa4\xe2\x80\x895 \xc2\xb5m of WBCs) accounted for 52.8% of the absolute CTCs number, while 12 (19.7%) of the included patients had detectable vimentin-positive CTCs (vimThis study demonstrates an important morphologic, karyotypic and phenotypic CTCs heterogeneity in advanced lung cancer patients. The majority of Vim'', 'b'821'', 'b'132'', 'b"[('ctcs', 16), ('patients', 12), ('advanced', 6), ('lung', 6), ('vimentin', 4), ('expression', 4), ('cancer', 4), ('cell', 4), ('investigate', 2), ('presence', 2), ('clinical', 2), ('relevance', 2), ('blood', 2), ('obtained', 2), ('subtraction', 2), ('enrichment', 2), ('situ', 2), ('hybridization', 2), ('platform', 2), ('applied', 2), ('identify', 2), ('enumerate', 2), ('characterize', 2), ('based', 2), ('size', 2), ('aneuploidy', 2), ('chromosome', 2), ('quantification', 2), ('analysis', 2), ('performed', 2), ('chemotherapy', 2), ('administration', 2), ('two', 2), ('cycles', 2), ('treatment', 2), ('detected', 2), ('small', 2), ('\xc2\xb5m', 2), ('wbcs', 2), ('accounted', 2), ('absolute', 2), ('number', 2), ('included', 2), ('detectable', 2), ('vimthis', 2), ('study', 2), ('demonstrates', 2), ('important', 2), ('morphologic', 2), ('karyotypic', 2), ('phenotypic', 2), ('heterogeneity', 2), ('majority', 2), ('vim', 2)]"', 'b"[('of', 8), ('ctc', 8), ('and', 7), ('patient', 6), ('(', 6), (',', 6), ('in', 5), (')', 5), ('the', 4), ('advanc', 3), ('lung', 3), ('.', 3), ('%', 3), ('vimentin', 2), ('express', 2), ('with', 2), ('wa', 2), ('cancer', 2), ('on', 2), ('cell', 2), ('were', 2), ('detect', 2), ('To', 1), ('investig', 1), ('presenc', 1), ('it', 1), ('clinic', 1), ('relev', 1), ('cancer.peripher', 1), ('blood', 1), ('obtain', 1), ('from', 1), ('61', 1), ('treatment-na', 1), ('subtract', 1), ('enrich', 1), ('immunostaining-fluoresc', 1), ('situ', 1), ('hybrid', 1), ('se-ifish', 1), ('platform', 1), ('appli', 1), ('to', 1), ('identifi', 1), ('enumer', 1), ('character', 1), ('base', 1), ('size', 1), ('aneuploidi', 1), ('chromosom', 1), ('8', 1), ('chr8', 1), ('quantif', 1), ('analysi', 1), ('perform', 1), ('befor', 1), ('chemotherapi', 1), ('administr', 1), ('after', 1), ('two', 1), ('cycl', 1), ('therapy.befor', 1), ('treatment', 1), ('60', 1), ('98.4', 1), ('small', 1), ('\xe2\x89\xa4', 1), ('5', 1), ('\xc2\xb5m', 1), ('wbc', 1), ('account', 1), ('for', 1), ('52.8', 1), ('absolut', 1), ('number', 1), ('while', 1), ('12', 1), ('19.7', 1), ('includ', 1), ('had', 1), ('vimentin-posit', 1), ('vimthi', 1), ('studi', 1), ('demonstr', 1), ('an', 1), ('import', 1), ('morpholog', 1), ('karyotyp', 1), ('phenotyp', 1), ('heterogen', 1), ('major', 1), ('vim', 1)]"', 'b'4'', 'b"('ctcs', 'patients', 'advanced', 'lung', 'vimentin', 'expression', 'cancer', 'cell', 'investigate', 'presence', 'clinical', 'relevance', 'blood', 'obtained', 'subtraction', 'enrichment', 'situ', 'hybridization', 'platform', 'applied', 'identify', 'enumerate', 'characterize', 'based', 'size', 'aneuploidy', 'chromosome', 'quantification', 'analysis', 'performed', 'chemotherapy', 'administration', 'two', 'cycles', 'treatment', 'detected', 'small', '\xc2\xb5m', 'wbcs', 'accounted', 'absolute', 'number', 'included', 'detectable', 'vimthis', 'study', 'demonstrates', 'important', 'morphologic', 'karyotypic', 'phenotypic', 'heterogeneity', 'majority', 'vim')"', 'b'(16, 12, 6, 6, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0026273772073281353'', 'b'[-0.22959844551773345, -0.02869980568971668, -0.020872585956157586, -0.017328184567376108, -0.01434990284485834, -0.010250962892566332, -0.008661327399452808]'', 'b'-2.7455747977904816'', 'b'[-0.3862943611198906, -2.4657359027997265, -2.784189633918261, -2.970291913552122, -3.1588830833596715, -3.499809670330265, -3.6728288344619067]'', 'b'-0.30537830062687227'', 'b'[0.35477033930157137, 2.264516521360329, 2.5569824478968806, 2.7278976243418445, 2.9010985820465818, 3.2288777155440322, 3.4038383128645004]'', 'b'2'', 'b'0.09044966024175446'', 'b"['Chromosomes, Human, Pair 8', 'Female', 'Follow-Up Studies', 'Humans', 'Liver Neoplasms', 'Lung Neoplasms', 'Male', 'Middle Aged', 'Neoplastic Cells, Circulating', 'Progression-Free Survival', 'Prospective Studies', 'Vimentin']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'94'', 'b'Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer.'', 'b'To investigate the presence of vimentin expression in CTCs and its clinical relevance in patients with advanced lung cancer.Peripheral blood was obtained from 61 treatment-naive patients with advanced lung cancer. Subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) platform was applied to identify, enumerate and characterize CTCs based on cell size, aneuploidy of chromosome 8 (Chr8) and vimentin expression. Quantification and analysis of CTCs were performed on patients before chemotherapy administration and after two cycles of therapy.Before treatment, CTCs were detected in 60 (98.4%) patients, small cell CTCs (\xe2\x89\xa4\xe2\x80\x895 \xc2\xb5m of WBCs) accounted for 52.8% of the absolute CTCs number, while 12 (19.7%) of the included patients had detectable vimentin-positive CTCs (vimThis study demonstrates an important morphologic, karyotypic and phenotypic CTCs heterogeneity in advanced lung cancer patients. The majority of Vim'', 'b'821'', 'b'132'', 'b"[('ctcs', 16), ('patients', 12), ('advanced', 6), ('lung', 6), ('vimentin', 4), ('expression', 4), ('cancer', 4), ('cell', 4), ('investigate', 2), ('presence', 2), ('clinical', 2), ('relevance', 2), ('blood', 2), ('obtained', 2), ('subtraction', 2), ('enrichment', 2), ('situ', 2), ('hybridization', 2), ('platform', 2), ('applied', 2), ('identify', 2), ('enumerate', 2), ('characterize', 2), ('based', 2), ('size', 2), ('aneuploidy', 2), ('chromosome', 2), ('quantification', 2), ('analysis', 2), ('performed', 2), ('chemotherapy', 2), ('administration', 2), ('two', 2), ('cycles', 2), ('treatment', 2), ('detected', 2), ('small', 2), ('\xc2\xb5m', 2), ('wbcs', 2), ('accounted', 2), ('absolute', 2), ('number', 2), ('included', 2), ('detectable', 2), ('vimthis', 2), ('study', 2), ('demonstrates', 2), ('important', 2), ('morphologic', 2), ('karyotypic', 2), ('phenotypic', 2), ('heterogeneity', 2), ('majority', 2), ('vim', 2)]"', 'b"[('of', 8), ('ctc', 8), ('and', 7), ('patient', 6), ('(', 6), (',', 6), ('in', 5), (')', 5), ('the', 4), ('advanc', 3), ('lung', 3), ('.', 3), ('%', 3), ('vimentin', 2), ('express', 2), ('with', 2), ('wa', 2), ('cancer', 2), ('on', 2), ('cell', 2), ('were', 2), ('detect', 2), ('To', 1), ('investig', 1), ('presenc', 1), ('it', 1), ('clinic', 1), ('relev', 1), ('cancer.peripher', 1), ('blood', 1), ('obtain', 1), ('from', 1), ('61', 1), ('treatment-na', 1), ('subtract', 1), ('enrich', 1), ('immunostaining-fluoresc', 1), ('situ', 1), ('hybrid', 1), ('se-ifish', 1), ('platform', 1), ('appli', 1), ('to', 1), ('identifi', 1), ('enumer', 1), ('character', 1), ('base', 1), ('size', 1), ('aneuploidi', 1), ('chromosom', 1), ('8', 1), ('chr8', 1), ('quantif', 1), ('analysi', 1), ('perform', 1), ('befor', 1), ('chemotherapi', 1), ('administr', 1), ('after', 1), ('two', 1), ('cycl', 1), ('therapy.befor', 1), ('treatment', 1), ('60', 1), ('98.4', 1), ('small', 1), ('\xe2\x89\xa4', 1), ('5', 1), ('\xc2\xb5m', 1), ('wbc', 1), ('account', 1), ('for', 1), ('52.8', 1), ('absolut', 1), ('number', 1), ('while', 1), ('12', 1), ('19.7', 1), ('includ', 1), ('had', 1), ('vimentin-posit', 1), ('vimthi', 1), ('studi', 1), ('demonstr', 1), ('an', 1), ('import', 1), ('morpholog', 1), ('karyotyp', 1), ('phenotyp', 1), ('heterogen', 1), ('major', 1), ('vim', 1)]"', 'b'4'', 'b"('ctcs', 'patients', 'advanced', 'lung', 'vimentin', 'expression', 'cancer', 'cell', 'investigate', 'presence', 'clinical', 'relevance', 'blood', 'obtained', 'subtraction', 'enrichment', 'situ', 'hybridization', 'platform', 'applied', 'identify', 'enumerate', 'characterize', 'based', 'size', 'aneuploidy', 'chromosome', 'quantification', 'analysis', 'performed', 'chemotherapy', 'administration', 'two', 'cycles', 'treatment', 'detected', 'small', '\xc2\xb5m', 'wbcs', 'accounted', 'absolute', 'number', 'included', 'detectable', 'vimthis', 'study', 'demonstrates', 'important', 'morphologic', 'karyotypic', 'phenotypic', 'heterogeneity', 'majority', 'vim')"', 'b'(16, 12, 6, 6, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0026273772073281353'', 'b'[-0.22959844551773345, -0.02869980568971668, -0.020872585956157586, -0.017328184567376108, -0.01434990284485834, -0.010250962892566332, -0.008661327399452808]'', 'b'-2.7455747977904816'', 'b'[-0.3862943611198906, -2.4657359027997265, -2.784189633918261, -2.970291913552122, -3.1588830833596715, -3.499809670330265, -3.6728288344619067]'', 'b'-0.30537830062687227'', 'b'[0.35477033930157137, 2.264516521360329, 2.5569824478968806, 2.7278976243418445, 2.9010985820465818, 3.2288777155440322, 3.4038383128645004]'', 'b'2'', 'b'0.09044966024175446'', 'b"['Chromosomes, Human, Pair 8', 'Female', 'Follow-Up Studies', 'Humans', 'Liver Neoplasms', 'Lung Neoplasms', 'Male', 'Middle Aged', 'Neoplastic Cells, Circulating', 'Progression-Free Survival', 'Prospective Studies', 'Vimentin']"' );
INSERT INTO mytable ( `id`, `ARTITLE`, `ABREST`, `PER_CHARACTER`, `WORDS`, `PER_WORD`, `PER_WORD_stem`, `SENTENCE`, `zipf1_x`, `zipf1_y`, `tfidf`, `tfidf_p`, `tfidf1`, `tfidf_p1`, `tfidf2`, `tfidf_p2`, `similarity_index`, `similarity_value`, `mesh_word` ) VALUES ( 'b'95'', 'b'Radiomics in predicting tumor molecular marker P63 for non-small cell lung cancer.'', 'b'To establish a radiomics signature based on CT images of non-small cell lung cancer (NSCLC) to predict the expression of molecular marker P63.\xe2\x80\xa9 Methods: A total of 245 NSCLC patients who underwent CT scans were retrospectively included. All patients were confirmed by histopathological examinations and P63 expression were examined within 2 weeks after CT examination. Radiomics features were extracted by MaZda software and subjective image features were defined from original non-enhanced CT images. The Lasso-logistic regression model was used to select features and develop radiomics signature, subjective image features model, and combined diagnostic model. The predictive performance of each model was evaluated by the receiver operating characteristic (ROC) curve, and compared with Delong test.\xe2\x80\xa9 Results: Of the 245 patients, 96 were P63 positive and 149 were P63 negative. The subjective image feature model consisted of 6 image features. Through feature selection, the radiomics signature consisted of 8 radiomics features. The area under the ROC curves of the subjective image feature model and the radiomics signature in predicting P63 expression statue were 0.700 and 0.755, respectively, without a significant difference (P>0.05). The combined diagnostic model showed the best predictive power (AUC=0.817, P<0.01).\xe2\x80\xa9 Conclusion: The radiomics-based CT scan images can predict the expression status of NSCLC molecular marker P63. The combination of the radiomics features and subjective image features can significantly improve the predictive performance of the predictive model, which may be helpful to provide a non-invasive way for understanding the molecular information for lung cancer cells.'', 'b'1462'', 'b'245'', 'b"[('features', 16), ('model', 16), ('radiomics', 14), ('image', 12), ('ct', 10), ('subjective', 10), ('signature', 8), ('expression', 8), ('predictive', 8), ('images', 6), ('nsclc', 6), ('molecular', 6), ('patients', 6), ('feature', 6), ('lung', 4), ('cancer', 4), ('predict', 4), ('marker', 4), ('combined', 4), ('diagnostic', 4), ('performance', 4), ('roc', 4), ('consisted', 4), ('p', 4), ('establish', 2), ('based', 2), ('cell', 2), ('methods', 2), ('total', 2), ('underwent', 2), ('scans', 2), ('retrospectively', 2), ('included', 2), ('confirmed', 2), ('histopathological', 2), ('examinations', 2), ('examined', 2), ('within', 2), ('weeks', 2), ('examination', 2), ('extracted', 2), ('mazda', 2), ('software', 2), ('defined', 2), ('original', 2), ('regression', 2), ('used', 2), ('select', 2), ('develop', 2), ('evaluated', 2), ('receiver', 2), ('operating', 2), ('characteristic', 2), ('curve', 2), ('compared', 2), ('delong', 2), ('test', 2), ('results', 2), ('positive', 2), ('negative', 2), ('selection', 2), ('area', 2), ('curves', 2), ('predicting', 2), ('statue', 2), ('respectively', 2), ('without', 2), ('significant', 2), ('difference', 2), ('showed', 2), ('best', 2), ('power', 2), ('conclusion', 2), ('scan', 2), ('status', 2), ('combination', 2), ('significantly', 2), ('improve', 2), ('may', 2), ('helpful', 2), ('provide', 2), ('way', 2), ('understanding', 2), ('information', 2), ('cells', 2)]"', 'b"[('the', 20), ('.', 13), ('featur', 11), ('of', 10), ('imag', 9), ('and', 9), (',', 9), ('were', 8), ('model', 8), ('radiom', 7), ('predict', 7), ('p63', 6), ('CT', 5), ('subject', 5), ('signatur', 4), ('(', 4), (')', 4), ('express', 4), ('a', 3), ('nsclc', 3), ('to', 3), ('molecular', 3), (':', 3), ('patient', 3), ('by', 3), ('examin', 3), ('combin', 3), ('cell', 2), ('lung', 2), ('cancer', 2), ('marker', 2), ('245', 2), ('scan', 2), ('wa', 2), ('select', 2), ('diagnost', 2), ('perform', 2), ('roc', 2), ('curv', 2), ('consist', 2), ('statu', 2), ('P', 2), ('can', 2), ('for', 2), ('To', 1), ('establish', 1), ('base', 1), ('on', 1), ('non-smal', 1), ('method', 1), ('A', 1), ('total', 1), ('who', 1), ('underw', 1), ('retrospect', 1), ('includ', 1), ('all', 1), ('confirm', 1), ('histopatholog', 1), ('within', 1), ('2', 1), ('week', 1), ('after', 1), ('extract', 1), ('mazda', 1), ('softwar', 1), ('defin', 1), ('from', 1), ('origin', 1), ('non-enhanc', 1), ('lasso-logist', 1), ('regress', 1), ('use', 1), ('develop', 1), ('each', 1), ('evalu', 1), ('receiv', 1), ('oper', 1), ('characterist', 1), ('compar', 1), ('with', 1), ('delong', 1), ('test', 1), ('result', 1), ('Of', 1), ('96', 1), ('posit', 1), ('149', 1), ('neg', 1), ('6', 1), ('through', 1), ('8', 1), ('area', 1), ('under', 1), ('in', 1), ('0.700', 1), ('0.755', 1), ('respect', 1), ('without', 1), ('signific', 1), ('differ', 1), ('>', 1), ('0.05', 1), ('show', 1), ('best', 1), ('power', 1), ('auc=0.817', 1), ('<', 1), ('0.01', 1), ('conclus', 1), ('radiomics-bas', 1), ('significantli', 1), ('improv', 1), ('which', 1), ('may', 1), ('be', 1), ('help', 1), ('provid', 1), ('non-invas', 1), ('way', 1), ('understand', 1), ('inform', 1)]"', 'b'13'', 'b"('features', 'model', 'radiomics', 'image', 'ct', 'subjective', 'signature', 'expression', 'predictive', 'images', 'nsclc', 'molecular', 'patients', 'feature', 'lung', 'cancer', 'predict', 'marker', 'combined', 'diagnostic', 'performance', 'roc', 'consisted', 'p', 'establish', 'based', 'cell', 'methods', 'total', 'underwent', 'scans', 'retrospectively', 'included', 'confirmed', 'histopathological', 'examinations', 'examined', 'within', 'weeks', 'examination', 'extracted', 'mazda', 'software', 'defined', 'original', 'regression', 'used', 'select', 'develop', 'evaluated', 'receiver', 'operating', 'characteristic', 'curve', 'compared', 'delong', 'test', 'results', 'positive', 'negative', 'selection', 'area', 'curves', 'predicting', 'statue', 'respectively', 'without', 'significant', 'difference', 'showed', 'best', 'power', 'conclusion', 'scan', 'status', 'combination', 'significantly', 'improve', 'may', 'helpful', 'provide', 'way', 'understanding', 'information', 'cells')"', 'b'(16, 16, 14, 12, 10, 10, 8, 8, 8, 6, 6, 6, 6, 6, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2)'', 'b'0.0026191998775535017'', 'b'[-0.11636500523626428, -0.024606864067266986, -0.01764265725577633, -0.014448993103692425, -0.008777425717196332, -0.007731896177808698, -0.007200697203760771, -0.006596442892955671, -0.006288608891284408, -0.006046739318542699, -0.00577671535941577, -0.0050662102617336155, -0.004934277702834303, -0.004858365738175314, -0.0044687798063405, -0.0043259420956355535, -0.003980981775446954, -0.0037756136679834205, -0.003576897159142188]'', 'b'-2.6375861597263857'', 'b'[-1.0794415416798357, -2.6375861597263857, -2.970291913552122, -3.174387269895637, -3.6728288344619067, -3.8040210447332568, -3.875197323201151, -3.962844630259907, -4.0106352940962555, -4.049856007249537, -4.099866427824199, -4.231108616854587, -4.2574953720277815, -4.272999558563747, -4.356586274672012, -4.389071729816501, -4.476463551931511, -4.529429087511423, -4.583496308781699]'', 'b'-0.26251788317050206'', 'b'[1.0048737651985222, 2.466303515727493, 2.777403635561418, 2.9813354851261202, 3.44946410251188, 3.5883000846813835, 3.655440051324644, 3.738116996494668, 3.783197515522915, 3.820194074341651, 3.8841368638870786, 4.00847326203181, 4.033471580950448, 4.048159957640048, 4.127348450992909, 4.158124564334198, 4.259152036667361, 4.30954634148439, 4.360988850268111]'', 'b'90'', 'b'0.11827650652285465'', 'b"['Biomarkers, Tumor', 'Carcinoma, Non-Small-Cell Lung', 'Humans', 'Lung Neoplasms', 'Retrospective Studies', 'Tomography, X-Ray Computed']"' );
